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Abstract 
 
Introduction: Current evaluation approaches for new medical technologies are problematic 
for a plethora of reasons relating to measuring their expected costs and consequences, but 
also due to hurdles in turning assessed information into coverage decisions. Most adopted 
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methodologies focus on a limited number of value dimensions, despite the fact that the value 
of new medicines is multi-dimensional in nature. Explicit elicitation of social value trade-
offs is not possible and decision-makers may adopt intuitive or heuristic modes for 
simplification purposes, based on ad hoc procedures that might lead to arbitrary decisions. 
 
Objectives: The objective of the present thesis is to develop and empirically test a 
methodological framework that can be used to assess the overall value of new medical 
technologies by explicitly capturing multiple aspects of value while allowing for their trade-
offs, through the incorporation of decision-makers’ preferences in a structured and 
transparent way. The research hypothesis is that Multiple Criteria Decision Analysis 
(MCDA) can provide a methodological option for the evaluation of new medicines in the 
context of Health Technology Assessment (HTA), to support decision-making and 
contribute to more efficient resource allocation.   
 
Methods and Empirical Evidence: The first paper proposes a conceptual methodological 
process, based on multi-attribute value theory (MAVT) methods comprising five distinct 
phases, outlining the stages involved in each phase and discusses their relevance in the HTA 
context. The second paper conducts a systematic literature review and expert consultation in 
order to investigate the practices, processes and policies of value-assessment for new 
medicines across eight European countries and identifies the evaluation criteria employed 
and how these inform coverage recommendations as part of HTA. The third paper develops 
a MAVT value framework for HTA, incorporating a generic value tree for new medicines 
composed from different levels of criteria that fall under five value domains (i.e. therapeutic, 
safety, burden of disease, innovation and socio-economic), together with a selection of 
scoring, weighting and aggregating techniques. In the fourth and fifth papers, the value 
framework is tested empirically by conducting two real-world case studies: in the first, the 
value tree is adapted for the evaluation of second-line biological treatments for metastatic 
colorectal cancer (mCRC) patients having received prior oxaliplatin-based chemotherapy; 
in the second, the value tree is conditioned for the evaluation of third-line treatments for 
metastatic castrate resistant prostate cancer (mCRPC) patients having received prior 
docetaxel chemotherapy. Both case studies were informed by decision conferences with 
relevant expert panels. In the mCRC decision conference multiple stakeholders participated 
reflecting the composition of the English National Institute for Health and Care Excellence 
(NICE) technology appraisal committees, whereas in the mCRPC decision conference a 
10 
 
group of evaluators participated from the Swedish Dental and Pharmaceutical Benefits 
Agency (TLV), thereby adopting the TLV decision-making perspective.   
 
Policy Implications: The value scores produced from the MCDA process reflect a more 
comprehensive benefit metric that embeds the preferences of stakeholders and decisions-
makers across a number of explicit evaluation criteria. The incorporation of alternative 
treatments’ purchasing costs can then be used to derive incremental cost value ratios based 
on which the treatments can be ranked on ‘value-for-money’ grounds, reflecting their 
incremental cost relative to incremental value.   
 
Conclusion: The MCDA value framework developed can aid HTA decision-makers by 
allowing them to explicitly consider multiple criteria and their relative importance, enabling 
them to understand and incorporate their own preferences and value trade-offs in a 
constructed and transparent way. It can be turned into a flexible decision tool for resource 
allocation purposes in the coverage of new medicines by payers but could also be adapted 
for other decision-making contexts along their development, regulation and use.  
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Chapter 1 – Introduction to Health Technology Assessment, Thesis 
Research Questions and Overview  
 
1.1 Introduction and the case for improving the way we measure the value of health 
care interventions  
One of the foremost challenges health care systems are facing is the scarcity of resources in 
combination with rising demand for services, putting their sustainability in danger. As a 
result, decisions relating to the allocation of health care resources has been inevitable, either 
between different competing services and interventions (i.e. priority setting) or across 
different patients (i.e. rationing). However, the methodological approach of allocating 
resources in an efficient and fair way that gives legitimacy to the decision outcomes has been 
far from obvious 4-9. This is in large part due to i) the complexity of the decisions, as a variety 
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of different factors and objectives need to be balanced through the involvement of a range 
of stakeholders, ii) the importance of the decision outcomes, as they have a dramatic impact 
on human health, and iii) the ethical and social responsibilities behind the provision of health 
care which traditionally has been perceived as a government duty, given that health on its 
own is regarded as a public good or even a human right.   
 
1.1.1 Resource Allocation Methods in the National Health Service 
The need for priority setting in health care had not always been realised; its 
acknowledgement came following a lengthy and incrementally evolving process 
characterised by the interplay of scientific advancements, culture changes and politics.  
However, the process of priority setting in the last 20 years has remained unchanged. The 
example of the British National Health Service (NHS) provides an insightful case study. 
Nowadays, priority setting takes place across all levels of the organisational hierarchy of the 
health care system: the central government decides the overall budget of the NHS, 
commissioners and providers determine their purchases among alternative services and 
interventions, and clinicians allocate their time and resources 10.  A similar decision context 
was evident in the 1990s. As Klein described in 1993, “micro-decisions about priority setting 
are constrained by macro-decisions about resource allocation taken at superior levels in the 
organisational hierarchy” 11(p. 309), according to an almost identical landscape where 
cabinet decided on the NHS budget, Department of Health decided the priority targets, and 
purchasers decided on services 11. 
As a result of the multi-level context of priority setting, rationing can be implemented 
in various ways: rationing by deterrence, when obstacles to patient access are imbedded; 
rationing by deflection, when the responsibility of service provision is passed on to another 
agency; rationing by dilution, where the quality of service declines; rationing by denial, 
when a particular treatment is refused to get funded; and rationing by selection, when a 
treatment is only allowed for a particular population sub-group 10,12. It seems that rationing 
by deterrence or delay was the first of these models to emerge, with Roy Parker already 
describing this approach in the mid-70s 13. All these rationing instruments were already 
applied more than two decades ago, possibly with the exception of the relatively harsher 
approaches of rationing by denial and selection which became more abundant due to 
increased fiscal pressures later on 11. 
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The decision-making tool used for budget distribution has not changed either. 
Quality Adjusted Life Year (QALY), which is calculated by multiplying the value of each 
health state by the respective length of time of each state, provides in a single common 
summary measure the total health improvement, therefore providing a simple tool for 
resolving complex choices and turning it into the most widely used measure of health status 
for the assessment of health benefits 14,15. However since then, it had been argued that the 
Quality Adjusted Life Year (QALY) is flawed as a way of priority setting in health care 16 
and that it does not originate directly from individual’s utility function therefore only partly 
reflecting the individual’s true preferences 17, while it had been acknowledged that it is 
“beset by methodological problems about the valuation of different states of health, by lack 
of data about incomes, and by the problem of patient heterogeneity” 11 (p. 310). Although it 
was more or less agreed that priority should ideally take place based on demonstration of 
effectiveness or need, both of which were problematic concepts however (at least back in 
that time), the former due to its uncertainty and the latter due to its ambiguity. And Klein 
therefore continued with the realisation that the process was not “rational” (probably in a 
logical or reasonable sense) but instead priorities were “emerging from pluralistic bargaining 
between different lobbies, modified by shifting political judgements made in the light of 
changing pressure” 11 (p. 310). In doing so though he argued that given the multiplicity of 
conflicting values (i.e. objectives) brought along such discussions, the idea of “a machine 
grinding out priorities” and making decisions for us would be “absurd”, and that the 
limitation of pluralistic bargaining was that it was not pluralistic enough but instead 
dominated by some (clinical) voices. As a consequence he finally argued that in order for 
the process to become more rational the technical characteristics of the decision-making 
process should be improved, according to an “open dialogue, […], in which arguments can 
be tested against evidence and the conflicts between different values or preferences can be 
explored” 11(p. 310), a rationality concept that he acknowledged goes back to Aristotle’s 
work of finding “good reasons” to justify decisions 18.  
Consensus has now been reached that emphasis should be placed on the process of 
decision-making in order to assess the efficiency and fairness of decision outcomes. Daniel’s 
and Sabin’s Accountability for Reasonableness ethical framework has been cited by most 
for this reason 19, which states that for decisions to be fair and legitimate their processes 
should meet a number of conditions: they should be publicly available, based on relevant 
reasoning, and revisable in light of new evidence, all three conditions of which could be 
assured through enforcement mechanisms (i.e. regulation) 20. Given that allocation of 
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resources is also a political process, the application of such an ethical framework is very 
much needed. 
 
1.1.2 Pharmaceuticals and Need for Value Assessment  
Pharmaceutical spending is the third largest component of health care expenditure after 
hospital and ambulatory spending, accounting for between 10% and 20% of total expenditure 
on health in most OECD countries (the OECD average being 16.5% in 2010, or 1.5% of 
GDP) 21.  Faster uptake of new and more expensive drugs has caused an escalating trend in 
pharmaceutical spending per capita in many developed economies22. 
Although new, branded medicines account for only about 25% of all drugs dispensed 
by volume, they account for 70% to 85% of pharmaceutical spending across most OECD 
countries 23; price growth is mostly attributable to innovative medicines in a relative small 
number of therapeutic categories such as cancer, infection and central nervous system 
products 22.  
Most expensive new medicines are associated with uncertainty in clinical benefit, 
alongside high cost.  The associated clinical uncertainties usually relate to two aspects: first, 
safety due to potential unknown adverse drug events and, second, real effectiveness in daily 
clinical practice.  Both of these uncertainty aspects could potentially be attributed to  the 
design of the clinical research studies most of which fall short of a number of necessary 
features for their findings to be useful 24, such as their information gain (i.e. is the study large 
and long enough to be sufficiently informative?), pragmatism (i.e. does the study reflect real 
life?),  and patient centeredness (i.e. does the study reflect patient priorities?). Failure to 
compare all relevant treatment options and the relatively short-term or ‘truncated’ time 
horizons of the studies act as additional limitations 25. As a result, the clinical uncertainty of 
new medicines in tandem with their high cost in prices have led to the assessment and 
appraisal of their benefits and costs by the payers in order to estimate their value and 
determine whether they should be covered, and possibly at what price 26-28.  
In contrast to commodity markets, such as those for generic medicines, the price 
mechanism in more complex markets such as the one of innovative medicines has a more 
diversified role: besides reflecting the actual value of a product to consumers in the present 
time, i.e. static efficiency, it also needs to encourage future investments and the potential 
societal gains emerging from them in the future, i.e. dynamic efficiency 28. In this context, 
the emergence of value based pricing (VBP), highlights the need to set drug prices after 
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assessing their value to a variety of stakeholders, such as patients, health care systems and 
even society at large 27,29,30.  One of the main purposes of VBP is to essentially improve 
patient access to effective and innovative drugs while ensuring their prices are reflective of 
their value 31.  
Central to VBP is the application of Health Technology Assessment (HTA) processes 
that evaluate the clinical benefits, and usually, costs of new health care interventions 
(including drugs, diagnostics and medical devices), compared to existing available 
alternatives in order to inform pricing and reimbursement decisions. Despite the extensive 
uptake and use of HTA practices and processes in recent years, there are several conceptual 
and methodological issues inherent in the use of the current value assessment (VA) 
approaches that limit their success.  
The implication of ever increasing pharmaceutical expenditure in combination with 
the finite amount of resources available for health care is that health care decision-makers 
such as payers and commissioners of care, need to allocate resources efficiently, while 
ensuring patient access to effective new medicines. This observation is one of the central 
drivers of the thesis. It is suggested that the problematic nature and the technical difficulties 
associated with assessing the value of new medical technologies (NMTs) in practice, 
including their link to decision-making, are the key obstacles to overcome in order to address 
the above issues.  
1.1.3 Primer on Economic Value Theories 
A brief background of various value propositions in a historical context is useful to 
understand the evolution of economic value theory which could be generally classified into 
pre-classical, classical and neo-classical thinking.  In medieval times, “value” was generally 
perceived by theorists to depend on utility and scarcity, with a subjective approach to value 
being generally adopted 32,33.  It was in the 17th century, when the pre-classical thinking on 
value started to emerge, that cost of production started to be considered as part of the value 
function 32,34. According to William Petty, the market price of a commodity would fluctuate 
around its “natural value” that would depend on land and labour (the factors of production), 
therefore proposing a more natural or objective theory of value 32,35. Petty’s theory was 
eventually reduced to a labour explanation expressed in labour cost, therefore representing 
a labour cost theory of value. According to a similar - but not identical - logic, Richard 
Cantillon proposed to express cost of production in units of land, therefore adopting a land 
theory of value 32,36,37. Ferdinando Galiani was among the pre-classical economists that 
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continued to support a subjective, utility-based, approach to value evident from the medieval 
period, the utility theory of value 32-34.  John Law first proposed the use of a two dimensional 
approach considering both demand and supply factors to determine the value of a good in 
society, based on which he tried to explain the water-diamond paradox of value as part of 
which the high value of water, essential for life, was priced at lower market price to the value 
of diamond, inessential to human life 38. By distinguishing between “value in exchange” and 
“value in use”, he regarded that diamonds’ “high value in exchange” is due to their relative 
scarcity, his reasoning essentially fitting the marginal utility approach that ultimately 
resolved the paradox in the 19th century turning his work into a milestone 39.  
The seminal work of Adam Smith signalled the beginning of the classical thinking, 
pushing back towards Petty’s labour theory of value, compared to other pre-classical 
economists 40. After realising that a labour theory would not hold in an advanced economy, 
he proposed a cost of production value theory consisting of elements from labour, land and 
capital theories. David Ricardo then adopted Smith’s rejected labour hypothesis proposing 
that in free markets the value of (freely reproducible) commodities is derived from their 
scarcity and the quantity of labour needed for their production 41.  Karl Marx subsequently 
built on Ricardo’s labour theory of value, which supported that commodities can be viewed 
as functions of labour time 42. Although John Stuart Mill allegedly also continued to work 
Ricardo’s labour theory, he recognised that a commodity’s market value is related to both 
demand and supply effects, placing his value approach closer to the neo-classical school of 
thought 43.  
The latest era of neo-classical thinking was marked in the 19th century by the work 
of William Stanley Jevons, Carl Menger and Leon Walras who almost simultaneously 
developed  the idea of marginal utility, trying to find a cause and effect relationship between 
value and utility that excluded the cost of production 44-46. Their work solved the water-
diamond paradox of value, essentially supporting the notion that value entirely depends on 
utility as Jevons had said, and more precisely on marginal utility. In contrast to Jevons, 
Menger did not believe that goods provide units of utility, or “utils”, but instead that goods 
value is derived because they serve various uses whose importance differs and which satisfy 
peoples wants 45. It was Leon Walras and Alfred Marshall that later combined together both 
utility and cost of production (i.e. demand and supply) theories to produce a complete two-
dimensional value theory 47,48. Walras’ biggest contribution was the General Equilibrium 
Theory, attempting to demonstrate how a whole economy works together and reaches 
equilibrium as part of a complex economic system integrating both the demand and supply 
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side factors 46. Marshall proposed a Partial Equilibrium concept and emphasised that the 
price of a good is determined both by supply and demand factors, and also introduced the 
price elasticity of demand concept, along with the consumer and producer surplus concepts  
49.   Marshall’s concept of externalities was then developed further by Arthur Cecil Pigou, 
arguing that the existence of externalities is sufficient justification for government 
intervention, advocating the use of taxes to discourage activities that lead to negative 
externalities, and the use of subsidies to encourage activities that created positive 
externalities 50,51. The above economic value theories and in particular utility theory were 
then extended by and used in the field of decision analysis which emerged in the 1960s.   
 
1.1.4 Utility Theory and Value Theory in Decision Analysis 
Decision analysis was originally defined by Howard as “a logical procedure for the 
balancing of the factors that influence a decision” incorporating “uncertainties, values, and 
preferences in a basic structure that models the decision” 52.  Preferences reflect how 
desirable or choice-worthy an option or characteristic might be over another alternative 
option or characteristic, usually interpreted in a comparative way. By definition, decision-
making is inherently subjective as it depends on individual utility and preferences which 
differ among individuals. The logic behind DA was then described by Raiffa as “divide 
and conquer”: “decompose a complex problem into simpler problems, get one’s thinking 
straight on these simpler problems, paste these analyses together with logical glue, and 
come out with a program of action for the complex problem” 53.   
The main outcome of decision analysis theoretical axioms is that first, the utility of 
an alternative is the indication of its desirability, and second, that an alternative A with higher 
utility U(A) should be preferred to an alternative B with lower utility U(B), in other words 
expressing the rationality rule of utility maximisation, i.e. 
 
 
                                                                                         (1) 
 
Decision analysis seems to be particularly useful for coping with the complexities 
arising from uncertainty and multiple conflicting objectives 53. Uncertainties can be traded-
off against some value aspects of the outcomes, formally through the incorporation of 
probabilities. Similar trade-offs can be made among different objectives and their associated 
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values. These trade-offs are judgements, depending on the decision maker’s assessment of 
the relative desirability of the available options across their dimensions in tandem with the 
relative importance of these dimensions. However, given that trade-offs are personal, there 
are no universal rules for making them, being subjective in nature 54. Therefore, the notion 
of rationality is used, with the goal of making rational inferences and decisions. Possibly the 
most prominent of such criteria rules would be the maximisation of (expected) utility or 
value 55.  
In decision analysis there is a clear conceptual difference between value functions, 
which assess the marginal benefit of an option, and utility functions, which incorporate 
preferences, therefore assessing both marginal benefit and risk attitude. The former is 
employed for riskless choices and the latter for choices under uncertainty. Expectation 
mainly relates to the concept of probability theory, with expected utility or value being a 
weighted average of the pay-off for an outcome (utility or value) and its respective 
probability of actually occurring 54. Expected utility and expected value are, therefore, 
calculated in a similar way but the pay-offs in the former case correspond to subjective 
utilities rather than objective quantities, with their formal terminology being subjectively 
expected utilities (SEUs): both the utilities and the probabilities incorporated are numbers, 
but are subjective in nature giving rise to numerical subjectivity, the notion of subjective 
judgments expressed as numbers 56.  In the context of HTA, the evaluation of new medical 
technologies predominantly relates to the evidence-based assessment of their value by 
measuring their marginal benefits and therefore we choose to use the value term rather than 
utility, which reduces the heterogeneity of the value judgements based on expected utility.  
 
The expected value (EV) of an event could then be written as  
 
                                  𝐸𝑉 =  𝑝1𝑣1 +  𝑝1𝑣2 + 𝑝3𝑣3 + ⋯ + 𝑝𝑛𝑣𝑛                                       (2) 
 
Or alternatively as 
𝐸𝑉 =  ∑ 𝑝𝑖𝑣𝑖
𝑛
𝑖=1
 
(3) 
Where pi is the probability that event i will take place and vi is the value or pay-off 
associated with the event.  
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Given that the evaluation of health care interventions as part of HTA predominantly relates 
to the assessment of their value using existing evidence and not expected evidence, for 
simplicity reasons we choose to detach expectation and the probability concept while 
assuming the existence of evidence for the measurement of marginal benefit.  However, it 
could also be argued that in various cases absence of (satisfactory or adequate) evidence 
essentially introduces an expectation variable given the attached probabilities of the 
respective outcomes to take place (e.g. clinical outcome), especially as part of early-HTA 
settings where a new medicine might still be under clinical development. 
Overall, based on value theory alternative a is preferred over alternative b, if and 
only if V (a) > V (b), and is judged to be indifferent if and only if V (a) = V (b), where V is a 
real number reflecting the value associated with the performance of the alternatives based 
on which preference orderings are produced2 54. In multi-attribute value theory (MAVT), 
which is essentially the extension of value theory for the evaluation of problems with 
multiple value dimensions, partial value functions for each criterion, for example vi(a), are 
first constructed and then aggregated together. Once again, the partial value function must 
satisfy the previous definition of a preference function according to which an alternative a 
is preferred to an alternative b for criterion i, if and only if vi(a) > vi(b), with a similar 
indifference working hypothesis existing only if vi(a) = vi(b). Importantly, the working 
assumptions required for the formation of the partial value functions are interrelating with 
the aggregation type used 2.   
Typically, an additive (linear) aggregation approach is adopted, taking the following 
form: 
 
𝑉(𝑎) =  ∑ 𝑤𝑖𝑣𝑖(𝑎)
𝑚
𝑖=1
 
(4) 
Where m is the number of criteria, and wivi(a) the weighted partial value function of criterion 
i for option a. Normally, partial value functions are standardised using lower and higher 
reference levels at 0 and 100 corresponding to “worst” and “best” or “least preferred” and 
“most preferred” outcomes. The “weight” wi represents the relative importance of criterion 
                                                 
2 Assuming preferences are complete (i.e. for any pair of options, either one is strictly preferred to the other or 
they are indifferent) and transitive (i.e. if an alternative A is preferred to an alternative B, and if B is preferred 
to an alternative C, then A is preferred to C)  
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i, which can be conceived as a parameter reflecting the gain associated with the replacement 
of the worst outcome by the best outcome for this particular criterion 2, which should be 
elicited using weighting techniques that assess their value trade-offs. Typically, the 
quantitative swing weighting technique is used asking for judgments of relative value 
between ‘swings’ (i.e. changes) from standard lower level x* to higher reference level x* on 
each x-th attribute), with each swing (i.e. a relative change from a lower to a higher attribute 
level) being valued between 0 and 100 and the most valuable swing anchored as 100 54. 
Normalised weights are then calculated, as a proportion of each swing weight, so the 
normalised weights summed to 100%. Overall, specification of the additive model requires 
the use of explicit reference values of 0 and 100 and positive weights summing one (or 
100%). The additive model is assumed as a working hypothesis and therefore the model 
construction is done to respect these properties underlying the additive value model.  
In order to enable the use of simple aggregation rules (e.g. additive value models, 
where scores and weights of the different individual criteria are multiplied and then added 
altogether in a weighted average manner), preference independence between the different 
criteria needs to be upheld 2. Preference independence is a key property; it implies that an 
option’s value score on a criterion can be elicited independently of the knowledge of the 
option’s performance on the remaining criteria. It should be noted that preference 
dependence (cardinal and ordinal) is not the same as environmental dependence (e.g. 
statistical correlation); two different criteria attributes could be statistically correlated (i.e. 
environmentally dependent) but at the same time preference independent and vice-versa. If 
this requirement is not observed, an additive aggregation function should not be employed 
unless the criteria are restructured to combine non-preference-independent criteria into a 
single criterion. 
Usually, simpler aggregation rules such as the additive model are preferred over more 
complex rules such as multiplicative models for merging scores and weights. This is  
mainly because of their simplicity and comprehensible nature which is easily explained and 
understood by any decision-makers 2, but also the considerably smaller errors associated 
with its use compared to the errors coming from the incorrect aggregation of preferences 
through more advanced models as evident on  empirical evidence from simulation studies 
57. Eventually, if the above requirements cannot be satisﬁed, then more complex aggregation 
rules would have to be applied to combine scores with weights. In turn, other aggregation 
and disaggregation approaches are available in the DA literature but this thesis is not 
covering them58.  
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1.1.5 Problematic  
Due to the different levels at which resource allocation needs to take place, and the fact that 
priority setting is a process focusing on the general population in contrast to the process of 
rationing which focuses on individual patients, a mix of slightly opposing principles act as 
objectives for resource allocation 10. On one hand there is the purely utilitarian principle of 
maximising the health impact on the whole population 59, and on the other hand there is a 
set of, usually secondary, ethical objectives relating to the distribution of health that mainly 
aim to prioritise interventions which target the more vulnerable 60, such as the poor 61, 
seriously sick 62, women and children 63.  
These objectives should in theory be operationalised through the application of a 
plurality of criteria, most of which are characterising either the intervention under 
consideration or the condition it is indicated for. The intervention is usually assessed through 
the notion of benefit risk-ratio, essentially an evaluation metric reflecting whether the 
benefits of implementing the intervention outweigh the risks, by accounting both for the 
impact on health and the impact on resources needed. The condition is assessed through its 
burden or severity, which is usually approximated through its seriousness (morbidity and 
mortality related) and the availability of treatments.  
As Baltussen and Niessen have described, a number of priority setting approaches 
have already been developed over the last 20 years, but all of these tend to concentrate on 
single value dimensions 64. These include the “evidence based medicine” approach for 
prioritising interventions according to their established effectiveness, “cost-effectiveness 
analysis” (and other forms of full economic evaluation) for prioritising according to 
efficiency by accounting both for effectiveness and costs, “equity analyses” for prioritising 
according to distributional impact, and “burden of disease analysis” for prioritising diseases 
according to their burden (through morbidity and mortality). 
Most of the current values assessment approaches adopted as part of HTA mainly 
consider (comparative) clinical efficacy in combination with or without clinical cost-
effectiveness techniques, while increasingly incorporating real world data after the drug has 
entered the market, thus essentially reflecting comparative effectiveness and efficiency 28. 
However, there is considerable arbitrariness in the selection of evaluation criteria used to 
interpret evidence and determine value, including which metrics to use for measuring 
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efficacy and effectiveness, what type of costs to consider, and very importantly how to 
account for other key dimensions of benefit. 
The value of NMTs is multi-dimensional and not only limited to clinical benefit and 
cost but spans the disease severity and target population size, the nature of the intervention 
and whether for example it is curative or preventive, economic impact and budgetary 
constraints, together with other factors such as evidence quality 64-66. Thus, the 
methodological framework of these value assessment approaches is inadequate and at best 
partial mainly because the evaluation criteria used to assess evidence and determine value 
are incomplete.  Many important value considerations falling under the burden of disease 
the treatment addresses, the treatment’s innovation level and its overall socioeconomic 
implications, are not adequately reflected in the evaluation process.  Typically, as part of 
traditional economic evaluation techniques these value dimensions are not considered, and 
if they are, this might be done in an implicit and non-methodical manner, by considering a 
value concern only informally on an ad-hoc basis through committee deliberation and 
possibly as part of non-transparent negotiations with the manufacturer. For example, such 
an ad hoc approach would characterise the evaluation of expensive life-extending end-of-
life (EOL) treatments in the English context 67, which has generated important questions 
about the credibility and consistency of the whole process 68.  In addition, there are technical 
issues in achieving consensus on value, for example, what should the importance of each 
criterion be and how to account for uncertainty and incomplete evidence.  Essentially, an 
explicit definition of value that relies on a comprehensive set of parameters is missing 69.  
Due to the complexity of these multi-criteria problems, decision-makers tend to 
adopt intuitive or heuristic approaches for simplification purposes, but as a consequence 
important information might get lost or not utilised leading to choices based on an ad hoc 
priority setting process 64. Under these conditions, requiring multiple trade-offs across a 
range of societal values, decision-makers seem not to be well equipped to make well-
informed, “rational” decisions 70,71. Therefore the need has arisen for a transparent approach 
that can help decision-makers to maximise societal welfare through better resource 
allocation decisions across the field of health care. Decision-makers have shown interest in 
incorporating additional dimensions of value through the use of multi-criteria methods 72. 
These include the European Medicines Agency (EMA) for benefit risk assessment 73, the 
Institute of Medicine in the US for prioritising vaccines 74, the Institute for Quality and 
Efficiency in Health Care (IQWiG) in Germany for distinguishing between multiple clinical 
endpoints 75,  as well as the National Institute for Health and Care Excellence (NICE) in 
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England for the assessment of ultra-rare therapies 76.  As a result, it would be expected that 
decision-makers and other stakeholders would benefit from clear and comprehensive ways 
that allow them to assess all critical value dimensions of new health care interventions, in 
order to make better decisions about priority setting. Not having such methods creates a 
conceptual, methodological and policy gap.  
A more explicit definition of value could incorporate a wider set of parameters than 
is currently the case, in combination with a more comprehensive methodological approach 
of assessment that includes views from all relevant stakeholders. This could then lead to the 
development of a supporting tool for decision-making, being flexible enough to enable 
decision-makers exercise their judgment, help them weigh the trade-offs and elicit their 
preferences when pursuing multiple objectives, while contributing to the debate on more 
efficient resource allocation.  
 
1.2 Research Questions and Thesis Overview 
The thesis’ working hypothesis is that a value assessment system for health care technologies 
characterised by comprehensiveness, consistency and transparency could potentially enable 
better prioritisation decisions for problems with complex information.  Eventually, this could 
lead to a better understanding of the decisions’ rationale, therefore enhancing their 
acceptability. 
 
1.2.1 Research Questions  
The main research question of this thesis is the following: ‘How to develop, if possible, a 
methodological framework that assesses the overall value of new medical technologies in a 
universal way by capturing aspects of value that are not explicitly addressed by other 
available methodologies? Could Multiple Criteria Decision Analysis (MCDA) provide a 
useful alternative for value assessment and what techniques or options are available for the 
context of HTA? Given that the above outlined research hypothesis is based on the 
application of MCDA methodology, the need to address a number of secondary research 
questions arises, which forms the basis for the empirical chapters of the thesis and proposed 
research papers, notably: 
1) How to design a robust methodological process subscribing to MCDA principles for 
assessing the value of NMTs in HTA?  
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2) What are the current practices, processes and policies of value assessment for new 
medicines across a number of jurisdictions in Europe that employ explicit evaluation 
frameworks as part of their HTA processes and what are the parameters of value 
acting as evaluation criteria?  
3) How to develop a sound MCDA methodological framework based on decision theory 
for the evaluation of new medicines that incorporates and models a multitude of value 
parameters for use in HTA? 
4) How to adapt and apply an MCDA value framework in practice to rank a set of 
medical technologies according to their value by eliciting the preferences of 
stakeholders, possibly linking their elicited value scores with hypothetical coverage 
decisions? 
 
1.2.2 Thesis Overview 
MCDA methods have been proposed for use in the field of public services1 such as transport 
77,78 and health care 64,79,80, including for priority setting of health programmes or 
interventions 81-84 and the regulatory approval of pharmaceuticals 85-87, but has not been 
successfully implemented for the purpose of measuring the value of NMTs as part of HTA. 
However, MCDA could be used for value assessment at HTA level because of its potential 
comprehensiveness in accommodating a multiplicity of criteria with distinct weightings to 
assess value, its encompassing nature in terms of extensive stakeholder engagement, and 
transparency. Only very recently have others advocated the use of MCDA for HTA, 
recognising its potential value in the appraisal process and arguing that it could be used as 
an aid to decision-making, given that methodological considerations are addressed 68,88-91. 
Still, various aspects of such a methodology remain to be advanced and become aligned with 
current HTA systems needs for its use to be embraced by decision-makers, as for example 
what evaluation criteria and techniques to use (and how to choose from), and how to link 
results with policy making decisions.  
Following Chapter 1, the thesis introduces current methods of value assessment in 
Chapter 2, including their perceived limitations. Five research papers are undertaken to 
address the overarching thesis question as part of Chapters 3-7 and which relate to each of 
the subsidiary research questions respectively, forming the main empirical body of the thesis. 
Research question 1 is addressed as part of Chapter 3 (Paper 1), research question 2 is 
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addressed as part of Chapter 4 (Paper 2), research question 3 is addressed as part of Chapter 
5 (Paper 3), with research question 4 addressed as part of Chapters 6 and 7 (Papers 4 and 5).   
 
Paper 1 
Paper 1 builds a generic methodological process to act as the conceptual basis for the 
development of a robust MCDA value framework in the context of HTA. It provides an 
introductory classification of different MCDA schools of thought before suggesting a 
specific methodological process for applying such methods in HTA. Overall, it aims to bring 
together theoretical foundations of MCDA with HTA application, thus possibly acting as a 
manual of good practice, while also suggesting different means of linking its use with policy-
making.      
The generic process of MCDA includes a number of common stages that would have to 
be adapted to the context of health care and HTA 1,92: 
a. Establish the decision context. Define the aim of the analysis, who are the decision-
makers and any other key players; 
b. Establish objectives that indicate the overall purpose to be achieved and identify 
criteria of favourable and unfavourable effects; 
c. Identify the options to be evaluated against the criteria; 
d.  Assign ‘scores’ to the options by assessing the performance of each option against 
the criteria and their value. 
e.  Assign ‘weights’ to the criteria by assigning relative weights to each of the criteria 
to reflect their relative importance to the decision. 
f. ‘Aggregate’ scores and weights for each of the option by combining them together 
to derive overall value scores. 
g. Analyse the results. 
h. Conduct a sensitivity analysis to validate the results by testing the influence of 
changes in the scores or weights. 
This process seems to be highly relevant to HTA and thus its application to health care 
settings; a decision perspective is initially decided, candidate technologies are assessed 
against pre-defined criteria, and results are then examined.  However, a compelling 
adaptation has to be made to reflect the special case of the HTA context alongside the 
associated conceptual/methodological issues.  
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Overall, in order for the above tasks to be completed effort is needed in studying and 
learning the theoretical foundations of advanced decision sciences, understanding the 
characteristics of different MCDA methods, and reviewing past MCDA applications in 
various sectors for the development of a new conceptual methodological process that is 
adapted for the needs of HTA and in alignment with decision theory principles.  
 
Paper 2 
Paper 2 systematically reviews and synthesises evidence on the value measurement methods 
and techniques applied across a number of jurisdictions in Europe that employ HTA 
processes, focusing on the different evaluation criteria employed. The aim is to critically 
review, through literature and expert consultation, the value parameters considered as part 
of current methods applied for assessing and appraising the value of new medicines, with 
the view to incorporate these dimensions as value domains into the next paper, thus forming 
a model that feeds the value framework.  
The application of MCDA in other contexts, such as transport, is relatively 
straightforward because the main aim of the analysis is usually conceptually easy to 
understand, and thus the appropriate criteria are easily identifiable.  For example, when 
encountered with the objective of deciding on the location for the construction of a new 
railway, it would be expected to end up with criteria reflecting the following concerns: urban 
and environmental impact, integration with the rest of the transport network, complexity of 
construction and costs 93. In contrast, in the field of HTA, the concept of “value” is much 
more complicated and a complete set of criteria needs to be identified and adapted to describe 
the value of a new medical technology in a specific context or disease area. Consequently, a 
significant contribution is needed in order to establish a definition of value, by considering 
all possible and relevant value dimensions of NMTs and selecting the right attributes to 
describe those dimensions.   
The databases of PubMed and Social Science Citation Index (through the Web of 
Science portal) are searched for peer review literature published in English3 using the 
following keywords: ‘value assessment AND pharmaceuticals/methodologies criteria’ and 
‘health technology assessment AND pharmaceuticals/ methodologies criteria’.  A review 
protocol for identifying the relevance of articles is used for inclusion and exclusion of the 
various studies.  Additional input is included from the policy and grey literature. The 
                                                 
3 Study countries also publish reviews and recommendations in English. 
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literature findings are validated and further insights are obtained from consultations with 
policy experts and using semi-structured interviews.  
Understanding the methodologies that exist and the manner in which the criteria for 
value assessment are implemented in different HTA settings is required to identify the 
current limitations of existing value frameworks and the metrics of valuing NMTs from a 
comparative perspective; evidence of additional parameters that contribute to the perceived 
value of technologies, such as the burden of disease, the innovation level of the treatment, 
and wider socioeconomic implications, could inform the production of a robust 
methodological approach for more encompassing value assessment.  The above critical 
review of the literature, in combination with expert communication, is used to identify, and 
subsequently feed into the development of a more comprehensive methodological 
framework for value assessment, by helping to identify and select a complete set of criteria 
that entirely describe the “value” of NMTs.  In this context, the implementation of an MCDA 
framework can be a logical way forward.  
In sum, achievement of the above tasks involve collecting both secondary and 
primary data, conducting a systematic literature review by studying specific literature of 
different countries and HTA agency guidelines, combining evidence together, seeking expert 
feedback, conducting semi-structured interviews, validating evidence and analysing results.   
Paper 3 
Paper 3 outlines the development of the value framework including the design of a value 
assessment model taking the form of a value tree. It commences with the theoretical axioms 
of Decision Analysis (DA), introducing the logic behind DA and the use of MCDA as a 
decision-making tool. It then links the findings of the systematic review and expert 
consultation with the new conceptual methodological process (Papers 2 and 1 respectively) 
for the design of a value tree, informing the selection of criteria needed to capture the value 
of new medicines. Finally, it outlines different types of MCDA methods, before suggesting 
a combination of techniques to operationalise the value tree so that it can be used for 
evaluating new drugs in HTA.  
The MCDA value framework is generic for NMTs but focuses on the application of new 
medicines, illustrating the adaptation of the two initial phases of the MCDA methodological 
process from Paper 1, together with a recommendation for the use of specific MCDA 
techniques, notably: 
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1. Establish the decision context. Define the aims of MDCA, and who the decision-
makers and other key players are;  
For the purpose of value-based assessment of NMTs, the decision context could 
adopt a societal point of view that aims to maximise social welfare.  Key stakeholders 
involved could be regulators, health care professionals, methodology experts, 
patients, and possibly manufacturers.  
2. Identify the objectives or criteria that capture value relevant to the decision-making 
context;  
Possibly the most fundamental step affecting the MCDA model and the results of the 
analysis is to decide on the evaluation criteria for which the options are scored 
against.  These criteria, or grading parameters, represent factors that are important 
when assessing the “value” of a drug in a VBP context, and could be chosen through 
the critical review and expert consultation carried out in the previous paper of the 
thesis and the limitations identified therein. The identification of a complete set of 
evaluation criteria with the objective of exhaustively describing all potential 
dimensions of value has not been successfully undertaken yet and forms a key 
intellectual contribution of the thesis.  In particular, drug–indication characteristics 
are grouped into clusters addressing a particular treatment characteristic.  Criteria 
clusters (groups) are constructed according to decision analysis theory on the 
principles of completeness (non-excludability), non-redundancy (parsimony), 
operationability (usefulness), and mutual independence of preferences (preference 
scores on one criterion are not affected by preference scores of the rest criteria)1. Five 
such key value domains, forming the relevant criteria clusters, are identified: (a) 
burden of disease, (b) therapeutic impact, (c) safety profile, (d) innovation level, and 
(e) socioeconomic impact.  These areas form the higher or top-level criteria levels 
where the most important trade-offs take place and each of them in turn is made up 
of a number of more specific lower or sub-level criteria whose hierarchical 
representation takes the form of a value tree. A DA software is used (M-MACBETH) 
as a decision support system and tool to organise the clusters of evaluation criteria 
into a value tree which forms the basis of model, and also for scoring the options, 
weighting the criteria, analysing the results and conducting sensitivity analysis. 
3. Provide an overview of MCDA modelling techniques, in regards to scoring, 
weighting and aggregating; 
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A recommendation of particular MCDA methods and precise combination of 
techniques for the stages of ‘scoring’, ‘weighting’, and ‘aggregation’ is provided, 
completing the development of a new value framework. 
From a policy perspective, this paper aims to provide a new methodological 
framework for assessing the overall value of new medicines from a societal 
perspective, while providing an explicit and complete set of evaluation criteria.   
To undertake and complete these tasks, effort is needed in understanding the use of advanced 
decision science methods and techniques, reviewing past MCDA applications, collecting 
secondary and primary data, conducting multiple rounds of literature reviews, seeking expert 
feedback, presenting the results and consulting with experts, combining evidence together 
and analysing results and linking decision science theory with HTA practice, so that a new 
methodological framework is developed that can serve the needs of decision-makers. 
 
Papers 4 and 5 
Paper 4 and Paper 5 constitute two separate case studies where the previously described and 
developed new MCDA framework is applied in practice to two different disease indications, 
namely (a) metastatic colorectal cancer (mCRC) and (b) metastatic castrate-resistant prostate 
cancer (mCRPC).  Each of the papers involves an empirical testing of the methodological 
framework as well the adaptation of the generic value tree developed in Paper 3.  Different 
drug treatments for each disease indication are used as the alternative options for the 
analysis, which are eventually assessed and compared with each other. Drugs are scored 
across a set of criteria, criteria are weighted according to their relative importance and overall 
value scores are produced, based on which the alternative treatments are ranked.  
Cancer acts as a suitable example to describe the situation where difficult choices in 
resource allocation have to be made:  new medicines for a life threatening condition and 
possibly with relatively incremental benefits across a range of value dimensions are coming 
in the market at much higher costs. Both case studies look at highly prevalent cancers for 
which there are available multiple expensive treatments, therefore forming the conditions of 
a problem that requires the assessment of value before an informed and rational choice is 
made. The first case study (Paper 4) relates to mCRC, eliciting preferences from a group of 
different experts and stakeholders in an attempt to mimic the composition of evaluation 
committees as in the case of the Technology Appraisal committees of the National Institute 
for Health and Care Excellence (NICE), the national HTA agency in England and Wales. 
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The second case study (Paper 5) relates to mCRPC, however preferences are elicited from 
the perspective of decision-makers, by working together with a group of evaluators from the 
national HTA agency of Sweden (TLV). 
The methodology for both papers is based on the contents of Paper 3, outlining the 
development of the generic methodological framework for value assessment in the context 
of HTA.  The value framework is adapted to the circumstances of each of the two disease 
conditions and the treatments available for each of them in order to be able to fully reflect 
their value, for example by incorporating specific evaluation criteria.  Ultimately the aim for 
both papers is to test the newly developed methodological framework in practice.  
Both primary and secondary data are used. Secondary literature sources (PubMed, 
Social Science Citation Index, and publicly available HTA appraisal reports) inform 
important value aspects of the drugs assessed which influence the adaptation of the general 
MCDA model developed in Paper 3 (e.g. selection of disease-specific clinical and surrogate 
endpoints). Primary data sources (i.e. expert opinion) are used for the validation of the 
model, and for the scoring and weighting steps of the process through a DA facilitated-
workshop with stakeholder participation. 
More specifically, for the purpose of scoring and weighting a facilitated workshop in 
the form of a decision conference is organised. In the first case study (Paper 4), key 
stakeholders participate including health care professionals (e.g. clinicians, pharmacologists, 
public health specialists), methodology experts (e.g. health economists, statisticians) and 
patient advocates (e.g. representatives from patient organisations), where a proportion of 
participants comes from existing or past NICE appraisal committees members that are 
responsible for the appraisal of cancer drugs.  Approximately 7-15 experts should participate 
in the workshop, a number which has been shown to be ideal because it tends to preserve 
individuality while also allowing group processes; in other words, it is small enough to allow 
participants to reach an agreement but sufficiently large enough to represent all perspectives 
and interests 94.  On the other hand, for the purpose of the second case study (Paper 5), a 
smaller number of participants would be needed (e.g. 3-6 experts), given that all of them 
would come from the same stakeholder group being affiliated with the Swedish HTA 
agency.  
An impartial facilitator (DA expert) coordinates the workshop and guides its process 
without contributing to it, intervening as appropriate to ensure the participating group 
remains task-oriented and achieves its objectives in the time available 95 . The workshop 
starts with an outline of the objectives and a presentation of the evidence available for the 
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different options relating to the assessment criteria.  Initially the existing model is validated 
(as adjusted already through evidence from the literature), possibly involving on-the-spot 
amendments.  Once the structure of the model is agreed upon, participants are invited to 
score the performance of the various options against the criteria and weight the relative 
importance of the criteria.  Finally, results are presented.  The DA software M-MACBETH 
is used for the above stages.   
Overall, the objective of the workshops is to elicit value judgements and the 
preferences of stakeholders and experts by mimicking the deliberation process used in HTA 
decision-making; the selected criteria are validated, options are scored against the criteria, 
and criteria are weighted according to their relative importance, producing overall value 
scores for each option so that they can be ranked according to their total value.  
Results are analysed using tables and graphical illustrations where each individual 
criterion contribution to overall score is revealed; plotting the scores of any criterion or group 
of criteria against others (e.g. therapeutic vs. safety) permits one to compare options and 
visualise their performance against specific value dimensions. Sensitivity analysis is 
conducted to test the impact of different possible weights or scores on the overall value of 
the alternative treatments, thus testing input vagueness and possibly helping to resolve any 
existing preferences disagreements between the various stakeholders.  The outcome is a 
combined perception of total value with the level of information available up to that point.  
 From a policy perspective these two papers provide case studies of applying in 
practice a conceptually new methodological MCDA framework for assessing the value of 
new medicines for the treatment indication of cancer, while empirically producing 
quantitative evidence relating to their value, in the form of MCDA weighted value scores.   
In order to undertake and complete these tasks, effort is needed in applying decision 
science methods and techniques in practice, collecting both secondary and primary data, 
conducting literature reviews, presenting the results and consulting with experts, organising, 
conducting and facilitating decision conferences, combining evidence together and 
analysing results, and producing policy recommendations. 
 
1.2.3 Research Design and Methodology 
Overall this thesis adopts a deductive logic approach according to which an idea is developed 
(development of the new value framework) and then evidence is collected to test this 
framework (application of the value framework) following which a discussion takes place 
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96. Chapter 4 (Paper 1) adopts an exploratory research design investigating what are some of 
the critical features for a robust methodological approach of value assessment for NMTs in 
the context of HTA and based on MCDA principles96. Chapter 5 (Paper 2) adopts a 
descriptive research design outlining what evaluation criteria are considered as part of 
current HTA methods in different countries, analysing existing data through a systematic 
literature but also generating primary data through expert consultations96. Chapter 6 (Paper 
3) adopts a combination of exploratory and descriptive research designs, making use of the 
findings from the previous two chapters in combination with decision analysis theory to 
explore and outline the development of the new value framework. Chapters 7 and 8 (Papers 
4 and 5) adopt an evaluative research design to test the newly developed value framework 
in practice by aiming to assess the value of a set of alternative therapies and generating new 
primary data through two case studies that involve decision conferences for the collection of 
preferences from participants. Overall, this thesis uses characteristics of qualitative 
(Chapters 4-6) and quantitative (Chapters 7-8) methodologies, meanwhile adopting 
participatory/action methodology characteristics97. Ultimately, it aims to advance an action 
for change, possibly creating debate and discussion, being practical and collaborative in 
nature, while expecting that other stakeholders might engage as active collaborators 97.  
 
1.2.4 Policy Implications  
The proposed research agenda acknowledges that pharmaceutical policies must often 
balance multiple conflicting interests.  An evaluation framework for medical technologies 
should satisfy primarily health policy goals and to some extent may afford to accommodate 
industrial policy goals, by assessing value of innovative technologies according to a 
comprehensive set of criteria and incentivising investment in socially desirable R&D.  
The ultimate goal of pharmaceutical policies in a health system is to promote 
population health by improving patient health outcomes as efficiently as possible.  
Pharmaceutical innovation is one key driver for the production of therapeutic benefits in the 
form of innovative therapies.  Both a comprehensive value-based assessment system and 
well-aligned incentives are necessary in order to encourage R&D and sustain future 
innovation.  Only in this way will resources be allocated in the most efficient way, 
maximising social welfare through the development of technologies with the greatest value.  
At the same time, health systems need to contain escalating pharmaceutical expenditure and 
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ensure that patients continue to have access to such innovative technologies with high 
(social) value. 
Decision-makers need clear and explicit criteria in order to make transparent 
decisions about value which can then enable them to make health care coverage decisions 
based on complete and robust information that reduces risk and mitigates uncertainty on 
value, while at the same time providing them with stability and predictability in budget 
allocations.  This thesis aims to provide decision-makers with additional tools to make these 
decisions. The key principle of VBP is to ensure that public health resources are used in a 
way that produce the greatest possible value for patients.  However, methodological and 
conceptual pitfalls of existing VBP methods mainly relating to the incomplete and ad hoc 
assessment of key value dimensions act as an obstacle.  This thesis will have direct 
applicability to health care decision-makers seeking to make coverage decisions for new 
technologies and the extent to which these are included in the benefits catalogue.  
 
1.3 Conclusion 
The methodological approach for allocating health care resources in an efficient and fair way 
that gives legitimacy to the decision outcomes has been far from clear. The British National 
Health Service provides an insightful example where priority setting takes place across all 
hierarchical levels of the health care system from central government, which decides on the 
overall budget, to commissioners which determine purchases among alternative 
interventions, to clinicians who allocate their resources. Over the last two decades, the 
decision context has remained similar, together with the use of the QALY that has acted as 
the decision-making metric for budget distribution 11. However since then, research has 
identified a number of methodological challenges due to technical and problematic concepts 
that would have to be overcome for the decision-making process to improve and outcomes 
to become rational. For example, Klein had suggested the exploration of conflicts between 
different values or preferences and testing of arguments against evidence as part of open 
dialogues 11, whereas Daniels’ and Sabin’s Accountability for Reasonableness ethical 
framework has been proposed as a way of producing fair decisions through a legitimate 
process where they are publicly available, based on relevant reasoning and revisable in light 
of new evidence 20.  
Pharmaceutical costs are the third largest component of health care expenditure in 
most OECD countries, experiencing an escalating trend that is partially caused due to the 
uptake of new branded medicines with high prices in a small number of therapeutic 
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categories such as cancer treatments. Clinical uncertainty of new medicines in combination 
with their high costs has led to the evaluation of their benefits and costs by payers as part of 
HTA, in order to estimate their value, coverage and possibly price. The rewarding 
mechanism for innovative medicines has to consider both the current value to consumers, 
i.e. patients, while also encouraging future societal gains, with the emergence of value based 
assessment and pricing suggested as a way of improving patients’ access while ensuring that 
prices reflect value to a variety of stakeholders.  
A mix of objectives would have to be balanced out, possibly though the application 
of a plurality of evaluation criteria characterising the intervention of the target indication, 
however most priority setting approaches tend to focus on single value dimensions despite 
the fact that the value of new medicines is multi-dimensional in nature. Current value 
assessment approaches tend to work towards comparative effectiveness and efficiency, but 
there is considerable arbitrariness in the selection of evaluation criteria and how to account 
for other key benefit dimensions. Explicit elicitation of social value trade-offs is not possible 
and decision-makers may adopt intuitive or heuristic modes for simplification purposes 
given these multi-criteria problems, based on ad hoc decision making procedures. A more 
comprehensive and transparent methodological approach incorporating a wider set of 
benefits and their potential value trade-offs based on stakeholder preferences, may lead to 
the development of a decision support tool for decision-makers that contributes towards a 
more efficient, rational and legitimate resource allocation.  
The research question of the thesis is whether and how a methodological framework 
can be developed in order to capture value of NMTs in a more encompassing way. By 
departing from current principles of value assessment through traditional HTA, the thesis 
argues in favour of the use of MCDA in the context of HTA, rather than economic 
evaluation. 
In order to fulfil the research objective, five research papers are undertaken, 
addressing each of the secondary research questions separately and comprising Chapters 4 
to 8 of this thesis as following. Chapter 4 (Paper 1) forms the conceptual framework of the 
thesis and outlines the methodological process adopted for the development of the MCDA 
value framework, addressing research question 1. Chapter 5 (Paper 2) is a systematic 
literature review and expert consultation in Europe, addressing research question 2, which 
feeds the development of the next paper. Chapter 6 (Paper 3) forms the methodological 
framework output of the thesis and describes the development of a value measurement 
model, addressing research question 3.  Chapters 7 and 8 (Papers 4 and 5) form real world 
45 
 
applications of the newly developed value framework, addressing research question 4 in the 
form of two separate case studies. Chapter 9 outlines the conclusions of this thesis, examines 
the policy implications of the findings, outlines the limitations of the methods and results, 
and recommends future research directions. 
In sum, the intellectual and academic contribution of this thesis progresses in parallel with 
the subsidiary research questions and relates to the research, design, development and 
testing of a new value framework in practice for the purpose of HTA, based on MCDA 
principles and in alignment with decision theory.    
 
 
 
Chapter 2 – Current Methods of Value Assessment of Medical 
Technologies 
 
As part of current HTA practices, a number of value assessment approaches are used across 
different settings that can be applied on their own or in combination, namely (a) assessment 
of clinical benefit, (b) economic evaluation and (c) risk sharing and managed entry 
agreements. But are these methods ‘sufficient’ to capture the overall value of NMTs and aid 
the decision-making process? If not, what other methods might act better in assessing value 
and why?  
 
2.1 Current Methods of Value Assessment in Health Technology Assessment 
The concept of HTA was originally applied in 1978 by the US Office of Technology 
Assessment 98. HTA can be defined as “a method of evidence synthesis that considers 
evidence regarding clinical effectiveness, safety, cost-effectiveness and, when broadly 
applied, includes social, ethical, and legal aspects of the use of health technologies”, with 
the aim of advising on coverage and reimbursement decisions 99 (p. 271). Currently, most 
countries in the European Union (EU) adopt some form of HTA procedure as a means of 
assessing the value of NMTs for health care systems with publicly funded health services 
100. The overall purpose of HTA is to determine the value of a health technology by 
evaluating its benefits and - and most often - its costs, compared to existing alternatives of 
care, by considering both clinical and economic evidence in order to inform coverage and 
pricing decisions 101,102, predominantly of new medicines 99. 
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2.1.1 Assessment of Clinical Benefit 
The simplest type of HTA centres around the evaluation of the clinical/therapeutic benefit 
of a new drug relative to a comparator, usually the best available alternative or the standard 
of care. This is a criterion applied by the vast majority of EU countries, either on its own 
(e.g. France and Germany) or in combination with other criteria (e.g. through cost-
effectiveness in the United Kingdom or Sweden) as part of assessing the value of NMTs. 
  By comparing the relative therapeutic benefit across different medicines, their 
marginal clinical value is assessed and can be linked with reimbursement and/or pricing 
decisions 28.  The higher the relative therapeutic benefit of a product, the higher its clinical 
value, hence the stronger the justification for coverage and premium pricing. 
In most cases this therapeutic or clinical benefit relates to the clinical performance 
of the drug in patients that act as the subjects of RCTs, that are conducted as part of the 
marketing authorisation process, thus relating to efficacy 103.  Ideally however, the clinical 
performance evaluated should be based on evidence from real world clinical practice that 
reflects effectiveness. 
Although a suitable comparator should be the most relevant competing medicinal 
product currently available for the respective disease indication 104, in reality this is rarely 
the case because of the lack of head to head clinical trials. Instead, most clinical trials use 
placebo or best supportive care as a comparator. Consequently, in order for the therapeutic 
benefit of different drugs to be assessed against each other, an indirect or mixed comparison 
approach is followed 105,106.  
 
2.1.2 Economic Evaluation  
Once the additional criterion of cost is incorporated as part of a more comprehensive value 
assessment process, then the procedure starts to follow the concept of economic evaluation.  
Different HTA approaches use the basic concept of traditional economic evaluation, or 
economic analysis, according to which the costs and consequences of an alternative A, are 
compared with the cost and consequences of another alternative B.  More precisely, the 
difference in costs is compared with the difference in outcomes (or effects) for two or more 
alternatives and the cost per unit of outcome is assessed, known as incremental cost 
effectiveness ratio (ICER) which reflects opportunity cost.  
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Economic evaluation could thus be defined as the comparative analysis of alternative 
courses of action in terms of both their costs and their consequences107, with its basic tasks 
being to identify, measure, value, and compare the consequences and costs of the alternatives 
being assessed.  In other words, economic evaluations help us to answer the question of 
whether a particular health technology is “worth doing compared with other things we could 
do with these same resources”, or similarly whether we are “satisfied that the health care 
resources should be spent in this way rather than some other way” (p. 7)108.  
 The theoretical background of economic evaluation is grounded in welfare 
economics, a branch of economics providing the basis for evaluating efficiency in resource 
allocation by markets and policy makers, by developing propositions which may be used to 
rank (e.g. from better to worse) economic situations based on their associated social welfare 
109,110. According to welfare analysis theory, individuals aim to maximise their personal 
utility with societal welfare being the overall welfare of society, equal to the aggregation of 
these individual utilities or individual welfare; then, the only objective of governments in 
taking societal decisions is to maximise welfare 111,112.   
According to the New Welfare Economics approach4, social welfare is dependent on 
the dimensions of efficiency and social justice (equity), and can only be maximised by the 
joint pursuit of both113,114. Pareto efficiency usually acts as the efficiency goal; this is an aim 
that is relevant to all theories of society and is a necessary but not sufficient condition for an 
increase in social welfare. On the other hand, equity or distribution goals will depend on the 
distributive justice theory adopted (i.e. the definition of social justice chosen), ranging from 
utilitarian (Benthamite) to Max-Min (Rawlsian) and in between (egalitarian), affecting the 
specification of social welfare function (SWF) which incorporates value judgments about 
interpersonal utility 114. 
Under ideal conditions describing a first-best economy, institutions such as perfect 
markets will allocate resources optimally (Pareto-efficient) in a manner that agrees with the 
aim of societal welfare 114.  However, when these conditions fail and such idealised 
institutions are absent, intervention is needed and economic evaluation can in theory be used 
for the efficient allocation of resources 111,114. This can take place in the form of cost-benefit 
analysis, a specific application of welfare economics techniques. 
                                                 
4 This approach makes no assumptions regarding interpersonal comparability of utility, in contrast to the Old 
Neoclassical approach, which starts out with such assumptions. 
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In the context of health care, the concept of efficiency faces significant difficulties 
in quantifying benefits; health is hard to measure and health outcomes are often hard to 
evaluate, causality of improvement in health is complex (e.g. to what extent is improvement 
in health caused by medical care and not due to natural recovery?), and improved health is 
difficult to value (i.e. valuing human life could be regarded as immoral and is practically 
challenging) 114.   
There are three main types of economic evaluation, their key difference lying in the 
nature of outcomes, or effects, being considered (Appendix to Chapter 2) notably: (a) cost-
benefit analysis (CBA), which measures health outcomes in monetary units; (b) cost-
effectiveness analysis (CEA), which measures a clinical effect that is common between the 
alternatives being compared (e.g. ‘life years gained’); and (c) cost-utility analysis (CUA) 
which measures the utility associated with the effects of comparators being assessed. In the 
context of CUA, utility refers to the preference of individuals or society on any particular 
type of health outcomes and is usually measured using the QALY, which as defined above 
is a utility-adjusted health outcome that combines the dimensions of length of life and quality 
of life in a single index number. The use of monetary units for the purpose of measuring 
costs is common across all three types of economic evaluation, however the types of costs 
included varies by each setting, depending on the perspective adopted.   
The selection of which type of economic evaluation to use depends primarily on the 
nature of the problem being assessed, but also on the practical challenges associated with the 
measurement of outcomes and costs, the institutional framework, and the perspective 
adopted in terms of the role of economic evaluation itself 115. Due to limitations associated 
with the use of monetary measures of benefit5 111,116-118, in combination with a rising 
availability of new clinical effectiveness measures, the extension to CEA and consequently 
to CUA is relative easy and straightforward thus turning them into the preferred 
methodologies 111. 
However, evidence on the effectiveness of medical treatment is still limited and the 
QALY approach as we will see below is associated with a number of limitations.  Therefore, 
although the efficiency aim in health care is obvious enough, methodological problems 
associated with the measurement of benefits renders the assessment of efficiency 
problematic. 
                                                 
5 Assignment of monetary units to health care outcomes is conceived as a difficult task and willingness-to-pay 
(WTP) may be influenced by ability to pay thus possibly reflecting non-health attributes of health care options. 
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2.1.3 Risk Sharing and Managed Entry Agreements  
Within the context of HTA, managed entry agreements (MEAs) act as an additional tool 
aiding decision-makers to account for uncertainty related to clinical outcomes or the overall 
budget in a particular indication 22.  The term MEA is collectively referring to a variety of 
schemes for addressing clinical uncertainty due to lack of information on effectiveness at the 
time of HTA appraisal, such as risk-sharing agreements and performance-based agreements, 
with the aim of sharing the financial risk between payers and manufacturers 119.  For instance, 
through the use of MEAs, coverage may be gained once health outcomes uncertainty has 
been addressed; this can mean that the use of a new treatment is restricted to specific sub-
groups of patients with satisfactory clinical performance in relation to cost, or through the 
submission (and acceptance) of additional, real world evidence of the treatment’s 
effectiveness by the manufacturer often in combination with price discounts and money-
back guarantees 120. The usefulness of MEAs in policy-making relates to the development 
of effectiveness evidence in order to reduce risk and uncertainty about the value of a new 
technology; yet, such additional evidence do not necessarily take into consideration a 
broader set of value parameters. 
 
2.2 Limitations of Current Value Assessment Approaches  
The way value of NMTs is conducted across different settings presents a number of 
shortcomings, in particular (a) the absence of an explicit value for money definition, (b) the 
inadequate and ad hoc nature of the value criteria used and (c) the heterogeneity over HTA 
recommendations across settings, partly as a result of the above.   
 
2.2.1 Absence of an Explicit Value Definition 
As part of CUA, the QALY has been established as the preferred type of outcome many 
HTA bodies use, thus acting as a central variable of interest 121.  Although EQ-5D is a generic 
instrument used to derive patient quality of life across different health states, there is a debate 
of whether it reflects patient preferences accurately enough in order to study a treatment’s 
impact, given that reference scores used to build the measuring scale have been elicited from 
healthy individuals 122,123.  
By comparing the ICER of different alternatives using cost per QALY gained, an 
option with lower ICER is preferred over an alternative with higher ICER. An external 
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reference point is usually applied that reflects a ‘value for money’ range of acceptance, 
usually taking the form of a willingness to pay (WTP) threshold from a decision-maker’s 
perspective such as WTP for the gain of an additional QALY. In England, the National 
Institute for Health and Care Excellence (NICE) is the HTA agency responsible for 
producing evidence based guidance and advice for health care resources with the ultimate 
goal to improve outcomes for people using the NHS and other public health and social care 
services. As Devlin and Parkin had acknowledged 124, NICE had stated in its own guidance 
that a “sufficient level of cost-effectiveness is in the range of £20,000 and £30,000” 125, 
however NICE later reported that such comments were misinterpreted and that it does not 
have such a threshold 126; it is therefore believed that the above range constitutes an implicit 
range 127-129. A range of different WTP thresholds exist across different HTA settings 130, 
which are however arbitrary in nature and lack a scientific basis of elicitation.  
Evidence support that NICE coverage decision outcomes are affected by several 
factors beyond cost-effectiveness estimates (including uncertainty, burden of illness, quality 
of the evidence, availability of treatments and budget impact) and that modelling three 
decision outcomes (i.e. routine use, restricted use, no recommendation) instead of two (i.e. 
positive, negative decisions) better explains decision processes in some settings 131.  Other 
research suggests that for drugs of particular therapeutic areas such as cancer and orphan 
diseases, any cited implicit thresholds may not be rigidly adhered to, showcasing the 
recommendation of drugs with ICER up to £59,000 by NICE and other agencies, and 
proposing the existence of differential weights of importance across different diseases 132-
136. 
 
2.2.2 Value Criteria: How Complete Are They? 
Besides important theoretical and conceptual limitations inherent in the calculation and use 
of QALYs in health care decision-making 16,17,137,138, the argument that the incremental ‘cost 
per QALY’ metric does neither adequately nor explicitly capture a number of important 
value dimensions suggests that it cannot be used as a sole approach to value assessment 
28,132,139.  Additional criticisms of current HTA processes include the relative lack of 
transparency and existence of uncertainty 133,140-144. Altogether this evidence is consistent 
with other studies indicating the rationale for a shift towards more transparent VBP 
26,27,29,30,145.  
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There is generally an acceptance of the fact that other social factors in addition to 
‘scientific value evidence’, based solely on clinical cost-effectiveness and the ICER, should 
play a role in decision-making. These include burden of disease, the broad balance between 
benefits and costs, cost impact on available budgets and resources, clinical and policy 
importance of the health topic under consideration, and other policy objectives such as the 
long-term benefits of innovation 146-148, including the balancing of long-term product 
innovation (dynamic efficiency) with short-term product pricing (static efficiency) 149,150.  
However, it is not known which of the above ‘social value judgments’ are explicitly 
or transparently considered by HTAs or decision-makers, what their relative importance is, 
and what the trade-offs are that HTA bodies are willing to make. This gives rise to 
arbitrariness in the set of criteria used, resulting in non-transparent processes and lack of 
‘accountability for reasonableness’ 151,152; in turn, important equity and fairness 
considerations can emerge relating to the distribution of health care among individuals, 
including the conditions under which it is acceptable to place more weight on a QALY for 
one person compared to another 148. The importance of special considerations such as disease 
severity is illustrated in the case of end of life treatments in the UK context, in essence giving 
a greater weight on QALYs gained for terminal illnesses 153, on the grounds that society 
places a special value on extending the lives of the terminally ill 67.  The on-going debate in 
the UK about VBP reflects additional considerations that need to be taken into account in 
order to help determine the full value of a health technology based on a broader range of 
relevant factors 31,139,154. 
 
2.2.3 Coverage Heterogeneity 
The above limitations associated with the arbitrary and implicit definition of value and the 
subjectivity in the evaluation criteria used to measure it, often lead to differences in the 
assessment and appraisal processes resulting in discrepancies of health care coverage 
recommendations across settings, even for the same drug-indication pair 101,155-160. Other 
reasons which may affect the impact and outcome of HTA recommendations include 
differences in responsibilities, abilities and national priorities of the HTA agencies and the 
constraints and timeframes in which they operate 160-164.    
Decision outcomes and coverage heterogeneity can be justified on the grounds of 
different national (or, at times, regional) preferences, including different budget constraints.  
However, inconsistencies of medicines’ eligibilities for reimbursement across geographical 
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jurisdictions, possibly even within the same country, give rise to an international ‘post-code’ 
lottery type of access to medicines, with important implications related to equity and fairness 
101.  Indeed, several studies have acknowledged the need for well-defined decision-making 
procedures that are more fair and explicit 165-167. By ensuring ‘accountability for 
reasonableness’ and by providing a better understanding of the rationale behind decision-
making, decisions will also have enhanced legitimacy and acceptability 152,155. 
 
2.3 Summary of Gaps in the Literature and Likely Ways Forward   
2.3.1 Gaps in the Literature 
Most of the current value assessment approaches seem to examine the efficacy/effectiveness, 
or cost-effectiveness of new health care interventions by addressing only a partial dimension 
of ‘overall value’ that mainly relates to ‘scientific value judgements’ of their therapeutic 
aspect (e.g. safety, efficacy, effectiveness), possibly in relation to cost.  For example, the 
cost/QALY approach considers the incremental (quality-adjusted) therapeutic benefit, in the 
form of QALYs gained, relative to its incremental cost.  Hence, current methodologies have 
been subjected to criticism because they neither adequately nor explicitly capture social 
value judgement elements related to the burden of disease the treatment addresses, the 
overall innovation level of the treatment, and wider socioeconomic implication elements.    
Therefore, in the context of value assessment for NMTs, the following gaps have been 
identified: 
1. A conceptual framework for value definition is needed that takes into account a wider 
set of explicit evaluation criteria. 
2. A clear, transparent and comprehensive set of evaluation criteria to be used in value 
assessment is also required, pointing towards the need for a methodological 
framework.   
3. Considering the limitations of the cost/QALY metric, few other, if any, approaches 
have been put forward that capture the link between value and HTA decisions in 
order to achieve efficient allocation of resources. 
More robust and complete assessment procedures characterised by transparency in terms 
of value criteria used, possibly taking the form of value functions, could lead to more rational 
evidence-based decision-making, hence to more efficient resource allocation and higher 
society welfare, while also raising public confidence and fairness in terms of homogeneity 
and consistency of decision outcomes. 
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2.3.2 Decision Analysis and Multiple Criteria Decision Analysis as a Means of Addressing 
the Pitfalls of Current Value Assessment Methods  
The limitations of the current approaches in value assessment and the identified literature 
gaps suggest that there is a need for an alternative methodological approach of value 
assessment that encompasses multiple criteria explicitly, so that value can be a function of a 
number of parameters. Additionally, questions remain on how to derive weights for the 
different factors and how to incorporate the views of all relevant stakeholders. 
Decision analysis (DA) could provide the foundation for an alternative way of 
measuring and eliciting value of new therapies as it provides a comprehensive approach for 
quantitative modelling 53.  
More specifically, analysis of the literature on methodological tools for assessing 
value quantitatively as part of decision-making process indicates MCDA; it acts both as an 
approach and a set of techniques, ordering a set of options by looking at the degree to which 
a number of different objectives are achieved 1,168.  It is a way of eliciting preferences for a 
sum of options which are characterised by varying levels of performance with respect to a 
number of, often conflicting, objectives; it does so by disaggregating a complex problem 
into simpler components or objectives, measuring the performance of options against the 
objectives, weighting up these objectives according to their relative importance, and re-
assembling the components by aggregating scores and weights to show the overall picture 
1,53.  
One of the key aims of MCDA techniques is to enable decision-makers to reach a 
decision by laying out the problem, objectives, values and options they are faced with in a 
clear and transparent way. This is achieved by organising, synthesising and presenting 
relevant information across stakeholders, which is of complex and, often, of conflicting 
nature 2.  Although results will always be as good and certain as evidence used, “uncertainty 
on value” could be improved because of a more structured and comprehensive assessment 
based on wider value dimensions.  While MCDA can aid the decision-making process, it 
cannot replace decision-makers’ judgement or experience 2. However, it can supply to 
decision-makers detailed information for a comprehensive set of parameters of interest, in a 
transparent way and across a wide range of stakeholders at the same time. Overall, MCDA 
acts as an aid to decision-making, seeking to explicitly integrate objective measurement with 
value judgement while managing subjectivity in a transparent way.  
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2.3.3 Emergence of New Value Frameworks Based on Multi-Criteria Approaches  
Over the past few years, the need for a more “rational” approach to value assessment and 
decision-making has been illustrated through a number of initiatives on the development of 
new value frameworks aiming to aid reimbursement agencies, health care professionals and 
patients to make better choices on the use of new therapies by better understanding their 
value 169. This serves as a testament to the above gaps in the value assessment of NMTs 
presented earlier in this chapter.   
Among some of the most known value frameworks that have attracted a lot of 
attention include those proposed by the American College of Cardiology and the American 
Heart Association (ACC/AHA) 170, the American Society of Clinical Oncology (ASCO) 171, 
the European Society of Medical Oncology (ESMO) 172, the Institute for Clinical and 
Economic Review (ICER) 173, the Memorial Sloan Kettering Cancer Centre (MSKCC) 174, 
the National Comprehensive Cancer Network (NCCN) 175, and the Working Group on 
Mechanisms of Coordinated Access to Orphan Medicinal Products (MoCA-OMP)  176. 
Essentially these value frameworks adopt multi-criteria evaluation approaches in an attempt 
to decompose complex problems into simpler ones and address them separately, therefore 
representing an important step towards a more inclusive Value Based Assessment (VBA) 
process. However aspects of these frameworks are based on weak methodologies with no 
strong theoretical foundations and as such might offer little value to decision-makers 177. 
Despite this proliferation of value frameworks, “value” remains an elusive target and a wider 
consensus is still needed about what dimensions of “value” to be included in HTA 69.   
 
2.4 Conclusion 
Most EU countries adopt some type of HTA procedure in order to assess the value of NMTs 
and more precisely that of new medicines in order to inform coverage and pricing decisions. 
These procedures include the assessment of the clinical benefit, assessment of clinical 
benefit in combination with related costs as part of different types of economic evaluation, 
and risk sharing and managed entry agreements aiming to reduce risk and uncertainty by 
delaying reimbursement decisions until data on real clinical outcomes (i.e. effectiveness) 
and costs become available.  
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However, technical shortcoming due to methodological and theoretical limitations in 
the application of economic evaluation such as the absence of an explicit value definition 
and the use of incomplete and often arbitrary value criteria can result in ad hoc evaluation 
procedures that give rise to coverage recommendations, often lacking any ‘accountability 
for reasonableness’ that might negatively influence their legitimacy and acceptability.  
It seems that most of the current value assessment approaches address only partial 
dimensions of medicines’ overall value that mainly reflect scientific value judgements of 
their therapeutic benefit possibly in relation to cost, without however adequately nor 
explicitly capturing elements of social value judgements. As a result, in the context of value 
assessment there is a lack of a conceptual and methodological value framework that takes 
into account a wider set of evaluation criteria in a transparent and comprehensive way with 
few alternative methodologies to economic evaluation having been tested.  
An alternative methodological approach of value assessment that encompasses 
multiple parameters explicitly seems to be needed, and MCDA could act as a way of eliciting 
preferences for a set of NMTs which are characterised by varying levels of performance with 
respect to a number of, often conflicting, objectives. Overall, such a methodology could 
possibly act as a decision-making tool, seeking to explicitly integrate objective measurement 
with value judgement while managing subjectivity in a transparent way.  
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Chapter 3 – Paper 1 
Conceptual Framework: Towards a Robust Methodological Framework 
for the Application of Multiple Criteria Decision Analysis in the Context 
of Health Technology Assessment6 
 
Summary 
In recent years, multiple criteria decision analysis (MCDA) has emerged as a likely 
alternative to address shortcomings in health technology assessment (HTA) by offering a 
more comprehensive perspective to value assessment and acting as an alternative priority 
setting tool. In this paper, I argue that MCDA needs to subscribe to robust methodological 
processes related to the selection of objectives, criteria and attributes in order to be 
meaningful in the context of healthcare decision-making and fulﬁl its role in value-based 
assessment (VBA). I propose a methodological process, based on multi-attribute value 
theory (MAVT) methods comprising ﬁve distinct phases, outline the stages involved in each 
phase and discuss their relevance in the HTA process. Importantly, criteria and attributes 
need to satisfy a set of desired properties, otherwise the outcome of the analysis can produce 
spurious results and misleading recommendations. The application of MCDA as described 
here has the potential to offer three distinct advantages to decision-makers in the context of 
HTA and VBA. These relate to, first, a more complete assessment of value arising from the 
elicitation of preferences across a wider set of explicit criteria, second, the flexibility in 
distinguishing value through the incorporation of weights that reﬂect differences in relative 
importance, and, third, the encompassing nature of the entire process which can be informed 
by direct stakeholder engagement, all features being fully transparent and facilitating 
decision-making. 
 
3.1 Introduction 
The use of economic evaluation methods, particularly cost- effectiveness analysis (CEA) 
and cost-utility analysis (CUA), to assess the incremental beneﬁt of new medical 
                                                 
6 Chapter 3 has been published with co-author Prof Panos Kanavos as: Angelis A, Kanavos P (2016). 
Value-based assessment of new medical technologies: towards a robust methodological framework 
for the application of multiple criteria decision analysis in the context of health technology 
assessment. PharmacoEconomics. May;34(5):435-46. 
 
57 
 
technologies in relation to the best alternative care has increased considerably over the past 
2 decades. In this context, the use of the QALY has been established as the preferred measure 
of health gain across many settings 108,178-180. This is despite its frequent dependence on 
restrictive assumptions 181, the non-alignment of public versus patients’ decision utilities, 
which would differ from their respective experienced utilities 182, and the reliance on generic 
tools, such as the EQ-5D, that may not reﬂect patient experience adequately 183-185. 
At the same time, there is increased recognition that economic evaluation has 
limitations because it does not capture a number of important dimensions of value, and is 
therefore lacking in comprehensiveness. In partial recognition of that, economic evaluation 
has recently evolved into a deliberative process across different settings, whereby 
independent decision-making committees often allow for other dimensions of value to be 
considered, at least implicitly. 
Additionally, there is increasing evidence that decision-makers are reluctant to make 
coverage recommendations on economic evaluation alone 186 and, consequently, ‘value’ 
based on economic evaluation results could be informed by additional dimensions of beneﬁt. 
Recently, decision-makers in England and Wales considered additional parameters of beneﬁt 
on an ad hoc basis 187, highlighting the need to seek a broader and more trans- parent 
assessment methodology 31,154, in the context of value-based pricing 28,30,188,189. 
Even under such enhanced settings, the decision-making framework often lacks 
transparency, not least because different stakeholders attach different value judgements to 
the criteria considered. Consequently, value assessment is not simply a question of what 
additional beneﬁts to consider and possibly include in the decision-making process, but, 
importantly, involves how to arrive at a clear process that elicits and accounts for the 
preferences of different stakeholders in a transparent way. The ongoing debate in the UK on 
value-based pricing is a testament to these issues 190. 
Overall, the lack of comprehensiveness in value dimensions considered, the non-
systematic use of additional value concerns and the lack of transparency in terms of decision-
makers’ value trade-offs, altogether reflect an arbitrariness and inconsistency in the appraisal 
process. As a result, ‘unexplained’ heterogeneity or inconsistency in the decision-making 
process could have important implications for fairness, equity and resource allocation 
outcomes. Therefore, the development of alternative methodological approaches for 
assessing the value assessment of medical technologies that would overcome the above 
limitations could eventually contribute towards a more efﬁcient resource allocation with 
improved impact on equity that would perceived fairer by society. 
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In recent years, multiple criteria decision analysis (MCDA) has emerged as a likely 
alternative to address the current shortcomings of Health Technology Assessment (HTA) 
based on economic evaluation 90,91,191-194. One of the conclusions of a recent review of 
MCDA approaches adopted in healthcare was that decision-makers display a positive 
attitude towards its potential to improve decision-making 72. Conceptually, there are three 
main reasons why MCDA could provide a useful alternative to economic evaluation-based 
HTA processes. The ﬁrst relates to the inclusion of a comprehensive list of value dimensions 
in an explicit manner, beyond what economic evaluation methods currently capture. This 
enables value assessment to be conducted in an encompassing manner and, in principle, 
addresses a key limitation of economic evaluation. The second relates to the assignment of 
quantitative weights across the different evaluation criteria. In doing so, the relative 
importance of various value dimensions is explicitly incorporated, improving the 
transparency of the preference-elicitation process. The third is stakeholder participation and 
the possibility to include all relevant stakeholders in the value-assessment process. This is 
both insightful - enabling stakeholder views to be heard in a dynamic environment, where 
all inputs are considered prior to making decisions about coverage - and politically correct, 
increasing the legitimacy of decision processes, as all stakeholder views are accounted for 
in an open and transparent way. 
Despite the above, the methodological details of MCDA implementation in the 
context of healthcare decision-making have not been sufﬁciently discussed, and there is no 
adequate guidance on how MCDA should be conducted in HTA, particularly in relation to 
which criteria to incorporate and how. 
In this paper, I outline a methodological process for the development of a robust 
MCDA framework and debate its implementation in the context of HTA. In doing so, I 
provide a broad classiﬁcation of MCDA methods while also accounting for and building on 
the classiﬁcations proposed in the literature 1,2,54,92,195-197. I then focus on value-based 
methods, speciﬁcally MAVT methods, and argue in favour of using these because of their 
comprehensive nature. Further, I argue that several key principles need to be fulﬁlled in order 
for any MCDA framework to be methodologically sound and for the results produced to be 
robust and policy relevant. These principles apply to the MCDA main phases and stages as 
well as to the properties that the selected criteria and attributes need to satisfy, while 
establishing their relevance in the context of HTA and value-based assessment (VBA). I 
discuss these principles and their implications in the context of HTA by drawing on concrete 
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examples. Finally, I discuss a number of practical issues relating to the use of MCDA in 
HTA and provide a link to policy making. 
 
3.2 A Methodological Process Applying MCDA Principles in HTA and Value 
Assessment of Medical Technologies 
3.2.1 Overview of Different MCDA Methods 
MCDA is both an approach and a group of techniques aiming to aid decision-making by 
laying out the problem, objectives and available options in a clear and transparent way. 
Different MCDA methods exist, with variable degrees of complexity making use of different 
analytic models. These methods can be broadly categorised by ‘school of thought’, notably 
(1) value-measurement methods, including (multi-attribute) value theory and utility theory 
methods, (2) ‘satisﬁcing’ and aspiration level methods, (3) outranking methods, and (4) other 
methods such as fuzzy and rough sets methods 1,2,54,92.  
However, no universal categorisation of MCDA methods exists, and others have 
proposed groupings that differ from the above 195-197. Each MCDA method has its own 
advantages and disadvantages. The choice of method is informed by the type of problem to 
be addressed, the type of judgements required, the set of axioms employed to support 
decision-making, and the kind of responses needed. Some methods address choice problems, 
while others address ranking problems or classiﬁcation and sorting problems. 
Value measurement methods aim to order a set of alternative options through the 
production of overall numerical value scores. These methods are appropriate when the 
analysis considers criteria to be compensatory in nature, i.e. when a bad performance on one 
criterion can be compensated from a good performance on another criterion. They include 
multi-attribute value theory (MAVT) methods for deterministic consequences, and multi-
attribute utility theory (MAUT) methods (see section 1.1.4).  
Most of the outranking methods require similar procedures and data availability to 
value measurement methods based on which options are selected, their performance in 
respect to a set of criteria is assessed, weights are assigned and evidence is aggregated 
together; however, by some it is assumed that it lies out of the MCDA methodological 
spectrum, being a separate type of methods themselves 1. Outranking mainly recognises the 
fact that options with poor performance on just a single criterion could be practically 
unacceptable in reality, as commonly the case when politics are taken into account 198. 
Outranking is a concept similar to that of dominance, stating that for option A to outrank 
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option B, there should be enough evidence to judge that A is at least as good as B, with no 
strong evidence to prove it against. In other words, we could say that alternative a outranks 
alternative b, given that there is “sufficient credible evidence” to validate that “a is at least 
as good as b, taking all criteria into account” 2 (p.107). The same type of pairwise comparison 
must then take place for every pair of options being assessed. The outranking approach 
acknowledges the fact that preference functions are generally imprecise measures and that 
the emphasis should lie within the strength of evidence for the affirmation that “a is at least 
as good as b”, rather than on the strength of preference itself 2. As a consequence and in 
contrast to the preference relationships evident in value measurement methods, four 
preference states might arise: two when an outranking relationship holds true and two when 
an outranking relationship is absent; a definite preference for one alternative over the other, 
an indifference between the two alternatives, and in addition to value measurement 
preference states an “incomparability” between the two alternatives where lack of strongly 
enough credible evidence leads to neither a definite preference of an alternative nor to 
indifference. Essentially, this group of methods is more appropriate for the decision context 
where multiple alternative options are available and the aim is to identify a subset of options 
that fulfil some minimum requirements of performance, therefore assuming a non-
compensatory nature of criteria performance in contrast to value based methods.  
The key assumption underlying satisficing and aspiration methods is the existence of 
decision-makers’ aspiration levels that characterise whether an option’s performance would 
be acceptable, or in other words satisfactory. The idea is to identify the closest to satisficing 
a predefined goal of satisfactory level of criteria achievement through the comparison of 
alternatives 2. These methods are also non-compensatory, aiming to address complex 
problems through formal quantitative decision models. However they are more applicable 
for decision problems where the alternative options are not simultaneously known but 
instead they become available sequentially, or in situations where there is such a high 
number of alternatives available that cannot be assessed simultaneously 199. 
 
3.2.2 MCDA in the Context of Multi-Attribute Value Theory 
The methodological process I am proposing in this paper for the context of HTA pertains to 
the category of value-measurement methods. This is predominantly because of the multiple 
problems that can be addressed, the simplicity of the judgements required and the relatively 
limited restrictions imposed by the axioms employed. The value-measurement methods 
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category is widely used in healthcare because of these features. Nevertheless, some aspects 
(e.g. the MCDA phases and the criteria properties) are applicable across different MCDA 
methods beyond the value-measurement methods category. 
Value-measurement methods usually aim to address ranking or choice problems, 
ordering a set of alternative options with respect to their performance on a number of 
objectives or criteria, through the production of overall numerical value scores. A value (or 
real number) V is associated with the performance of an alternative a, in order to produce an 
ordering of preferences for all alternatives being considered, while being consistent with the 
assumptions of complete and transitive preferences. These methods include linear additive 
methods, multi-attribute value theory (MAVT) methods for deterministic consequences, and 
multi-attribute utility theory (MAUT) methods. 
I suggest the use of MAVT methods because of their comprehensiveness and 
methodological robustness54, as well as their ability to reduce ambiguity and motivational 
biases. This is in consistency with recent work on good practices for MCDA in Health Care 
Decisions 200. The MAVT methods framework adheres to a number of phases and stages and 
includes (1) the deﬁnition of objectives, (2) the selection of criteria, (3) the scoring of 
options, and (4) the assignment of weights to the selected criteria. 
The choice of technique that will inform parts of the process, including scoring, 
weighing and aggregation, is an important decision. Under MAVT methods, partial value 
functions for individual criteria are constructed in the ﬁrst instance and are subsequently 
aggregated. Essentially, value functions reﬂect decision-makers’ preferences for different 
levels of performance on the attribute scale (Figure 4.1). Importantly, the assumptions 
required for the formation of the partial value functions are interlinked with the aggregation 
type of technique used. In the sections that follow, I present and discuss these fundamental 
principles in the context of healthcare decision-making and use examples to illustrate their 
application and interpretation. 
 
 
 
 
 
 
Figure 3.1: Value function for scoring the performance of alternative options 
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3.2.3 MCDA Phases under MAVT Methods 
While the general features of MCDA phases have already been discussed elsewhere 2, the 
MCDA process could be divided into ﬁve distinct phases in the context of HTA; these would 
be (1) problem structuring, (2) model building, (3) model assessment, (4) model appraisal, 
and (5) development of action plans (Figure 4.2). These phases, and especially model 
building stages, are taking place in an iterative and constructive way rather than being 
linearly followed. 
Problem structuring involves an understanding of the problem to be addressed. This 
includes key concerns, envisaged goals, relevant stakeholders that may participate in or 
contribute to decisions, and identiﬁcation of uncertainties in terms of a new technology’s 
clinical evidence and its quality. 
The phases of model building, model assessment and model appraisal involve the 
construction of decision-makers’ value judgements within and across the criteria of interest, 
while being consistent with a set of assumptions, aiming to help decision-makers elicit and 
order their preferences across the alternative options evaluated. For example, if overall 
survival (OS) is a criterion, then the respective value associated with a range of plausible 
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incremental OS gains (e.g. 3, 6, 9, or more months) is of interest to know and so is the 
intensity with which stake- holders would prefer certain changes within the attribute range 
(e.g. an increase in OS from 3 to 6 months could be of greater value to some stakeholders 
than an increase in OS from 6 to 9 months) (Figure 4.1). 
Finally, given that the outcome of the analysis needs to inform decision-making, 
action plans need to be shaped involving a clear pathway for result implementation. In the 
case of HTA, this could involve prioritising resource allocation as part of coverage decisions 
that take place following the evaluation of new medical technologies. 
Although these ﬁve phases are presented as part of a linear process, in reality they 
could be part of an iterative process, moving from a later step back to a previous step before 
advancing. For example, as part of the model assessment phase, it could become evident that 
some of the criteria do not possess all the required properties, in which case the model should 
be adapted accordingly as part of the model-building phase. 
 
3.2.4 MCDA Stages under MAVT Methods 
3.2.4.1 Problem structuring 
Each MCDA phase comprises a number of stages (Figure 4.2). Initially, as part of the 
problem-structuring phase, the decision context needs to be established where the problem 
under investigation and the aims of the analysis are clearly outlined and deﬁned, and relevant 
decision-makers and other key stakeholders are identiﬁed. For example, in the context of 
VBA of a new technology, the decision problem may be to assess the new technology’s 
beneﬁts and costs from a broader societal perspective relative to other therapeutic 
alternatives to identify the most valuable treatment for a health system. The decision-makers 
in this context would be payers or insurers (including commissioners of care), whereas 
healthcare professionals, patients and their carers, technology suppliers and methodology 
experts, including decision-analysis experts conducting and coordinating the MCDA 
process, would be the relevant stakeholders. The process of identifying the appropriate 
decision-makers and stakeholders would be speciﬁc to the country or setting. This particular 
phase could be conducted by researchers or, alternatively, an HTA agency in settings where 
such an agency exists. 
Figure 3.2: Multiple criteria decision analysis (MCDA) methodological process in the context of health technology assessment 
 
3.2.4.2 Model building 
Subsequently, as part of the model-building phase, objectives need to be established and/or 
relevant criteria identiﬁed to reﬂect decision-makers’ goals and areas of concern. 
Additionally, attributes need to be selected to operationalise these criteria and enable their 
assessment. This involves a deliberative process in order to obtain a good understanding of 
the decision problem and what decision-makers want to achieve (objectives), through which 
the values of concern (criteria) will eventually emerge. The assessment takes place based on 
the selected criteria and attributes. For example, when evaluating a new medical technology 
relative to an older one, criteria from a number of domains could be selected, such as 
therapeutic beneﬁt, safety proﬁle, burden of illness, innovation level and socioeconomic 
impact 192,201. In principle, these criteria domains would emerge from decision-makers’ 
values of concern; in practice, they could be identiﬁed from the literature in combination 
with semi-structured interviews with decision-makers. Quality of evidence, mainly relating 
to relevance and validity of the available evidence, is another crucial parameter that should 
be considered. This phase could be carried out by MCDA researchers in collaboration with 
the decision-makers and possibly stakeholders whose value concerns should be considered. 
As part of the model-building phase, the alternative options need to be selected, and 
evidence on their performance across criteria/attributes needs to be identiﬁed. For example, 
the treatment alternatives for a particular disease must be identiﬁed and data on expected or 
observed performance across criteria must be collected, either through secondary research 
(e.g. from published randomised controlled trial results) or through primary research if data 
are not available from secondary sources (e.g. clinical or patient opinion). Following the 
completion of this stage, attribute ranges will be set based on the performance of the 
alternative treatment options that shall inform the next stages of the process. Depending on 
the technique used, plausible attribute ranges can be set by taking into account any pre-
existing preferences of decision-makers in relation to maximum and minimum allowable 
performance levels on the different criteria. For example, the OS gains of three different 
treatments could range from 2 to 12 months, and therefore the respective attribute range 
should be broad enough to include all these gains (i.e. at least from 2 to 12 months). It could 
also be the case that the decision-maker is not willing to consider any treatments offering 
incremental OS gains of less than 3 months; in this instance, the attribute range could be 
rescaled and adapted to decision-makers’ revealed preferences (i.e. to range from a minimum 
66 
 
of 3 months upwards), with the treatment option offering 2 months of OS excluded from the 
analysis. 
 
3.2.4.3 Model assessment  
In the context of the model-assessment phase, the performance of options against the 
identiﬁed criteria must be assessed (i.e. scoring, which delivers intra-criteria information), 
and criteria must be weighed according to their relative importance (i.e. weighing, which 
delivers inter-criteria information), revealing preferences for different levels of performance 
within criteria and across different criteria, respectively. In the case of the OS example, a 
numerical value score would be assigned to the options being evaluated with regards to their 
performance on OS gains. As part of MAVT methods, the construction of value functions 
can take place through different techniques (direct rating, indirect, bisection techniques). All 
require the deﬁnition of attribute reference levels that will form the minimum and maximum 
points of the value scale. Although the two limits of the attribute range are usually assigned 
a value of 0 and 100, reﬂecting the minimum and maximum points of the value scale, 
respectively, other reference points can also be used. Using the OS example, 3 months could 
be used as the lower reference level and 12 months as the higher reference level, making up 
the 0 and 100 points of the value scale, respectively. The attribute performance of the options 
can then be assessed indirectly through the use of the value functions that will convert their 
performance into value scores (Figure 4.1). The process of scoring and weighing completes 
the construction of value judgements. 
A critical aspect in the entire process is the relative importance of the different criteria 
to decision-makers. For this reason, relative weights are assigned to the criteria by directly 
involving decision-makers and stakeholders. For example, in the case of a new drug–
indication pair, the importance of the therapeutic beneﬁts vis-a`-vis an existing therapeutic 
alternative (e.g. OS gain and quality-of-life improvement) could be found to be twice as 
important as its safety impact (e.g. adverse events); therefore, the relative weight of the 
therapeutic cluster of criteria would be twice as high as the product’s safety proﬁle. These 
weights should only be viewed as scaling constants or trade-off factors, with no algebraic 
meaning, assigned to enable comparability across criteria to reﬂect their relative importance. 
Methodologically, and contrary to what has been argued elsewhere 90,194, I would 
argue that it is important for the criteria weights to be derived ex-post following the selection 
of the alternative treatments and therefore the formation of the attribute ranges, rather than 
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ex-ante 202. Theoretically, this is tantamount to arguing for MAVT models, where the 
construction of value functions precedes the criteria weights, rather than for direct rating 
methods, where weights are ﬁrst attached, based on an ex-ante derivation, and the options 
are then scored. Conceptually, my preference for the ex-post derivation of weights is justiﬁed 
by the nature of health technologies and the conditions they treat: the relative importance of 
different criteria and, therefore, their respective weights are context speciﬁc and depend on 
the performance of the alternative options in a given context. By means of an example, 
assume that for two treatments (A and B), weights need to be established for the same criteria 
(OS and hepatotoxicity), measured through ‘number of months gained’ and ‘incidence of 
hepatotoxicity’, respectively. The weight assigned to each criterion is very likely to be 
different if treatment A and B range between 1 and 10 months (1,10 months) in OS and from 
10 to 11 % (10,11 %) in hepatotoxicity, compared to the scenario that they range between 
10 and 11 months (10,11) and from 1 to 10 % (1,10 %), respectively. 
 
3.2.4.4 Model appraisal 
As part of the appraisal phase, scores and weights are combined to create a value index 
(‘aggregating’). The details of this step may differ according to the type of aggregation 
model used, to include additive or multiplicative value models depending on the level of 
preference independence present among criteria. Empirical evidence suggests that errors due 
to the use of additive value aggregation models are in real settings very small and 
considerably smaller than the errors associated with the wrong aggregation of partial value 
functions that can possibly result from the incorrect application of more advanced models2. 
Overall, the individual criteria scores and their respective weights are combined to 
produce weighted scores and are summed to arrive at an overall value score for each 
treatment option. In combination with sensitivity analysis, results are examined to determine 
the robustness of the results obtained. The outcome of this process is a ranking of all 
treatment options based on their respective value scores. Decision-makers can use this 
evidence to make resource-allocation decisions. Throughout the MCDA stages, including 
scoring and weighing, the participating stakeholders are able to interact to exchange views, 
reach consensus or simply provide their individual preferences 2. To that end, they can 
compare their individual views and preferences, they can aggregate such preferences by 
voting to reach consensus, or they can share commonly deﬁned modelling and judgement 
elements after joint discussion. 
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3.2.5 MCDA Techniques Using MAVT Methods 
Several MCDA techniques are available with regards to scoring, weighing and aggregating. 
These techniques mainly relate to the value judgement and preference-elicitation processes, 
and the choice of technique depends on the particular type of method adopted 1,195-197. As 
part of MAVT methods, the value functions based on which options are scored can be 
constructed using different options: (1) direct rating techniques, (2) indirect techniques, and 
(3) indifference or bisection techniques 2,54. Direct rating techniques involve decisions 
around the form of the value function and whether they increase monotonically (highest 
attribute level is the most preferred), decrease monotonically (lowest attribute level is the 
most preferred), or range non-monotonically (an intermediate attribute level is the most 
preferred). 
Indirect techniques generally assume a monotonic function and involve a series of 
questions aiming to uncover decision-makers’ preferences by considering differences in the 
attribute scale and their relation to the value scale. Indifference techniques explore the 
magnitude of increments in the attribute scale that correspond to equal units in the value 
(preference) scale. Finally, bisection techniques explore the estimation of points on the 
attribute scale that serve as midpoints on the value (preference) scale. 
I would suggest the use of indirect elicitation techniques because of their 
comprehensiveness and unbiased nature. This is mainly because decision-makers’ intra-
criterion preferences are ﬁrst elicited for the attribute range, producing a transparent 
valuation relationhsip across the performance of the options and a value scale. Options are 
then scored indirectly using the attributes’ emerging value functions to convert the 
performance of the options into value scores, without revealing any information about the 
identity of the respective options at any point during the process. In the case of decision 
contexts requiring repeat decisions, indirect MAVT techniques making use of value 
functions are recommended in order to ensure the efficient and consistent scoring of 
alternatives as they become available for evaluation 200.  
An example of such an indirect technique is MACBETH (Measuring Attractiveness 
by a Categorical Based Evaluation Technique), a convenient indirect approach to elicit value 
functions by only requiring qualitative judgements about the difference of value between 
different pairs of attribute levels 203. It uses seven semantic categories to distinguish between 
the value or attractiveness of different attribute levels, ranging between ‘‘no difference in 
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value’’ and ‘‘extreme difference in value’’. Overall, it builds a quantitative model of values 
based on qualitative (verbal) difference judgements, and by analysing judgmental 
inconsistencies, it facilitates the move from ordinal preference modelling to cardinal 
preference modelling. 
Once criteria have been scored and value functions have been derived, criteria 
weights can be elicited, usually through a swing weighting technique. Finally, criteria scores 
and weights are combined, usually through an additive aggregation approach. 
 
3.3 Model-Building and the Construction of a Value Tree: Properties to Ensure a 
Robust MCDA Model 
Model building is one of the most important MCDA phases. Establishing objectives and 
deﬁning the actual criteria and attributes are critical stages in this context because they form 
the foundation of MCDA. For the analysis to be robust and, ultimately, meaningful, I outline 
a number of properties to which criteria and attributes should adhere. 
 
3.3.1 Objectives, Criteria and Attributes in the Context of Model Building 
Depending on the decision problem under consideration, the term ‘objective’ or ‘criterion’ 
may be preferred over the other, both representing key factors that form the basis of the 
analysis. The main difference between the two is that ‘objectives’ usually reﬂect a direction 
of preference, whereas ‘criteria’ do not. Objectives and criteria may be further decomposed 
into sub-objectives and sub-criteria; structuring all objectives and/or criteria in the form of a 
tree offers an organised overview of the values under consideration. This is known as a value 
tree. The quantitative or qualitative performance measures associated with criteria or 
objectives are known as ‘attributes’. Attributes operationalise the use of criteria and 
objectives by measuring the extent to which criteria or objectives are achieved. For example, 
in the context of a new cancer treatment, an objective for decision-makers could be to 
‘maximise life expectancy’; ‘overall survival’ could act as a criterion, while ‘median number 
of months from randomisation to death’ could be the relevant attribute (Figure 4.3). 
It is not uncommon for a criterion to require more than a single attribute to be 
measured adequately. For example, in the case of ‘tolerability’ as part of a new drug’s safety 
proﬁle, decision-makers could benchmark against the ‘proportion of patients discontinuing 
the treatment’ as well as the ‘proportion of patients interrupting treatment or reducing the 
70 
 
dose due to adverse events’. Other examples of value tree hierarchies—made up of criteria 
and attributes—together with their respective data sources are shown in Figure 4.3. 
Depending on the type of decision problem, the selection of objectives, criteria and 
attributes can either precede or follow the identiﬁcation of the alternative options as part of 
different methodological approaches (Table 4.1) 2,3,204. In the context of the “value- focused 
thinking” approach, objectives and criteria are selected prior to specifying or assessing the 
alternative options, thus being part of a top-down manner for structuring a value tree 
according to which overall objectives or criteria are decomposed into sub-objectives or sub-
criteria 3. Alternatively, in accordance with the more traditional “alternative focused 
thinking” methodology, a bottom-up approach can be implemented whereby objectives and 
criteria emerge following the comparison of the options, based on distinguishable attributes 
that differentiate them 204. 
In the context of HTA, a “value-alternative hybrid thinking” logic that contains 
elements from both methodological approaches could be adopted. Decision-makers could 
have a generic set of predetermined objectives and criteria reﬂecting their values of concern 
in a top-down approach. These could then be adapted for the purposes of the decision-
making problem in a bottom-up approach. Thus, the general values of concern would be 
tailor made in a dynamic manner to better assess the differences of alter- native treatments 
being compared. For example, decision-makers’ concerns could normally include the 
existence of any contraindications or warnings and precautions associated with a drug for 
the indicated patient population of interest. However, it is possible for all alternative 
treatments evaluated for a particular disease to have no contraindications and to have 
identical minor warnings and precautions for use. These criteria could therefore be excluded 
from that particular assessment in order to be concise. 
 
 
Figure 3.3: Value tree hierarchies and data sources using a multiple criteria decision analysis (MCDA) process for value assessment 
Table 3.1: Different methodological approaches for selecting objectives and criteria 
Approach “Value 
focused thinking” 3 
“Alternative 
focused thinking” 
204 
“Value alternative 
hybrid thinking” 
Decription Objectives and 
criteria selected 
first prior the 
identification or 
assessment of the 
alternative options 
Options first 
compared so that 
objectives and 
criteria emerge 
based on their 
attributes 
Generic set of 
objectives and 
criteria created first 
which then 
becomes adapted 
for the particular 
decision problem  
Value tree 
formation 
Top-down 
approach 
Bottom-up 
approach 
Top-down followed 
by bottom-up  
 
3.3.2 Key Criteria Properties 
In order for the analysis to provide the highest possible insight and to enhance its actual 
value to decision-makers, both criteria and attributes need to adhere to a number of key 
properties 3,204-206. If they do not, the results obtained through scoring and weighing could 
be spurious and, therefore, meaningless for decision-making. First, objectives or criteria 
need to be essential, in that all necessary objectives of the decision problem should be 
considered, and all the critical values under consideration should be included through the 
incorporation of the respective criteria. In the context of a value tree, all therapeutic, safety, 
burden of illness, innovation and socioeconomic criteria should be included in the model. 
Second, criteria need to be understandable, so that all participants in the decision- making 
process have a clear understanding of them and their implications. Third, criteria need to be 
operational; namely, the performance of the options against the criteria should be 
measurable. Fourth, it is crucial that criteria are non-redundant, i.e. there should be no 
overlap or double counting between the different criteria, otherwise the elicited criteria 
weights would not be accurate and, consequently the overall results would be misleading. 
Finally, criteria need to be concise and only the smallest set that can adequately capture the 
decision problem should be used, striving for simplicity and parsimony, rather than 
complexity. 
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The aggregation stage is very important because it produces the overall value scores 
of the alternative options. In order to enable the use of simple aggregation rules (e.g. additive 
value models, where scores and weights of the different individual criteria are multiplied 
and then added altogether in a weighted average manner), preference independence between 
the different criteria needs to be upheld 2 (see section 1.1.4).  
 
3.3.3 Key Attribute Properties 
For selected attributes to be adequate or meaningful, sufﬁcient properties require them to be 
unambiguous (in that a clear relationship should exist between the consequences of an option 
and the levels of attribute used to describe these consequences), comprehensive (the attribute 
levels should cover the full range of consequences), direct (the attribute levels should 
describe the consequences of alternative options as directly as possible), operational 
(information required for the attributes should be collectible in practice and value trade-offs 
- between the objectives or criteria - can be made), and understandable (the consequences 
and value trade-offs can be readily understood and communicated across the decision-
makers and other stakeholders by using the attribute) 206. For an additive value model to be 
used, attributes should be preference independent (see section 1.1.4). 
A suggested systematic methodology for selecting the best possible attributes 
initially involves an aim for a single natural attribute, namely one that is in general use and 
has a common interpretation measuring directly the degree to which an objective or a 
criterion is met. If no such single attribute is appropriate then a set (i.e. more than one) of 
natural attributes should be considered that adequately describe objective/criteria 
consequences. If this is not possible, exploration of ‘constructing’ attributes that directly 
measure consequences should be attempted. Such attributes are explicitly developed to 
measure directly the achievement of an objective. A proxy attribute, i.e. a less informative 
attribute that indirectly measures a criterion of concern, should be selected only after careful 
consideration and following the elimination of constructed attributes 206. 
 
3.4 ‘Incremental’ Versus ‘Clean Slate’ MCDA Approaches and Link to Policy 
Making 
The application of MCDA in current HTA practices has been criticised partly because 
criteria should be perceived as attributes of beneﬁt and the fact that cost and uncertainty or 
quality of evidence cannot be accounted for as beneﬁts 207. In turn, costs can be considered 
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by incorporating the ‘impact on costs’ as a criterion, other than the purchasing cost of the 
treatment itself, which is essentially looking at savings or increased outlays. Poor quality of 
evidence could be addressed through the incorporation of penalty functions that may be 
added when signiﬁcant uncertainty exists, reducing the performance scores of relevant 
options. For example, if the clinical data relating to an OS gain are regarded as highly 
uncertain for any reasons relating to the external and/or internal validity of the clinical 
trial/data, then the performance score of the observed OS gain for the particular treatment 
could be reduced by a signiﬁcant factor, e.g. 25–50 %, based on expert opinion. However, 
the use of penalty functions might be incompatible with the use of an additive model and 
therefore should be used with caution, as for example within descriptors of performance.  As 
identiﬁed through a recent review, a number of other formal approaches also exist to quantify 
and incorporate uncertainty when conducting MCDA for healthcare decisions, the most 
commonly used being fuzzy set theory, probabilistic sensitivity analysis, deterministic 
sensitivity analysis, Bayesian framework and grey theory 208. 
Another consideration relates to the appropriate process of eliciting weights, and the 
argument that if they are to emerge during the decision-making process it will prove difﬁcult 
to achieve predictability, consistency and accountability, but also that scientiﬁc and social 
value judgements might become mixed and prone to strategic behaviour, with pre-speciﬁed 
weights being the way forward 207. Indeed, producing global weights that are applicable 
across all decision contexts would seem a very challenging task; however, weights elicited 
ex-ante would be hardly accurate in capturing the precise trade-offs under consideration for 
the reasons discussed in Section 2.2.3. By contrast, eliciting weights ex-post would be more 
reﬂective of decision-maker preferences and less susceptible to strategic manipulation; 
however, their application would be mostly restricted at a local decision context. A further 
source of criticism stems from the question of what attributes of beneﬁt are lost due to 
additional cost and whether these attributes of beneﬁt foregone can be accounted for by 
including the incremental cost-effectiveness ratios (ICERs) as criteria 207. Given that cost 
effectiveness and cost are not attributes of beneﬁt, one would need to know what additional 
costs are required to improve the composite measure of beneﬁt and what attributes of beneﬁt 
will be given up as a consequence of costs. 
Some of the above criticisms arise chieﬂy when MCDA is applied as a 
‘supplementary’ approach to CEA to adjust the ICER by incorporating additional parameters 
of value. Instead, some of the above criticisms could in theory  be overcome by using a 
‘pure’ MCDA approach to derive value without the use of CEA (also described as 
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‘incremental’ and ‘clean slate’ approaches, respectively 191). In any case, further research 
would be needed to fully address some of the remaining practical limitations. 
The aggregate metric of value emerging from the MCDA process (the value index) 
is more encompassing in nature, as multiple evaluation criteria are incorporated in the 
analysis. By adopting this value index metric as the beneﬁt component and incorporating the 
purchasing cost of the different options, the cost per incremental MCDA value unit gained, 
i.e. the incremental cost value ratio(s) (ICVR), could act as the basis of allocating resources 
in a way comparable to that of an ICER; for instance, options with lower ICVRs would be 
interpreted as more valuable and could be prioritised versus options with higher ICVRs. 
Based on this approach, issues relating to the deﬁnition of efﬁciency through the 
establishment of thresholds that reﬂect opportunity costs would still need to be addressed; 
however, they lie outside the scope of this paper. 
The resulting value index scores would be context speciﬁc, reﬂecting stakeholder 
preferences: the value index incorporates value judgements and preferences for a set of 
options based on a group of criteria, all of which can be informed through stakeholder input. 
Unless identical value judgements and preferences are assumed for the same group of 
criteria, a value score for an option in one setting could be different from that in another 
setting. The MCDA process, as proposed in this paper, respects stakeholder preferences in 
individual settings, whilst reducing decision-making inconsistency by introducing clarity, 
objectivity and greater transparency about the criteria based on which decisions can be 
shaped. 
 
3.5 Conclusion 
I have proposed a methodological process, with different phases and stages, outlining the 
use of MCDA in the context of HTA based on MAVT methods. Although a variety of 
MCDA techniques exist, it is likely that the most important stages that act as the foundations 
to the analysis are the establishment of objectives and the deﬁnition of criteria and attributes. 
I have focused on best practice requirements, as reﬂected through the appropriate properties 
needed for criteria and attribute selection, all of which feed into the model-building phase. 
Compared with economic evaluation techniques, such as CEA, HTA through MCDA 
is found to have a number of important advantages. These include the multitude of criteria 
that can be used to assess value, the explicit weights that are assigned to reﬂect differences 
in the relative importance of the criteria, the extensive stakeholder engagement across all 
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stages and the transparent nature of the MCDA process, leading to a ﬂexible and 
encompassing approach to value assessment and appraisal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 – Paper 2 
Evaluation Criteria and Decision-Making Practices in Health Technology 
Assessment: a Systematic Review and Expert Consultation across 8 EU 
countries7 
 
                                                 
7 Chapter 4 has been published with co-authors Dr Ansgar Lange and Prof Panos Kanavos as: Angelis 
A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: 
results of a systematic review and expert consultation across eight European countries. Eur J Health 
Econ (2017). In press; doi:10.1007/s10198-017-0871-0   
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Summary 
Although health technology assessment (HTA) systems base their decision-making process 
either on economic evaluations or comparative clinical benefit assessment, a central aim of 
recent approaches to value measurement, including value based assessment and pricing, 
points towards the incorporation of supplementary evidence and criteria that capture 
additional dimensions of value.   
The aim of this chapter is to study the practices, processes and policies of value-
assessment for new medicines across eight European countries and the role of HTA beyond 
economic evaluation and clinical benefit assessment. A systematic (peer review and grey) 
literature review was conducted using an analytical framework examining: (a) 
‘Responsibilities and structure of HTA agencies’; (b) ‘Evidence and evaluation criteria 
considered in HTAs’; (c) ‘Methods and techniques applied in HTAs’; and (d) ‘Outcomes 
and implementation of HTAs’. Study countries were France, Germany, England, Sweden, 
Italy, Netherlands, Poland and Spain, so that the sample is representative of different health 
systems and HTA approaches across Europe. Evidence from the literature was validated and 
updated through two rounds of feedback involving primary data collection from national 
experts.   
All countries assess similar types of evidence, however the specific criteria/endpoints 
used, their level of provision and requirement and the way they are incorporated (e.g. 
explicitly vs. implicitly) varies across countries, with their relative importance remaining 
generally unknown. Incorporation of additional ‘social value judgements’ (beyond clinical 
benefit assessment) and economic evaluation could help explain heterogeneity in coverage 
recommendations and inconsistency in decision-making.   
More comprehensive and systematic assessment procedures characterised by 
increased transparency in terms of selection of evaluation criteria, their importance and their 
intensity of use could lead to more rational evidence-based decision-making, possibly 
resulting in the improvement of efficiency in resource allocation, while also raising public 
confidence and fairness. 
 
4.1 Background  
Current value assessment and appraisal approaches of medical technologies using economic 
evaluation or adopting comparative clinical benefit assessment in order to inform coverage 
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decisions and improve efficiency in resource allocation have been subject to criticism for a 
number of reasons.  
Most health technology assessment (HTA) systems base their decision-making 
process on cost per outcome metrics of economic evaluations as, for example, the cost per 
QALY 180. However a key limitation of the QALY approach is the inadequacy of capturing 
social value that goes beyond clinical outcome and cost 209-211. It is clear that a central aim 
of more recent approaches to value measurement, including value based assessment and 
value based pricing, may need to incorporate other parameters that capture different or 
additional dimensions of value into the overall valuation scheme 145,212. Although in different 
HTA settings a number of additional criteria beyond scientific value judgements are 
incorporated to assess the evidence submitted and inform coverage decisions 213, their use 
remains implicit or ad hoc rather than explicit. 
  Another drawback is caused through the way which value is assessed and appraised, 
often resulting in unexplained heterogeneity of coverage decisions across settings even for 
the same drug-indication pair 158-160,214-217. Although some of this decision-making 
differentiation can be justified on the grounds of different budget constraints and national 
priorities, inconsistencies of medicines’ eligibility for reimbursement across countries give 
rise to an international ‘post-code’ lottery for medicines access even in the same 
geographical region, with important implications for equity and fairness especially when 
differences remain unexplained 215. Several studies have acknowledged the need for well-
defined decision-making processes that are fairer and more explicit 218-220. By ensuring 
‘accountability for reasonableness’ and providing a better understanding of the rationale 
behind decision-making, decisions will also have enhanced legitimacy and acceptability 
19,216.  
By reviewing and synthesising the evidentiary requirements (both explicit and 
implicit), the methods and techniques applied and how they lead to decisions, the objective 
of this study is to provide a critical review of value assessment and appraisal methods for 
new medicines including the evaluation criteria employed, across a number of jurisdictions 
in Europe that employ explicit evaluation frameworks as part of their HTA processes. In 
more detail, the study seeks to determine whether HTA processes incorporate additional 
criteria beyond economic evaluation or clinical benefit assessment and, if so, which ones 
and how they inform coverage recommendations. To my knowledge, to date no study has 
provided a similar review and analysis of HTA policies and practices for innovative 
medicines across different European countries to this extent. In fulfilling the above aims, the 
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next section outlines the methods and includes the components of the analytical framework 
adopted for this purpose; subsequently, the evidence collected from eight European countries 
is presented and discussed, before presenting the policy implications.  
 
4.2 Methods 
An analytical framework is adopted to facilitate the systematic review of HTA processes and 
capture their salient features across settings following previous evidence 221. Based on that, 
the relevant evidence was collected relying both on primary and secondary sources. The 
evidence base covered eight EU Member States that have arms-length HTA bodies and 
recognised HTA processes. The study took place in the context of Advance-HTA, an EU-
funded project aiming to contribute to advances in the methods and practices for HTA in 
European and elsewhere 222. 
Secondary sources of evidence comprised a systematic review of the country-specific 
value-assessment peer review literature using the newly adapted analytical framework to 
investigate the practices, processes and policies of value-assessment and their impact, as 
observed in the study countries.  
Evidence from the literature was validated by means of two rounds of feedback 
involving primary data collection: the first was from Advance-HTA consortium partners 222, 
while the second involved a detailed validation of the study’s results by national experts 
following the incorporation of all literature results and feedback from Advance-HTA 
partners.  
4.2.1 Analytical Framework Outlining the Components of a Value Assessment Framework  
Existing frameworks for analysing and classifying coverage decision-making systems for 
health technologies were reviewed and adjusted according to the needs of the current 
examination which focuses on the assessment and appraisal stages of the coverage review 
procedure from the HTA institution’s point of view, without having a special interest on the 
decision outcomes per se, or their translation into reimbursement decisions 223-225.  
The main value assessment characteristics necessary to outline the practices and processes 
different countries of interest as reflected through their HTA bodies were classified using 
four key components, each of them having a number of different (sub-) components: (a) 
‘Responsibilities and structure of HTA agencies’; (b) ‘Evidence and evaluation criteria 
considered in HTAs’; (c) ‘Methods and techniques applied in HTAs’; and (d) ‘Outcomes 
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and implementation of HTAs’ were considered to be the main components needed in order 
to sufficiently capture the features of the different value assessment systems.  
In the context of the study the second component, (b), carried greater weight because 
a key subject of the investigation was to explore and analyse the different evaluation criteria 
beyond those informing economic evaluations or clinical benefit assessment. The sub-
components of the main components are described below and are shown in Figure 4.1. 
 
Figure 4.1: Main components and sub-components of the analytical framework applied 
 
 
4.2.1.1 Responsibilities and structure of national HTA agencies 
This component considers the operational characteristics of HTA agencies. It includes 
details about the function and responsibilities of HTA bodies, the relevant committees within 
agencies tasked with assessment and appraisal, details on the topic selection process, and 
whether methodological guidelines exist for the conduct of pharmacoeconomic analysis. 
 
4.2.1.2 Evidence and evaluation criteria considered in HTAs 
This component relates to the types of evidence evaluated and the particular evaluation 
criteria considered. Generally, the assessed evidence can be classified into features relating 
to the disease (indication) under consideration, or into characteristics relating to the 
technology being assessed. The former is reflected through ‘Burden of Disease’ (BoD), i.e. 
the impact that the disease has, which mainly depends on the severity of the disease and the 
unmet medical need. The latter group of a technology’s characteristics can be classified into 
clinical benefit (mainly therapeutic impact and safety considerations), innovation (e.g. 
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clinical novelty and nature of treatment), and socioeconomic impact (e.g. public health 
impact, productivity loss impact) categories. Other characteristics relating to efficiency (e.g. 
cost-effectiveness, cost), ethical/equity considerations, accepted data sources, and relative 
importance (i.e. weighting) of the evidence are also listed.  
 
4.2.1.3 Methods and techniques applied in HTAs 
This component is associated with the evaluation methods and techniques used. In terms of 
the analytical methods applied (i.e. comparative efficacy/effectiveness, type of economic 
evaluation), methodologies differ according to their outcome measure and their elicitation 
technique, the choice of the comparator(s), and the perspective adopted. In relation to the 
clinical evidence used to populate the analysis, crucial details involve preferred data sources 
(i.e. study designs), data collection approaches (e.g. requirement for systematic literature 
reviews) and synthesis (e.g. suggestion for meta-analysis) of the data. In terms of resources 
used, important specifics include the types of costs included and data sources used. For both 
clinical outcomes and costs, discount rate(s) applied and time horizons assumed are 
included, together with the existence of any explicit or implicit cost-effectiveness thresholds 
based on which decisions are made. 
 
4.2.1.4 Outcomes and implementation of HTAs 
The final component relates to the outcomes of the evaluation procedures and their 
implementation. Key characteristics include the public availability of the evaluation report, 
the policy implications and whether outcomes are applied in practice (e.g. pricing vs. 
reimbursement), the usage of any access restrictions, how are decisions disseminated and 
implemented, whether appeal procedures are available and the frequency of decision 
revisions. 
 
4.2.2 Systematic Literature Review  
The systematic literature review methodology was based on the Centre for Review and 
Dissemination (CRD) guidance for undertaking systematic reviews in health care 226.  
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4.2.2.1 Inclusion criteria (country selection and study period) 
The study countries (and the respective agencies) were France (Haute Autorité de Santé, 
HAS), Germany (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG), 
Sweden (Tandvårds- och läkemedelsförmånsverket, TLV), England (National Institute for 
Health and Care Excellence, NICE), Italy8 (Agenzia Italiana del Farmaco, AIFA), 
Netherlands (Zorginstituut Nederland , ZIN (formerly College voor zorgverzekeringen, 
CVZ)), Poland (The Agency for Health Technology Assessment and Tariff System, 
AOTMiT) and Spain (Red de Agencias de Evaluación de Tecnologías Sanitarias y 
Prestaciones del Sistema Nacional de Salud (RedETS) and the Interministerial Committee 
for Pricing (ICP)) 9. The study countries were selected because of the variation in their health 
system financing (tax-based vs. social insurance-based), the organisation the health care 
system (central vs. regional organisation), the type of HTA in place (predominantly 
economic evaluation vs. predominantly clinical benefit assessment) and the perspective used 
in HTA (health system vs societal), so that the sample is representative of different health 
systems and HTA approaches across Europe.  
The study period for inclusion of relevant published studies was from January 2000 
to January 2014, with article searches taking place in February 2013 in the first instance and 
an update taking place at the end of January 2014. The year of 2000 was selected as the start 
date because the HTA activity of most countries started or significantly expanded in scope 
since then. Feedback from the Advance-HTA consortium partners was provided in August 
2014. Additional input, including the most recent updates on national HTA processes, was 
also collected from HTA experts and national competent authorities. 
 
4.2.2.2 Identification of evidence 
The electronic databases of MEDLINE (through PubMed resource) and Social Science 
Citation Index (through Web of Science portal) were searched for peer review literature only 
using a search strategy for English articles published up until the time of the literature search 
(including all results from the oldest to the latest available) using the following keywords: 
                                                 
8 Other HTA bodies exist on regional level (e.g. UVEF is responsible for HTAs in the Veneto region). 
9 RedETS is the Spanish Network of regional HTA agencies coordinated by Instituto de Salud Carlos III 
(ISCIII) and could be regarded as the National HTA advisory body at central level. However at national level 
it does not assess pharmaceuticals but mostly non-drug health technologies such as screening programmes and 
medical devices. Instead, the Interministerial Committee for Pricing (ICP), led by the Dirección General de 
Farmacia under the Ministry of Health, is the committee responsible for the assessment of drugs, producing 
mandatory decisions at national level regarding the reimbursement and pricing of pharmaceuticals. 
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‘health technology assessment + pharmaceuticals’; ‘health technology assessment + 
methodologies’; ‘value assessment + pharmaceuticals’; ‘value assessment + methodologies’.  
In addition, reference lists from the studies selected were screened (see below, ‘study 
selection & data extraction’), retrieving any additional studies that could be potentially 
relevant.  Furthermore, grey literature was searched including published guidelines from the 
HTA bodies available online through each agency’s website.   
 
4.2.2.3 Study selection & data extraction 
Articles were selected according to a four-stage process as outlined in Figure 4.2 226. As part 
of the first stage, all titles and abstracts were reviewed, with abstracts not relevant to the 
topic excluded; in cases where content relevance could not be determined articles were 
passed through the next stage. In the second stage, all relevant abstracts were assessed 
against a number of pre-determined selection criteria; these included: i) language (only 
English articles included), ii) study country (only studies examining the eight countries of 
interest included), iii) study context (only national coverage HTA perspectives included), iv) 
study type (product-specific technology appraisal reports were excluded), v) record type 
(conference proceedings or titles with no abstracts available were excluded). In the third 
stage, full articles for all abstracts meeting the eligibility criteria were retrieved; in addition, 
relevant studies identified from reference screening and grey literature, including published 
guidelines from HTA agencies, were incorporated (non-English articles cited by English 
documents were included at this stage). Finally, in the fourth stage full articles were 
reviewed and relevant data were extracted. An Excel template listing the value assessment 
components (categories and sub-categories) of interest was used for data extraction. Data 
were extracted in free text form, with no limitations on the number of free text fields and as 
little categorisation of data as possible, in order to avoid loss of information.  
4.2.3 Expert Consultation 
Upon consultation of the preliminary results with the partners of the Advance-HTA project 
consortium, it became obvious that in a few cases (primarily in France and, to a lesser degree 
in Sweden), the evidence from the peer review literature did not reflect actual practices being 
even contradictory in some cases. As a result, comments and feedback were solicited from 
the project’s consortium partners. Finally, updated results tables were subsequently shared 
with HTA experts in the study countries which were asked to review and validate the outputs 
of the study. Experts were affiliated with academic research institutions or national 
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competent authorities and provided further evidence and guidance, including additional 
literature sources outside the originally selected review period, if applicable. Experts’ inputs 
from these two rounds of consultation are quoted as personal communications from the 
Advance-HTA project 227.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Flow chart of the systematic literature review process 
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4.3 Results  
Figure 4.2 shows a flow chart of the review process and the resulting number of articles in 
each stage. In total, 2778 potentially eligible peer review articles were identified in the 
electronic databases and 255 articles were identified as potentially useful and were read in 
full. Of these, 130 articles met the eligibility criteria and an additional 18 articles were 
identified as possibly relevant through reference screening and grey literature.  The content 
of 101 articles from the literature review was finally used to inform the findings 
65,76,124,131,216,224,228-321.  An additional five studies were identified during the expert 
consultation process and were taken into consideration in discussing and interpreting the 
results 322-326.  
 
4.3.1 Responsibilities and Structure of National HTA Agencies  
Across the study countries, HTA agencies mainly exist in the form of autonomous 
governmental bodies, having either an advisory or regulatory function. Usually, a technical 
group is responsible for early assessment of the evidence following which an expert 
committee appraises the request for coverage and produces recommendation(s) for the final 
decision body.  
The topic selection process is generally not entirely-transparent, with the belief that 
most agencies predominantly assess new medical technologies, and more precisely 
medicines, that are expensive and/or with uncertain benefits. In some cases, topic selection 
is not applicable as all technologies that apply for reimbursement need to be assessed. 
In all study countries, official country-specific pharmacoeconomic guidelines for the 
evaluation process are available, mainly concerning methodological and reporting issues 
267,284; in England, in addition to the evaluation process, guidelines also exist for the purpose 
of application submission requirements, including the description of key principles of the 
appraisal methodology adopted by NICE 267. For all countries the application of the 
guidelines is recommended. A summary of the responsibilities and structure of the national 
HTA agencies in the study countries is presented in Table 4.1. 
 
4.3.2 Evidence and Evaluation Criteria Considered in HTAs 
Generally all countries assess the same groups of evidence, however the individual 
parameters considered and the ways they are evaluated differ from country to country. All 
countries acknowledge the existence of a wide variety of data sources including scientific 
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studies (e.g. clinical trials, observational studies), national statistics, clinical practice 
guidelines, registry data, surveys, expert opinion and evidence from pharmaceutical 
manufacturers 283. A summary of the evidence and the evaluation criteria under consideration 
across the study countries is presented in Table 4.2. 
 
4.3.2.1 Evaluation principles and their relevance to priority setting  
In France the assessment of the product’s medical benefit (Service Médical Rendu, SMR) 
and improvement of medical benefit (Amélioration du Service Médical Rendu, ASMR) 
determine the reimbursement and pricing of the drug respectively. As of October 2013, 
economic criteria have been introduced with the Commission for Economic Evaluation and 
Public Health (CEESP) evaluating the cost-effectiveness (without a cost-effectiveness 
threshold in place) of products assessed to have an ASMR I, II or III that are likely to impact 
social health insurance expenditures significantly (total budget impact greater than EUR 20 
million), being used by the Economic Committee for Health Products (CEPS) in its price 
negotiations with manufacturers 327. Nevertheless, and under this current framework, these 
economic evaluations have not the same impact on price negotiation with ASMR which are 
directly linked with pricing but instead their role is limited to a consultative one.  
Table 4.1: Responsibilities and structure of national HTA agencies 
  FRANCE  
(HAS / CEESP) 
GERMANY 
(IQWiG) 
SWEDEN  
(TLV) 
ENGLAND  
(NICE) 
ITALY  
(AIFA) 
NETHERLANDS 
(ZIN) 
POLAND  
(AOTMiT) 
SPAIN 
 (RedETS/ISCIII or 
ICP10) 
Function Autonomous 
Advisory 
Autonomous, 
Advisory 
Autonomous, 
Regulatory 
Autonomous, 
Advisory 
Autonomous, Regulatory  Autonomous, 
Advisory 
Autonomous, 
Advisory 
Autonomous, Advisory  
Expert 
committee 
Transparency 
Commission,  
Economic 
Evaluation and 
Public Health 
Commission 
(CEESP) 
Assessment: 
IQWiG scientific 
personnel; 
Appraisal: 
Federal Joint 
Committee (G-
BA)  
The Board for 
Pharmaceutical 
Benefits 
Technology 
Appraisal 
Committee  
AIFA's Technical 
Scientific Committee and 
AIFA’s Pricing and 
Reimbursement 
Committee (CPR) 
Committee for 
societal 
consultation 
regarding the 
benefit basket 
Transparency 
Council 
Interministerial 
Committee for Pricing11 
(ICP) 
Topic 
selection 
HAS 
(About 90% 
submitted by the 
manufacturers, 
10% requested by 
the MoH)12 
Not applicable 
(all drugs 
applying for 
marketing 
authorization as 
of 2011) 
TLV (only 
outpatient and 
high price drugs) 
DH in 
consultation with 
NICE based on 
explicit 
prioritisation 
criteria13 
AIFA (all drugs submitted 
by manufacturers)  
Mostly on its own 
initiative; 
sometimes at the 
request of MoH 
MoH14 (in the case 
of manufacturer 
submission – 
triggered by MAH)  
Not subject to any 
specific known 
procedure15 
Guidelines 
for 
economic 
analysis 
Yes Yes (however, 
CBA is not 
standard practice) 
Yes Yes  In progress Yes Yes Spanish 
recommendations on 
Economic Evaluation of 
Health Technologies  
                                                 
10 RedETS is the Spanish Network of regional HTA agencies, coordinated by ISCIII, responsible for the evaluation of non-drug health technologies. The ICP, led by the 
Dirección General de Farmacia under the Ministry of Health, is the committee responsible for the evaluation of drugs producing mandatory decisions at national level. 
11 The ICP involves representatives from the Ministry of Health, Ministry of Industry and Ministry of Finance together with a dynamic (i.e. rotating) set of expert representatives 
from the autonomous communities. 
12 An economic evaluation is performed only for a subset of new products meeting certain criteria (manufacturer claims a high added value / product is likely to have a significant 
impact on public health expenditures). 
13 Criteria include expected health benefit, population size, disease severity, resource impact, inappropriate variation in use and expected value of conducting a NICE technology 
appraisal. 
14 Regulated by law: the Act of August 27th 2004 on healthcare benefits financed from public funds; the Act of May 12th 2011 on the reimbursement of medicinal products, 
special purpose dietary supplements and medical devices. 
15 For new drugs, manufacturers have to submit a dossier for evaluation when they apply for pricing and reimbursement. Topic selection for non-drug technologies under the 
action of RedETS is well developed with the participation of informants from all autonomous communities based on a two round consultation 
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Table 4.2: Evidence and evaluation criteria considered in HTAs 
Burden of Disease 
 FRANCE  
(HAS / CEESP) 
GERMANY (IQWiG) SWEDEN  
(TLV) 
ENGLAND  
(NICE) 
ITALY  
(AIFA) 
NETHERLANDS 
(ZIN) 
POLAND  
(AOTMiT) 
SPAIN 
(RedETS/ISCIII 
or ICP) 
Severity  Yes, as part of 
SMR 
Yes, as part of added 
benefit assessment 
Yes (impact 
on WTP 
threshold)16 
Yes (mainly as 
part of EoL 
treatments) 
Yes (implicitly) Yes17 Yes18 Yes 
Availability of treatments (i.e. 
unmet need) 
Yes (binary: 
Yes/No) 
True for other 
technologies rather than 
pharmaceuticals19 
Yes, indirectly 
(captured by 
severity) 
Yes (clinical need 
as a formal 
criterion) 
Yes20  Yes21 Yes22 Yes 
Prevalence (e.g. rarity) Yes, informally As part of G-BA’s23 
decision-making process 
Yes  Yes Yes24 Yes Yes25 Yes 
Therapeutic & Safety impact 
                                                 
16 Severity can be defined on the basis of several elements of the condition, including the risk of permanent injury and death. 
17 Both explicitly and implicitly; more recently they tend to explicitly take into account “burden of disease” measures. 
18 Regulated by law: the Act of August 27th 2004 on healthcare benefits financed from public funds. 
19 In evaluations performed by the G-BA to determine the benefit basket (i.e. not drugs, which are covered automatically after marketing authorization and value assessment 
plays a role for the price) availability or lack of alternatives and the resulting medical necessity are considered to determine clinical benefit.   
20 Explicitly stated in the legislation as a criterion to set price. 
21 Estimate the number of treatments that is considered necessary and compared that with the actual capacity. 
22 Not obligatory by law; considered in the assessment process in AOTMiT on the base of HTA Guidelines (good HTA practices). 
23 Lower accepted significance levels for p-values (e.g. 10% significance levels) for small sample sizes such as rare disease populations; acceptance of evidence from surrogate 
endpoints rather than only ‘hard’ endpoints; additional benefit is considered proven at marketing authorisation if budget impact is less than €50m per annum. 
24 Decisions on price and reimbursement of orphan drugs are made through a 100-day ad hoc accelerated procedure, although criteria for HTA appraisals do not differ from 
non-orphan drugs. 
25 Commonness, but not rarity, regulated by law (the Act on healthcare benefits); rarity is considered in the assessment process in AOTMiT on the base of HTA Guidelines. 
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Efficacy Yes (4 
classifications 
via SMR, 5 via 
ASMR)26 
Yes (6 classifications)27 Yes Yes Yes Yes Yes28 Yes 
Clinically meaningful outcomes Yes 
(preferred) 
Yes (preferred) Yes Yes (preferred) Yes Yes Yes29 Yes 
Surrogate/intermediate outcomes Considered Considered Considered Considered Considered Considered Considered30  Considered 
 
HRQoL outcomes  Generic; 
disease-
specific 
Not specified31 Generic 
(preferred); 
disease-
specific 
Generic; disease-
specific  
Generic; 
disease-
specific  
Yes Yes32 Yes (including 
patient well-
being) 
Safety  Yes Yes33 Yes Yes Yes Yes Yes34 Yes 
Dealing with uncertainty Implicitly 
(preference 
for RCTs), 
Explicitly 
Explicitly (classification 
of empirical studies and 
complete evidence) 
Implicitly 
(through 
preference for 
RCTs) 
Explicitly (quality 
of evidence), 
Implicitly 
(preference for 
RCTs), Indirectly 
Yes, registries 
and MEAs are 
used to 
address 
uncertainty  
Implicitly (if 
included in the 
assessment 
studies) 
No35 Can be 
considered as 
part of 
economic 
evaluations 
                                                 
26 SMR, 4 classifications for actual clinical benefit: Important/High (65% reimbursement rate), Moderate (30%), Mild/Low (15%), Insufficient (not included on the positive 
list); ASMR, 5 classifications for relative added clinical value: Major (ASMR I), Important (ASMR II), Moderate (ASMR III), Minor (ASMR IV), No clinical improvement 
(ASMR V). 
27 The possible categories are: major added benefit, considerable added benefit and minor added benefit. Three additional categories are recognized: non-quantifiable added 
benefit, no added benefit, and lesser benefit. 
28 Regulated by law: the Act of August 27th 2004 on healthcare benefits financed from public funds. 
29 Regulated by law: the Act on the reimbursement. 
30 Weak preference; if no LYG/QALY data available. 
31 Considered if measured using validated instruments employed in the context of clinical trials. 
32 Regulated by law: the Act on the reimbursement. 
33 Based on the following ranking relative to comparator: greater harm, comparable harm, lesser harm 
34 Regulated by law: the Act on healthcare benefits; the Act on the reimbursement. 
35 Not obligatory by law; considered in the assessment process in AOTMiT on the base of HTA Guidelines (good HTA practices). 
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(robustness of 
evidence) 
(rejection if not 
scientifically 
robust) 
Innovation level 
Clinical novelty Yes (as part of 
ASMR) if 
efficacy/ safety 
ratio is positive 
Implicitly as part of 
added therapeutic 
benefit consideration36 
Yes, but only if 
it can be 
captured in the 
CE analysis 
Yes Yes Yes Yes37 Yes38  
Ease of use and comfort Not explicitly, 
in some cases39 
Not explicitly 
considered for benefit 
assessment40  
Yes (to some 
extent) 
Not explicitly  No Not standard, 
case-by-case 
basis 
No41 Not explicitly, 
indirectly42 
Nature of treatment/technology Yes (3 
classifications)
43 
Not explicitly 
considered for benefit 
assessment 
 
Not explicitly Yes (when above 
£20,000) 
No Implicitly Yes44 Yes (through the 
degree of 
innovation 
criterion) 
Socio-economic impact 
Public Health Benefit/Value Yes, rarely via 
“intérêt de 
Yes46 Yes, indirectly47 As indicated in 
guidance to NICE 
Implicitly Yes (explicit 
estimates) 
Yes49 Social utility of 
the drug and 
                                                 
36 Not a criterion per se, implicitly considered if patient benefit is higher than that of existing alternatives. 
37 The Act on healthcare benefits considers the following classifications: saving life and curative, saving life and improving outcomes, preventing the premature death, improving 
HRQoL without life prolongation. 
38 Incremental clinical benefit is considered as part of the therapeutic and social usefulness criterion. 
39 Only considered in the ASMR if it has a clinical impact (e.g. through a better compliance). 
40 The IQWiG’s general methodology (not specifically for new drugs) states that patient satisfaction can be considered as an additional aspect, but it is not adequate as a sole 
deciding factor. 
41 Not obligatory by law (unless captured in HRQoL/QALY); considered in the assessment process in AOTMiT on the base of HTA Guidelines. 
42 Through the therapeutic and social usefulness criterion. 
43 Ranking includes the following classifications: Symptomatic relief, Preventive treatment, Curative therapy. 
44 Regulated by law: the Act on healthcare benefits considering the following classifications: saving life and curative, saving life and improving outcomes, preventing the 
premature death, improving HRQoL without life prolongation; thus no “innovativeness” per se. 
46 Manufacturer dossiers need to include information on the expected number of patients and patient groups for which an added benefit exists as well as costs for the public 
health system (statutory health insurance). 
47 The following principles are considered: Human dignity, Need/solidarity, Cost-efficiency, Societal view. 
49 Regulated by law: the Act on healthcare benefits considering: impact on public health in terms of priorities for public health set; impact on prevalence, incidence – qualitative 
assessment rather than quantitative. 
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Santé 
Publique”45 
to be considered 
in the evaluation 
process48 
rationalisation 
of public drug 
expenditures 
Social Productivity Not explicitly50 Yes51  
 
Indirect costs 
considered 
explicitly (to 
some extent) 
Considered, but 
not explicitly 
incorporated as 
part of ICERs 
Direct costs 
only52 
Yes No53 Yes, either 
explicitly or 
implicitly 
Efficiency considerations 
Cost-Effectiveness Yes54  Yes (cost-benefit)55 Yes (cost-
efficiency as a 
principle) 
Yes Yes Yes Yes, 
mandatory 
by law 
Yes (not 
mandatory) 
Cost/Budget Impact Analysis Not mandatory 
but BIA is 
highly 
recommended
56 
BIA (mandatory) Cost only 
considered for 
treatments of 
the same 
condition; BIA 
not mandatory 
BI to NHS, PSS, 
hospitals, primary 
care 
Yes Yes Yes, payer 
affordability 
mandatory 
by law 
Yes (BI to NHS) 
Other evidence and criteria 
                                                 
45 Public health interest (interêt santé publique; ISP) is incorporated into the SMR evaluation. ISP considers 3 things: whether the drug contributes to a notable improvement in 
population health; whether it responds to an identified public health need (e.g. ministerial plans); and whether it allows resources to be reallocated to improve population health. 
48 Factors include cost-effectiveness, clinical need, broad priorities for NHS, effective use of resources and encouragement of innovation, and any other guidance issued by the 
Secretary of State. 
50 Only potentially as part of economic evaluations. 
51 Productivity loss due to incapacity as part of the cost side, productivity loss due to mortality as part of the benefit side (no unpaid work, e.g. housework). 
52 Indirect costs can be taken into account in a separate analysis. 
53 No social perspective obligatory by law; may be provided but problematic to use for recommendation/decision. 
54 Already implemented but analysis conducted separately by the distinct Commission for Economic Evaluation and Public Health (CEESP). The health economic evaluation 
does not impact the reimbursement decision. 
55 Cost-benefit analysis is not standard practice in the evaluation but rather can be initiated if no agreement is reached between sickness funds and manufacturer on the price 
premium or if the manufacturer does not agree with the decision of the G-BA regarding premium pricing (added benefit). 
56 ASMR V drugs should be listed only if they reduce costs (lower price than comparators or induce cost savings). 
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Place in therapeutic strategy Yes57  Evaluation usually 
specifies the line of 
treatment 
Evaluation 
usually 
specifies the 
line of 
treatment 
Broad clinical 
priorities for the 
NHS (by Secretary 
of State) 
Yes Not explicitly No Yes58  
Conditions of use Yes (e.g. the 
medicine is 
assessed in 
each of its 
indications, if 
several)  
No, drug is in principle 
reimbursable for the 
whole indication 
spectrum listed on its 
authorisation59 
Yes, coverage 
can be 
restricted 
based on 
evidence at 
sub-population 
level 
Yes, coverage can 
be restricted 
based on 
evidence at sub-
population level 
Implicitly Yes, 
indications 
Yes, coverage 
can be 
restricted to 
strictly 
defined sub-
populations 
Yes (several 
medicines are 
introduced 
with Visado – 
Prior 
Authorization 
Status) 
Ethical considerations Not 
incorporated in 
assessment60 
Sometimes (implicitly) Yes Yes61  Implicitly Yes, explicitly 
(e.g. solidarity 
and 
affordability)
62 
Considered on 
the basis of 
HTA 
Guidelines 
Not explicitly 
Weights of different criteria Not 
transparent 
Not transparent  “Human 
dignity” usually 
being 
overriding63 
Not transparent Not transparent Therapeutic 
value is the 
most 
important 
criterion 
Not 
transparent 
Not 
transparent 
and not 
consistent 
across 
regions64 
                                                 
57 The commission will also make a statement on if a drug shall be used as first choice or only if other existing therapeutics are not effective in a patient. 
58 In the form of the new IPT – Informes de Posicionamiento Terapéutico /Therapeutic Positioning report. 
59 Sub-groups are examined during as part of benefit assessment but in order to guide pricing, not reimbursement eligibility. If a drug has an added benefit for some groups but 
not for others, a so-called “mixed price” is set that reflects both its added benefit for some patients and lack thereof for others. 
60 The assessment in France is purely ‘scientific’ i.e. focuses on the absolute and comparative merits of the new therapy and its placement in the therapeutic strategy. 
61 NICE principles include fair distribution of health resources, actively targeting inequalities (SoVJ); equality, non-discrimination and autonomy. 
62 Also indirectly through an ethicist seat in the Committee. 
63 No clear order between “need & solidarity” and cost-efficiency. In the entire health system a more complete ordering is seen where human dignity takes precedence over the 
principles of need & solidarity, which takes precedence over cost-efficiency. 
64 Not all regions have neither HTA bodies nor regional committees for drug assessment. However, at regional level drugs assessment is limited to prioritizing (or not) its use 
by means of guidelines or protocols together with some type of incentives to promote savings. 
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Accepted data sources (for 
estimating number of patients, 
clinical benefits and costs) 
Clinical trials, 
observational 
studies, 
national 
statistics, 
clinical 
guidelines, 
surveys, expert 
opinions 
RCTs65, national or local 
statistics, clinical 
guidelines, surveys, 
price lists, expert 
opinions 
Clinical trials, 
observational 
studies, 
national 
statistics, 
clinical 
guidelines, 
surveys, expert 
opinions 
Clinical trials, 
observational 
studies, national 
or local statistics, 
clinical guidelines, 
surveys, expert 
opinions 
Clinical trials, 
observational 
studies, national 
statistics, clinical 
guidelines, 
surveys, expert 
opinions, 
scientific 
societies‘ 
opinion 
Clinical trials, 
clinical 
guidelines, 
expert 
opinions 
Clinical trials, 
observational 
studies, 
national or 
local statistics, 
clinical 
guidelines, 
surveys, 
expert 
opinions 
Clinical trials, 
observational 
studies, 
national 
statistics, 
clinical 
guidelines, 
surveys, 
expert 
opinions 
                                                 
65 For therapeutic benefit, other designs such as non-randomised or observational studies might be accepted in exceptional cases if properly justified, e.g. in the case that RCTs 
are not possible to be conducted, if there is a strong preference for a specific therapeutic alternative on behalf of doctors or patients, if  other study designs can provide 
sufficiently robust data, etc. 
 
 In Germany the new Act to Reorganize the Pharmaceuticals Market in the Statutory 
Health Insurance (SHI) System [Gesetz zur Neuordnung des Arzneimittelmarktes in der 
gesetzlichen Krankenversicherung (AMNOG)] came into effect on 1 January 2011. Since 
then, all newly introduced drugs are subject to early benefit assessment. Pharmaceutical 
manufacturers have to submit a benefit dossier for evaluation by the Institute for Quality and 
Efficiency in Health Care (IQWiG). A final decision is made by the Federal Joint Committee 
(Gemeinsame Bundesausschuss, G-BA). Benefit for new drugs encompasses the “patient-
relevant therapeutic effect, specifically regarding the amelioration of health status, the 
reduction of disease duration, the extension of survival, the decrease in side effects or the 
improvement of quality of life” 323. Importantly, all new drugs are reimbursed upon 
marketing authorisation and benefit assessment mainly determines price rather than 
reimbursement status. 
In Sweden, a prioritisation framework with three explicit factors for the allocation of 
resources is used: i) human dignity; ii) need and solidarity; and iii) cost-efficiency 
238,249,271,294. However, in the specific legislation for the pharmaceutical reimbursement 
system, human value is generally seen as the overriding criterion with no clear order between 
the other two 227. Marginal benefit or utility, according to which a diminishing cost-
effectiveness across indications and patient groups is explicitly recognized, could be 
regarded as a fourth principle mainly meaning that there are no alternative treatments that 
are significantly more suitable 294,312,313.  
In England, the Secretary of State for Health has indicated to NICE a number of 
factors that should be considered in the evaluation process: (i) the broad balance between 
benefits and costs (i.e. cost-effectiveness); (ii) the degree of clinical need of patients; (iii) 
the broad clinical priorities for the NHS; (iv) the effective use of resources and the 
encouragement of innovation; and (v) any guidance issued by the Secretary of State 237,268,287. 
Decisions are supposed to reflect society’s values, underlined by a fundamental social value 
judgment 296.  
The Netherlands focuses on four priority principles when assessing medical 
technologies: (a) the “necessity” of a drug (severity / burden of disease) 65,242; (b) the 
“effectiveness” of a drug, according to the principles of Evidence-Based Medicine (EBM) 
242,253; (c) the “cost-effectiveness” of a drug 231; and (d) “feasibility”, that is how feasible and 
sustainable is to include the intervention or care provision in the benefit package 232,248.  
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In Italy, reimbursement of pharmaceuticals at the central level is evaluated by 
AIFA’s Pricing and Reimbursement Committee (CPR) which sets prices and reimbursement 
conditions for drugs with a marketing authorisation based on evidence of the following 
factors: product’s therapeutic value (cost/efficacy analysis) and safety (pharmacovigilance), 
degree of therapeutic innovation, internal market forecasts (number of potential patients and 
expected sales), price of similar products within the same or similar therapeutic category, 
product prices in other European Union Member States 227. In autonomous regions, pricing 
and reimbursement of new drugs does not require –except for very innovative drugs– 
epidemiologic or economic evaluation studies nor assessment of cost impact from adoption 
of new drugs, as in other countries 227,280. 
An HTA in Poland is considered complete if it contains (a) a clinical effectiveness 
analysis; (b) an economic analysis; and (c) a healthcare system impact analysis. No studies 
derived from the search referred to the evidence assessed or the different parameters 
considered by AHTAPol (now AOTMiT) in Poland in more detail  290.  
Finally, in Spain, different regions apply a range of different assessment 
requirements, but in general four main evidence parameters are considered: (a) the severity 
of the disease; (b) the therapeutic value and efficacy of the product; (c) the price of the 
product; and (d) the budget impact for the Spanish National Health System. The assessment 
is usually a classification or cost-consequences analysis that does not take into account the 
long-term effects of a therapy or the possible need of specialized care utilisation. Patient 
well-being and quality of life are also considered  230.  
 
4.3.2.2 Evaluation criteria taken into account in HTAs 
Burden of Disease 
In France, both the severity and the existence of alternative treatments are acting as formal 
criteria, thus essentially defining the concept of ‘need’ 65. Severity is considered as part of 
the SMR, taking into account symptoms, possible consequences (including physical or 
cognitive handicap) and disease progression (in terms of mortality and morbidity) 227. The 
existence of alternatives is scored against a categorical 2-level scale (yes vs. no) 258,259. 
In Germany, severity is considered as part of added (clinical) benefit assessment. The 
clinical assessment is based on “patient-relevant” outcomes, mainly relating to how the 
patient survives, functions or feels, essentially accounting for the dimensions of mortality, 
morbidity and health-related quality of life (HRQoL) 265.  
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In Sweden, severity of the condition and availability of treatments (reflected through 
marginal benefit / utility as a sub-principle) appear to be two of the primary criteria for 
priority-setting with more severe indications being explicitly prioritized via greater 
willingness to pay 65,294,312,313.  
In England, the degree of unmet clinical need is a formal criterion taken into account, at least 
partially being reflected by the availability of alternative treatments 65,315. NICE 
acknowledges that rarity has a key role in the assessment of orphans and NICE’s Citizens’ 
Council has stated that society would be willing to pay more for rare and serious diseases 
263. The severity of the disease is taken into account mainly through the special status of life-
extending medicines for patients with short-life expectancy as reflected through the issuing 
of supplementary advice of life extending end-of-life (EOL) treatments by NICE 270,315.  
Severity of disease, availability of treatments and prevalence of the disease is 
generally considered across the remaining countries, either explicitly or implicitly, although 
not always as mandatory requirements by law but just good HTA practices (e.g. Poland for 
the case of treatments availability) 227.  
 
Therapeutic impact and safety 
Clinical evidence relating to therapeutic efficacy and safety acts as the most important formal 
criteria of the evaluation process in France 328. The product’s medical benefit or medical 
service rendered (SMR) relates to the actual clinical benefit of the drug, responding to the 
question of whether the drug is of sufficient interest to be covered by social health insurance. 
It takes into consideration the following criteria: (a) the seriousness of the condition; (b) the 
efficacy of the treatment; (c) side effects of the drug; (d) its place within the therapeutic 
strategy given other available therapies; and (e) its interest for public health 227,267.  
Similarly to France, in Germany all clinically relevant outcomes are considered and 
final clinically meaningful outcomes (e.g. increase in overall survival, reduction of disease 
duration, improvement in HRQoL) are preferred over surrogate and composite endpoints 
265,267,273,283,302. HRQoL endpoints are considered if measured using validated instruments 
suited for application in clinical trials 227,323. With regards to uncertainty, the Institute ranks 
the results of a study according to “high certainty” (randomized study with low bias risk), 
“moderate” (randomized study with high bias risk), and “low certainty” (non-randomized 
comparative study). The complete evidence base is then assessed and a conclusion is reached 
on the probability of the (added) benefit and harm graded according to major added benefit, 
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considerable added benefit and minor added benefit. Three additional categories are 
recognized: non-quantifiable added benefit, no added benefit, lesser benefit 227,265.  
All types of clinically relevant outcomes are accepted in Sweden, with the inclusion 
of final outcomes, surrogate endpoints, and composite endpoints, with generic QoL 
endpoints being preferred over disease-specific endpoints 227,273. Generally, all effects of a 
person’s health and QoL are supposed to be considered as part of the assessment stage, 
including treatment efficacy and side effects 312,313,328.  
In England once again data on all clinically relevant outcomes are accepted with final 
clinical outcomes (e.g. life years gained) and patient HRQoL being preferred over 
intermediate outcomes (e.g. events avoided) or surrogate endpoints and physiological 
measures (e.g. blood glucose levels) 243,273,314,320; particular outcomes of interest include 
mortality and morbidity. Safety is mainly addressed through the observation of adverse 
events 315. Uncertainty is addressed explicitly through quality of evidence, implicitly, 
through preference for RCTs and indirectly, through submissions rejection if evidence is not 
scientifically robust. 
Italy, the Netherlands, Poland and Spain include surrogate and composite endpoints 
in the analysis, in addition to disease-specific quality of life endpoints. Therapeutic value is 
the most critical criterion for reimbursement in the Netherlands as part of which patient 
preference data and user friendliness might also be considered 253.  
All countries take into consideration safety data to reflect clinical harm, mainly in the form 
of adverse events incidence and severity.  
 
Innovation level  
In the French setting, clinical novelty is considered by definition through the 
product’s improvement of medical benefit (ASMR) relating to the relative added clinical 
value of the drug which informs the pricing negotiations 227. Additional innovation 
characteristics relating to the nature of the treatment (e.g. differentiating between 
symptomatic, preventive and curative) are also considered but as a second line of criteria 
227,275,320,328.  
In Germany, clinical novelty is considered implicitly as part of the consideration of 
added therapeutic benefit for premium pricing. Ease of use and comfort can be reflected 
indirectly through treatment satisfaction for patients which can be considered as an 
additional aspect, however not as an explicit factor, similarly to the nature of 
treatment/technology 324.  
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In Sweden, innovation characteristics relating to the added therapeutic benefit (only 
if it can be captured in the CE analysis) as well as ease of use and comfort are included in 
the assessment process 65,227,320,328.  
As reflected through NICE’s operational principles, the encouragement of innovation 
is an important consideration in England. By definition, the incremental therapeutic benefit 
as well as the innovative nature of the technology is formally taken into account as part of 
the product’s incremental cost effectiveness ratio (ICER) 315.  
Among the remaining countries, clinical novelty is essentially considered in all 
countries; ease of use and comfort might only be considered implicitly and informally if at 
all, whereas there are mixed approaches in terms of a treatment’s technology nature.  
 
Socioeconomic impact 
In terms of socioeconomic parameters, in France, ‘expected’ public health benefit acts as 
another explicit dimension via an indicator known as public health interest (“Intérêt de Santé 
Publique”, ISP), which is assessed and scored separately by a distinct committee as part of 
the SMR evaluation but is not used often 65,227,256,275.  
In Germany, public health benefit is reflected through the requirement from 
manufacturers to submit information on the expected number of patients and patient groups 
for which an added benefit exists as well as costs for the public health system (statutory 
health insurance) 227,324. All direct costs have to be considered, including both medical and 
non-medical (when applicable), whereas indirect costs are not a primary consideration but 
can be evaluated separately if they are substantial, with productivity losses due to incapacity 
being included only on the cost side 264. In turn, productivity losses due to mortality are only 
considered in the outcome on the benefit side (to avoid double counting). Budget impact 
analysis (BIA) is mandatory and should include any one-off investments or start-up costs 
required in order to implement a new technology, with methodology and sources clearly 
outlined 264,267.  
Among the other study countries, any public health impact of the drug is usually 
considered but not necessarily in an explicit manner, whereas social productivity is usually 
reflected through the incorporation of indirect costs, either explicitly or implicitly 227. In 
England for example, criteria on social productivity are also considered but not explicitly 
incorporated as part of cost-effectiveness ratios.  
Efficiency 
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Up until now, cost was not acknowledged as an explicit or mandatory criterion, but BIA, 
while not mandatory, is highly recommended in France 227. Although the expert committee 
had been reluctant to use cost-effectiveness criteria in the evaluation process (282,328, 
following the bylaw of 2012 (which took effect in 2013) the role of economic evidence was 
strengthened 259. The CEESP gives an opinion on the efficiency of the drug based on the 
relative added clinical value (ASMR) of alternative treatments.  
In Germany economic analysis (cost-benefit-analysis) is not standard practice in the 
evaluation but rather can be initiated if no agreement is reached between sickness funds and 
the manufacturer on the price premium or if the manufacturer does not agree with the 
decision of the G-BA regarding premium pricing (added benefit); instead, BIA is mandatory 
(Advance-HTA, 2016). ‘Cost-effectiveness’ acts as one of the most important formal 
evaluation criteria in Sweden. Parameters having a socioeconomic impact, such as avoiding 
doctor visits or surgery, productivity impact, and, in general, savings on direct and indirect 
costs are also considered 312.  
As already reflected through NICE’s working principles, the relative balance 
between costs and benefits (i.e. value-for-money) and the effective use of resources should 
be taken into account in England (e.g. through the explicit cost-effectiveness criterion) 287. 
Some studies also suggest that the impact of cost to the NHS in combination with budget 
constraints (budget impact considerations) are taken into account alongside the other clinical 
and cost-effectiveness evidence 131,268,278,282,286.  
In the assessment process by ZIN, the cost-effectiveness criterion follows that of the 
therapeutic value and the cost consequences analysis. Cost-effectiveness is only considered 
for drugs with added therapeutic value, which are either part of a cluster and are reimbursed 
at most at the cluster reference price or are not reimbursed in the absence of possible 
clustering 234,253. The Netherlands usually performs its own BIA, although voluntary 
submission from the manufacturer is also an option 253,282. 
All other study countries evaluate the efficiency of new drugs through cost-
effectiveness evaluation and BIA, but this is not always mandatory.  
 
Other types of evidence 
Additional explicit parameters considered in France include the technology’s place in 
therapeutic strategy mainly in relation to other available treatments (i.e. first-line treatment 
vs. second-line treatment etc.), and technology’s conditions of use 227,258,259.  
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Germany is the only country which does not apply any conditions of use in regards 
to specific sub-populations, in principle reimbursing drugs across the whole indication 
spectrum as listed on the marketing authorisation 227.  
As reflected through the ethical prioritization framework that the Swedish TLV is 
using, the ethical considerations of human dignity, need and solidarity are acting as 
principles for the evaluations. 
Beside the notion of clinical need as reflected through NICE’s principles, other 
equity considerations include the ‘need to distribute health resources in the fairest way within 
society as a whole’ and the aim of ‘actively targeting inequalities’, both of which are 
explicitly mentioned by NICE as principles of social value judgements 287. Equality, non-
discrimination and autonomy are other explicit ethical considerations 65.  
The Netherlands also takes into consideration explicitly ethical criteria based on egalitarian 
principles, such as solidarity and affordability of the technology by individual patients 
65,227,271. 
In terms of the remaining countries, conditions for use might be applied for Italy, 
Poland and Spain, the therapy’s place in therapeutic strategy considerations exist for Italy 
and Spain, whereas ethical considerations are evident in Italy and Poland (implicitly or 
indirectly), however the use of any additional explicit parameters may not be transparent.  
 
4.3.2.3 Synthesising the evidence and taking into account all factors: Weights 
It is not clear how all the factors discussed so far interact with one another, what their relative 
importance is and what the trade-offs are that HTA bodies are prepared to make between 
them when arriving at recommendations 124,131. For example, in France, the weights of the 
assessment parameters considered and the appraisal process overall do not seem to be clear 
or transparent 328, although the evidence that informs this judgment is dated and may be 
contestable. In Spain, the assessment takes into account mainly safety, efficacy, 
effectiveness and accessibility and it does not consider efficiency and opportunity cost; still 
the way this is done and the weights of different criteria are not known 245. All countries 
consider a number of different data sources for the assessment process, with randomised 
controlled trials (RCTs) usually being the most preferred source for clinical data. 
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4.3.3 HTA Methods and Techniques Applied 
Assuming the existence of an additional benefit (or lesser harm) compared to existing 
treatment options, all countries are adopting a type of economic evaluation (mainly CUA or 
CEA) as an analytical method to derive the value of new technologies in addition to efficacy 
analysis, besides France and Germany, both of which formally used to apply a comparative 
assessment of clinical benefit as the preferred methodology but with economic evaluation 
progressively becoming more important as of 2013 but in the context of the existing method 
of assessment. A summary of analytical methods and techniques applied as part of HTA and 
their details is presented in Table 4.3. 
 
4.3.3.1 Analytical methods 
In Sweden and England the preferred type of economic evaluation is CUA with cost per 
QALY gained being the favoured health outcome measure, but CEA is also accepted 
237,243,267,272,283,285,287,305,318. In Sweden CBA with willingness-to-pay (WTP) as an outcome 
measure can also be applied.  
In France, up until now comparative assessment of clinical benefit incorporating final 
endpoints as an outcome measure acted as the preferred evaluation procedure. However, 
economic analysis of selected drugs with expected significant budget impact is continuously 
being considered more formally, especially if its choice is justified and any methodological 
challenges (especially associated with the estimation of QALYs) are successfully addressed 
65,258,259,267,283,302. The choice between CEA and CUA depends on the nature of the expected 
health effects (if expected significant impact on HRQoL then CUA, otherwise CEA). 
In Germany, economic evaluations are performed only within therapeutic areas and 
not across indications, thus an efficiency frontier approach of CBA using patient relevant 
outcomes is the preferred combination of analysis method-outcome measure 224,264,267,283,302. 
Since the introduction of the AMNOG, economic evaluations are mainly conducted for cases 
when price negotiations fail after the early benefit assessment and the arbitral verdict is 
challenged by the technology supplier or the statutory health insurer 264.  
Table 4.3: HTA methods and techniques applied 
Analysis Method 
 FRANCE  
(HAS / CEESP66) 
GERMANY (IQWiG) SWEDEN  
(TLV) 
ENGLAND  
(NICE) 
ITALY  
(AIFA) 
NETHERLANDS 
(ZIN) 
POLAND  
(AOTMiT) 
SPAIN 
(RedETS/ISCIII or 
ICP) 
Methods Comparative 
Efficacy/ 
Effectiveness 
(also CEA, CUA) 
CBA but also CUA 
and CEA (not 
standard practice) 
CUA (also CEA, 
CBA) 
CUA (also CEA, 
CMA) 
CMA, CEA, 
CUA, CBA67 
CEA, CUA, no 
CMA 
Cost-consequences 
analysis, CEA or CUA - 
obligatory, CMA (if 
applicable) 
Comparative 
Efficacy/ 
Effectiveness, 
CMA, CEA, CUA, 
CBA68 
Preferred Outcome 
measure 
Final outcome, 
Life Years (QALY, 
if CUA; Life 
Years, if CEA) 
Patient relevant 
outcome (can be 
multidimensional) - 
efficiency frontier 
(QALY) 
QALY (WTP, if 
CBA) 
QALY (cost per 
life year gained, 
if CEA) 
Final 
outcome, Life 
Years (QALY, if 
CUA or CEA; 
Life Years, if 
CEA) 
Effectiveness by 
intention-to-
treat principle, 
and expressed in 
natural units - 
preferably LYG or 
QALY 
QALY or LYG  QALY in CUA 
Utility scores 
elicitation technique 
EQ-5D and HUI3, 
from general 
French 
population 
Utility scores from 
patients, Direct 
(e.g. TTO, SG),  
Indirect (EQ-5D  
Utility scores 
from patients, 
Direct (e.g. 
TTO, SG), 
Indirect (EQ-
5D)  
Utility scores 
from general 
English 
population, 
Direct (e.g. 
TTO, SG), 
Indirect (EQ-
Both direct 
and indirect 
(EQ-5D) 
elicitation 
techniques 
Either Direct 
(TTO, SG, VAS), 
or Indirect (EQ-
5D); selection 
should be 
justified 
Direct or indirect utility 
scores69 
 Utility scores 
from general 
Spanish 
population,  
Direct (e.g. TTO, 
SG),  Indirect (EQ-
5D)70 
                                                 
66 In France, economic evaluations are undertaken only of select drugs with expected significant budget impact. 
67 A template for the submission of the P&R dossier to AIFA is in progress. 
68 For the case of drugs at central level carried out by ICP, comparative efficacy/effectiveness is taken into account. The ICP receives the so called “Informe de Posicionamiento 
Terapéutico” (Therapeutic Positioning report), a therapeutic assessment conducted by the Spanish Medicines Agency (Agencia Española del Medicamento) based on which 
confidential discussions around the appraisal of the drugs takes place but which does not take into consideration cost-effectiveness. Economic evaluations are mainly taking 
place for the case of non-drug technologies under the scope of RedETS. 
69 It is recommended to use indirect methods for preferences measurement – validated questionnaires in Polish. While measuring preferences with the EQ-5D questionnaire, it 
is advised to use the Polish utility standard set obtained by means of TTO. 
70 Surveys or previously validated HRQOL patient surveys. 
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5D), Systematic 
review 
Comparator Usually 'best 
standard of care' 
but can be more 
than one71 
Usually 'best 
standard of care' 
but can be more 
than one72 
Usually 'best 
standard of 
care' but can 
be more than 
one73 
Usually 'best 
standard of 
care' but can be 
more than 
one74 
Usually 'best 
standard of 
care' but can 
be more than 
one75 
Treatment in 
clinical guidelines 
of GPs; if not 
available, most 
prevalent 
treatment 
'Best standard of care' 
which is reimbursed in 
Poland76 
Best standard of 
care, usual care 
and/or more cost-
effective 
alternative 
Perspective Widest possible 
to include all 
health system 
stakeholders77 
Usually statutory 
health insurant78 
Societal Cost payer 
(NHS) or 
societal if 
justified 
Italian 
National 
Health 
Service79 
Societal (report 
indirect costs 
separately) 
The public payer's 
perspective, public payer 
+ patient (by law) 
Cost payer (NHS) 
and societal 
(rarely used), and 
they should be 
presented 
separately  
Subgroup analysis Yes (when 
justified) 
Yes Yes Yes Yes Yes Yes (if needed, but 
decreases validity) 
Yes 
Clinical Evidence 
Preferred study 
design 
Head-to-head 
RCTs; other 
designs accepted 
if no RCTs 
available 
Head-to-head RCTs; 
other designs 
accepted in the 
absence of RCTs 
Head-to-head 
RCTs; other 
designs 
accepted if no 
RCTs available 
Head-to-head 
RCTs; other 
designs 
accepted if no 
RCTs available 
Head-to-head 
RCTs; other 
designs 
accepted if no 
RCTs available 
Head-to-head 
RCTs 
Head-to-head RCTs; 
other designs accepted if 
no RCTs available. 
 
Head-to-head 
RCTs; other 
designs accepted 
if no RCTs 
available 
                                                 
 
71 Including most cost-effective, least expensive, most routinely used, and newest. 
72 Including most cost-effective, least expensive, and most routinely used. If the efficiency frontier approach is used as part of CBA, then “all relevant comparators within the 
given indication field” must be considered. 
73 Including most cost-effective, least expensive, and most routinely used. 
74 Including most cost-effective, least expensive, and most routinely used. 
75 Including most cost-effective, and most routinely used. 
76 These might include a) most frequently used; (b) cheapest; (c) most effective; and (d) compliant to the practical guidelines. 
77 Needs justification (especially if societal). 
78 Also community of statutorily insured, perspective of individual insurers, or the societal perspectives are possible. 
79 Societal perspective is not mandatory but it can be provided in separate analysis. 
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Systematic literature 
reviews for collecting 
evidence 
required/conducted 
by regulator 
Yes, guidelines 
provided/Yes, in 
French 
Yes / No Not mandatory Yes / Yes Yes / Yes  Yes / Yes Yes Not always80  
Meta-analysis for 
pooling evidence  
Not specified Not specified for 
new drugs  
 
Not specified Yes Yes Yes, encouraged Yes No81 
Data extrapolation Qualitative only, 
in absence of 
effectiveness 
data form RCTs 
No  
 
Quantitative, 
both in 
absence of RCT 
effectiveness 
data and in 
absence of 
long-term 
effects 
Qualitative and 
quantitative, 
both in absence 
of RCT 
effectiveness 
data and in 
absence of 
long-term 
effects 
Quantitative. 
Qualitative in 
absence of 
RCT 
effectiveness 
data 
Qualitative, in 
the absence of 
RCTs and in 
absence of long-
term effects 
Possible if needed but 
not recommended 
Quantitative, in 
the absence of 
effectiveness data 
Resources/costs 
Types Direct medical, 
direct non-
medical, indirect 
(both for patient 
and carer) 
Depending on 
perspective: direct 
medical, informal 
costs, productivity 
loss (as costs) 
Direct medical, 
direct non-
medical, 
indirect (both 
for patient and 
carer) 
Direct medical, 
social services 
Direct costs 
only. Indirect 
costs can be 
taken into 
account in a 
separate 
analysis 
Both direct and 
indirect costs 
inside and 
outside the 
healthcare 
system 
Direct medical costs, 
direct non-medical costs 
Direct and indirect 
costs (on rare 
occasions), costs 
of labour 
production losses 
or lost time, 
informal care 
costs 
                                                 
80 For non-drugs under RedETS, systematic literature review is always conducted. 
 
81 For non-drugs under RedETS, meta-analysis might be conducted. 
106 
 
Data source/Unit 
Costs 
Direct : PMSI 
(Programme de 
Médicalisation 
des Systèmes 
d'Information) 
 
Indirect: human 
capital costing, 
friction costing 
 
Statutory health 
insurance, further 
considerations 
depending on 
perspective chosen 
Drugs: 
pharmacy 
prices 
 
Indirect: 
human capital 
costing  
Official DoH 
listing 
Variety of 
sources82 
Reference prices 
list should be 
used 
Variety of sources83 Official 
publications, 
accounts of health 
care centres, and 
the fees applied to 
NHS service 
provision 
contracts 
Discounting 
Costs 4.0% (up to 30 
years) and 2.0% 
after 
3.0%  3.0% 3.5% Not available 
(update in 
progress) 
4.0% 5.0% 3.0% 
Outcomes 4.0% (up to 30 
years) and 2.0% 
after 
3.0% 3.0% 3.5% Not available 
(update in 
progress) 
Under review - 
will probably be 
set at same level 
as costs 
discounting 
3.5% 3.0% 
Sensitivity Analysis 0% , 3.0% (6% 
max) 
0% to 5% 0% to 5.0% 0% to 6.0% Not available 
(update in 
progress) 
Not obligatory 5% and 0% for costs and 
outcomes 
0% for outcomes 
5% for costs84 
From 0% to 5.0% 
Time Horizon 
Time Horizon Long enough so 
that all 
treatment 
At least the average 
(clinical) study 
duration; longer for 
chronic conditions, 
Time needed 
to cover all 
main outcomes 
and costs 
Long enough to 
reflect any 
differences on 
outcomes and 
Duration of 
the trial is 
considered85  
Primarily based 
on duration of 
RCTs86 
 
Long enough to allow 
proper assessment of 
differences in health 
outcomes and costs 
Should capture all 
relevant 
differences in 
costs and in the 
                                                 
82 Prices available in the Official Journal of the Italian Republic (Gazzetta Ufficiale), accounts of health care centres, the fees applied to NHS service, scientific literature/ad 
hoc studies. 
83 Including a) list of standard costs, b) formerly published research, c) local scales of charges, d) direct calculation. 
84 It is currently under revision (AOTMiT HTA Guidelines updating process) so may change soon. 
85 Additional long term evidence collected through monitoring registries. 
86 Secondary horizons include any longer needed depending on the context of interest. 
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outcomes can be 
included 
especially if lifetime 
gains are expected; 
same horizon for 
costs and benefits  
costs between 
technologies 
compared 
between the assessed 
health technology and 
the comparators 
effects of health 
treatments and 
resources87 
Thresholds 
Thresholds  No threshold 
(only eligibility 
threshold to 
conduct 
economic 
evaluation) 
 Efficiency frontier 
(Institute’s own 
approach) 
 No official 
threshold; 50% 
likelihood of 
approval for 
ICER between 
€79,400 and 
€111,700  
Implicit: ~ £20-
000 - £30,000 
per QALY; 
Empirical: 
£12,936 per 
QALY 
No threshold 
in use 
No official 
threshold  
3 x GDP per capita for 
ICUR(QALY) or ICER(LYG) 
Unofficial: 
€21,000 – €24,000 
/QALY (Recently 
provided by 
SESCS88 to the 
Spanish MoH) 
                                                 
87 In some cases, the time horizon will have to be extended to the individual's entire life. 
 
88 Servicio de Evaluación y Planificación, Canarias. 
 In the Netherlands and Italy the preferred type of economic evaluation is CUA if the 
improvement in quality of life forms an important effect of the drug being assessed, or, if 
this is not the case, a CEA 239,246. In Spain, any of the four methods of analysis may be used 
(CMA, CEA, CUA or CBA).  
 
4.3.3.2 Types of clinical evidence considered 
In relation to clinical evidence, all countries acknowledge that randomized controlled head-
to-head clinical trials is the most reliable and preferred source of treatment effects (i.e. 
outcomes), with data from less-rigorous study designs being accepted in most study 
countries (England, France, Germany, Sweden, Poland, Spain, Italy) e.g. when direct RCTs 
for the comparators of interest are not available 283,315,320.  
Most agencies require systematic literature reviews to be submitted by manufacturers 
as a source of data collection and carry out their own reviews. A meta-analysis of key-clinical 
outcomes is recommended for pooling the results together given the homogeneity of the 
evidence in England, Italy, Netherlands and Poland 283,315. 
If evidence on effectiveness is not available through clinical trial data, then France 
and Netherlands allow for a qualitative extrapolation based on efficacy data, with Spain 
conducting quantitative extrapolation and Sweden, England, Italy and Poland applying both 
qualitative and quantitative modelling. In Sweden, England and Netherlands, short-term 
clinical data are extrapolated also if data on long-term effects are absent. 
 
4.3.3.3 Resources/cost evidence 
In terms of resources used, in addition to direct medical costs, France and Sweden consider 
all relevant costs including direct non-medical and indirect costs, both for patients and carers 
267,283; however, only direct costs are considered in the reference case analysis and 
incorporated in the ICER in the case of France 258. Germany also takes into account informal 
costs and productivity gains separately as a type of benefit, whereas England additionally 
considers cost of social services.  
Poland incorporates direct medical costs and direct non-medical costs. In the 
Netherlands, the Health Care Insurance Board’s “Manual for cost research” applies for the 
identification, measurement and valuation of costs; pharmacoeconomic evaluations need to 
include both direct and indirect costs inside and outside the healthcare system 246. In Italy it 
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is recommended to include direct costs; indirect costs can be taken into account in a separate 
analysis  227. Spain incorporates both direct and indirect costs (the latter on rare occasions) 
as well as costs of labour production losses or lost time and informal care costs in the analysis 
227,302. Finally all countries recommend the application of country-specific unit costs 283. 
 
4.3.3.4 Discounting and time horizon 
In all study countries both costs and benefits are discounted 267,302,318,320, and uncertainty 
arising due to variability in model assumptions is investigated usually in the form of 
sensitivity analysis. Generally, in each country discounting levels for costs are equal to 
discounting levels for outcomes, ranging from 3% to 5%, with the complete range of 0% to 
5% (or even 6%) usually being explored with sensitivity analysis.  In Italy, information on 
discounting is not available at the moment given an update in progress by AIFA 227. In terms 
of a suitable time horizon, none of the countries uses an explicit time frame but instead they 
adopt a period that is long enough to reflect all the associated outcomes and costs of the 
treatments being evaluated, including the natural course of the disease 262,267.   
 
4.3.3.5 Acceptable “value for money” thresholds  
No explicit, transparent, or clearly defined cost-effectiveness thresholds exist in any of the 
countries except for Poland, Spain and, possibly, England.  
In line with the World Health Organization (WHO) suggestions of two to three times 
GDP per capita, a three times GDP per capita threshold has been implemented in Poland. 
Generally, a drug is deemed cost-effective by AOTMiT if estimates are greater than one time 
the GDP per capita, but smaller than 70,000 PLN per QALY/LYG 292. In Spain, a €21,000 - 
€24,000 per QALY threshold was recently provided by Servicio de Evaluación y 
Planificación Canarias (SESCS) to the Ministry of Health 227. 
In England, although some evidence suggests the existence of an implicit threshold 
ranging somewhere between £20,000 and £30,000 231,272,295,314, it is evident that such a range 
is not definite mainly because some products with a cost per QALY below these ranges 
receiving negative coverage decisions and other products above these ranges ending up with 
positive recommendations 243,288,304. Indeed, several studies point towards the existence of a 
threshold range based on which additional evidence on several factors are required for the 
recommendation of technologies with an ICER of above £20,000, and even stronger 
evidence of benefit in combination with explicit reasoning required for the coverage of 
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technologies with an ICER above £30,000 231,237,268,306,315,328. However, a more recent study 
using data on primary care trust spending and disease-specific mortality estimated an 
empirical based “central” threshold of £12,936 per QALY, with a probability of 0.89 of less 
than £20,000 and a probability of 0.97 to be less than £30,000 322. 
In Germany, the efficiency frontier approach is used to determine an acceptable 
“value for money”, even though this is not involved in the process of the initial rebate 
negotiations. In Sweden,  recent evidence suggested that the likelihood of approval is 
estimated to be 50% for an ICER between €79,400 and €111,700 for non-severe and severe 
diseases respectively 329.  In the Netherlands, there is no formal threshold in place but there 
have been some attempts to define one. The €20,000 per life-year gained (LYG) threshold 
used in the 1990s to label patients with high cholesterol levels eligible for treatment with 
statins has been mentioned in discussions on rationing, but was never used as a formal 
threshold for cost-effectiveness. The same was the case with a threshold that the Council for 
Care & Public Health wanted to implement based on criteria such as the gross domestic 
product (GDP) per capita, in line WHO recommendations, which for the Netherlands would 
translate into €80,000/ QALY 234. The Council also suggested that the cost per QALY may 
be higher for very severe conditions (a tentative maximum of €80,000) than for mild 
conditions (where a threshold of €20,000 or less may be applied) 232, but none of the above 
was ever implemented. 
 
4.3.4 HTA Outcomes and Implementation 
In all countries, assessment and appraisal of outcomes are mainly used as a tool to inform 
coverage decisions relating to the reimbursement status of the relevant technologies; all 
countries use the results to inform pricing decisions directly or indirectly. A summary of the 
types of HTA outcomes and implementations in the study counties is presented in Table 4.4. 
 
 
 
 
 
 
Table 4.4: HTA outcomes and implementation 
  FRANCE  
(HAS / CEESP) 
GERMANY 
(IQWiG) 
SWEDEN  
(TLV) 
ENGLAND  
(NICE) 
ITALY  
(AIFA) 
NETHERLANDS (ZIN) POLAND  
(AOTMiT) 
SPAIN 
(RedETS/ISCIII or 
ICP) 
Publicly Available 
Report 
Yes, both in 
French and 
English89 
 
 Yes Yes (summary 
report with 
some details on 
cost-
effectiveness) 
Yes Yes, in the Official 
Journal of the 
Italian Republic 
(Gazetta Ufficiale) 
Yes  Yes (in Polish on the 
AOTMiT website), but 
confidential 
information is publicly 
unavailable  
No for drugs90 
Policy 
Implication 
Reimbur
sement 
Yes, through 
SMR91 
Yes Yes Yes Yes Yes Yes Yes 
Pricing  Yes, through 
ASMR92 
Yes Yes No, only 
indirectly as it 
has an impact 
on product's 
ICER 
Yes Yes, except certain 
expensive 
medicines93 
Yes, if reimbursement 
decision is positive 
Yes 
Access restrictions Yes, various 
restrictions in 
place94 
Existence of 
managed 
entry 
agreements 
but details not 
Yes, restrictions 
for specific 
subpopulations, 
temporary 
decisions and 
Yes, major and 
minor 
restrictions as 
well as 
performance 
Yes, various 
managed entry 
agreements95  
Yes, system of 
coverage with 
evidence 
development (CED)  
 
Yes, including major 
and minor96 
Yes 
                                                 
89 Economic Evaluation reports are available but some parameters are deleted in the public version (elements related to medicines costs mainly). 
90 For non-drug technologies under RedETS usually yes in the form of bulletins and web pages of HTA agencies. 
91 The level of SMR determines if a drug shall be reimbursed and if yes, at which level (low 15%, mod 30%, high 65%). 
92 The level of ASMR is used for pricing negotiations with manufacturers. 
93 A bureau of the government on a case-by-case approach negotiates rebates with the industry for certain expensive medicines (actual price is ‘secret’ but hospitals can ask for 
an add-on). 
94 Including recommendation to only reimburse this medicine in second intention, restrictions to specific sub-populations,  
Financial risk-sharing (price-volume agreements and budget caps). 
95 Such as PVAs, cost-sharing, budget cap, monitoring registries, payment by results, risk-sharing, therapeutic plans, and “AIFA notes”. 
96 Major include restricted to specific subpopulations (monitoring of use); Minor include requiring a lower price so called Risk Sharing  
Schemes (cost sharing in practice). 
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publicly 
available 
risk sharing 
agreements 
 
based 
agreements  
Dissemination Publicly 
available 
online  
Dossier 
assessment, 
Reports, 
Rapid reports, 
Addendums 
Informational 
material 
distributed to 
the major 
stakeholders, 
decisions 
published 
online 
 Publicly 
available online 
Monthly AIFA 
publication of price 
lists of reimbursed 
products. Annual 
publication of data 
on pharmaceutical 
expenditure and 
consumption  
(Rapporto Osmed) 
Online for general 
public and distributed 
to stakeholders 
 Publication online  No for drugs97 
Implementation Prescription 
guidelines, 
drug 
formularies 
and positive 
list 
Prescription 
advice issued 
by G-BA based 
on 
therapeutic 
assessment 
(“Therapiehin
weise”) 
Drug 
formularies 
Prescription 
guidelines, drug 
formularies  
A product can be 
assigned to Class A, 
H or C98 
 
 
Positive list.  
In case of therapeutic 
equivalent, the drug 
is either not accepted 
for public 
reimbursement or 
subject to a reference 
pricing system 
Different 
reimbursement lists 
categories99 
Inclusion in the 
national 
reimbursement 
list  
Appeal Yes100  Yes, through 
arbitration 
board101 
Yes Yes Companies can 
appeal to Court but 
there is no specific 
appeal procedure 
Yes No Yes 
                                                 
97 RedETS reports for non-drugs become publicly available. 
98 Class A refers to products reimbursed by the NHS. Class H refers to products for hospital use. Class C refers to non-reimbursed products. 
99 Pharmacy drugs (Rx drugs; 30% or 50% patient co-payment, lump sum, no co-payment); drug programmes (selected diseases and patients; free); chemotherapy drugs 
(hospital settings; free); drugs reimbursed in off-label indications. 
100 Manufacturers can appeal to decisions made by both commissions. They are then called for an audition to explain their position. 
101 Manufacturers have the right to commission CBA if they do not agree with the established added benefit. 
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Revision Yes, every 5 
years or 
sooner if 
decision from 
HAS or request 
from the MoH. 
Yes, at least 
one year after 
benefit 
assessment102 
Yes  Yes Yes103 
 
Yes, but not on a 
regular basis104 
Yes, 2 years after first 
assessment, 3 year 
after 2nd, 5 years after 
3rd assessment 
Yes 
                                                 
102 In some cases, decisions are time-limited, revision takes place once the term is over. 
103 The negotiation process leads to a 2 year confidential, renewable contract between AIFA and the manufacturer. 
104 In practice, providers that have no adequate reimbursement due to a new innovation will ask the Dutch healthcare authority for a revision of reimbursement. The agency 
then investigates if a revision is reasonable and what the new reimbursement should be. 
4.3.4.1 Timing and public availability  
Generally the time needed for the evaluation of a health technology to be completed differs 
from country to country. However, in line with the EU Transparency Directive, all countries 
must have reached a decision on pricing and reimbursement within 180 days post marketing 
authorisation 328. In all countries the final decision report is publicly available, usually 
through the HTA agency’s website 216,328, and the policy implication of the evaluation 
outcome relates to the pricing and reimbursement status of the technology: reimbursement 
(List), no reimbursement (Do Not List), or conditional reimbursement (List with 
Restrictions) 278,328. 
 
4.3.4.2 Policy implications 
In France and Sweden, only drugs with additional therapeutic value can “obtain a higher 
reimbursement basis” 328; in France, by assessing the evidence of the product’s medical 
benefit or medical service rendered (Service Médical Rendu, SMR), the improvement in 
medical benefit and added therapeutic benefit (Amélioration du Service Médical Rendu, 
ASMR) are derived, which determine the reimbursement status and influence the price level 
of the product respectively, whereas in Sweden the outcome of the evaluation can also drive 
the price setting in addition to coverage decisions 312,313.  In Germany, the outcome of the 
clinical/economic evaluation will be used mainly to inform the negotiation between sickness 
funds and manufacturer on the price premium. In England reimbursement status has no direct 
effects on price, but indeed price indirectly affects the reimbursement status of the drug as it 
will have an impact on the ICER. In the Netherlands, the positive outcome of an HTA results 
to the inclusion of the medical technology in the positive list 253. In terms of the 
reimbursement decision, if the cost-effectiveness analysis for a new innovative drug is of 
good quality, reimbursement will principally not be denied on the basis of cost-effectiveness, 
despite potentially relatively high cost-per-QALY values 234. Finally, in Italy, if a 
reimbursement status is approved, the pricing is decided simultaneously. If the 
reimbursement decision is negative, the product will be put on the negative list and price is 
determined by the manufacturer (“free pricing”). 
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4.3.4.3 Access restrictions  
All countries apply access restrictions usually relating to specific indications or specific 
population sub-groups. France mainly uses financial risk-sharing (price-volume) agreements 
328. Sweden issues temporary decisions for cases when there is insufficient certainty around 
the (clinical) evidence 328 and risk sharing agreements may take place to speed up the 
reimbursement process upon the requirement of additional evidence ex post the review 294, 
in addition to restricting access for specific sub-populations. In England, major and minor 
restrictions exist: the former relate to cases where the technology is indicated only for 
second-line treatment (and beyond) or for only specific sub-population, and the latter relate 
to the need for specialist supervision or treatment monitoring 268; performance based 
agreements (or response rules) also exist, especially in regards to the use of biologics and 
cancer drugs, according to which a pre-specified clinical (endpoint) condition must be 
reached at a specific post-assessment time point for the coverage of the technology to 
continue  235. In the Netherlands, the system of coverage with evidence development (CED) 
for high cost and orphan inpatient drugs has been extensively used between 2006 and 2011. 
Currently, financial-based agreements and performance-based risk sharing agreements are 
considered as well. In Poland, restrictions could be applied to a positive recommendation, 
which can be either major, e.g. restricted to specific subpopulations (monitoring of use), or 
minor: e.g. requiring a lower price (so called Risk Sharing Schemes, but cost sharing in 
practice) 227. In Spain, MEAs are concluded at the regional level. PVAs agreements are 
usually applied to single new products where the negotiated price is conditioned by the 
expected number of units sold.  
 
4.3.4.4 Dissemination and implementation 
Most countries employ dissemination procedures in order to support the implementation of 
their decisions, including prescribing guidelines and national drug formularies 253. In France, 
since 2013, there is a public online drug database allowing the general public to access data 
and documents on marketed drugs 260. In Germany, IQWiG prepares a variety of 
dissemination products besides the dossier assessment including technical scientific reports 
(and rapid reports where no commenting procedures take place) but also public and user-
friendly health information and working papers on recent developments on the field and 
methodological aspects 265. The dossier assessment is provided by the G-BA which can also 
issue prescription advice 227. In Sweden, at least for the review of products that are already 
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on the positive list, informational material in the form of a fact sheet is produced (possibly 
accompanied by supplementary information taking the form of a PowerPoint presentation 
and an FAQ sheet), covering the analysis, the appraisal and the conclusion of the evaluation, 
distributed to the major stakeholders on the date of the decision and about a week before it 
becomes publicly available online 312,313. In England, NHS is legally obliged to implement 
NICE guidance and fund the recommended technologies within 3 months from the outcome 
of the decision, possibly by displacing resources from the use of other technologies 243,315. 
In Poland, since the Reimbursement Act (issued in 2011, effective from January 1st, 2012), 
drugs can be reimbursed under different lists 227. Pharmacy reimbursement includes 
prescribed-only medicines available to patients through four main categories of co-payment. 
Chemotherapy drugs are available in hospital setting free of charge. Other “regimen” 
programs are available under which drugs for selected diseases are reimbursed free to strictly 
defined patient populations whose eligibility is decided from a clinicians’ committee.  
 
4.3.4.5 Appeal mechanisms and review of decisions  
Most countries have appeal mechanisms in place in case of dissent, and they all revise their 
decisions either according to fixed time schedule or on a rolling basis 320,328; in France, the 
drug registration is subject to renewal every 5 years and a drug may also be subject to post-
registration studies. Sweden re-evaluates its old reimbursement list, and both Sweden and 
England may revise technologies once new evidence becomes available. On average the 
positive recommendations (with or without restrictions) are around 90% for NICE 241.  
Although it appears that revisions were taking place systematically after four years for in-
patient drugs and on an ad hoc basis for out-patient drugs 242,328, more recent evidence 
suggests that in practice, the process is irregular and providers that have no adequate 
reimbursement due to a new innovation will ask the Dutch healthcare authority for a revision 
of reimbursement. The agency then investigates if a revision is reasonable and what the new 
reimbursement should be 227. In Italy, the negotiation process leads to a two year 
confidential, renewable contract between AIFA and the manufacturer 227, and a possible 
revision is feasible on the grounds of a new product exceeding the original forecast of a 
company.  
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4.4 Discussion 
In all study countries HTA agencies are autonomous bodies. The evaluation process of 
medical technologies includes an initial assessment of evidence conducted by technical 
groups, followed with the appraisal of the assessed evidence from an expert committee that 
is producing reimbursement and coverage recommendation(s) for the final decision body 
which can be either the payer (e.g. MoH, HIF), or the HTA agency itself. 
In addition to the comparative assessment of clinical benefit, most countries 
implement a type of economic evaluation (mainly CUA or CEA) as the main analytical 
method to determine the value of new technologies, with the preferred health gain measure 
usually being the QALY or other alternative patient-relevant (if not final) outcomes. For the 
elicitation and measurement of utility scores, preference-based elicitation techniques (e.g. 
time trade-off, standard gamble) are used to elicit utility scores either from patients or the 
general population.  
The evaluation (assessment and appraisal) outcome is mainly used as an aid to make 
coverage decisions in relation to the reimbursement status of the medical technologies, but 
in all countries the analysis outcomes are used to influence pricing decisions as well 
(indirectly in England). Access restrictions for sub-populations or sub-indications, possibly 
through the application of risk sharing agreements, have become common practice across 
many jurisdictions. Information material is often disseminated by the HTA agencies to a 
range of stakeholder groups; the implementation of the agencies decisions is usually taking 
the form of prescription guidelines and drug formularies. Technology suppliers across all 
jurisdictions have the option of dissent/appeal and revision of the decision is taking place 
either every a standard period of time or when new evidence becomes available. 
The results show that different additional criteria beyond economic evaluation or 
clinical benefit assessment are captured or included in the evaluation process that may 
explain heterogeneity in coverage recommendations and decision-making. 
Overall, all countries assess similar types of evidence, however the specific endpoints 
used, their level of provision and requirement, the way they are incorporated (e.g. explicitly 
vs. implicitly) and their relative importance varies across countries. The main evidence 
assessed could be divided into six clusters of information: (a) burden of disease, (b) 
therapeutic & safety impact, (c) innovation level, (d) socioeconomic impact, (e) efficiency 
considerations and (f) other sources of evidence and criteria. 
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4.4.1 Conceptual and Methodological Limitations in Value Assessment  
Current value assessment approaches mainly consider (comparative) clinical efficacy in 
combination with clinical cost-effectiveness techniques, while increasingly incorporating 
real world evidence following drug market entry, thus reflecting comparative effectiveness 
and efficiency. However, there is considerable subjectivity in the criteria selection used to 
interpret evidence and determine product value, often lacking a sound basis and therefore 
leading to arbitrariness, for example relating to which metrics to use for measuring efficacy 
and effectiveness, what type of costs to consider, and very importantly how to account for 
other key dimensions of value.  
Most of the value assessment approaches examine the efficacy/effectiveness, or cost-
effectiveness of new interventions by mostly addressing only a partial dimension of ‘overall 
value’ in a systematic and explicit manner that mainly relates to ‘Scientific Value 
Judgments’ (ScVJ) of their therapeutic aspect (e.g. safety, efficacy, effectiveness), possibly 
in relation to cost. However, the value of new medical technologies is multi-dimensional and 
not only limited to clinical benefit and cost. In addition to commonly used ScVJ which is 
based solely on “scientific” evidence relating to clinical cost-effectiveness and ICERs, other 
“social” value factors falling under the information clusters of burden of disease, innovation 
level and socioeconomic impact also play a definitive role in decision-making through the 
exertion of ‘Social Value Judgements’ (SoVJ), however they are rarely formally 
incorporated in the evaluation process.  
In most settings, the absence of clarity on the use of SoVJ, including their interplay 
with ScVJ and their influence on decisions remains unknown. Social value elements are 
usually considered implicitly by HTAs or decision-makers, mostly non-transparently on an 
ad hoc basis. For most of them it is not known what their relative importance is, and what 
the trade-offs are that HTA bodies are willing to make. As a result, the definition of value 
could be regarded as an elusive concept given that a multiplicity of evaluation criteria applies 
across different settings and with differential intensity in a non-systematic manner.  
 
4.4.2 Policy Implications and Ways Forward  
Following the technical review of policy initiatives and opportunities for collaboration and 
research for access to new medicines in Europe, WHO proposes for more extensive use of 
HTA in decision-making 330. However for this to take place a more holistic perspective and 
coordinated actions would be needed.   
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Decision-makers as well as other stakeholders need clear, comprehensive and 
transparent ways of assessing clinical and economic benefit and the impact those new 
treatments have from a wider socio-economic perspective in order to make rational decisions 
about priority setting. Not having such methods creates a conceptual, methodological and 
policy gap. Appropriate adaptations on the current methodologies or development of new 
transparent conceptual frameworks seem to be needed.   
NICE in England is one of the forerunner agencies in acknowledging, formalising 
and creating a methodological landscape for SoVJ, which include, first, the burden of disease 
the treatment addresses, hence the clinical and policy importance of the health topic under 
consideration; second, the cost impact on resources from a societal perspective; third, policy 
objectives relating to the long-term benefits of innovation 146-148, and, in general, the broader 
balance between benefits and costs. The existing influence of disease severity could be 
illustrated from the case of end of life treatments, where QALYs gained for terminal illnesses 
are having a greater weight 153, on the grounds that society places a special value on 
extending the lives of the terminally ill 67. Decision-makers have been exploring new ways 
of considering additional value parameters, while highlighting the need for “a broader and 
more transparent assessment” methodology, suggesting a move towards value based 
assessment 31,154.    
Aspects of HTA shortcomings have also been reflected by various recent initiatives 
seeking to establish “value frameworks” aiming to aid pricing and clinical practice decisions 
by considering a variety of parameters for the assessment of value, possibly in relation to 
costs. A lot of that work has been driven by health care professional associations 170-172,174,175. 
However, attention should be paid on their methodologies, for recommendations to be robust 
and avoid misguided decisions 177. All these initiatives have attempted to adopt multi-criteria 
evaluation approaches, albeit in a very simplified and relatively abstract manner. Other 
approaches embedded in decision analysis could address benefit-risk assessment 
considerations of health care interventions 72,331. Considering the limitations this systematic 
review has highlighted in the context of HTA as it is practised currently, it looks as though 
multi-criteria decision analysis methods could be explored to capture the value of new 
medical technologies in a holistic manner and, through this, facilitate HTA decision-making 
processes in a spirit of transparency, encompassing and robustness 332,333.  
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4.5 Conclusion  
The study highlights a number of significant similarities but also considerable differences in 
practices, processes and policies of value-assessment for new medicines across the study 
countries. These differences could exist because of different national priorities between 
countries, but also because of different processes and methodological frameworks adopted 
for the elicitation of decision-makers’ preferences. Overall, there is significant uncertainty 
with regards to what additional value criteria to incorporate, how to establish their relative 
importance, and whose preferences to consider. Currently, all these decisions are subject to 
DMs’ discretion but are, in most cases, exemplified in a less than transparent way, potentially 
resulting in some form of bias. 
Procedures characterized by greater transparency or clarity in terms of value criteria 
used and a higher degree of encompassing and methodological robustness could lead to more 
rational evidence-based decision-making, contributing to more efficient resource allocation 
and, potentially, higher societal welfare, while also raising public confidence and fairness in 
terms of homogeneity and consistency of decision outcomes. 
The limitations of the current value assessment methodologies and the identified 
conceptual and policy gaps suggest that there is a need for alternative methodological 
approaches that encompass multiple evaluation criteria explicitly, so that value can be an 
explicit function of a number of parameters beyond those currently used. This is increasingly 
becoming imperative in the context of European collaboration, particularly if some form of 
joint assessment at EU level is likely to emerge beyond 2020. Decision analysis and multi-
criteria evaluation approaches could provide the foundation for alternative ways of 
measuring and eliciting value of new medicines and technologies as they provide a 
comprehensive alternative for quantitative modelling.  
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Chapter 5 – Paper 3 
Methodological Framework: a Multiple Criteria Decision Analysis Value 
Measurement Model and Techniques for the Evaluation of New 
Medicines in Health Technology Assessment105 
 
Summary 
Escalating drug prices have catalysed the generation of numerous “value frameworks” with 
the aim to inform payers, clinicians and patients around the assessment process of new 
medicines for the purpose of coverage and treatment selection decisions.  Although this is 
an important step towards a more inclusive Value Based Assessment (VBA) approach, 
aspects of these frameworks are based on weak methodologies and could potentially result 
in misleading recommendations or decisions.  
A Multiple Criteria Decision Analysis (MCDA) methodological process based on 
Multi Attribute Value Theory (MAVT) is adopted for building a multi-criteria evaluation 
model. A five-stage model-building process is followed, using a top-down “value-focused 
thinking” approach, involving literature reviews and expert consultations. A generic value 
tree is structured that captures decision-makers’ concerns for assessing the value of new 
medicines in the context of Health Technology Assessment (HTA) and in alignment with 
decision theory.  
The resulting value tree (Advance Value Tree) spans three levels of criteria (top level 
criteria clusters, mid-level criteria, bottom level sub-criteria or attributes) relating to five key 
domains that can be explicitly measured and assessed: (a) burden of disease, (b) therapeutic 
impact, (c) safety profile (d) innovation level, and (e) socioeconomic impact. A combination 
of MAVT modelling techniques is proposed for operationalising (i.e. estimating) the model: 
an indirect elicitation technique for value functions based on pairwise qualitative judgments 
for scoring the alternative options (MACBETH), an indirect qualitative swing weighting 
technique for assigning relative weights of importance to the criteria (MACBETH-
                                                 
105 Chapter 5 has been published with co-author Prof Panos Kanavos as: Angelis A, Kanavos P. 
Multiple Criteria Decision Analysis (MCDA) for Evaluating New Medicines in Health Technology 
Assessment and Beyond: the Advance Value Framework. Social Science & Medicine (2017). In 
press; doi.org/10.1016/j.socscimed.2017.06.024 
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weighting), and a simple additive aggregation technique for combining scores and weights 
together.   
Overall, the combination of these MCDA modelling techniques for the elicitation 
and construction of value preferences across the generic value tree provides a new value 
framework (Advance Value Framework) enabling the comprehensive measurement of value 
in a transparent and structured way. Given the fully flexibility to meet diverse requirements 
and become readily adaptable across different settings, it enables its use as a decision-
support tool for policy-makers around the coverage and reimbursement of new medicines.  
 
5.1 Background 
Scarce resources, rising demand for health services, ageing populations and technological 
advances threaten the financial sustainability of many health care systems and render 
efficient and fair resource allocation a cumbersome task 4,6-9. Decision-making in health care 
is inherently complex as numerous objectives need to be balanced, usually through the 
involvement of many stakeholders. One set of tools used widely to improve efficiency in 
resource allocation is Health Technology Assessment (HTA). The use of HTA has expanded 
significantly over the past 20 years and is used to assess and appraise the value of new 
medical technologies as well as inform coverage decisions.  
Evidence-based medicine 334,335, economic evaluations 336,337, burden of disease 
estimates 338, and budget impact analysis 282 can be used to inform decisions on resource 
allocation. Nevertheless, they offer limited guidance to decision makers, as their results 
cannot be integrated and judged simultaneously and neither can the value trade-offs 
associated with them 64. The use of economic evaluation techniques such as cost 
effectiveness analysis (CEA) has become the preferred analytical method adopted by many 
HTA agencies. However, not all the value concerns of decision-makers for evaluating the 
performance of different health care interventions are adequately reflected in a cost 
effectiveness model 339. For example, the use of cost utility analysis (CUA) and the cost per 
unit of quality adjusted life year (QALY) has become the metric of choice by many HTA 
agencies when assessing and appraising value. By definition though, it only considers length 
of life in tandem with health related quality of life, and does not adequately capture social 
value such as the wider innovation and socioeconomic impact 209,210.  
Due to the complexity of these multiple criteria problems, decision-makers tend to 
adopt intuitive or heuristic approaches for simplification purposes, but as a consequence 
important information may be under-utilised or be altogether excluded leading to choices 
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based on an ad hoc priority setting process 64. Eventually the decision making process tends 
to be explicitly informed solely by evidence from economic evaluations, with social value 
concerns being considered on an implicit and ad hoc basis. As a consequence, when faced 
with multiple trade-offs across a range of societal values, decision makers seem not to be 
well equipped to make informed and rational decisions 70,71, therefore diminishing the 
reasonableness and credibility of the decision outcomes. It is probably the case that a more 
“rational” approach is needed that can simultaneously take into account the multiplicity of 
criteria, and that can aggregate the performance of alternative interventions across the 
criteria of interest while accounting for differences between their relative importance, 
therefore enabling the overall construction and analysis of decision makers’ preferences in 
a simple and transparent way. The multiple initiatives that have emerged over the past few 
years through the development of value frameworks aiming to aid reimbursement agencies, 
health care professionals and patients understand the value of new therapies and make better 
choices about their use serve as a testament to this particular gap.  
Some of the most prominent and well known value frameworks that have attracted a 
lot of attention include those proposed by the American College of Cardiology and the 
American Heart Association (ACC/AHA) 170, the American Society of Clinical Oncology 
(ASCO) 171, the European Society of Medical Oncology (ESMO) 172, the Institute for 
Clinical and Economic Review (ICER) 173, the Memorial Sloan Kettering Cancer Centre 
(MSKCC) 174, the National Comprehensive Cancer Network (NCCN) 175, and the Working 
Group on Mechanisms of Coordinated Access to Orphan Medicinal Products (MoCA-OMP)  
176 among others. These value frameworks adopt multiple criteria approaches in an attempt 
to decompose complex problems into slightly simpler ones and address these sequentially. 
As such, they are an important step towards a more inclusive Value Based Assessment 
(VBA) process despite being perceived as weak and atheoretical and potentially of little 
value for policy or clinical decision-making 177. Despite the proliferation of value 
frameworks, ‘value’ remains an elusive target and a wider consensus about what dimensions 
of value to include may still be some way off, maybe with the exception of frameworks that 
are applied in clinical practice (as potential value dimensions are more restricted in nature).  
The use of multiple criteria decision analysis (MCDA) methods has been proposed 
as an alternative methodological approach for assessing the value of health care interventions 
in different contexts, ranging from licensing decisions at the marketing authorization stage 
331, to coverage decisions at the HTA stage 196, to treatment selection decisions at prescribing 
level 340. MCDA methods can be used for quantifying benefits, risks and uncertainties in 
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order to aid the decision-making process, by considering an explicit set of criteria and their 
relative importance under a fully transparent process, while incorporating a wide range of 
stakeholder views to express a more societal perspective.  
A methodological process towards the development of a robust MCDA framework 
observing key principles to ensure methodological robustness and consisting of different 
phases and stages for implementation in the context of HTA has already been proposed 332. 
Possibly the most fundamental phase of the MCDA process with the highest impact on the 
overall outcomes relates to model building and the criteria selection phase, essentially 
directing the value concerns being addressed based on which the alternative options will be 
assessed against. 
In this paper I focus on model building and criteria selection, describing the 
development of a generic value based model taking the form of a value tree for the purpose 
of assessing the value of new medicines in the context of HTA by capturing value for 
decision makers. Although in theory such a value tree can be generic for any type of health 
technology, including drugs, medical devices and other health interventions, for ease of 
illustration, I focus on new medicines.  In Section 2, I discuss the theoretical foundations of 
MCDA, starting with the theoretical axioms of decision analysis that essentially address the 
question of “what is the basis of MCDA”.  In section 3, I outline the methods for model 
building and the selection of different evaluation criteria. Section 4, presents the results 
involving the assembly of decision makers’ concerns into a comprehensive generic value 
tree, which provides insights into “what is value in the context of HTA”. Section 5 presents 
the discussion, introducing different MCDA methods and proposes ways to operationalise 
the value tree through a precise combination of MCDA techniques and addresses the 
question of “how to apply MCDA in HTA” through the use of a new value framework.  
Finally, section 6 draws the main conclusions. 
 
5.2 Theoretical Foundations 
Decision analysis was originally defined by Howard as “a logical procedure for the balancing 
of the factors that influence a decision” incorporating “uncertainties, values, and preferences 
in a basic structure that models the decision” 52. The logic behind decision analysis was 
described as divide and conquer whereby a complex problem is decomposed into simpler 
problems and each individual problem is analysed separately before all analyses are 
connected together, resulting in a program of action for the complex problem 53. The 
methodology of decision analysis is simplified to 4 main steps, notably (a) structure the 
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decision problem; (b) assess possible impacts of each alternative; (c) determine preferences 
(values) of decision makers; and (d) evaluate and compare alternatives 52,53. 
The starting point for this discussion is that the value of new medical technologies is 
multidimensional and not limited to their clinical effect or benefit. Besides the traditional 
dual clinical consideration of health benefits and risks, taking the form of efficacy and safety 
considerations, or the emerging dual economic consideration of health benefits and costs, 
taking the form of health outcomes and costs per outcome unit, other factors may also be 
important for determining the value of a new medicine. The severity and unmet need of the 
disease, the clinical novelty and convenience to patients, or the wider benefits to society 
have been at times perceived as important considerations of value to decision makers for the 
purpose of achieving efficient resource allocation 31.    
Based on that, the value of new medical technologies can be illustrated as a function 
of different evaluation parameters, as part of a linear additive model, namely: 
 
                                       𝑉𝑎𝑙𝑢𝑒 = 𝑓(𝑎𝑖𝑗, 𝑏𝑖𝑗, 𝑐𝑖𝑗, 𝑑𝑖𝑗, … , 𝑛𝑖𝑗)            (5) 
 
where a, b, c, d,… n denote the different parameters of interest, i denotes the medical 
technology’s value in regards to a particular parameter and j denotes the relative importance 
weight of the same parameter based on decision-maker or other stakeholder views. 
Additionally, questions remain on how to incorporate the views of all relevant stakeholders 
and how to derive relative weights for the different parameters.  
Given that the value of new medical technologies is based on a multitude of value 
dimensions and the limitations of current approaches to value assessment, there is a need for 
an alternative methodological approach of value assessment that encompasses multiple value 
domains explicitly, therefore a decision analysis method that addresses multiple attributes of 
benefit is required. 
Among methodological tools for assessing value quantitatively as part of decision-
making process, MCDA could be indicated as an adequate method, ordering a set of 
alternative options based on the degree to which a number of different objectives are 
achieved 1,168. One of the main aims of MCDA methods is to enable decision makers reach 
a decision by facilitating them to learn and understand more about the problem, objectives, 
and values being faced, through organising and synthesising information of complex and 
conflicting nature 2. MCDA can facilitate decision making by explicitly integrating objective 
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measurement with value judgement while managing subjectivity in a transparent way, 
however it cannot act as a substitute to decision-making.  
Having introduced the theoretical foundations of decision analysis and the overall 
MCDA process, the next step is to focus on the model-building phase by applying MCDA 
principles. As part of the model-building phase, the criteria selection stage is crucial, 
involving their identification and assembly into a hierarchical structure taking the form of a 
tree 56,341. The aim is to arrive at a generic value model for new medicines that can be adapted 
to capture all relevant dimensions of value across different decision-making contexts and 
therapeutic indications. Criteria represent the key concerns influencing a particular decision. 
Structuring all the criteria in the form of a tree is known as a value tree and provides an 
organized schematic representation of the various concerns under consideration by the 
decision-maker. The criteria-based evaluation of options is operationalised through the use 
of performance descriptors, either of a qualitative or quantitative nature, known as attributes 
which essentially measure the fulfilment of the criteria (Box 1). 
 
 
Box 1: Definitions of decision analysis terminology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Criterion: an ‘individual measurable indicator’ of a key value dimension 1 or 
more precisely, a ‘particular perspective according to which alternative 
technologies may be compared 2.  
Attribute: a ‘quantitative or qualitative measure of performance associated with a 
particular criterion’ 2, or in other words a descriptor of performance or impact  
requiring ordering of preference 3 
Value tree: an organized schematic representation of the various objectives, 
criteria and attributes under consideration. 
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5.3 Methods 
5.3.1 Model Building Approaches 
The three main steps in building a multi-criteria model are to (a) structure a value tree that 
identifies and represents the objectives or key concerns of decision makers, (b) define 
attributes at the bottom level of the value tree to measure the achievement of these objectives, 
and (c) select decision alternatives 204.  
Structuring a value tree can generally be done using two approaches; either through 
a top-down approach (known as value-focused thinking), which is driven by the overall 
objective or value concern and is decomposed into lower levels of sub-objectives or sub-
concerns; or a bottom-up approach (known as alternative-focused thinking), which is driven 
by the alternative options under consideration based on attributes that distinguish between 
them and which are grouped into higher levels of objectives and concerns 54.  
Given the aim of the study is to build a generic model that can subsequently be 
adapted and applied across different decision-making contexts, I used the top-down 
approach (value-focused thinking) 3, so that the model can reflect the overall value concerns 
of decision makers while being adaptable to different decision problems. In other words I 
aimed to incorporate the value dimensions of new medicines in general that decision makers 
want to capture as part of the evaluation process.  With regards to the completion of the 
remaining two tasks (attribute definition and selection of decision alternatives), I recommend 
the adoption of the bottom-up approach (alternative-focused thinking) following the 
definition of the decision problem 342, so that the model can become decision-specific to 
precisely assess the performance of alternative treatments as needed. As such, I suggest the 
completion of the two tasks and the model building process as part of particular applications, 
where the comparison of actual decision options feeds into the selection of precise attributes 
for distinguishing their value.  
Overall, in order to complete the three main steps, I have proposed a “value-
alternative hybrid thinking” 332, under which the core structure of the value tree takes place 
as part of a top-down approach, and the definition of attributes is ultimately completed 
following the selection of the decision alternatives as part of a bottom-up approach.  
Importantly, both criteria and attributes of the value tree must possess a number of 
properties for the results to be robust 332; these include being essential, non-overlapping and 
concise (for the case of criteria); unambiguous, comprehensive and direct (for the case of 
attributes); understandable, operational, and preference-independent (for both criteria and 
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attributes) 2,204-206. A discussion on these properties as well as the significance of adhering 
to them in the context of HTA to ensure a robust process for the application of MCDA is 
provided elsewhere.  
 
5.3.2 HTA Adaptation Approach and Staging 
In the context of HTA, it would be reasonable to assume that the value concerns (i.e. the 
criteria) of decision-makers would encompass all the key factors that are necessary for a 
comprehensive appraisal of value of a new medicine or health care intervention, with their 
relevant disease-technology characteristics and impacts on patients outcomes and health 
systems resources acting as descriptors of performance (i.e. attributes) for measuring the 
extent of satisfying these criteria. However, a universal or common set of decision-makers’ 
value concerns (i.e. criteria) and their measures (i.e. attributes) are neither clearly defined, 
nor well-established, both within and across health systems. Therefore, a definition of value 
in the context of HTA is currently absent 69,339.  
In order to capture different decision-makers’ concerns in a comprehensive manner 
that ultimately would lead to the structuring of a generic value tree, a five-stage iterative 
model-building process was followed, involving both secondary and primary data collection 
and adopting a top-down ‘value-focused thinking’ approach, as shown in Figure 5.1. The 
five steps were as follows: 
First, I conducted a systematic review of the peer-reviewed literature to identify what 
value dimensions are considered in the evaluation processes of HTA bodies in eight EU 
countries 339. The Centre for Review and Dissemination guidance for undertaking systematic 
reviews in health care was followed 226.  The eight study countries (and their HTA bodies) 
were France (Haute Autorité de Santé, HAS), Germany (Institut für Qualität und 
Wirtschaftlichkeit im Gesundheitswesen, IQWiG), Sweden (Tandvårds- och 
läkemedelsförmånsverket, TLV), England (National Institute of Health and Care Excellence, 
NICE), Italy (Agenzia Italiana del Farmaco, AIFA), the Netherlands (Zorginstituut 
Nederland, ZIN (formerly College voor zorgverzekeringen, CVZ)), Poland (The Agency for 
Health Technology Assessment and Tariff System, AOTMiT) and Spain (Red de Agencias 
de Evaluación de Tecnologías Sanitarias y Prestaciones del Sistema Nacional de Salud 
(RedETS) and the Inter-ministerial Committee for Pricing (ICP)).The rationale for their 
selection was the variation in their health system financing (tax-based vs. social insurance-
based), the organisation of the health care system (central vs. regional organisation), the type 
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of HTA in place (predominantly economic evaluation vs. predominantly clinical benefit 
assessment) and the perspective used in HTA (health system vs societal), so that the sample 
is representative of different health systems and HTA approaches across Europe. Inclusion 
criteria for the review were the following: (i) English language, (ii) evidence from the eight 
study countries of interest (and their respective agencies), (iii) HTA context from a national 
coverage perspective, and (iv) a publication date between January 2000 to January 2014106. 
The electronic databases of Medline and Social Science Citation Index were searched for 
English peer review literature using the keywords “health technology assessment” OR 
“value assessment” AND “pharmaceuticals” OR “methodologies”. Reference lists of the 
selected studies were screened, and the HTA bodies’ websites were searched for any 
published guidelines. Material on the “type of evidence and evaluation criteria considered in 
HTAs” was collected and analysed, along with material on the “responsibilities and structure 
of national HTA models and processes”, “methods and techniques applied in HTA”, and 
“outcomes and implementation of HTAs”. The identified value dimensions sourced from the 
“evidence and evaluation criteria” component of the review would form the fundamental 
domains of the model, taking the form of top-level criteria groups (i.e. clusters) and 
informing their decomposition into lower level criteria, which comprised the core structure 
of the value tree.     
Second, literature findings were supplemented with expert consultation, where 
national agency HTA experts from the countries of interest where invited to review and 
validate the results. This took place because upon an early communication of the preliminary 
results with the partners of the Advance-HTA project consortium 222, it became obvious that 
in a few cases the evidence from the peer review literature may have been outdated and, in 
some cases contradictory, and did not reflect actual practices. As a result, the findings of the 
systematic literature review were validated with national experts from the agencies in 
question.  
Third, I incorporated findings from other relevant literature of health care 
interventions evaluation, including grey literature, to identify value concerns of decision 
makers that might not be reflected as part of the current or formal HTA evaluation criteria 
in place.  I considered studies on the benefit-risk assessment of new drugs from a licensing 
perspective 73,331,343-350, value based pricing and assessment from a payer perspective 
                                                 
106 Product-specific technology appraisals or evaluation studies and conference proceedings or records with 
no abstract available were excluded.   
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31,139,154,190,351-354, and patient access from a social responsibility perspective 176,355. The 
findings from this step supplemented the lower level criteria and their decomposition into 
bottom-level sub-criteria or attributes. 
Fourth, following the completion of the above steps, the emerging structure of the 
value tree and its criteria were subjected to a detailed consultation with 28 HTA experts who 
provided feedback on the comprehensiveness of the model, but also on its perceived 
usefulness and practical limitations, as part of the Advance-HTA project 222. These experts 
were selected because of their relevant expertise and because they acted as partners, 
Scientific Advisory Board members and affiliated scientists in the Advance-HTA project 
and included health care professionals (e.g. clinicians, nurses, pharmacologists), 
methodology experts (e.g. health economists, HTA experts, statisticians) patient 
representatives and policy-makers/regulators, who were affiliated with a wide range of 
academic and research institutions at international level, including nine academic-research 
institutions with health economics and/or HTA centres107, four HTA bodies108, one HTA 
research network109, one coordinating patient and health care professional organisation110 
and one international public health organisation111. Based on the feedback received from 
these experts, the structure of the value tree was revised in an iterative manner, mainly 
informing the bottom-level sub-criteria or attributes.  
Finally, following a series of dissemination activities as part of the Advance-HTA 
project involving presentations and seminars as part of capacity building workshops, 
feedback was collected from a wide range of stakeholders (mainly decision-makers from 
ministries of health, health insurance organisations and HTA agencies) and key opinion 
leaders across settings beyond the eight countries identified originally, where the aim was to 
validate results and further enhance the encompassing nature of the model by capturing 
additional expert and wider geographical perspectives 356-359. Specifically, the value tree was 
disseminated at four workshops attended by a total of 230 participants from the Latin 
                                                 
107 London School of Economics and Political Science (LSE), London School of Hygiene and Tropical 
Medicine (LSHTM), Instituto Superiore di Sanita (ISS), Universidad de Castilla – La Mancha (UCLM), 
Institute za Ekonomska Raziskovanja (IER), Technische Universitaet Berlin (TUB), Escuela Andaluza de 
Salud Publica (EASP), Universite Paris XII - Val de Marne (UPEC), and University College London (UCL). 
108 NICE International, Agencja Oceny Technologii Medycznych (AOTM), Tandvårds- och 
läkemedelsförmånsverket (TLV), and Haute Autorité de Santé (HAS). 
109 European Network for Health Technology Assessment (EUnetHTA). 
110 European Brain Council (EBC). 
111 Pan American Health Organisation (PAHO). 
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American (November 2014 and September 2015) and Eastern European regions (September 
2014 and 2015), in order to capture perspectives from low- and middle-income countries in 
these regions in the form of smaller focus groups of 10-15 participants. 
 
Figure 5.1: The five-stage criteria selection process for structuring the value tree as part of a 
top-down ‘value-focused thinking’ approach.  
 
 
 
Throughout the five stages of the model-building process, the various pieces of 
evidence collected to inform criteria selection and their structuring into a value tree took 
place in alignment with decision theory principles, aiming to satisfy the required criteria 
properties so that the model produced is rigorous and the analysis outcome robust 204. For 
example, an additional criterion would be added if a value concern was not captured in the 
initial set of criteria so that all the essential value concerns of decision makers could be 
Task: Systematic literature review in HTA
Evidence collected: Value dimensions considered as HTA criteria in EU study countries
Model input: Top-level criteria clusters and decomposition into lower level criteria
Task: Expert consultation in HTA
Evidence collected: Value dimensions considered as HTA criteria in EU study countries
Model input: Validation of top-level criteria clusters and decomposition into lower level criteria
Task: Targetted examination of methodological and grey literature 
Evidence collected: Value concerns beyond current HTA formal criteria 
Model input: Lower level criteria and decomposition into bottom-level sub-criteria or attributes
Task: Consultation with Advance-HTA project partners 
Evidence collected: Feedback on the comprehensiveness and usefuless of the value tree
Model input: Revision of bottom-level sub-criteria or attributes 
Task: Dissemination and consultation with external experts audiences
Evidence collected: Feedback on the comprehensiveness and usefuless of the value tree
Model input: Enhanced validation of bottom-level sub-criteria or attributes 
Stage 5
Stage 2
Stage 3
Stage 4
Stage 1
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addressed. Further, if a particular criterion was perceived to reflect the same value concern 
as another criterion, one of them was removed in order to avoid double-counting. Similarly, 
two individual criteria could be replaced if their underlying concern could be reflected from 
a single criterion on the basis of conciseness; generally, only the smallest number of criteria 
required for evaluation should be included, in order to strive for simplicity. Individual 
criteria could be replaced with other criteria if their meaning was not clear in order to 
improve comprehension; similarly, individual criteria would be replaced if their 
measurement was not possible, in order to ensure high levels of functionality. Finally, if by 
assessing the value of one criterion it became evident that knowledge on the performance of 
another criterion would be required, then the two criteria would be aggregated into a single 
one in order to become preference-independent.  
Despite this cautionary approach, the value tree aims to capture a comprehensive 
generic set of value concerns that can be adapted to different decision-making contexts, 
problems, indications or treatments.  As a result, the individual criteria could be compared 
across different decision-making settings and jurisdictions, to reflect similarities and 
differences of decision-makers’ value concerns as evidenced by the inclusion of particular 
criteria and the way of their measurement (i.e. precise attributes).   As a result, following the 
completion of the model-building phase involving the precise attribute definition and the 
selection of alternative treatment options for the case of specific decision problems, some of 
these criteria might not satisfy the required properties in which case the underlying issues 
should be addressed with caution. For example, following the operationalisation of two 
criteria with specific attributes it might become evident that there is possible double-
counting between them, in which case one of the two would have to be excluded. A few 
cases in which the theoretical properties of some criteria could be put into question have 
emerged following consultation with experts; these are discussed in the respective sections. 
Overall, the five-stage process took place between February 2013 and end-October 2015. 
 
5.4 Results – The Advance Value Tree 
The findings from the systematic literature review and expert consultation in HTA which 
acted as the first and second stages of the model-building process are briefly presented, 
mainly because it informed the primary identification of value dimensions which established 
the core structure of the value tree. Then the completed value tree is outlined and the logic 
behind its various components and value dimensions discussed, including the overall criteria 
grouping and decomposition from top-level criteria clusters into lower level criteria and 
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bottom level sub-criteria or attributes. Finally, I briefly suggest how to deal with quality of 
evidence, and more precisely with clinical validity concerns.  
 
5.4.1 Primary Identification of Value Dimensions: Findings from the Systematic Literature 
Review and Expert Consultation in HTA 
In total, 2778 articles abstracts were screened out of which 255 articles were selected to be 
read in full based on their relevance, with the content of 101 articles being ultimately used. 
The main groups of value dimensions that were found to be considered as evaluation criteria 
among the study group of European countries as identified through the first and second 
stages of the model-building process included: (a) burden of disease, (b) therapeutic impact, 
(c) safety profile, (d) innovation level, and (e) socioeconomic impact 339. Individual value 
dimensions falling under these main groups of evidence, together with their intensity of use 
by each country are shown in Table 6.1. Based on the available evidence, these five clusters 
of evaluation criteria were perceived to comprise the minimum critical aspects of value 
dimensions of interest to decision-makers for evaluating the value of new medicines as part 
of HTA, providing the core foundation of the value tree.  
 
5.4.2 Incorporating the Value Dimensions into a Generic Model: The Advance Value Tree 
Ultimately, the resulting generic value tree spans three levels of evaluation criteria (top-, 
middle- and bottom-level), where top-level groups of criteria (i.e. criteria clusters) are 
decomposed into middle-level criteria and bottom-level sub-criteria or attributes, relating to 
the five key value domains described above that can be explicitly measured and assessed: 
(a) burden of disease (BoD), (b) therapeutic impact (THE), (c) safety profile (SAF) (d) 
innovation level (INN), and (e) socioeconomic impact (SOC). With the exception of BoD 
cluster, which relates to the disease or indication of interest, the remaining four clusters relate 
to the impact or characteristics of the medicine. The hierarchical representation of the three 
levels of evaluation criteria forms the different components of the value tree, which I called 
‘Advance Value Tree’, as shown in Figure 5.2. In particular evaluation contexts, the 
hierarchical organisation of these value concerns could be perceived to represent a 
combination of objectives and indicators rather than a value tree in their strict sense.    
Although additional types of value concerns might exist falling under other 
categories66,360,361, such as efficiency (e.g. cost-effectiveness), equity (e.g. priorities, 
fairness, ethics, etc.) and implementation complexities (e.g. organisational, skill and 
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legislative requirements), they are not included as criteria because they would contradict 
with the desired criteria properties and the adopted scope of “value”. Strictly, these 
dimensions do not represent intrinsic disease-technology characteristics or impacts on 
patient outcomes and health system resources but, instead, go beyond to capture extrinsic 
characteristics and impacts that generally depend on the value tree’s core variables, or other 
features of the health care systems reflecting a wider health systems goals and building block 
perspective 362.  
For example, efficiency is a composite concept comprising two components, i.e. cost 
and benefit, with the latter already reflected in the model and thus its inclusion would violate 
the principle of non-overlap leading to double-counting. Concerns relating to equity, 
implementation complexities, and other characteristics of the overall health systems’ context 
(e.g. stakeholder pressure and political power), are usually of subjective nature and not easily 
quantifiable, therefore making it hard to operationalise. All these extrinsic value dimensions 
do not relate to the “value” of a new medicine per se, but instead depend on the settings of 
the particular health system under consideration. They could therefore be considered or 
incorporated on an optional basis and as needed for the particular decision context and 
problem in question, possibly through the use of other analytical frameworks 90,363. 
Examples of iterations in the value tree that have resulted from consultations with 
experts include the aggregation of ‘safety’ and ‘tolerability’ criteria into a single ‘safety & 
tolerability’ criterion when a potential overlap between their measures became evident 
following discussions with clinicians (described in the ‘Safety profile’ section below), or the 
addition of a ‘Carer’ sub-criterion under the ‘Indirect costs’ criterion to capture the wider 
socioeconomic impact of a treatment following discussion with patients.  
Table 5.1: Value dimensions considered as evaluation criteria among the study group of European countries and their intensity of use 
    France Germany Sweden England Italy Netherlands Poland Spain 
Burden of 
disease                   
  Severity *** ** ** ** * ** ** ** 
  Availability *** * * *** * ** * ** 
  Prevalence * ** * * ** ** ** ** 
Therapeutic                   
  Direct endpoints *** *** *** *** *** *** *** *** 
  
Surrogate 
endpoints ** ** ** ** ** ** ** ** 
Safety                    
  Adverse events *** *** *** *** *** *** *** *** 
  Tolerability ** ** ** ** ** ** ** ** 
  Contra & warnings ** ** ** ** ** ** ** ** 
Innovation                   
  Clinical novelty *** * * * ** ** *** ** 
  
Nature of 
treatment *** * * ** x * *** ** 
  
Ease of use & 
comfort * * ** * x * x * 
Socioeconomic                   
  Public health ** ** * ** * *** *** * 
  Budget Impact * *** ** *** ** ** *** ** 
  Social productivity * ** *** ** * ** * ** 
*** mandatory/ formal/explicit/ planned/ directly/ grading system           
** "considered", e.g. recommended, informal/implicit but planned, formal/explicit but ad hoc/indirectly, etc.     
* optional/ informal/implicit/ad hoc/ indirectly/ no grading system           
x 
not considered in any 
way                 
Figure 5.2: The generic set of value dimensions for new medicines Advance Value Tree 
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5.4.2.1 Burden of disease  
‘Burden of Disease’ (BoD) forms a special set of value dimensions as they do not relate to 
the medical technology itself, but to the disease it is indicated for and, as such, could 
encompass the severity and unmet need of the disease the treatment addresses 352,364. Severity 
of the disease relates to the condition’s degree of seriousness in respect to mortality and 
morbidity-derived disability, which could be defined on the basis of disability-adjusted life 
years (DALYs) lost 338, or the expected remaining life years adjusted for their quality of life 
365. Unmet need reflects the availability of treatments, essentially the degree to which there 
are existing treatments 31 and could relate to methods of diagnosis, prevention or treatment 
366. Because these dimensions are preference-dependent (i.e. in order to assess the impact of 
unmet need one needs to consider the severity of the disease) they are operationalised 
through the use of a single aggregated attribute which could be defined as the gap between 
the health status that patients with a particular medical condition can attain using existing112 
medical interventions and the health status they could expect if they did not have that medical 
condition, or in other words “the number of QALYs lost by a patient because of their 
condition” 352. Therefore, the BoD attribute reflects the difference in the years of life 
remaining (adjusted) with the respective HRQoL for patients receiving existing 
technologies, versus the years of life remaining (adjusted) with the respective HRQoL for 
healthy individuals (of the same age). The larger the difference or the gap between the two 
(i.e. diseased vs. healthy states), the higher the disease burden.  
The size of the population being affected by the disease, and the possible 
differentiation of a disease on the grounds of high prevalence or low prevalence is not taken 
into account because it could be perceived as unethical. The justification of a special status 
of a disease based on its prevalence would be questionable, as it entails valuing one disease 
differently to another because they are a more common vs. a less common disorder 367. The 
only justification for providing special status to rare diseases would be on equity grounds, 
using the rationale that “patients suffering from rare conditions should be entitled to the same 
quality of treatments as other patients” 368. However, this concern is already addressed 
through the unmet need criterion and the associated (un-) availability of effective treatments; 
consequently, the inclusion of a criterion for capturing ‘population size’ would essentially 
                                                 
112 Ideally the “existing” medical intervention or treatment should not be one of the options being assessed so 
that there is no double counting with the Therapeutic Impact cluster. “Existing” could be defined at the HTA 
level, i.e. in respect to what has been approved for reimbursement, and if nothing has been approved then in 
terms of best supportive care (BSC).  
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lead to double-counting and, therefore, is not inserted. Valuing a condition ‘more’ or ‘less’ 
as a result of prevalence would be incompatible with other equity principles and theories of 
justice 367.  
 
5.4.2.2 Therapeutic impact 
For most medical conditions there is a set of multidimensional health outcomes that need to 
be jointly used to capture overall patient benefit including survival, functional status, 
sustainability of recovery and others, including complications 369. Outcomes are distinct 
from biologic indicators, the former usually relating directly to health status in contrast to 
the latter which act as predictor of results.  
The ‘Therapeutic impact’ cluster captures clinical benefit by measuring both direct 
outcomes and indirect indicators relating to the efficacy and/or the effectiveness of an 
intervention with the view to reflecting the health status but also disease recovery, 
progression or prevention (complication outcomes are considered separately in the “Safety 
Profile” cluster discussed in the next section).  
In order to distinguish between direct outcomes and indirect indicators, based both 
on the literature and subsequent expert consultation, “Therapeutic Impact” criteria have been 
divided into (a) direct, clinically meaningful outcomes and (b) indirect, surrogate indicators 
respectively; the latter are used as substitutes for direct endpoints being usually disease-
specific in nature (e.g. HbA1c for complications in diabetes mellitus, prostate-specific 
antigen (PSA) for prostate cancer, blood pressure for cardiovascular disease). Specifically, 
a direct endpoint is defined as a “characteristic or variable that reflects how a patient feels, 
functions, or survives” while an indirect endpoint is defined as a “biomarker intended to 
substitute for a clinical endpoint” which is “expected to predict clinical benefit (or harm or 
lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other 
scientific evidence” 370 (page 91).In turn, the definition of a biomarker states that it is a 
“characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” 370(page 91). 
 However, both types of endpoints are useful and, for specific indications, a 
biomarker (i.e. indirect indicator) might be more directly related to real health status than 
self-reported outcomes (i.e. direct outcome); this could be a reason why an increasing 
number of studies in health economics use biomarkers instead of self-assessed measures of 
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health. Below I propose a further decomposition of direct meaningful endpoints and indirect 
surrogate endpoints, once again guided by the five-stage evidence collection process.  
 
Direct meaningful endpoints 
Direct clinically meaningful endpoints can be divided into objective and subjective 
endpoints 371 and, possibly, other health related outcomes 372. Objective direct endpoints 
mainly refer to survival, disease exacerbation/alleviation and clinical events. The availability 
of evidence on different endpoints depends on the study designs adopted by the respective 
clinical trials for evaluating the clinical benefit of interventions and, therefore, would depend 
on their type or nature.  
Subjective direct endpoints mainly relate to HRQoL and disease symptoms. HRQoL 
embraces the broader concept of health that includes physical, emotional and social 
wellbeing 373, by including both personal health status and social wellbeing 374 usually being 
“subjectively” assessed through patient reported outcome measures (PROMs). HRQoL is 
multidimensional 375,376 and can generally be measured through the use of generic PROM 
that provide a summary of HRQoL attributes through the production of health utilities 374, 
such as SF-36 and EQ-5D instruments113. Generic PROM instruments do not target specific 
population groups and for the case of particular disease states they might not be sensitive 
enough to adequately capture the impact across all HRQoL dimensions in which case disease 
specific instruments might be needed. From a societal perspective all these dimensions 
should be considered both for the cases of patients and carers.   
Importantly, following consultation with experts, it became apparent that the 
assessment of particular combinations of objective and subjective endpoints as for example 
OS and HRQoL (e.g. through EQ-5D) might be preference dependent. For example, in the 
context of a metastatic cancer setting, stakeholders highlighted that their preferences related 
to the performance of different therapies in terms of OS would be meaningful only if the 
HRQoL performance was also known for the same therapies. Where preference dependence 
is evident, the dependent attributes should be combined into a single attribute, as for example 
QALYs, essentially aggregating them into a common attribute capturing both OS and 
HRQoL considerations. 
 
                                                 
113 Generic PROM instruments do not target specific population groups and for the case of particular disease 
states they might not be sensitive to adequately capture the impact across all HRQoL dimensions in which case 
disease specific instruments might be needed. 
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Indirect surrogate endpoints 
Indirect surrogate endpoints can be divided into validated and non-validated. Validation of 
a surrogate endpoint is the process of retrospectively linking it to the actual clinical endpoint 
(or outcome), i.e. demonstrating a relationship between the two by evaluating how well the 
surrogate endpoint predicts the clinical outcome of interest 370. Besides the existence of a 
strong statistical correlation between the surrogate and the clinical endpoint that is needed 
in order to entail an accurate prognosis of the clinical outcome, i.e. ‘individual-level 
surrogacy’, there is also a prerequisite for clinical correlation through the existence of 
biologic plausibility, i.e. scientific evidence on the causality between the disease, surrogate 
and outcome; importantly, there is also a need for demonstrating “trial-level surrogacy” 
which refers to the correlation between a change in the surrogate and a change in outcome 
due to a therapeutic intervention 377. Although trial-level data are usually coming from 
multiple trials or units for the same type of intervention, for a surrogate to be validated it 
means that its “validity is generalizable to include other interventions that affect the 
surrogate endpoint”  370(page 93). As a result of these requirements, surrogate endpoints are 
rarely validated. Generally, most only manage to predict the clinical endpoint or outcome of 
interest whilst others fail to predict the clinical endpoint and are used only as a measure of 
biological activity 378.  
 
5.4.2.3 Safety profile  
The safety profile of an intervention comprises information relating to the degree of its safety 
and toxicity for the indicated patient population of interest. It is usually measured through 
safety and tolerability, but can also be reflected through any contra-indications for its use 
and special warnings (and precautions) for any particular sub-populations.  
 
Safety and tolerability 
Safety has been traditionally reflected through the incidence of adverse events. An adverse 
event (AE) refers to an adverse outcome occurring when a drug is administered to a patient 
or at some time afterwards, in which case the drug might or might not be the cause of the 
AE 379. If such outcomes can be attributed with some degree of probability and through a 
causative link to an action of the drug, then they are known as adverse drug events (ADEs).  
The magnitude of both AEs and ADEs is measured through the combination of their 
seriousness and their frequency (or probability of taking place). Given that seriousness and 
probability of adverse events seem to be preference dependent, an aggregated attribute 
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reflecting ‘seriousness and frequency’ would be needed. Seriousness could be 
operationalised through the use of the Common Terminology Criteria for Adverse Events 
(CTCAE) classification, which contains five grades of adverse events ranging from mild 
(Grade 1) to death (Grade 5), with three grades in between (moderate, severe, life-
threatening) 380. However, for cases that overall survival is already incorporated in the value 
tree under the therapeutic impact cluster, then considering Grade 5 adverse events which 
relate to deaths would constitute double counting and should be excluded. In turn, given that 
the distinction of adverse events between mild and moderate and between severe and life-
threatening is often subjective, they could be aggregated and categorised as “non-serious” 
versus “serious”, the former comprising Grade 1 and 2, and the latter comprising the Grade 
3 and 4 adverse events. Frequency could be operationalised through the use of absolute 
incidences (percentages), or, alternatively, using a frequency classification system such as 
the Naranjo scale which expresses frequency in terms of definite, probable, possible or 
doubtful 381.  
Tolerability refers to the overall ability of the patient to tolerate the intervention, 
mainly in regards to bearing and enduring any adverse events. It is usually reflected through 
the variables of treatment discontinuation and treatment interruption or reduction, measured 
either as the proportion of patients discontinuing the treatment (or interrupting/reducing its 
dosing) or the time to treatment discontinuation (TTTD) from the treatment.  
Importantly however, as it became apparent following consultation with clinical 
experts, in the case of discontinuation (or interruption or reduction) of a treatment being due 
to the incidence of known ADEs, then incorporation of both measure types could lead to 
double-counting and therefore caution would be needed to choose the most appropriate 
between the two.  
 
Contraindications, special warnings and precautions 
Contra-indications refer to factors114 that act as a reason for an intervention not to be used 
by a patient, thus having an impact on the number of potential patients using and benefiting 
from it. Strictly speaking, contraindications can be categorised as absolute and relative. In 
the former there are no circumstances under which the patient might use the intervention, 
compared to the latter whose risk might be outweighed in favour of other considerations 
(e.g. x-rays for a pregnant woman with a risk of having a child with birth defects). Special 
                                                 
114 usually related to its risk and safety but can also be related to its benefit and efficacy/effectiveness 
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warnings and precautions for use are designed with the view to notifying potential risks 
associated with the use of the intervention in regards to specific patient sub-populations with 
particular characteristics. These characteristics mainly relate to the administration of 
concomitant medication, the coexistence of other accompanying diseases and the presence 
of idiosyncratic patient pathological features that as a result might influence the expected 
action of the drug; as a consequence, caution in the form of careful monitoring is usually 
suggested.  
In the real world, some patients with known contra-indications (or special warnings 
and precautions) for a treatment might end up receiving it, in which case incorporation of 
any evident ADEs or tolerability consequences that can be related to them as attributes in 
the value tree, would lead to double counting between the two and should therefore be 
addressed with caution, similar to the case between ADEs and discontinuation.  
 
5.4.2.4 Innovation level  
“Innovation” in the context of medical technologies, ranging from biopharmaceuticals and 
diagnostics to medical devices, is a complicated concept lacking a universal consensus 382. 
From a patient perspective, “innovation” mainly relates to “therapeutic innovation” requiring 
novelty of effectiveness: value needs to be created by generating improved health outcomes 
that were previously unattainable, the degree of which could be assessed through the 
combination of the significance of the unmet medical need the drug addresses and the extent 
to which it improves the health outcomes for that need 383. Below I discuss secondary 
innovation dimensions over and above “therapeutic innovation”, given that the significance 
of unmet medical need and the extent of health outcomes improvement are captured under 
the “Burden of Disease” and “Therapeutic Impact” clusters respectively. These dimensions 
include (a) the mechanism of action, (b) the technology’s spillover effects, and (c) patient 
usefulness (convenience). 
 
Mechanism of action 
The innovativeness of new medicines can be differentiated according to their type or nature, 
based on whether they offer a novel mechanism of action, or whether they act through more 
typical mechanisms of action. A relatively practical and objective way of measuring that 
would be through the use of WHO’s Anatomical Therapeutic Chemical (ATC) Classification 
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System115. Moving from general to specific, this classification has 5 main dimensions 
relating to anatomical, therapeutic, pharmacological, chemical and molecular levels which 
could act as the respective criteria. By this logic, a medicine characterised by a novel 
therapeutic action, would be more innovative than a medicine with a novel pharmacological 
action and so on. In other words, the broader the level at which the drug (or combination) 
differentiates as ‘original’ compared to current existing alternatives, the more innovative the 
nature of that drug (or combination) would be.  
As a result, the drug’s relative market entrance in regards to the different innovation 
subgroups (i.e. ATC levels) could act as the respective attributes, in order to reflect, for 
example, whether it is first-in-chemical-class (i.e. first entrance of a technology at level 4, 
chemical subgroup level), second-in-pharmacological-class (i.e. second entrance of a 
technology at level 3, pharmacological subgroup), and so on.  
 
Spill-over (dynamic efficiency) 
Any type of innovation can have R&D spill-over effects that can lead to the development of 
subsequent innovation(s), entailing a certain degree of diffusion of scientific knowledge 
and/or technical know-how. Innovation ‘spill-over effects’ could be defined as “the R&D 
positive externalities that can lead to the development of subsequent innovation(s)”, thus 
essentially relating to dynamic efficiency in regards to long-term product innovation at 
future market conditions. These effects could take the form of internal (within the innovator) 
or external (outside the innovator) effects 384. As Lipsey and Carlow have argued, ‘major 
radical innovations never bring new technologies into the world in a fully developed form’, 
but “appear in a crude and embryonic state with only a few specific uses” 385. Instead, 
successive improvements are accumulated through the processes of ‘learning by doing’ and 
‘learning by using’ 386, the former referring to the improvement of workers’ skills at the 
manufacturing level 387, while the latter relating to enhancements of knowledge at the level 
of utilisation by the final user 388. Subsequent to the market entry of a new drug, new uses 
(i.e. new indications) for the same drug could be uncovered following its investigation for 
                                                 
115 In the Anatomical Therapeutic Chemical (ATC) classification system, the active substances are divided into 
different groups according to the organ or system on which they act and their therapeutic, pharmacological and 
chemical properties. Drugs are classified in groups at five different levels. The drugs are divided into fourteen 
main groups (1st level), with pharmacological/therapeutic subgroups (2nd level). The 3rd and 4th levels are 
chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. The 2nd, 3rd and 
4th levels are often used to identify pharmacological subgroups when that is considered more appropriate than 
therapeutic or chemical subgroups. 
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use by patients with other diseases, or next generation drugs could be successively developed 
either for the same disease indication or a different one. New scientific knowledge and/or 
technical know-how could be diffused into other contexts/sectors, leading to innovations 
therein. Because the impact on future innovation is uncertain, it would be practically 
challenging if not impossible to be predicted and assessed at a single point in time 389, as for 
example the rate at which performance improvements take place and the speed at which new 
uses are discovered. In reality, a significant portion of any such spill-over effects will need 
time to materialize requiring them to be in the market for a period of time.  
Although these effects can relate to new uses for the same technology, new 
technologies for the same use, or new technologies for new uses, only the first ones are 
considered here because the latter two are not operational116. Essentially, this criterion would 
refer to the extent to which the drug has a spill-over effect in the context of expansion into 
new indications and could be operationalized by examining the number of new indications 
for which the drug is investigated for at each stage of clinical development (e.g. Phase I, 
Phase II, Phase III, Marketing Authorisation phase).  
 
Patient usefulness (ease and convenience) 
Aspects relating to patient usefulness would be another group of innovation-related 
dimensions. Satisfaction of patients with medical care has been shown to correlate with 
compliance, i.e. the willingness and ability to follow health-related advice including 
adherence to prescribed medication, while also acting as predictor of future compliance 390-
392. Satisfaction can be categorised into a range of different domains, including symptom 
relief/efficacy, side effects, ease and convenience, impact on HRQL, general satisfaction, 
and other domains specific to the given question 393. Given that most of these domains are 
associated with the health outcomes of the treatment, or are of a generic nature, only ease 
and convenience are considered here, essentially relating to mode of administration, dosing 
schedule, medication restrictions, and product-specific designs. Poor compliance has been 
reported as the most common cause of non-response to medication, with evidence supporting 
                                                 
116 It would be very hard, if not impossible, to identify whether a new technology has been developed solely 
from the R&D process of another technology, hence it is hard to establish a causative link. For example, for 
the case of a new technology developed by the same manufacturer of the parent technology, it could be the 
case that actually the later technology was the one that helped with the development of the first technology, 
but delays in the manufacturing and/or regulatory processes caused one to be marketed before the other. For 
the case of a new technology developed by a different manufacturer, it could be the case again that the 
second manufacturer actually had developed on its own (from in-house R&D) the new technology. 
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that better health outcomes are produced when patients adhere to treatment 
recommendations compared to those who do not adhere 394. 
Therefore, any improvements on the above can be translated into greater patient 
satisfaction and possibly better treatment compliance, which could lead to improved health 
outcomes, either through an increase in clinical effectiveness or due to a decrease in adverse 
events. In turn, individualising treatment and minimising its complexity has been proposed 
for encouraging adherent behaviour 395; for example, once-daily dosing had been suggested 
as an important part of enhancing compliance, patient convenience and regimen 
simplification in hypertension 396, among others.  Given that patient health outcomes are 
already incorporated in the value tree, it would be expected that it is necessary to assume an 
explicit disconnection between better patient satisfaction and improved health outcomes in 
order to avoid double-counting. This theoretical rationality would support the notion that 
greater satisfaction through improved ease and convenience is a critical value dimension of 
new medicines in its own right, contributing to product novelty.117  
Specific aspects of improved ease and convenience can include less invasive delivery 
systems, improved posology because of reduced dosing frequency or duration of 
administration and abolition of special administration instructions (e.g. no instructions vs. 
“take without food”). An altered delivery system could involve a change in dosage form (e.g. 
tablet, liquid, spray, gel) or a change in route of administration (RoA) (e.g. oral, 
subcutaneous, transdermal), but because these two variables are almost always correlated 
(e.g. a tablet will most probably administered orally, and a gel will most probably 
administered transdermally), both aspects could be captured through a common ‘delivery 
system’ attribute reflecting the combination of dosage form and RoA. Differences in 
posology could be captured by an attribute reflecting the combination of dosing frequency 
in a given time period and treatment duration of each dose. However, following consultation 
with patients it became apparent that in order to assess a treatment’s ‘posology’, one might 
need to consider the treatment’s ‘delivery system’, therefore suggesting for preference 
dependence between the two. As a result, the two types of value concern were aggregated 
into a common ‘delivery system and posology’ criterion. Special instructions could be 
assessed by an attribute reflecting the existence of any guidelines accompanying the 
administration of the treatment (e.g. with vs without food, crushing tablets, etc.). 
                                                 
117 Nevertheless, in reality a strict dissociation between satisfaction and health outcomes might not be required 
in the first place because of the gap between efficacy data and effectiveness data (see Appendix to Chapter 5). 
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Alternatively, the medication regimen complexity index118 (MRCI) could be used as an all-
inclusive proxy attribute to operationalise the assessment of ease and convenience as it 
incorporates a number of medication regimen aspects, including dosage forms, dosage 
frequency and administration instructions 397. 
 
5.4.2.5 Socioeconomic impact  
Socioeconomic impact dimensions are used to incorporate any other concerns or benefits in 
the wider context, which mainly relate to (a) public health and (b) economic considerations.  
 
Public health impact 
Public health impact is mainly associated with any risk reduction in transmitting and 
developing the disease under consideration or any other disease within the broader 
population, thus reflecting a societal dimension of prevention. The levels of risk reduction 
could range between no risk reduction, to reduction of prevalence risk factors, to reduction 
in transmission, to prevention and prophylaxis from the disease 90, and as a result such a 
variable would be more applicable to the case of infectious diseases and diseases with known 
risk factors. The emergence and dissemination of resistance among pathogenic bacteria to 
the available antibiotics used in medical practice, leading to the latter’s drop in effectiveness 
would be a good example. A hypothetical new class of antibiotics that can effectively treat 
a bacterial strain known to have developed antimicrobial resistance, would offer an 
important risk reduction of the disease within the broader population by ‘dealing with 
resistance’ and inhibiting its transmission. The added value of such a drug would materialise 
through the combination of improved health outcomes (as reflected via the “Therapeutic 
impact” cluster) and through a risk reduction in disease transmission as reflected via the 
“Public health impact” dimension in the socio-economic impact cluster. 
  
Economic impact 
Economic impact dimensions reflect the economic burden of the disease and can be mainly 
divided into direct costs and indirect costs. Cost of illness studies are used to identify and 
measure all costs related to a particular disease and although different studies can employ 
different methodologies and designs they usually adopt a common classification of cost 
                                                 
118 An index for medication administration complexity, being adjusted to the dimensions of dosage form, 
dosing frequency and additional administrative directions needed. 
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types 398. Direct costs can be either medical or non-medical; medical costs are the costs 
resulting directly from the disease treatment and include diagnostic tests, prescription drugs, 
inpatient care (hospital or physician), outpatient care (physician or ER), nursing home care, 
rehabilitation care and home health care including any disposable or replacing items (e.g. 
prosthetic limbs). Direct non-medical costs refer to non-healthcare costs and include costs 
related to transportation, relocation, household, comfort/rehabilitation items, property 
alterations and counselling services.  
However, including ‘cost’ as a value dimension is prone to criticism, mainly because 
criteria should be conceived as attributes of benefit 207. For that reason ‘impact on costs’ 
rather than absolute costs are considered, looking at the marginal difference versus an 
alternative option that could act as a neutral benchmark, being exclusive of the purchasing 
costs of the drug; this comparator could fall outside the scope of the analysis and for example 
could be best supportive care of the case of an oncology indication. Options’ purchasing 
costs could be incorporated in the analysis later on to establish the efficiency of the 
technology by considering its total value in relation to its total cost.  
Indirect costs reflect productivity losses arising from patient absenteeism, 
presenteeism, premature retirement, and premature mortality 399. In addition, as it became 
evident following consultation with patients, indirect costs for carers (i.e. caregivers) are an 
important dimension of productivity losses that should be considered as part of a societal 
context and relate either to financial costs (in case they are not already included in the 
medical and non-medical costs) or time-off work. 
 
5.4.3 Dealing with Quality of Clinical Evidence  
In the context of health care decision-making, several attributes of evidence quality could be 
identified including adherence to the requirements of the regulator or decision-maker, 
completeness of reporting according to the regulator’s guidelines, consistency of reporting 
with the sources cited, relevance of evidence to the context in question and validity of 
evidence in regards to scientific standards or methodological guidelines of research 90.  
Focusing on the validity of clinical evidence, which would be mainly relevant for evidence 
feeding the performance measurement of alternative options under the therapeutic impact 
(THE) cluster, this could be decomposed into internal and external validity characteristics. 
Internal validity refers to the extent to which an observed effect can be attributed to the true 
effect of the intervention under investigation, or, in other words, the extent to which it is free 
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from bias, in contrast to external validity which relates to whether the clinical effects found 
in a clinical study (e.g. RCT) can also occur outside of the study’s settings, i.e. beyond 
experimental settings in real clinical settings 226,400,401.  Rather than operationalising these 
evidence quality (i.e. validity) concerns through their incorporation as criteria and attributes 
in the value tree, ‘penalty’ functions could instead be applied when the clinical evidence 
used for the alternative options are of different quality. This is because it would not be 
methodologically robust to incorporate quality of evidence concerns as criteria; doing so 
would entail that the quality of evidence used to assess the performance of the options across 
the respective criteria could be compensated by the options’ performances across the same 
criteria.  
A penalty factor could be applied through a function that multiplies it with the 
performance of the alternative options across the relevant THE criteria or their respective 
value scores, in order to adjust them for their validity. This penalty factor would be tailor-
made for the particular decision-making context, being defined based on the relative 
importance of evidence validity as a source of concern to decision-makers. For example, 
assuming that a weak internal validity is associated with the comparative treatment effect of 
a new drug due to inadequate allocation concealment and lack of double-blinding, a “strict” 
decision-maker might be willing to “discount” the clinical performance of the drug on some 
of its clinical endpoints up to X% of their original level. The lower the validity of the 
evidence, the higher the impact that the penalty functions would have on the performances 
of the drugs or their respective value scores across the relevant THE criteria. However, it 
should be noted that the concept of penalty function should generally be used with caution 
because penalty functions may be incompatible with the use of an additive value model 
(unless they are used within the attributes). 
A useful categorisation for the quality of clinical evidence is provided by the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) system, a 
framework developed for the purpose of producing consistent clinical guidelines in terms of 
rating quality of evidence and grading strength of recommendations 402. According to 
GRADE, high quality evidence could be defined as evidence for which ‘further research is 
very unlikely to change our confidence in the estimate of effect’, in contrast to very low 
quality evidence for which ‘any estimate of effect is very uncertain’403. In turn, the Cochrane 
Collaboration tool for risk of bias and the RE-AIM framework could be applied for the 
assessment of internal and external validity respectively, the findings of which could then 
be used for the estimation of the penalty factor by feeding the penalty function.  
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Based on a systematic classification of internal validity sources, the Cochrane 
Collaboration has developed a tool for assessing the risk of bias in RCTs, for a series of 
items covering different bias domains and their sources 404. These bias domains are broken 
down into seven different types based on which RCTs can be assessed and rated (as “low”, 
“unclear” or “high” risk of bias), namely selection bias (with sources of bias including 
random sequence generation, and allocation concealment), performance bias (blinding of 
participants and personnel), detection bias (blinding of outcome assessment), attrition bias 
(incomplete outcome data), reporting bias (selective reporting) and other bias (i.e. anything 
else).  
On the other hand, the RE-AIM framework which was originally developed by 
Glasgow and colleagues to evaluate the public impact of health interventions, could be 
partially applied in order to assess the external validity of clinical trials, mainly through the 
dimensions of reach, adoption, implementation and maintenance 405. 
 
5.5 Discussion - The Advance Value Framework 
5.5.1 Robustness of the Advance Value Tree 
In this paper I developed and proposed a generic model taking the form of a value tree for 
assessing the value of new medicines in the context of HTA as part of a methodological 
approach, which moves away from traditional economic evaluation, uses decision theory 
and adopts multi-criteria evaluation methods.  The model consists of a value tree (Advance 
Value Tree) with three levels (top-level: 5 clusters; middle-level: 10 criteria; bottom-level: 
27 sub-criteria or attributes), as shown on Figure 5.2. 
Conceptual and theoretical advantages emerge from the methodological and 
empirical process that was adopted to build the structure of the Advance Value Tree. A five-
stage iterative model-building process was followed involving extensive rounds of literature 
reviews and expert consultation, with the aim to make it as comprehensive as possible whilst 
maintaining its flexibility and adaptability to serve the needs of decision-makers for different 
decision problems. A key advantage of the Advance Value Tree is its strong alignment with 
decision theory principles, adopting a top-down ‘value-focused thinking’ approach while 
paying attention to the required criteria properties.  
 For the case of specific decision problems and following the selection of particular 
treatment options, the value tree would become adapted in a bottom-up approach in order to 
be able and capture the particular value dimensions of the actual treatment-indication pairs. 
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This would involve the definition of precise attributes, which should again take place in 
alignment with decision theory principles and would complete the model-building phase of 
the process. 
Following the model-building phase, model-assessment and model-appraisal phases 
need to be completed, as part of which the model can be estimated by applying different 
types of MCDA modelling techniques for the formation of value judgements and elicitation 
of preferences across the options. 
 
5.5.2 MCDA Methods and Selection of Modelling Techniques to Operationalise the 
Advance Value Tree 
Multiple MCDA methods exist of varying complexity that could be used for the estimation 
of the model. Specifically, an MCDA modelling technique is required for expressing 
preferences on the performance of each option against each criterion (scoring), while 
equating the preference units across all criteria (weighting), and combining preferences of 
individual criteria together into a combined overall preference (aggregating). Therefore, 
“modelling” in this context acts as an instrument for enabling decision-makers to understand 
their own preferences, by helping them to construct their perceptions given a set of 
assumptions, as part of the overall process of identifying the best decision 2.  
Among the plurality of existing MCDA approaches, they could be categorized into 
three main groups of methods governed by different “schools of thought”, notably (a) value 
measurement methods, including multi-attribute value theory (MAVT) and multi-attribute 
utility theory (MAUT) methods, (b) outranking methods, and (c) ‘satisficing’ and aspiration 
level methods as suggested by others 1,2,54,92. These three main groups of methods are 
essentially referring to different classifications of preference modelling.   Other 
classifications have also been proposed as there is no consensus on a universal categorization 
195-197,199.  
The methodological process I have proposed pertains to the value measurement 
methods category 332, mainly because of the multiple decision contexts that it can be applied 
to and the simplicity of the value judgements required (in addition to limited restrictions 
imposed by the axioms employed), features which would probably influence their adoption 
into the most widely used MCDA methods in health care 72.  Specifically, I suggest in favour 
of MAVT methods because of their comprehensiveness and robustness 54, as well as their 
ability to reduce ambiguity and motivational biases. I would therefore suggest the 
151 
 
operationalisation (i.e. estimation) of the Advance Value Tree through such a MAVT 
approach. This is also consistent with recent work on good practices for MCDA in Health 
Care Decisions 200. Yet, the value tree and the incorporated criteria clusters could also be 
operationalised through other MCDA methods that go beyond the value measurement 
category. 
With MAVT methods, value functions for the scoring of the options can be elicited 
in different ways by mainly using direct or indirect rating techniques 2,54. In contrast to direct 
rating techniques, indirect techniques aim to uncover decision makers’ preferences indirectly 
through a series of questions that involve differences in the attribute scale and their relation 
to the value scale. Techniques that explore what is the magnitude of increments in the 
attribute scale that yield equal units in the value scale are known as indifference techniques, 
whereas techniques that estimate points on the attribute scale that act as midpoints on the 
value scale are known as bisection techniques; both of these could be regarded as sub-types 
of indirect techniques.  
Overall, I suggest the use of indirect elicitation techniques, partly because of their 
unbiased nature given that preferences over the attribute range are first elicited and options 
then scored indirectly by converting their performance into value scores by producing a 
transparent valuation relationhsip across the complete attribute range. For the case of 
decision contexts requiring repeat decisions, indirect MAVT techniques making use of value 
functions are recommended in order to ensure the efficient and consistent scoring of 
alternatives as they become available for evaluation 200, however indirect MAVT techniques 
could also benefit one-off decisions as they would ensure transparency between the 
performance of a criterion and the respective value preferences. 
In respect to theoretical relevance, choice-based, matching and swing weighting 
methods are based on MAVT (and MAUT) which need to satisfy a number of axioms for 
the description of rational choices as described earlier; in contrast, other methods might relax 
some of these axioms, as in the case of Analytical Hierarchy Process (AHP) that does not 
assume transitivity of preferences and neither necessarily scales of interval properties but 
only ordinal. Furthermore, the correspondence of a technique with the analytical 
requirements (i.e. level of precision) underlying MAVT methods is paramount given that the 
aim is to estimate a precise value of an option for informing specific decision-making actions 
200, conditions which are best met by swing weighting and decompositional techniques; in 
contrast, in different contexts as in the case of simpler ranking problems, a lower level of 
correspondence with analytical requirements could be acceptable. Finally, in terms of 
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cognitive load posed, some techniques might require more data to be considered than others, 
as for example the simultaneous comparison of multiple criteria required by Discrete Choice 
Experiments, in contrast to others such as AHP and MACBETH which only consider 
pairwise comparisons.  
Among the variety of MAVT techniques that could be applied to operationalise the 
Advance Value Tree I would propose the use of “Measuring Attractiveness by a Categorical 
Based Evaluation Technique” (MACBETH) because of its robustness and simplicity. 
MACBETH is an approach for the indirect elicitation of value functions through pairwise 
comparisons of attribute levels and the use of seven word categories to express differences 
in their value (ranging from “no difference” to “extreme difference”) 203,406. By building a 
matrix of qualitative judgements of differences in value, it facilitates the move from ordinal 
preference modelling to cardinal preference modelling, resulting in the development of a 
quantitative value function model as part of an interactive and constructive approach based 
on strong theoretical foundations 407. As a result, the cognitive load experienced by the 
decision-makers is at a minimum, offering an easy and comfortable way to express value 
judgements and elicit preferences, with numerous real world applications illustrating its 
usefulness as a decision support tool 408-411. In addition, the use of MACBETH can be 
explored for deriving and incorporating subjective probabilities through the design and 
deployment of value - risk matrices which could be used under uncertainty412,413.     
As part of weighting, trade-offs between criteria are elicited taking the form of 
quantitative weights to convert criteria value scores into a common value scale 200. Using 
direct rating techniques of criteria ‘importance’, as for example, requiring the distribution of 
100 points over attributes to reflect their relative importance, is associated with two, 
potentially serious, problems: first, they could produce flatter importance weight 
distributions instead of ratio estimation 54, which could lead to an underestimation of trade-
offs between attributes 414, and second, they might be insensitive to the attribute ranges used 
for the performance assessment (i.e. measurement scales) 415. 
 Attempting to assign ‘importance’ weights without taking into account the attribute 
ranges (i.e. measurement scales) are known to be one of the most common mistakes in 
making value trade-offs 3,202. Instead, the use of indirect swing weighting technique for 
eliciting relative criteria weights is recommended as common practice through the decision 
analysis literature 54,203,205,416. This technique involves judgements of relative value between 
changes (i.e. ‘swings’) from lower performance levels to higher performance levels on each 
attribute, which is then valued between 0 and 100, the most valuable being anchored at 100 
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54. Alternatively, a Discrete Choice Experiment (DCE), which is based on random utility 
theory 417 could be conducted to incorporate a randomness element on responder choices and 
reflect preference heterogeneity 200. However, the number of criteria would have to be 
relative small as most DCEs in the field of health care include up to five attributes 418. 
Methodological guidance on the sound design and implementation of DCEs taking the form 
of good research practice is provided elsewhere 419. Both of these techniques better meet 
conditions needed in order to treat weights as scaling constants 200, in alignment with 
decision theory.  
Finally, in terms of aggregating, a technique is needed for combining criteria scores 
and weights together and, more specifically, for selecting a function that allows the 
combination of the attributes in consistency with responder (e.g. stakeholders) preferences 
414.  The application of a simple additive (i.e. linear weighted average) model is the most 
commonly applied function in health care applications 200, mainly because of its simplicity 
and comprehensible nature making it easily explained and understood by decision-makers 2. 
However, its use is associated with a number of properties, the most restrictive of which is 
the existence of preference independence across criteria and attributes, entailing that no two 
or more criteria or their attributes can independently have a large impact on the overall 
benefit of the options, in which case a multiplicative or multi-linear model should be used 
54. Such models are less commonly used though as they are perceived to be more complex 
to populate 205; additionally, the incorrect aggregation of preferences through such more 
advanced models can result in considerably greater errors than additive models as evident 
from  empirical evidence of simulation studies 57. 
Ultimately, results should be examined and sensitivity analysis be conducted, 
possibly in combination with robustness analysis, in order to validate the model and findings. 
Deterministic sensitivity analysis can be used to explore the impact of baseline weight (or 
scores) changes on the rankings of the options and address parameter uncertainty. 
Robustness analysis can be used as part of an n-way sensitivity analysis to test how 
simultaneous changes in the criteria scores (or weights) would impact the ranking of the 
alternative treatments. As a result, differences in viewpoints and any disagreements between 
stakeholders can be resolved, as for example by testing whether the ranking of the treatments 
might be sensitive or not to a criterion’s relative weight.   
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5.5.3 The Advance Value Framework in Perspective  
The application of MCDA modelling techniques for the estimation of the Advance Value 
Tree through the construction of value judgements and elicitation of preferences based on 
the MAVT methodological process I have proposed 332, provides a new value framework 
based on MCDA principles for the purposes of HTA. The results of the analysis could be 
used to inform discussions and negotiations on coverage and reimbursement decisions. 
Overall, this value framework, which I call Advance Value Framework (AVF), adopts an 
encompassing societal perspective, incorporating views from the wider stakeholder 
community while assuming that the payer is the ultimate decision maker; however, the 
choice of perspective could be adapted to different circumstances and decision-making 
contexts. The AVF can be used for assessing the value of new medicines through the 
comprehensive set of criteria outlined through the Advance Value Tree; in addition to 
scientific value judgments relating to therapeutic impact and safety, the value tree allows for 
the incorporation of social value judgements relating to burden of disease, innovation level 
and socioeconomic impact, all of which can be captured explicitly.  
Finally, the AVF operationalises the Advance Value Tree through the 
implementation of the combination of (a) an indirect MAVT technique for the elicitation of 
preferences in the form of value functions (MACBETH), (b) an indirect (qualitative) swing 
weighting technique, and (c) a simple additive (linear) aggregation approach, altogether 
producing a decision-making tool easy to be used by all stakeholders, appropriately flexible 
to meet diverse requirements, and readily adaptable across different settings. I propose this 
combination of techniques because of their comprehensiveness and methodological 
robustness, but also their ability of reducing ambiguity and motivational biases. The results 
of the analysis would be used to inform discussions and negotiations around the coverage 
and reimbursement decisions. 
In reality, the precise choice of scoring, weighting and aggregating techniques will 
ultimately depend on a number of characteristics of the decision-making problem under 
consideration, in relation to theoretical relevance, level of precision required in the 
evaluation of the options and cognitive burden posed to stakeholders and decision-makers 
200. Deciding on the optimal combination of modelling techniques represents an important 
topic that requires further research to better understand the impact of different technique 
combinations on the above issues and the results of the analysis.  
Table 5.2 provides a comparative breakdown of the main features of existing value 
frameworks and the Advance Value Framework. The development of these value 
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frameworks is an important step towards a more inclusive Value Based Assessment (VBA) 
process as part of decision-making contexts in health care. However an ideal framework 
should be comprehensive enough in terms of the incorporation of value dimensions in order 
to allow for an adequate capture of value, while on the same time giving the users flexibility 
for criteria selection based on their specific needs. In any case, individual dimensions 
involved should possess a number of technical characteristics, if they are to be combined for 
overall value score rankings to be derived 204,206,332.  
For example they should be operational so they can be measured and non-overlap so 
that there is no double counting among them. Importantly, for some frameworks it is not 
clear how to operationalise performance measurement of the alternative options across the 
different value dimensions considered (so that options can be assessed) and how to mediate 
trade-offs among them, and in some cases such efforts seem to lack a theoretical basis, not 
least because they are derived in an arbitrary manner. Although most of the value 
frameworks focus mainly on the benefit component of the evaluation process relating to 
measuring the value of new medicines, issues relating to budget constraints or value for 
money considerations are crucial to consider in the prioritisation of resource allocation and 
should be the subject of further research. 
 
5.6 Conclusion  
By using a five-stage methodological iterative approach informed by secondary sources and 
extensive primary research and consultation, I have developed a generic value tree (Advance 
Value Tree) which is embedded in decision theory. The tree incorporates a number of 
evaluation criteria that have traditionally been considered in the context of HTA, either 
explicitly in a systematic manner, or implicitly on an ad hoc basis. This work builds on the 
theoretical foundation of MAVT, based on which the structure of the value tree was derived, 
influencing the inter-relationship between the different criteria and the extent to which they 
adhere to a number of critical theoretical properties. I subsequently outlined the assembly of 
the evaluation criteria in the form of a generic value tree and finally I introduced a number 
of MCDA methods and proposed a precise combination of techniques for operationalising 
the value model into a value framework (The Advance Value Framework) for use by 
decision-makers and stakeholders. In undertaking the above, I focus mainly on the benefit 
component of the evaluation process relating to measuring the value of new medicines while 
also accounting for how it could be used in practice given budget constraints in order to 
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obtain best value for money.  Future research could aim to test the value framework in 
practice, possibly through case studies involving specific interventions, in order to better 
understand potential advantages and limitations. 
 
Table 5.2: Comparison of the Advance Value Framework with other value frameworks 
Framework ACC/AHA ASCO 
 
ESMO 
 
ICER 
 
MSKCC 
 
NCCN 
 
MoCA AVF 
Decision 
context 
Clinical practice 
 
Shared 
decision 
making 
 
Clinical practice 
 
Coverage/ 
reimbursement 
 
Pricing 
 
Shared 
decision 
making 
 
Pricing and 
reimbursement 
Health 
Technology 
Assessment 
Key actor 
 
Physicians 
 
Patients - 
Physicians 
 
Physicians 
 
Payer 
 
Payer-Provider 
 
Patients - 
Physicians 
 
Payers - 
Manufacturers 
All 
stakeholders 
Value 
parameters 
-Clinical benefit 
vs. risks 
-"Value" (cost-
effectiveness) 
-Clinical 
benefit 
(efficacy) 
-Toxicity 
(safety) 
-Cost 
(efficiency) 
-Variability of 
estimated 
Hazard Ratio 
-Observed 
absolute 
difference in 
treatment 
outcomes: 
 
-Clinical care 
value 
-Health system 
value 
-Dollars per life 
year 
-Toxicity  
-Novelty 
-Cost of 
development 
-Rarity 
-Population 
burden of 
disease 
 
-Efficacy of 
regimen 
-Safety of 
regimen  
-Quality of 
evidence 
-Consistency 
of evidence 
-Affordability 
of regimen  
-Alternatives 
available/ unmet 
need 
-Relative 
effectiveness 
-Response rate 
-Degree of 
certainty 
-Burden of 
disease 
-Therapeutic 
impact 
-Safety profile 
-Innovation 
level 
-Socio-
economic 
impact 
Conceptual 
basis 
Stakeholder 
consultation 
(writing 
committee) 
Stakeholder 
consultation 
(ASCO Value 
in Cancer 
Care Task 
Force) 
Stakeholder 
consultation 
(ESMO Task 
Force with input 
from the ESMO 
faculty and a 
team of 
biostatisticians, 
followed by the 
ESMO-MCBS 
Stakeholder 
consultation 
(Input from the 
ICER Policy 
Development 
Group, involving 
representatives 
from all major 
stakeholder 
groups) 
Developed by  
single clinician/ 
epidemiologist 
Stakeholder 
consultation 
(NCCN panel 
members) 
 
Stakeholder 
consultation (the 
MoCA working 
group that was 
formed by 
volunteers from 
a number of EU 
countries) 
Literature 
review; 
Stakeholder 
consultation 
(Advance-HTA 
partners and 
workshop 
participants, 
national 
experts); 
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Task Force, the 
ESMO 
Guidelines 
Committee and 
a range of 
invited experts)  
 
Decision 
theory 
 
Strengths  Quality of 
evidence (LOE) 
explicitly ranked; 
class of 
recommendation 
given separately 
and not 
averaged 
together with 
the level/quality 
of evidence as a 
single metric. 
Net Health 
Benefit score 
and costs 
illustrated 
side by side 
to facilitate 
the decision 
making 
process of 
patients by 
making full 
informed 
decisions.  
 
Both the 
variability of the 
estimated HR 
and the 
observed 
absolute 
difference in 
treatment 
outcomes are 
explicitly 
addressed. 
 
Integration of a 
technology's 
value-for-money 
with its' budget 
impact. 
 
A range of 
domains 
incorporated, 
both relating to 
the drug and 
the disease 
Easy and 
simple to 
comprehend 
visual output 
 
Easy to 
comprehend and 
practical to use 
because of its 
simplicity 
 
 
Multiplicity of 
explicit value 
domains; 
Assignment of 
quantitative 
relative 
weights; 
Transparent; 
Engagement 
of all 
stakeholders; 
Grounds on 
decision 
theory 
 
Chapter 6 – Paper 4 
Application of the MCDA Value Framework: a Simulation Exercise on 
Metastatic Colorectal Cancer with Multiple Stakeholders in the English 
Settings119 
 
Summary 
Multiple criteria decision analysis (MCDA) has appeared as a possible alternative to address 
limitations of traditional economic evaluation as part of health technology assessment 
(HTA), however there is limited  empirical evidence from real world applications. The 
objective of this paper is to test in practice a recently developed MCDA methodological 
framework through a proof-of-concept case study engaging multiple stakeholders.  
A multi-attribute value theory methodological process was used involving 
consecutive-recursive phases of problem structuring, model building, model assessment and 
model appraisal. A facilitated decision analysis modelling approach was adopted as part of 
a decision conference with thirteen participants. 
The scope of the National Institute for Health and Care Excellence (NICE) 
Technology Appraisals setting was used, but, in addition, supplementary evidence was 
considered for value concerns not explicitly addressed by NICE. Second-line biological 
treatments for metastatic colorectal cancer (mCRC) patients having received prior 
chemotherapy were evaluated, including cetuximab monotherapy, panitumumab 
monotherapy and aflibercept in combination with Folinic acid, (5-) Fluorouracil and 
Irinotecan (FOLFIRI) chemotherapy. Initially 18 criteria attribute were considered spanning 
across value domains relating to therapeutic impact, safety profile, innovation level and 
socioeconomic impact. 
Following validation during the decision conference, a total of nine attributes were 
finally included. The therapeutic impact criteria cluster produced a relative swing weight of 
47%, the safety profile cluster 23%, the innovation level cluster 19% and the socioeconomic 
                                                 
119 Chapter 6 has been submitted for peer review with co-authors Prof Gilberto Montibeller, Dr 
Daniel Hochhauser Prof Panos Kanavos as: Angelis A, Montibeller G, Hochhauser D, Kanavos P. 
Multiple Criteria Decision Analysis (MCDA) in the Context of Health Technology Assessment: a 
simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English settings 
(Under Review at BMC Medical Informatics and Decision Making)  
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impact cluster 12%. Cetuximab scored the highest overall weighted preference value score 
of 45.7 out of 100, followed by panitumumab with 42.3, and aflibercept plus FOLFIRI with 
14.4. Main limitation was the lack of comparative clinical effects across treatments and 
challenges included the selection of “lower” and “higher” reference levels on attributes, 
eliciting preferences across attributes where participants had less experience, and ensuring 
that all attributes possess the right decision theory properties. 
This first application of the Advance Value Framework produced transparent 
valuations for three mCRC treatments across an explicit set of evaluation criteria proving to 
aid the decision-making process for participants, however further research is needed to 
possibly enable its use as part of policy-making.   
 
6.1 Background  
The assessment and appraisal of new and expensive medicines by health technology 
assessment (HTA) bodies, health insurers, and gatekeeper agencies has received 
considerable attention in recent years, especially in countries with publicly funded health 
care systems. This is a consequence of negative, and sometime controversial, 
recommendations on the funding of new medicines due to their high costs. In several cases 
these medicines relate to treatments for severe diseases with high burden, leading to high 
patient dissatisfaction and public criticism. 
As a result, the methodological aspects for assessing and appraising new medicines 
have been placed under the microscope. The use of QALYs as part of economic evaluations 
in HTA, although it is a reasonable measure of health gain it has been argued as inadequate 
to express the wider patient perspective because it does not reflect other dimensions of social 
value relating to the burden of the disease, the innovation level of interventions and their 
wider socioeconomic impact 210. These limitations have led sometimes to the ad hoc and 
non-systematic use of additional parameters of value by policy-makers which, in 
combination with lack of judgements transparency, have given an impression of 
inconsistency in evidence appraisal and decision-making. Decision controversies however 
primarily exist because of varying value perspectives, with a disagreement evident among 
different stakeholders 420. Therefore, for any decision outcomes to be ultimately understood 
and regarded as “rationally-based”, the application of more comprehensive decision-making 
processes of an explicit and transparent nature is required. 
Developing alternative methodological approaches for the evaluation of new 
medicines could therefore overcome such limitations, contributing to a more complete 
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framework for measuring value and making resource allocation decisions. Recently, the use 
of multiple criteria decision analysis (MCDA) has appeared as a possible alternative to 
address current limitations of HTA that result from traditional economic evaluation 90,91,191-
194. Indeed, one of the conclusions of a recent systematic literature review on MCDA 
approaches applied in health care, including HTA, was that decision-makers are positive 
about the potential of MCDA to improve decision-making 72. 
However, there are limited studies using empirical evidence from real world MCDA 
applications with the involvement of stakeholders.  In this paper a case study is presented as 
proof-of-concept, applying a recently developed MCDA methodological framework 332,421. 
A decision conference workshop was organised with the participation of a wide range of 
stakeholders for evaluating and ranking the value of a set of drugs for the treatment of 
metastatic colorectal cancer (mCRC) following first line chemotherapy. A facilitated 
decision analysis modelling approach for expert panels was adopted 422. Metastatic 
colorectal cancer was chosen because of its high severity, the availability of several 
expensive alternative treatment options, and the fact that it has been the topic of appraisals 
by several HTA agencies, including a number by the National Institute for Health and Care 
Excellence (NICE) in England 423-428.  
The methodological details of the case study are extensively provided in the section 
below. The overall value rankings of the different drugs are presented in the results section, 
and the limitations of the study together with the challenges encountered are described in the 
discussion. 
 
6.2 Methods 
6.2.1 Methodological Framework  
An MCDA methodological process has been proposed based on Multi-Attribute Value 
Theory (MAVT) 54,205 that comprises five distinct phases. These include (a) problem 
structuring, (b) model building, (c) model assessment, (d) model appraisal, and (e) 
development of action plans 332. Further detail is provided in Appendix (6.1).  The process 
was operationalised using a decision support system enabling the use of graphics to build a 
model of values, acting as a facilitation and decision-making tool to inform both the 
structuring phases (a, b) and the evaluation phases of the process (c, d) 429.  
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6.2.2 Clinical Practice and Scope of the Exercise (Problem Structuring) 
This is a simulation exercise focusing on identifying and assessing the overall value of 
second-line biological treatments for mCRC following prior oxaliplatin-based (first line) 
chemotherapy, by adopting the respective scope from the latest Technology Appraisal (TA) 
of each technology that has been appraised by NICE (at the time of study design and data 
collection, February 2015). In doing so, the same or latest available clinical and economic 
evidence from the corresponding TAs were used to populate the performance of the 
alternative options across the respective criteria attributes of our value tree, but in addition 
supplementary evidence were used for value concerns not addressed by NICE. The scope of 
TA242 was adopted for the cases of bevacizumab, cetuximab and panitumumab 426, whereas 
the scope of TA307 was adopted for the case of aflibercept 427. For the case of regorafenib, 
no sufficient scope details existed in TA334 as the appraisal was terminated early “because 
no evidence submission was received” from the manufacturer 428, excluding it from the 
exercise.  
The TA242 scoping evaluated bevacizumab in combination with non-oxaliplatin 
chemotherapy, cetuximab monotherapy or combination with chemotherapy, and 
panitumumab monotherapy for mCRC after first-line chemotherapy. The populations 
covered for the case of cetuximab and panitumumab were mCRC patients expressing the 
wild-type (i.e. non-mutated) form of the v-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog (KRAS) gene, because these agents, which target the epidermal growth factor 
receptor (EGFR), have been shown to be ineffective for treatment of tumours expressing the 
mutated KRAS gene 430-432. KRAS expression does not impact on the case of bevacizumab. 
Bevacizumab was appraised only when in combination with non-oxaliplatin based 
chemotherapy, because under UK clinical practice oxaliplatin containing combinations (i.e. 
FOLFOX) are generally used in the first line. Once cancers demonstrate resistance to 
FOLFOX patients are then eligible for non-oxaliplatin based chemotherapy regimens such 
as FOLFIRI, therefore, patients treated with bevacizumab at second-line would normally 
receive it in combination with non-oxaliplatin based chemotherapies. Hence, the exclusion 
of oxaliplatin based chemotherapies from the scope of the TA and our exercise. 
The scope of TA307 specified the evaluation of aflibercept in combination with 
FOLFIRI that has progressed following prior oxaliplatin based chemotherapy. Again, the 
scope of the TA and our exercise considered aflibercept only in combination with non-
oxaliplatin chemotherapy for the same reason explained above. 
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6.2.3 Adaptation of the Advance Value Tree for Metastatic Colorectal Cancer (Model 
Building)   
Overall, a hybrid approach was adopted for the selection of evaluation criteria 332 containing 
elements both from the “value focused thinking” 3 and “alternative focused thinking” 
approaches 204. 
A generic value tree (Advance Value Tree) offering an organised overview of the 
various concerns when evaluating new medicines in an HTA context has been developed 
under the auspices of the Advance-HTA project120 using a combination of literature reviews 
and expert consultations 339,421. The aim was to identify all the necessary criteria for the 
assessment of value of new medical technologies under a prescriptive approach and it was 
designed in a top-down ‘value-focused thinking’ manner (criteria selected prior identifying 
the alternative options) 3,332, essentially generating the building blocks of a comprehensive 
value function. Ultimately, the resulting value tree  is decomposed into five value criteria 
clusters relating to i) the burden of disease the technology addresses (BoD), ii) the 
technology’s therapeutic impact (THE), iii) the technology’s safety profile (SAF), iv) the 
overall innovation level (INN) and, v) the wider socioeconomic impact (SOC).  
  
       𝑉𝑎𝑙𝑢𝑒 = 𝒇(𝑩𝒐𝑫, 𝑻𝑯𝑬, 𝑺𝑨𝑭, 𝑰𝑵𝑵, 𝑺𝑶𝑪)       (6) 
 
The generic value tree was later adapted for the context of mCRC in a bottom-up 
‘alternative-focused thinking’ approach (criteria emerged following the comparison of the 
alternative options) 204,332.  This adaptation resulted in the preliminary version of the mCRC 
specific value tree (Figure 6.1). Overall, out of the five criteria clusters of the generic value 
tree, the burden of disease cluster was removed because it was identical across all alternative 
therapeutic options considered given that all treatments were assessed for the same 
indication (mCRC). The rest remaining criteria clusters were decomposed into nine sub-
criteria clusters with a total of 18 criteria attributes. The list of attributes and their respective 
definitions are shown in Table 6.1. The selection of the mCRC-specific attributes and 
consequently the development of the respective value tree took place in alignment with key 
properties such as preferential independence and non-redundancies in order to ensure their 
                                                 
120 Advance-HTA is a research project funded by the European Commission's Seventh Research Framework 
Programme (FP7). It comprises several complementary streams of research that aim to advance and strengthen 
the methodological tools and practices relating to the application and implementation of Health Technology 
Assessment (HTA). It is a partnership of 13 Consortium members led by the London School of Economics - 
LSE Health. 
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selection is methodologically correct and theoretically robust according to decision theory 
principles 206. 
 
Figure 6.1: Preliminary value tree for metastatic colorectal cancer (pre-workshop) 
 
 
*image produced using the Hiview software version 3.2.0.4 
 
Table 6.1: Attributes definition and sources of evidence  
Cluster Attribute Definition Evidence source 
      
Aflibercept + 
FOLFIRI Cetuximab Panitumumab  
THERAPEUTIC 
IMPACT 
Overall survival The median time from treatment randomisation to 
death 
Van Cutsem et al 
2012433 
Price et al 
2014434 
Price et al 2014 
HRQoL  Health related uquality of life using EQ-5D score TA 307427 Hoyle et al 
2013435  
Hoyle et al 2013  
Progression 
free survival 
The median survival time on which patients have 
not experienced  disease progression (using RECIST 
criteria) 
Van Cutsem et al 
2012 
Price et al 2014 Price et al 2014 
Objective 
response rate 
The proportion of patients that experience 
complete response and partial response (using 
RECIST criteria) 
Van Cutsem et al 
2012 
Price et al 2014 Price et al 2014 
SAFETY 
 PROFILE 
Grade 3 AEs  The proportion of patients experiencing a Grade 3 
adverse event 
Van Cutsem et al 
2012 
Price et al 2014 Price et al 2014 
Grade 4 AEs  The proportion of patients experiencing a Grade 4 
adverse event 
Van Cutsem et al 
2012 
Price et al 2014 Price et al 2014 
Contra-
indications 
The existence of any type of contraindication 
accompanying the treatment 
EPAR436, 
Prescribing info 
EPAR437, 
Prescribing info 
EPAR438, 
Prescribing info 
  
ATC Level 1 The technology's relative market entrance in 
regards to its ATC Level 1 (Anatomical) 
WHO ATC index439 WHO ATC index WHO ATC index 
  
ATC Level 2 The technology's relative market entrance in 
regards to its ATC Level 2 (Therapeutic) 
WHO ATC index WHO ATC index WHO ATC index 
  
ATC Level 3 The technology's relative market entrance in 
regards to its ATC Level 3 (Pharmacological) 
WHO ATC index WHO ATC index WHO ATC index 
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INNOVATION 
LEVEL 
ATC Level 4 The technology's relative market entrance in 
regards to its ATC Level 4 (Chemical) 
WHO ATC index WHO ATC index WHO ATC index 
ATC Level 5 The technology's relative market entrance in 
regards to its ATC  Level 5 (Molecular) 
WHO ATC index WHO ATC index WHO ATC index 
Phase 1 The number of new indications for which the 
technology is investigated in  Phase 1 clinical trials 
ClinicalTrials.gov440 ClinicalTrials.gov ClinicalTrials.gov 
Phase 2 The number of new indications for which the 
technology is investigated in  Phase 2 clinical trials 
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov 
Phase 3 The number of new indications for which the 
technology is investigated in  Phase 2 clinical trials 
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov 
Marketing 
authorisation 
The number of new indications that the technology 
has gained an approval for at the stage of 
marketing authorisation 
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov 
Posology The frequency of doses in a given time period in 
combination with the duration of the 
administration 
EPAR,  
Prescribing info 
EPAR,  
Prescribing info 
EPAR,  
Prescribing info 
SOCIO-
ECONOMIC 
IMPACT 
Medical costs 
impact 
The impact of the technology on direct medical 
costs excluding the purchasing costs of the 
technology 
BNF 69, TA 307, 
Wade et al 2013441 
BNF 69, TA 
242426, Hoyle et 
al 2013 
BNF 69, TA 242, 
Hoyle et al 2013 
6.2.4 Evidence Considered and Alternative Treatments Compared (Model Building) 
The alternative treatment options compared in the exercise include cetuximab monotherapy 
(Erbitux ®), panitumumab monotherapy (Vectibix ®), and aflibercept (Zaltrap ®) in 
combination with FOLFIRI chemotherapy. Although there is published evidence for the 
efficacy of cetuximab in combination with chemotherapy, bevacizumab in combination with 
non-oxaliplatin-based chemotherapy, or regorafenib monotherapy as treatment options, 
these treatments were not included in the exercise because there was absence of relevant 
clinical evidence submitted to NICE as part of their respective TAs 426,428. 
Overall, evidence sources used to populate the preliminary model included two 
randomised clinical trials (RCTs) 433,434, the respective NICE TAs 426,427, any NICE Evidence 
Review Group (ERG) reports 441 or any  related peer review studies coming out 435,442,  
summaries of product characteristics (SPCs) available through EMA’s European Public 
Assessment Reports (EPAR) 436-438 (or highlights of prescribing information leaflets), 
Anatomical Therapeutic Chemical (ATC) classification system indexes through the portal 
of the WHO Collaborating Centre for Drug Statistics Methodology 439, and 
ClinicalTrials.gov listings 440. The source of evidence used for identifying the performance 
of options across the criteria attributes is shown in Table 6.1. It should be noted that among 
the two RCTs used for populating the performance of the treatments across the clinical 
attributes, one was a head to head trial directly comparing cetuximab versus panitumumab 
(ASPECCT trial) 434 and the other one comparing aflibercept in combination with FOLFIRI 
versus placebo with FOLFIRI (VELOUR trial)433. More details on the clinical evidence 
considered are shown in Appendix (6.2). 
 
6.2.5 Setting Attribute Ranges and Reference Levels (Model Building) 
As part of model building, attribute ranges were selected that were encompassed within 
minimum (min) and maximum (max) levels. Within the min-max attribute range,  “lower” 
(x_l) and “higher” (x_h) reference levels were defined to act as benchmarks for the 
preference value scores of 0 and 100 respectively, needed for the construction of criteria 
value functions and elicitation of relative weights (these are interval scales and thus the 
importance of setting up clear bounds for each attribute). Incorporation of such intermediate 
reference levels rather than extreme reference levels at the limits of the scale can protect 
against inaccuracies emerging from potential non-linearity in value at scale’s limits 2. As a 
result, value scores could possibly be negative or higher than 100 with v(xlower) = 0 and 
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v(xhigher) = 100, essentially conducting a linear transformation which is admissible to an 
interval scale such as a value scale.  
The methodological basis for setting the attribute ranges and the choice of reference 
levels was the following. For the case of clinical therapeutic attributes, the “higher reference 
levels” were normally based on BSC figures, coming from the median of the respective arms 
of the CO.17 and AMGEN trials; otherwise, if no BSC figure was available the placebo 
comparator arm from the VELOUR trial was used. The “lower reference levels” were based 
on the worst performances plausible, inferred either based on their lowest natural limit (for 
the case of continuous scale attributes, e.g. 0 months for OS) or based on the lowest 
evidence-based limit (for the case of non-natural constructed scale attributes, e.g. 0.6 utility 
for HRQOL as it was the lower utility used for progressive disease by NICE). The maximum 
levels of the attributes were simply derived by adding a 10% absolute increment to the 
performance level of the best performing option, essentially offering an error margin to the 
limits of the scale. This was performed to produce reference levels that corresponded to 
“worst performance” (plausible) and “satisfactory performance” (proxied by BSC), 
corresponding to the 0 and 100 anchor levels of the value function scale respectively, with 
options performing better than the satisfactory level scoring more than 100. By this way 
three attribute levels were defined in total: i) the “lower reference level” (x_l) (i.e. worst 
performance plausible), acting on the same time as minimum level (x_*); ii) the “higher 
reference level” (x_h) (i.e. BSC-based satisfactory performance); and iii) the maximum level 
(x^*) (i.e. 10% higher than the best performing option), to give x_*=x_l < x_h< x^*.  
For the purpose of eliciting preferences and producing the matrix of judgements 
using M-MACBETH, it was aimed to incorporate two intermediate attribute levels lying in-
between the three defined attribute levels (giving a total of five different attribute levels) so 
that the granularity of the scale is increased, essentially to improve the representation of any 
differences in value across the attribute ranges. In cases where the gaps between the three 
defined levels were disproportionate large, a third intermediate level was added for a more 
homogeneous dispersion, giving a total of 6 attribute levels (three defined and three 
intermediates), whereas in cases of disproportionate small gaps only one intermediate level 
was added giving a total of 4 attribute levels (three defined and one intermediate). In no 
cases there were less than 4 and more than 6 attribute levels in total.  
Similar but reverse logic was adopted for setting the reference levels of the safety 
attributes; the “higher reference levels” were based either on the median of the BSC arm 
from the AMGEN trial and the placebo comparator arm of the VELOUR trial (BSC data from 
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the CO.17 trial were not available for all attributes), or if this was not relevant on the median 
of the options (e.g. for the case of the existence of contra-indications). The “lower reference 
levels” were derived either by adding a 10% absolute increment to the worst performing 
option (e.g. 10% higher incidence for the case of AEs) or by choosing the worst performance 
plausible for the case of a constructed attribute with a non-continuous scale (i.e. for the 
existence of contra-indications). The maximum level of the attributes was defined by 
selecting the best performance plausible (e.g. 0% for incidence of AEs), whereas the 
minimum level (i.e. worst performance) was equal to the “lower reference level”.  
For the innovation attributes, the “higher reference level” was derived by using the 
median of the options (BSC performance was irrelevant to be used as satisfactory level), 
whereas the “lower reference level” was based on the worst performance plausible as 
inferred from the lowest limit of the scales (e.g. 5th entrance at an ATC level, or 0 number 
of new indications for which the technology is investigated in a given clinical development 
stage). The maximum level of the attributes was derived by either adding a 10% absolute 
increment to the performance level of the best performing option, for the case of natural 
attributes with a continuous scale (e.g. number of new indications for which the technology 
is investigated in a given clinical development stage), or alternatively by using the best 
performance plausible for the case of constructed attributes with discrete-level scales (e.g. 
1st entrance at an ATC level). The minimum level was equal to the “lower reference level”.    
For the socioeconomics attribute (impact on direct costs), the “higher reference level” was 
derived by using the median of the options (BSC performance was irrelevant to be used as 
satisfactory level), and the “lower reference level” was derived by adding a 10% absolute 
increment to the worst performing option (i.e. to the one with the biggest impact on costs. 
The maximum level was defined by selecting the best performance plausible, as inferred 
from the highest natural limit of the scale (i.e. £0 impact on costs), whereas the minimum 
level (i.e. worst performance) was equal to the “lower reference level”.   
A list of all attributes’ “lower and higher reference levels” together with their basis of 
selection, as shaped before the workshop is provided in Table 6.2. 
 
6.2.6 Decision Conference (Model Assessment and Appraisal) 
The model assessment and model appraisal phases of the exercise took place through a 
facilitated workshop with key stakeholders and experts, taking the form of a decision 
conference 443, organised and hosted at the London School of Economics and Political 
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Science on 30th of April 2015. A decision conference could be defined as “a gathering of key 
players who wish to resolve important issues facing their organisation, assisted by an 
impartial facilitator who is expert in decision analysis (DA), using a model of relevant data 
and judgements created on-the-spot to assist the group in thinking more clearly about the 
issues” 416(p.54); see also Franco and Montibeller (2010) 422. Typical stages of decision 
conference workshops include exploring the issues, structuring and building the model, 
exploring the model and agreeing on the way forward. In this case, the first two stages were, 
to a great extent, informed by preparatory work that had been conducted before the 
workshop, involving extensive literature review.  
Background material introducing the scope of the exercise in more detail was sent to 
the participants one week before the workshop. On the day of the workshop, the model was 
presented to the participants and was revised cluster by cluster in real time through a 
facilitated open discussion. It should be highlighted that the aim of the model in this 
evaluation context is to act as an aid for the group to interact and think about the decision 
problem, rather than to provide the “correct” answer 416,444. An iterative and interactive 
model-building process was adopted, where debate was encouraged and differences of 
opinion actively sought. Generally, overall agreement was reached in regards to criteria 
inclusion and exclusion; in the few instances where this was unattainable, criteria were left 
in the model for their impact to be tested as part of the sensitivity analysis stage, where 
distinctive viewpoints were finally resolved. 
 
 
 
Table 6.2: Pre-workshop attribute reference levels and basis of selection 
Cluster Attribute Metric Lower level Basis Higher level Basis 
THERAPEUTIC 
IMPACT 
Overall survival months 0 Minimum limit 
of the scale 
6.2 BSC 
HRQoL  utility score (EQ-
5D) 
0.6 Lower score 
used for 
progressive 
state in 
TA307427 
0.75 BSC 
Progression free 
survival 
months 0 Minimum limit 
of the scale 
1.9 BSC 
Objective 
response rate 
% of patients 0 Minimum limit 
of the scale 
11 FOLFIRI + 
Placebo 
(VELOUR trial)433 
SAFETY  
PROFILE 
Grade 3 AEs  % of patients 68 10% higher than 
the worst 
performing 
option 
32 Median of BSC 
(AMGEN trial)445 
and FOLFIRI + 
Placebo 
(VELOUR trial) 
Grade 4 AEs  % of patients 24 10% higher than 
the worst 
performing 
option 
10 Median of BSC 
(AMGEN trial) 
and FOLFIRI + 
Placebo 
(VELOUR trial) 
Contra-
indications 
types of contra- 
indications 
Lower expected 
benefit and 
higher expected 
risk 
Minimum limit 
of the scale 
Lower expected 
benefit 
Median of 
options 
INNOVATION  
LEVEL 
ATC Level 1 relative market 
entrance 
5th Minimum limit 
of the scale 
4th Median of 
options 
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ATC Level 2 relative market 
entrance 
5th Minimum limit 
of the scale 
4th Median of 
options 
ATC Level 3 relative market 
entrance 
5th Minimum limit 
of the scale 
3rd Median of 
options 
ATC Level 4 relative market 
entrance 
5th Minimum limit 
of the scale 
1st Median of 
options 
ATC Level 5 relative market 
entrance 
5th Minimum limit 
of the scale 
1st Median of 
options 
Phase 1 number of new 
indications 
0 Minimum limit 
of the scale 
17 Median of 
options 
Phase 2 number of new 
indications 
0 Minimum limit 
of the scale 
55 Median of 
options 
Phase 3 number of new 
indications 
0 Minimum limit 
of the scale 
18 Median of 
options 
Marketing 
authorisation 
number of new 
indications 
0 Minimum limit 
of the scale 
2 Median of 
options 
Posology duration of 
administration 
& frequency of 
doses 
Many hours, 
every 2 weeks 
Minimum limit 
of the scale 
(worst 
performing 
option) 
Up to an hour, 
every 2 weeks 
Maximum limit 
of the scale 
(best 
performing 
option) 
SOCIO-
ECONOMIC 
IMPACT 
Medical costs 
impact 
GBP (£) 7,086 10% higher than 
the worst 
performing 
option 
4,589 Median of 
options 
The composition of the group’s expertise and the numbers of the different 
stakeholders were decided based on the structure of the past NICE committees responsible 
for the appraisals of the alternative treatments 423,425-427. It was aimed to involve a small 
group between 7 and 15 participants; these group sizes have been shown to be adequate 
because they tend to preserve individuality while also allowing efficient group processes, as 
they are small enough to be able to work towards agreement, but large enough to represent 
all major perspectives 94. In total, 13 participants were involved, their areas of expertise and 
type of affiliation are shown in Table 6.3.  
Participants were contacted through an email invitation outlining the exercise and the 
purpose of the project, and background material introducing the scope of the exercise in 
more detail was sent one week before the workshop. Travel expenses for the participants 
were retrospectively covered.  
In terms of the decision-aiding methodology used, impartial facilitation was adopted 
with the aim of enhancing content and process interaction, while refraining from contributing 
to the content of the group’s discussions, essentially guiding the group in how to think about 
the issues but not what to think 416,446. In terms of facilities, the room of the workshop had a 
Π-shaped meeting table for all the participants to have direct eye contact, with an overhead 
projector screen surrounded by whiteboards. The M-MACBETH software was operated 
using a laptop, the screen of which was connected to the projector.   
The workshop lasted the whole day, from 9.00 am to 18.00 pm with one 45-minutes 
lunch break, and two 15-minutes coffee breaks. The day started with a brief introductive 
presentation and then moved on with an overview of the MCDA methodology adopted and 
the description of the value tree. The value tree was then presented and analysed cluster by 
cluster.  
At the beginning of each cluster the value tree was validated; the various criteria were 
explained, followed by a group discussion relating to their relevance and completeness. As 
a result of this iterative process, some of the criteria were excluded because they were 
perceived as irrelevant or non-fundamental, but no criteria were deemed to be missing. Then, 
value functions were elicited for the different criteria and criteria weights were elicited 
within the clusters. Finally, relative weights were assigned across clusters, which enabled 
calculating the overall WPV scores of the options.   
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Table 6.3: List of decision conference participants  
Participant Expertise Affiliation 
1 Medical oncologist - CRC expert NHS Trust - Teaching hospital  
2 Medical oncologist - CRC expert NHS Trust 
3 
Consultant - community 
paediatrician 
NHS Trust - HTA agency 
4 Public health expert Academia 
5 Pharmacist Independent 
6 Health economist Academia 
7 HTA expert Academia 
8 Health economist Academia 
9 HTA expert Academia 
10 Medical statistics Academia 
11 Patient Independent 
12 Patient carer Independent 
13 Patient advocate Charity 
 
 
6.2.7 MCDA Technique (Model Assessment and Appraisal) 
The model was operationalised through a value framework consisting of a value 
measurement method adopting a typical simple additive aggregation approach, where the 
overall value V(.) of an option a is given by Equation 4 421. Overall, the additive value model 
is assumed as a working hypothesis and therefore the model construction is undertaken to 
respect its underlying properties (see section 1.1.4), requiring positive weights summing one 
and the use of explicit reference values of 0 and 100, see Table 6.2 and 6.4.  
Value preferences can be elicited using different protocols. A method based on 
pairwise qualitative comparisons is MACBETH (Measuring Attractiveness by a Categorical 
Based Evaluation Technique), an approach using qualitative judgements about the difference 
of attractiveness between different pairs of attribute levels 406,447. Under MACBETH, which 
based on strong theoretical foundations 407, semantic judgements are converted into a 
cardinal scale therefore providing a simple, interactive and constructive approach, and its 
usefulness as a decision support tool has been shown through numerous applications for real 
world problems 408-411.    
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M-MACBETH, a decision support system based on the MACBETH approach 448, 
was used to elicit value preferences of the workshop participants and more precisely to build 
the value tree, elicit the value functions for the different attributes, assign relative attribute 
weights through a qualitative swing weighting approach, aggregate the preference value 
scores and weights using an additive aggregation (i.e. simple additive model) to derive 
overall weighted preference value (WPV) scores, and conduct sensitivity analysis 449. 
Besides a consistency check between the qualitative judgements expressed that is 
automatically provided by the software, a second consistency check was performed 
manually to ensure that an interval scale is obtained, i.e. validate the cardinality of the scale, 
by comparing the sizes of the intervals between the suggested scores and inviting participants 
to adjust them if necessary 450, an essential requirement for aggregation using simple additive 
value models. More technical details on MACBETH are provided in Appendix (6.3). 
 
6.2.8 Costs Calculation (Model Assessment and Appraisal) 
Drug costs were calculated according to prices (excl. VAT), pack sizes and dosage 
strengths as found on the British National Formulary (BNF 69), and the recommended 
dosage and treatment duration as reported on the respective NICE technology 
appraisals426,427. Vial wastage was assumed in all calculations. Drug administration costs for 
cetuximab and panitumumab were kept consistent with Hoyle et al. 442 and administration 
costs for aflibercept plus FOLFIRI consistent with the respective ERG Report 441.  
 
6.3 Results 
6.3.1 Criteria Validation and Amended Value Tree for Metastatic Colorectal Cancer   
The final version of the value tree, as emerged following the open discussion with the 
participants in the workshop is shown in Figure 6.2. In total, 9 out of the 18 attributes were 
removed from the value tree because they were judged from the participants to be non-
fundamental for the scope of the exercise, resulting in a value tree with half of its’ original 
size. Importantly, no criteria were deemed to be missing. In the therapeutic impact cluster, 
the Objective Response Rate (ORR) attribute was removed. In the safety profile cluster, the 
contra-indications attribute was removed and the Grade 3 Adverse Events (AEs) and Grade 
4 AEs attributes were proposed to be aggregated into a single attribute; however this 
aggregation required a significant modelling iteration, and due to time constraints it was 
decided to exclude the Grade 3 AEs attribute and only include Grade 4 AEs for the purpose 
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of the simulation exercise. In terms of the innovation cluster, participants had mixed views. 
Consensus (i.e. full agreement) was reached for the ATC L5, Phase 1 and Phase 2 attributes 
to be removed, and for the ATC L4 to be included as a binary variable (i.e. first entrance in 
the chemical class vs. second or subsequent entrance in the chemical class); however strong 
disagreement existed on whether to include Phase 3 and Market Authorisation attributes, 
with half of the participants in favour and half of the participants opposed to their inclusion. 
As a result, both of the attributes were left in the model and their impact was then tested at 
the end of the workshop as part of the sensitivity analysis stage.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Final Value Tree for metastatic colorectal cancer (post-workshop) 
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* image produced using the M-MACBETH (beta) software version 3.0.0 
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6.3.2 Validation of Attribute Ranges and Reference Levels 
Another important amendment in the model included a change in the definitions of the 
“lower” and “higher” reference levels, which define the 0 and 100 scores in the value 
functions and anchor the swing weights. For the case of clinical attributes a majority 
agreement was reached by the group’s participants that the “lower reference level” should 
actually correspond to the “satisfactory performance” (proxied by Best Supportive Care, 
BSC) rather than the “worst performance” plausible. As a result, the “lower reference level” 
was switched to the previously defined “higher reference level” (i.e. satisfactory 
performance), and the “higher reference level” was set equal to the maximum level.  The 
newly-defined attribute levels were therefore: i) the “lower reference level” (i.e. BSC-based 
satisfactory performance); the “higher reference level” (equal to the maximum, best 
performance plausible, level), and the minimum level (i.e. worst performance plausible). In 
doing so, the amended  “lower and higher reference levels” were now corresponding to 
“satisfactory performance” (proxied by BSC) and “best performance” respectively, with 
options performing worse than the “satisfactory” level getting a negative score, and all 
options obtaining less than 100 score.  
As a consequence, a similar change was introduced for the case of - the now single - 
safety profile attribute (Grade 4 AEs), with the “lower reference level” being defined based 
on “satisfactory performance”, the “higher reference level” based on “best performance” 
(i.e. minimum limit of the scale) and the minimum level remaining the same.  
For the case of innovation attributes, the “higher reference levels” were set equal to the “best 
performance” levels, with the “lower reference levels” remaining the same (equal to the 
worst performance). Similarly, for the case of the socioeconomic impact attribute (impact 
on direct medical costs) the “higher reference level” was also set equal to the “best 
performance” level, with the “lower reference level” remaining the same (equal to the worst 
performance). 
The arising changes in the attribute reference level definitions, before and after the 
workshop for each of the criteria clusters are shown in Table 6.4, with the final list of 
attributes’ “lower” and “higher” reference levels, together with their basis of selection 
provided in Table 6.5.  
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Table 6.4: Changes in the definitions of the attribute reference levels, pre- and post- 
workshop 
 
 
Attribute level Preliminary (pre-workshop) Final (post-workshop)
Maximum best performance
 best performance

"Upper reference" satisfactory performance
 best performance 

"Lower reference" worst performance satisfactory performance

Minimum worst performance worst performance 
Maximum 10% > best performing option 10% > best performing option
"Upper reference" BSC performance 10% > best performing option
"Lower reference" worst performance BSC performance
Minimum worst performance worst performance 
Maximum
best performance/ limit of scale best performance/ limit of scale
"Upper reference"
BSC performance
(or median performance of options)
best performance/ limit of scale
"Lower reference"
10% > worst performing option
(or worst  perfrormance)
BSC performance
(or median performance of options)
Minimum
10% > worst performing option
(or worst perfrormance)
10% > worst performing option
(or worst perfrormance)
Maximum
10% > best performing option 
or best performance/ limit of scale
10% > best performing option 
or best performance/ limit of scale
"Upper reference" median performance of options
10% > best performing option 
or best performance/ limit of scale
"Lower reference" worst performance/ limit of scale worst performance/ limit of scale
Minimum worst performance/ limit of scale worst performance/ limit of scale
Maximum best performance best performance
"Upper reference" median performance of options best performance
"Lower reference" 10%> worst performing option 10%> worst performing option
Minimum 30%> worst performing option 30%> worst performing option
Therapeutic Cluster
Safety Cluster
Overall
Innovation Cluster
Socioeconomic Cluster
Table 6.5: Post-workshop attribute reference levels and basis of selection 
Cluster Attribute Metric Lower level Basis Higher level Basis 
THERAPEUTIC 
IMPACT 
Overall survival months 6.2 BSC 14.9 10% higher that 
the best 
performing 
option 
HRQoL  utility score (EQ-
5D) 
0.75 BSC 0.9 10% higher that 
the best 
performing 
option/ general 
population 
Progression free 
survival 
months 1.9 BSC 7.6 10% higher that 
the best 
performing 
option 
SAFETY  
PROFILE 
Grade 4 AEs  % of patients 10 Median of BSC 
arm from 
AMGEN trial445 
and placebo + 
FOLFIRI arm 
from VELOUR 
trial433 
0 Maximum limit 
of the scale 
INNOVATION  
LEVEL 
ATC Level 4 relative market 
entrance 
≥2nd Minimum limit 
of the scale, 
binary variable 
1st Maximum limit 
of the scale, 
binary variable 
Phase 3 number of new 
indications 
0 Minimum limit 
of the scale 
21 10% higher that 
the best 
performing 
option 
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Marketing 
authorisation 
number of new 
indications 
0 Minimum limit 
of the scale 
3 10% higher that 
the best 
performing 
option 
Posology duration of 
administration 
& frequency of 
doses 
Many hours, 
every two 
weeks  
Minimum limit 
of the scale 
(worst 
performing 
option) 
Up to an hour, 
every two 
weeks 
Maximum limit 
of the scale 
(best 
performing 
option) 
SOCIO-
ECONOMIC 
IMPACT 
Medical costs 
impact 
GBP (£) 7,086 10% higher than 
the worst 
performing 
option 
0 BSC 
 
 
 
6.3.3 Options Performances, Criteria Weights and Overall Preference Value Rankings 
Two examples of value judgements matrices and their conversion into a linear and non-linear 
value function for the case of the Overall Survival (OS) and Health Related Quality of Life 
(HRQoL) attributes respectively are shown in Appendix (6.4), together with the value 
functions for the rest attributes. 
The performance of the options across the different attributes together with the 
“lower” and “higher” reference levels is shown in Table 6.6. The different columns 
correspond to the performance of the different options (including the two reference levels), 
across the respective attributes as shown across the rows. The table of overall WPV scores 
for all options across the different attributes, together with the respective attribute baseline 
weights is shown in Table 6.7; similarly to Table 6.6, the different columns correspond to 
the preference value scores of the different options (including the two reference levels), 
across the respective attributes as shown across the rows. Cetuximab scored the highest 
overall WPV score of 45.7, followed by panitumumab with an overall WPV score of 42.3. 
Aflibercept in combination with FOLFIRI was ranked last with an overall WPV score of 
14.4, partially due to its performance on Grade 4 AEs (21%) which lied below the lower 
reference level of the value scale (10%), producing an absolute preference value score of -
117.9 and a weighted preference value score of -27.4 . A stacked bar plot of the overall WPV 
scores of the alternative treatments across the attributes is shown in Figure 6.3. 
 The relative weights assigned to the different attributes are shown in Figure 6.4. The 
criteria are ranked based on their relative magnitude, ranging from the relatively more 
important criteria to relatively less important criteria (from left to right across the x-axis), 
taking into account the “lower” – “higher” ranges of the attributes. The OS and Grade 4 AEs 
attributes together assigned a relative weight totaling the relative weights of all other 
attributes together, i.e. 50%.  Out of 100, the therapeutic impact cluster attributes totaled 
overall a relative weight of 47, the safety profile cluster (single attribute only) a relative 
weight of 23, innovation level cluster attributes totaled overall a relative weight of 19, and 
the socioeconomic impact cluster (single attribute only) a relative weight of 12. 
 
 
 
 
 
Table 6.6: Options performance across the criteria attributes 
Attribute name Attribute metric Lower level 
Aflibercept + 
FOLFIRI 
Cetuximab Panitumumab Higher level 
Overall Survival months 6.2 13.5 10 10.4 14.9 
HRQoL utility (EQ-5D) 0.75 0.78 0.78 0.78 0.9 
Progression Free 
Survival 
months 1.9 6.9 4.1 4.4 7.6 
Grade 4 AEs % of patients 10 21 5 7 0 
ATC L4 
relative market 
entrance 
2nd 1st 1st 2nd 1st 
Phase 3 # of new indications 0 18 19 7 21 
Marketing 
Authorisation 
# of new indications 0 3 1 0 3 
Posology duration & frequency 
hrs, every 2 
weeks 
hrs, every 2 
weeks 
1 hr, every week 
≤hr, every 2 
weeks 
≤hr, every 2 
weeks 
Medical costs impact GBP (£) 7,086 6,738 4,589 1,940 0 
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Table 6.7: Overall weighted preference value (WPV) scores, partial preference value scores, relative weights, costs and cost per unit of value 
  
Lower 
level 
Aflibercept + 
FOLFIRI 
Cetuximab Panitumumab 
Higher 
Level 
Relative 
Weights 
Overall WPV score 0.0 14.4 45.7 42.3 100.0 100 
Overall survival 0.0 83.9 44.4 48.9 100.0 29 
Health Related Quality 
of Life 
0.0 15.0 15.0 15.0 100.0 13 
Progression free 
survival 
0.0 90.3 51.4 55.6 100.0 5 
Grade 4 AEs 0.0 -117.9 50.0 30.0 100.0 23 
ATC L4 0.0 100.0 100.0 0.0 100.0 6 
Phase 3 0.0 50.0 66.7 19.4 100.0 2 
Marketing 
Authorisation 
0.0 100.0 30.0 0.0 100.0 3 
Posology 0.0 0.0 37.5 100.0 100.0 7 
Medical costs impact 0.0 7.0 50.0 78.9 100.0 12 
Costs (£)   29,400 18,000 27,000     
Cost per unit of value   2,046 394 638     
 
 
 Figure 6.3: Stacked bar plot of treatments’ overall weighted preference value (WPV) scores 
across all attributes  
 
 
 
Figure 6.4: Criteria weights histogram 
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6.3.4 Value for Money Analysis 
By incorporating the total purchasing costs of the different drugs (including their 
administration costs), their overall WPV scores versus total costs plot is produced (Figure 
6.5). By using rounded up total cost figures of £18,000 for cetuximab (£12,824 drug cost 
and £5,191 administration cost), £27,000 for panitumumab (£23,643 drug cost and £3,374 
administration cost), and £29,400 for aflibercept in combination with FOLFIRI (£17,750 
drug cost and £11,630 administration cost), and dividing them with overall WPV scores, 
their costs per MCDA value unit were calculated to be £394, £638, and £2,046 respectively 
(Table 6.7). Therefore, in terms of value-for-money, aflibercept in combination with 
FOLFIRI is shown to be dominated by panitumumab, both of which are shown to be 
dominated by cetuximab which is associated with the highest overall WPV score and the 
lowest cost.   
 
Figure 6.5: Cost benefit plot of overall weighted preference value (WPV) scores versus costs 
 
 
* image produced using the M-MACBETH (beta) software version 3.0.0 
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6.3.5 Sensitivity and Robustness Analysis 
Deterministic sensitivity analysis was conducted to address parameter uncertainty by 
exploring the impact of baseline weight changes on the ranking of the options (figures shown 
in Appendix 6.5). In order for panitumumab to become better ranked than cetuximab any of 
the following changes in baseline weights would be needed: OS from 28.9 to 59.8, PFS from 
4.8 to 47.7, Grade 4 AEs from 23.3 to 7.5, ATC L4 from 5.8 to 2.5, Posology from 7 to 11.8, 
or Medical costs impact from 11.6 to 21.0.  
Similarly, for aflibercept plus FOLFIRI to become better ranked than cetuximab, OS 
weight from 28.9 to 60.3, PFS from 4.8 to 47.3, Grade 4 AEs from 23.3 to 5.6, or Market 
authorisation from 3.5 to 33.3. Finally, for aflibercept plus FOLFIRI to become better ranked 
than panitumumab, OS weight from 28.9 to 60.4, PFS from 4.8 to 47.2, Grade 4 AEs from 
23.3 to 5.4, ATC L4 from 5.8 to 26.4, Phase 3 from 2.3 to 49.0, or Market authorisation from 
3.5 to 24.6.  
Therefore, conclusions were fairly robust as treatment rankings were not influenced 
by changes of at least 50% or less on any of the baseline normalised weights, the most 
sensitive attributes being Posology and Medical costs impact attributes on the cetuximab 
versus panitumumab comparison (requiring a 69% and 81% change respectively for 
panitumumab to become better ranked), with changes of at least up to 100% on the remaining 
baseline normalised weights exerting no impact on the results.     
The robustness of the results was also tested by conducting 8-way sensitivity analysis 
in the reference levels of the attributes using the respective function of the M-MACBETH 
software (“Robustness analysis”), which showed that a simultaneous change of up to 5% 
across all of the attribute reference levels would not impact the ranking of the alternative 
treatments (figure in Appendix 6.5). 
However other types of uncertainty might exist, such as stochastic uncertainty, 
structural uncertainty and heterogeneity, which could be addressed through more advanced 
statistical approaches, including probabilistic sensitivity analyses, Bayesian frameworks, 
fuzzy set theory or grey theory 208. For example, uncertainty associated with the performance 
of the options due to sampling variation of clinical studies, or with the criteria weights due 
to inability to derive or agree on weights, might make the application of point estimates 
inappropriate in which case stochastic multi-criteria acceptability analysis (SMAA) might 
be preferred 451.  
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6.4 Discussion 
This was a simulation exercise following an MCDA methodological process adapted for the 
context of HTA 332 and testing a newly developed MCDA value framework in practice 
through a decision conference 421. The methodological process adopted is generally in 
alignment with recent good practice guidelines on the use of MCDA for health care decision-
making, in respect to design, implementation and review of the analysis 200.  
Overall, a set of different treatment options for the indication of mCRC at second-
line were assessed and ranked based on their overall WPV scores. These scores acted as 
value metrics or value indices, comprised from the performance of the alternative treatment 
options against an explicit set of criteria while adjusting for the relative importance of these 
criteria, as reflected by the preferences of the group. Finally, incorporation of drug costs 
(purchasing and administration costs) enabled the production of “cost per unit of value” ratio 
estimates while revealing the dominance of one treatment.  
Assuming that the participants of the workshop acted as a group responsible for 
choosing or recommending the funding of one of the alternative options, cetuximab would 
be the rational choice of the group assuming that the respective budget needed is available.  
Incorporation of budget impact considerations in the cost-value ratio estimates at system 
level could take place by taking into account the number of patients that will receive the 
treatment, however benefits and costs should be estimated in comparable units so that the 
results are not biased towards the cheapest alternative, as for example on a per-patient basis 
200. 
Participants’ feedback about the case study highlighted the importance of having a 
fully transparent evaluation model that can be used to construct and analyse value 
preferences, including value trade-offs, and pointed towards the existence of promising 
prospects with the use of the adopted methodology in the future.  
 
6.4.1 Strengths and Opportunities  
Among the biggest benefits of the methodology adopted is the explicit incorporation of 
multiple benefit dimensions, some of which are possibly hard-to-measure, but proved 
important nevertheless. 
Another central strength of the framework is the development of the evaluation 
model with a group of relevant stakeholders (health care professionals, methodology experts, 
patients), which proved to be essential for creating a shared understanding of what 
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constitutes value in this decision context. This was evident across all its phases, ranging from 
model-building to model appraisal, playing a profound role across all the stages. Starting 
with criteria selection, by sharing participants’ views and opinions among the group while 
seeking a consensus (i.e. full agreement if not majority agreement) approach, the original 
version of the value tree and its criteria were validated, amending its contents and leading to 
the exclusion of some attributes that seemed non-fundamental or irrelevant. For example 
Objective Response Rate (ORR), the sum (i.e. proportion) of patients that experience 
complete response and partial response (using the RECIST criteria), which was originally 
included in the value tree was decided to be removed because of irrelevance. Initially, the 
clinical view was raised that stable cancer (i.e. non-responding) might be just as good of an 
outcome as tumour shrinking. Although the argument was expressed that in theory ORR 
could help into controlling symptoms better, there is no firm evidence for this in the 
literature.  The HRQoL and Grade 4 AEs indices are instruments designed for the assessment 
of symptoms and ORR gives no additional utility. Thus, its inclusion in this regard would 
even entail double counting effects. In turn, it was suggested that ORR is primarily designed 
for measuring patient response and treatment efficacy under the settings of new drug 
development and not a major guide to clinical practice in the setting of advanced disease. 
With regard to clinical practice, the use of PFS as a metric could be perceived more complete 
and reflective.   
During model assessment and the elicitation of preferences through value functions, 
a structured discussion enabled the representation of all the different perspectives for the 
purpose of valuation. Although occasionally some of the participants might at first have had 
opposing views and beliefs in regards to their preference judgments, in most of the cases 
these conflicts were terminated or defused following extensive discussions. An example 
would be the elicitation of the Overall Survival (OS) value function which started with 
contrasting perspectives on how to assess additional months of life, but following far-
reaching dialogues around the added value of different life increments, an agreement was 
established that each additional month of life was associated with an equal magnitude of 
value, as revealed through a linear value function. 
The systematic assessment of all types of evidence together enabled the identification 
of strengths and weaknesses for each treatment, which in turn could be used to influence 
their use under clinical practice, or even support their redesign and improvement as part of 
clinical development process. For example, although aflibercept in combination with 
FOLFIRI (afli+FOL) was associated with the highest score in OS, overall it ranked last 
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because of a highly negative score in Grade 4 AEs. Given that AEs might be correlated with 
the dose of the treatment, and considering the preferences of the group, it could thus be 
suggested that a lower dose of afli+FOL could potentially produce a lower incidence of 
Grade 4 AEs at possibly acceptable reductions in OS as a trade-off (given the relatively 
higher score of the option on the latter attribute), which could improve its overall WPV score. 
Importantly, the clinical view was raised that in practice the dosage of afli+FOL 
administered to patients might be higher than what prescribing guidelines recommend, 
which would support the previous argument. However in reality a lower dose might give rise 
to much lower efficacy/effectiveness (not being linearly correlated), and this is strictly a 
hypothetical assumption aiming to give an insight on how the results of such an analysis 
could be taken into consideration.   
In turn, the negative score of afli+FOL on Grade 4 AEs was directly influenced by 
the definitions of the “higher” and “lower” reference levels, as outlined on Table 6.5. One 
could argue that setting the “higher reference level” on the basis of the minimum limit of the 
scale (i.e. zero) might be unrealistically idyllic. As part of a secondary post-workshop 
analysis the “higher” reference level of the Grade 4 AEs attribute was changed from 0% 
(best possible performance, minimum limit of the scale), to 2% (BSC performance) in order 
to test the impact on the score of the treatments, which resulted to an even higher negative 
score for afli+FOL (this is because the other options were now scoring higher, as their 
performance was located closer to the “higher” reference level). Assuming that such an 
analysis and discussion were conducted at an earlier stage of the drug’s life cycle, for 
example during Phase 2 clinical trials, these insights could instead influence future aspects 
of drug development by inducing changes into the formulation process and the envisaged 
posology characteristics of the drug.  
Another benefit of the evaluation was a clear separation between the performance of 
treatments and their valuation, based respectively on the availability of evidence across the 
attributes and the establishment of marginal value within criterion and value trade-offs 
across criteria, with the latter one being amenable to sensitivity analysis. The explicit 
modelling of preferences and values represented how much the group valued the marginal 
performances for each attribute, as well as their priorities for the different criteria, 
represented by the weights. This separation allowed assessing the robustness of results for 
variations of preferences. For example, sensitivity analysis at the end of the workshop in 
respect to the baseline weights of the innovation attributes, for which some of the participants 
did not totally agree with their elicited relative importance, assured the participants that the 
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ranking of the treatments was not sensitive to minor variations along their range (last column 
of Table 6.7).  
  
6.4.2 Limitations and Challenges 
Among the limitations of the case study was the use of un-synthesised evidence to inform 
the clinical attributes given the lack of relative treatment effects, therefore limiting the extent 
to which the results can inform real policy-making. An important challenge would relate to 
the technical difficulties in ensuring that all attributes possess the required theoretical 
properties, and more specifically the fact that potential preference-dependence was observed 
between the OS and HRQOL attributes which was addressed by deriving OS value functions 
that were effectively conditional on the range of the HRQOL attribute. However, it should 
be noted that the use of conditional value functions might be incompatible with the use of 
an additive model and therefore should only be used with caution, as for example within 
descriptors of performance (i.e. attributes). In order to be able to use an additive model under 
the existence of preference dependence, the effect between the two attributes would have to 
equal zero, or, in other words the product of their value scores would have to be zero; for a 
more extensive discussion around the use of linear additive model together with conditional 
value functions due to preference dependence see section 8.3.2.  Another limitation would 
be that the HRQOL of the progressive disease was not assessed because none of the 
treatments assumed to have any effects on it, something which might not hold true in other 
conditions. Among the main challenges included the evaluation of attributes in which 
participants had less experience which was addressed from expert opinion. These limitations 
and challenges are extensively discussed in the Limitations and Challenges section in the 
last chapter of the thesis (section 8.3.2).  
 
6.5 Conclusion  
The challenge to assess novel treatments and therapeutic combinations in a setting of 
significant budgetary pressure on health services require novel methodologies of assessment 
incorporating the preferences from groups of stakeholders across a set of multiple value 
dimensions.  In this study an integrated multi-criteria approach was described simulating an 
HTA context for the case of advanced colorectal cancer treatments.  Innovative approaches 
to decision-making for pricing and reimbursement of new therapies will be essential in the 
coming era of precision medicine and expensive but effective immunotherapies for cancer.  
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Future research could help validating the robustness of the methodology by conducting 
similar case studies with multi-stakeholder groups in different countries.    
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Chapter 7 – Paper 5 
Application of the MCDA Value Framework: a Case Study on Metastatic 
Prostate Cancer with the Swedish Dental and Pharmaceutical Benefits 
Agency TLV121 
 
Summary 
Escalating drug prices have catalysed the generation of numerous “value frameworks” with 
the aim to inform payers, clinicians and patients around the assessment process of new 
medicines for the purpose of coverage and treatment selection decisions. Although this is an 
important step towards a more inclusive value-based assessment approach, aspects of these 
frameworks are based on weak and atheoretical methodologies and could potentially result 
in misleading recommendations or decisions.  
Previous research has identified Multiple Criteria Decision Analysis (MCDA) as a 
potential methodology for assessing the value of drugs in Health Technology Assessment 
(HTA) and assist payers with resource allocation, however there are limited empirical 
evidence. The study applies in practice a theory-based MCDA framework through a proof-
of-concept case study while engaging HTA decision-makers in a real world application. 
A multi-attribute value theory methodological process involving problem structuring, model 
building, model assessment and model appraisal phases was adopted. The MACBETH 
approach was used: the different interventions were scored against the criteria through the 
development of value functions, weights were assigned to the criteria using a swing 
weighting technique and overall weighted preference value (WPV) scores were produced 
using simple additive aggregation. A facilitated decision analysis modelling approach was 
adopted as part of a decision conference. 
The scope of the Swedish Dental and Pharmaceutical Benefits Agency (TLV) was 
used, but in addition supplementary evidence was considered for value concerns not 
explicitly addressed by TLV. Third-line biological treatments for mCRPC were evaluated, 
including cetuximab, panitumumab and aflibercept in combination with FOLFIRI, in 
                                                 
121 Chapter 7 has been submitted for peer review and it is single-authored by myself as: Angelis A. 
Applying Multiple Criteria Decision Analysis (MCDA) in the context of Health Technology 
Assessment (HTA): a case study on metastatic prostate cancer with the Swedish HTA agency TLV 
(Under Review at International Journal of Technology Assessment in Health Care)  
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metastatic castrate resistant prostate cancer (mCRPC) patients having received prior 
docetaxel chemotherapy in second line treatment. Eighteen attributes were initially 
considered, spanning value domains relating to therapeutic impact, safety profile, innovation 
level and socioeconomic impact.  
A total of eight attributes were finally included. The therapeutic impact criteria 
cluster produced a relative weight of 44%, the safety profile cluster 33%, the socioeconomic 
impact cluster 15% and the innovation level cluster 7%. Enzalutamide scored the highest 
overall WPV score of 58.7, followed by abiraterone with 6.9 and cabazitaxel with 1.4 
(partially because of a highly “negative” performance in the treatment discontinuation 
attribute).  Dividing treatments’ purchasing costs with their overall WPV scores derived 
costs per unit of value at £419, £3,173, and £17,509 respectively. 
Main challenges included the relatively subjective nature of setting the “lower” and 
“higher” reference levels on each attribute from single clinical studies given the lack of meta-
analyses, the evaluation of clusters where participants had less experience, and the technical 
difficulties associated with ensuring that all evaluation criteria possess the ideal decision 
theory properties. 
Overall, the participants of the workshop felt this was a useful exercise and that the 
methodological framework has the prospects of facilitating decision-making, mainly 
because it provides the opportunity to explicitly assess the performance of the options across 
a number of criteria, while eliciting trade-offs on their importance, explicitly and 
transparently. However additional research is recommended to address technical difficulties 
and enable its use as part of policy-making.   
 
7.1 Background  
In recent years, the assessment and appraisal of new and expensive medicines by Health 
Technology Assessment (HTA) bodies, health insurers, and gatekeeper agencies has 
received considerable attention, especially in countries with publicly funded health care 
systems. At times, this has emerged as a consequence of negative coverage decisions for 
some medicines, often related to treatments for high burden diseases associated with 
significant mortality and morbidity. As a consequence, intense disputes often arise usually 
involving patients, clinicians and pharmaceutical manufacturers on one hand and HTA 
bodies, commissioners of care and decision-makers responsible for the allocation of 
resources on the other.  
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To a large extent this conflict can be attributed to current methodologies used for the 
evaluation of new medicines as they cannot adequately capture the different notions of value 
evident given the existence of diverse perspectives 420. For example, despite the fact that the 
QALY metric has managed to successfully combine the two vital dimensions of health 
benefit relating to life expectancy and quality of life, its sole and inflexible adoption as part 
of economic evaluations in HTA can at times be regarded as blunt and insufficient not least 
because it does not adequately reflect other important value dimensions of the treatment 210. 
This lack of comprehensiveness has led decision-makers to use additional parameters of 
value in an ad hoc and non-systematic manner often lacking transparency 339, with any 
inconsistency in the evaluation procedure threatening the perceived fairness of the decision 
and its acceptance from the public. 
More recently a growing number of resource-conscious clinicians have started to 
publicly oppose the use of highly expensive new drugs with marginal incremental clinical 
benefit in clinical practice on the grounds of poor value for money. Escalating drug prices 
have catalysed the generation of numerous ‘value frameworks’ with the aim to inform 
treatment selection decisions by clinicians, possibly shared together with patients 170-172,174. 
Although this is an important step towards a more inclusive value-based assessment 
approach, aspects of these frameworks are based on weak and atheoretical methodologies 
and could potentially result in misleading recommendations or decisions 177. 
Research and development of alternative methodologies for assessing the value of 
new medicines could overcome such limitations, contributing towards a more complete 
framework for measuring value and making resource allocation and treatment decisions. 
Multiple criteria decision analysis (MCDA) has recently surfaced as an alternative to 
traditional economic evaluation techniques with the prospects of addressing some of their 
limitations in HTA 72,90,91,191-194,332, but also for elicitng patient preferences and faciltating 
treatment selection 340,452,453. 
This is a proof-of-concept case study utilising a new value framework the author 
recently developed for assessing the value of metastatic castrate resistant prostate cancer 
(mCRPC) treatment options following first/second line chemotherapy 421. This work is a 
continuation of an earlier case study on the assessment of drugs for metastatic colorectal 
cancer involving preferences elicitation from a wide range of stakeholders in the English 
settings  454. It is the first from a series of case studies testing the value framework in practice 
by utilising value judgements and preferences from decision-makers of different national 
HTA agencies and social insurance bodies in Europe. A decision conference workshop 443 
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was organised with an experts panel consisting of assessors from the Swedish Dental and 
Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket, TLV) that 
adopted a facilitated decision analysis modelling approach 94,422. Metastatic prostate cancer 
was chosen as a case study topic mainly because of the disease severity and the availability 
of several expensive alternative treatment options highlighting a clear decision problem. 
Furthermore it has been a popular subject of appraisals by numerous HTA agencies, 
including TLV in Sweden and the National Institute for Health and Care Excellence (NICE) 
in England.  
The adaptation and application of the value framework is described in the methods 
section, the preference value rankings of the treatment options are shown in the results 
section, with some value-for-money considerations and limitations of the methodology as a 
decision-making tool described in the discussion section. 
 
7.2 Methods 
7.2.1 Methodological Framework  
An MCDA methodological process was adopted based on Multi-Attribute Value Theory 
(MAVT 54,205 involving the following five phases: (i) problem structuring, (ii) model 
building, (iii) model assessment, (iv) model appraisal, and (v) development of action plans 
332.  The process was operationalised using a decision support system enabling the use of 
visual graphics to build a model of values, acting as a facilitation and decision-making tool 
to inform both the structuring phases (i, ii) and the evaluation phases of the process 429 (iii, 
iv). Additional information on the methodological framework can be found in Appendix 
(7.1).  
 
7.2.2 Clinical Practice and Scope of the Exercise (Problem Structuring) 
Surgical or chemical castration are hallmarks of prostate cancer treatment since the 1940s 
455. For many years prostate cancer’s systemic therapy involved surgical or chemical 
continuous androgen deprivation 456,457, often in combination with first-generation anti-
androgens (i.e. combined androgen blockade) for patients who progress despite androgen 
deprivation and whose disease becomes hormone relapsed known as castrate resistant 
prostate cancer (CRPC) 458.   
In 2004 clinical evidence demonstrated the survival benefit of docetaxel 
chemotherapy in combination with prednisolone for CRPC patients, when compared to 
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mitoxantrone in combination with prednisolone 459,460. Since then a fruitful period in the 
development of prostate cancer drugs followed with a number of new molecules indicating 
significant clinical benefit in patients previously treated with docetaxel including 
abiraterone, cabazitaxel and enzalutamide 461-463. Cross-resistance appears to exist between 
abiraterone and enzalutamide indicating that it is unlikely to experience clinical benefit by 
switching from one treatment to the other 464,465, based on which NICE recommends only 
the use of either treatment and not both 466,467. Although specific patient sub-populations 
might be contra-indicated to any of the treatments, in most cases all three new and expensive 
drugs could be suitable for patients and therefore the topic of CRPC treatment coverage acts 
as a suitable decision context for the application of the methodological framework in 
assessing their value.  
Recent clinical studies have demonstrated a survival benefit for abiraterone or 
enzalutamide in CRPC patients in earlier line of treatment prior the administration of 
docetaxel chemotherapy 468,469. However the expected number of patients receiving 
abiraterone or enzalutamide before docetaxel is likely to be shrunk following the publication 
of more recent clinical evidence supporting that docetaxel in combination with androgen 
deprivation therapy lead to high gains in survival of CRPC patients 470,471. Consequently, the 
assessment of the three treatments - at the post-docetaxel stage - remains clinically relevant.  
The analysis presented here focuses on assessing the value of third line treatments 
for mPC following prior docetaxel-containing (i.e. second line) chemotherapy, essentially 
adopting ESMO’s clinical practice guidelines and the scopes of the respective Technology 
Appraisals (TAs) for each technology by NICE and TLV. In doing so, the same clinical 
evidence from the corresponding TAs was used to inform the respective criteria of the value 
tree, but this was further supplemented by additional evidence for value concerns not 
explicitly addressed by NICE and TLV. The scope of NICE TA255 was adopted for the case 
of cabazitaxel in combination with prednisone, the scopes of NICE TA259 and TLV 
TA4774/2014 were adopted for the case of abiraterone in combination with prednisone, 
whereas the scopes of NICE TA316 and TLV TA2775/2013 were adopted for the case of 
enzalutamide 466,467,472-474.  
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7.2.3 Adaptation of the Advance Value Tree for Metastatic Prostate Cancer (Model 
Building)  
Selection of evaluation criteria benefitted from a hybrid approach, which essentially 
combined features from “value focused thinking” 3 and “alternative focused thinking” 204. 
The author initially adopted a top-down approach for the selection of a generic set of 
evaluation criteria, prior the identification of any drug options, followed by a bottom-up 
approach for the adaptation of the generic criteria, which took place after the comparison of 
specific drug options’ characteristics 332. 
More precisely, initially as part of the Advance-HTA project122 and following a 
systematic review of the literature and consultations with experts 339, the author developed a 
generic value tree with higher-level criteria followed by lower-level criteria for assessing the 
value of new medicines in the HTA context 421. The structure of this emerging value tree 
(Advance Value Tree) consists of five value domains or criteria clusters, aiming to reflect 
all the essential value attributes of new medicines and their indication in a prescriptive 
manner. These included a) burden of disease (BoD), b) therapeutic impact (THE), c) safety 
profile (SAF), d) innovation level (INN) and, e) socioeconomic impact (SOC), with the first 
value domain relating to the disease of interest and the four latter domains relating to the 
actual medical intervention(s), essentially producing the following value function:  
  
  𝑉𝑎𝑙𝑢𝑒 = 𝒇(𝑩𝒐𝑫, 𝑻𝑯𝑬, 𝑺𝑨𝑭, 𝑰𝑵𝑵, 𝑺𝑶𝑪)   (6) 
 
The generic value tree was adapted for the case of mCRPC while striving to adhere to the 
ideal decision theory properties to ensure methodological robustness 206 producing a disease 
specific value tree with five criteria clusters decomposed into eight sub-criteria clusters and 
a total of 18 emerging criteria attributes (Figure 7.1). The definitions of all value attributes 
are listed in Table 7.1.   
The value tree was validated later on with the decision conference participants, 
therefore reflecting another type of mixed approach adopted in terms of values construction: 
initially, model adaptation and structuring took place based on the literature and in 
                                                 
122 Advance-HTA is a research project funded by the European Commission's Seventh Research Framework 
Programme (FP7). It comprises several complementary streams of research that aim to advance and strengthen 
the methodological tools and practices relating to the application and implementation of Health Technology 
Assessment (HTA). It is a partnership of 13 Consortium members led by the London School of Economics - 
LSE Health. 
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consultation with a clinical expert, which was then collectively validated and evaluated with 
the group before the completion of the model building phase 475. 
 
Figure 7.1: Preliminary value tree for metastatic prostate cancer (pre-workshop) 
 
 
 
*image produced using the Hiview software version 3.2.0.4 
 
 
 
Table 7.1: Attributes definition and sources of evidence 
Cluster Attribute Definition Evidence source 
      Abiraterone Cabazitaxel Enzalutamide 
THERAPEUTIC 
IMPACT 
Overall survival 
The median time from treatment 
randomisation to death 
de Bono et al 
2011462 
de Bono et al 
2010461 
Scher et al 
2012463 
HRQoL  Health related quality of life using EQ-5D score TA259466; TA316467 N/A  TA316 
Radiographic 
tumour 
progression 
The median survival time on which patients 
have not experienced  disease progression 
(using RECIST criteria) 
de Bono et al 2011 de Bono et al 
2010  
Scher et al 2012 
PSA response 
The proportion of patients having a ≥50% 
reduction in PSA   
Fizazi et al 2012476 de Bono et al 
2010 
Scher et al 2012 
SAFETY  
PROFILE 
Treatment 
discontinuation 
The proportion of patients discontinuing 
treatment due to AEs 
de Bono et al 2011 de Bono et al 
2010  
Scher et al 2012 
Contra-
indications 
The existence of any type of contra-indication 
accompanying the treatment 
EPAR477, 
Prescribing info 
EPAR478, 
Prescribing info 
EPAR479, 
Prescribing info 
INNOVATION 
 LEVEL 
ATC Level 1 
The technology's relative market entrance in 
regards to its ATC Level 1 (Anatomical) 
WHO ATC index439 WHO ATC index WHO ATC index 
ATC Level 2 
The technology's relative market entrance in 
regards to its ATC Level 2 (Therapeutic) 
WHO ATC index WHO ATC index WHO ATC index 
ATC Level 3 
The technology's relative market entrance in 
regards to its ATC Level 3 (Pharmacological) 
WHO ATC index WHO ATC index WHO ATC index 
ATC Level 4 
The technology's relative market entrance in 
regards to its ATC Level 4 (Chemical) 
WHO ATC index WHO ATC index WHO ATC index 
ATC Level 5 
The technology's relative market entrance in 
regards to its ATC  Level 5 (Molecular) 
WHO ATC index WHO ATC index WHO ATC index 
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Phase 1 
The number of new indications for which the 
technology is investigated in  Phase 1 clinical 
trials 
ClinicalTrials.gov440 ClinicalTrials.gov ClinicalTrials.gov 
Phase 2 
The number of new indications for which the 
technology is investigated in  Phase 2 clinical 
trials 
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov 
Phase 3 
The number of new indications for which the 
technology is investigated in  Phase 2 clinical 
trials 
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov 
Marketing 
authorisation 
The number of new indications that the 
technology has gained an approval for at the 
stage of marketing authorisation 
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov 
Delivery 
Posology 
The combination of the delivery system (RoA 
and dosage form) with the posology (frequency 
of dosing and duration of administration) of the 
treatment 
EPAR,  
Prescribing info 
EPAR,  
Prescribing info 
EPAR,  
Prescribing info 
Special 
instructions 
The existence of any special instructions 
accompanying the administration of the 
treatment 
EPAR,  
Prescribing info 
EPAR,  
Prescribing info 
EPAR,  
Prescribing info 
SOCIO-
ECONOMIC 
IMPACT Medical costs 
impact 
The impact of the technology on direct medical 
costs excluding the purchasing costs of the 
technology 
BNF 69,  
Prescribing info, 
Connock et al 
2011480, Riemsa et 
al 2013481, TA259 
BNF 69, 
Prescribing info, 
de Bono et al 
2010, TA255472 
BNF 69, TA316 
7.2.4 Evidence Considered and Alternative Treatments Compared (Model Building) 
The alternative treatment options compared in the analysis include cabazitaxel (Jevtana ®) 
in combination with prednisone, abiraterone (Zytiga ®) in combination with prednisone and 
enzalutamide (Xtandi ®) monotherapy.   
The evidence sources used include the peer review publications concerning the 
pivotal clinical trials of the alternative treatment options that were considered in the 
appraisals by NICE and TLV 461-463,476, NICE Evidence Review Group (ERG) reports 480,481, 
or peer review studies coming out of them 482,483 and a Swedish population study on health 
related quality of life 484, Product Information sections of the European Public Assessment 
Reports (EPAR) from the European Medicines Agency (Annex I and III) 477-479, Anatomical 
Therapeutic Chemical (ATC) classification system indexes through the portal of the WHO 
Collaborating Centre for Drug Statistics Methodology 439, and ClinicalTials.gov listings 440. 
The clinical evidence (falling under the THE and SAF criteria clusters) for each alternative 
treatment option were sourced from the same clinical studies that NICE and TLV evaluated 
(single pivotal trials for each drug).  The source of evidence used for identifying the 
performance of options across the evaluation criteria is shown in Table 7.1. Additional 
information on the evidence considered can be found in Appendix (7.2).  
 
7.2.5 Setting Attributes’ Ranges and References Levels (Model Building) 
In regards to model building, the attribute ranges were selected so that they would be bound 
by the minimum (min) and maximum (max) attribute limits. Within these min-max attribute 
limits, intermediate “lower” (x_l) and “higher” (x_h) reference levels were defined to serve 
as benchmarks for defining the preference value scores of 0 and 100 respectively, for 
constructing criteria value functions and eliciting their relative weights123 449. The emerging 
value scores of options could therefore take negative or higher than 100 values where 
v(xlower) = 0 and v(xhigher) = 100, essentially by conducting a linear transformation which is 
acceptable as an interval scale such as a value scale.   
Limits were assigned that included the current performance of the options as well as 
possible short-term future changes, ensuring that the limits would still be considered realistic 
by the assessors, essentially reflecting a “local” value scale adjusted for future expected 
performance 2. Table 7.2 outlines “lower and higher reference levels” for all attributes at the 
                                                 
123 these are interval scales and therefore is important to set up clear bounds/limits for each attribute 
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pre-workshop stage, and the basis of their selection124. For the case of the clinical attributes 
(falling under the THE and SAF value domains), the reference levels were decided in 
consultation with a clinical expert (urologic oncologist).  
The methodological basis adopted for setting the min-max attribute limits and the 
choice of the reference levels was the following. For the case of clinical therapeutic 
attributes, “lower reference levels” were based on BSC figures, coming from the median of 
the respective placebo arm of the AFFIRM trial, with the exception of the HRQoL attribute 
(EQ-5D index score) that was based on the utility of stable disease with no treatment coming 
from past NICE TAs 466,472. The “higher reference levels” were derived by adding a 20% 
absolute increment to the performance level of the best performing option, besides for the 
case of the HRQoL attribute (EQ-5D index score) that was based on the general Swedish 
population 484. The rationale was to use a “satisfactory performance” (proxied by BSC) and 
an “ideal performance” which could offer a flexibility margin to incorporate the performance 
of future improved options (proxied by 20% higher than today’s available), corresponding 
to the 0 and 100 anchor levels of the value function scale respectively, with options 
performing better than the satisfactory level scoring more than 0. Consequently two 
reference levels within the attribute range were defined in most cases: i) the “lower reference 
level” (x_l) (i.e. BSC-based satisfactory performance), acting on the same time also as the 
minimum limit of the attribute range (x_*); and ii) the “higher reference level” (x_h) (i.e. 
20% higher than the best performing option), acting on the same time as the maximum limit 
of the attribute range (x^*) to give x_*=x_l < x_h= x^*.  
Similar but reverse logic was adopted for setting the reference levels in the “treatment 
discontinuation” attribute of the safety cluster; the “lower reference level” was defined equal 
to the BSC (i.e. placebo) arm of the AFFIRM trial. However, contrary to the logic adopted 
so far for the therapeutic impact criteria, the “higher reference level” was not set equal to 
20% less (because the lower the figure the higher the value) than the best performing option, 
but rather equal to the minimum natural limit of the attribute scale (i.e. 0%) which was 
regarded as an “ideal” level. In turn, the minimum limit of the scale was derived by 
incorporating 20% to the worst performing treatment option A similar approach was used 
for setting the reference levels of the qualitative attribute of “contraindications”, defining the 
“higher reference level” equal to the maximum (i.e. most attractive) limit of the attribute 
scale (i.e. no contraindications) and the “lower reference level” equal to the minimum (i.e. 
                                                 
124 assuming no impact of LHRH analogue 
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least attractive) limit of the attribute scale, based on the performance of the alternative 
options therefore acting as reference levels of a “local” scale.  
For the innovation attributes, the “higher reference level” was set either equal to 20% 
higher than the best performing option for the case of natural quantitative attributes (e.g. 
number of new indications for which the technology is investigated in a given clinical 
development stage), or equal to the maximum limit of the scale for the case of constructed 
qualitative attributes (e.g. the existence of any special instructions, the technology's relative 
market entrance in regards to its ATC Level. Given that the BSC performance was irrelevant 
to be used as satisfactory level in the innovation attributes, and the fact that any efforts to 
derive a “satisfactory” level would by definition be subjective in nature, the minimum limit 
of the scale for each attribute was used as a “lower reference level”. Therefore the “lower 
reference level” was based on the worst performance plausible as inferred from the lowest 
limit of the scales, both for the case of natural quantitative attributes (e.g. 0 number of new 
indications for which the technology is investigated in a given clinical development stage), 
and the case of constructed qualitative attributes (e.g. worst possible combination of special 
instructions, 5th entrance at an ATC level).  
For the socioeconomics attribute (impact on direct costs), the “higher reference 
level” was based on the BSC’s impact on cost (i.e. £0 impact on costs), given that by 
definition impact on costs for all treatment options are incremental to BSC, and the “lower 
reference level” was derived by adding a 20% absolute increment to the worst performing 
option (i.e. to the one with the biggest impact on costs).  
For the purpose of eliciting preferences and producing the matrix of judgments using 
M-MACBETH, two additional intermediate attribute levels were aimed to be incorporated 
between the two defined attribute levels (giving a total of four different attribute levels) so 
that the granularity of the scale is increased, essentially to improve the representation of any 
differences in value across the attribute ranges. In cases where the gaps between the two 
defined levels were disproportionate larger, a third intermediate level was added for a more 
homogeneous dispersion, giving a total of five attribute levels (two defined and three 
intermediates), whereas in cases of disproportionate smaller gaps, one intermediate level was 
added giving a total of three attribute levels (two defined and one intermediate). In no cases 
there were less than three and more than five attribute levels in total, except for the case of 
“new indications at MA stage” for which the “higher reference level” was equal to 1 and the 
“lower reference level equal to 0”.  
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7.2.6 Decision Conference (Model Assessment and Appraisal) 
The model assessment and model appraisal phases of the exercise took place through a 
facilitated workshop with assessors from TLV, taking place as a decision conference and 
hosted at the head offices of TLV in Stockholm, Sweden. In total four experts acted as 
participants, including one medical investigator, two health economists and one chief 
pharmacist. Background material introducing the scope of the exercise in more detail was 
sent to the participants one week before the workshop.  
The author acted as an impartial facilitator and assisted the group’s interaction and 
thinking about the decision problem using the preliminary version of the mCRPC specific 
value tree (Figure 7.1) and the relevant data as the model’s starting point, based on which 
value judgements and preferences were elicited on-the-spot 416,422,444. On the day of the 
workshop the preliminary model was validated with the participants by revising it one cluster 
by cluster in real time through an open discussion, seeking group consensus (i.e. majority 
agreement if not full agreement) by adopting an iterative and interactive-model-building 
process where debate was encouraged and differences of opinion actively sought.  
In terms of the decision-aiding methodology used, the author acted as an impartial 
facilitator with the aim of enhancing content and process interaction, while refraining from 
contributing to the content of the group’s discussions, essentially guiding the group in how 
to think about the issues but not what to think 416,446. In terms of facilities, the room of the 
workshop had a Π-shaped meeting table for all the participants to have direct eye contact, 
with an overhead projector screen surrounded by whiteboards. The M-MACBETH software 
was operated using a laptop, the screen of which was connected to the projector. 
The workshop lasted two half-days (2 sessions in total), three to four hours each 
session, with a short coffee break around the middle of each session. In the first day, the 
workshop started with an overview of the MCDA methodology adopted and the description 
of the value tree. The value tree was then presented and analysed cluster by cluster. At the 
beginning of each cluster the value tree was validated; the various criteria were explained, 
followed by a group discussion relating to their relevance and completeness. As a result of 
this iterative process, some of the criteria were removed because they were perceived as 
irrelevant or non-fundamental. Then, value functions were elicited for the different criteria 
and relative weights were assigned within the clusters. Finally, relative weights were 
assigned across clusters, enabling the calculation of the options’ overall WPV scores.  
 
Table 7.2: Pre-workshop attribute reference levels and basis of selection 
Cluster Attribute name Attribute metric Lower level Basis Higher level Basis 
THERAPEUTIC 
IMPACT 
Overall survival months 13.6 BSC 22.1 20% higher than 
the best 
performing 
option 
HRQoL  utility (EQ-5D) 0.72 Utility used for 
progressive 
disease in TA259 
0.82 Utility scores of 
general 
population 
Radiographic 
tumour 
progression  
months 2.9 BSC 10.6 20% higher than 
the best 
performing 
option 
PSA response % patients 1.5 BSC 64.8 20% higher than 
the best 
performing 
option 
SAFETY  
PROFILE 
Treatment 
discontinuation (% 
of patients) 
% patients 10 BSC 0 Maximum limit of 
the scale 
Contra-indications types of contra- 
indications 
Hypersensitivity + 
hepatic 
impairment + low 
neutrophil counts 
Minimum limit of 
the scale 
No contra-
indications 
Maximum limit of 
the scale 
INNOVATION  
LEVEL 
ATC Level 1 relative market 
entrance 
5 Minimum limit of 
the scale 
1 Maximum limit of 
the scale 
ATC Level 2 relative market 
entrance 
5 Minimum limit of 
the scale 
1 Maximum limit of 
the scale 
ATC Level 3 relative market 
entrance 
5 Minimum limit of 
the scale 
1 Maximum limit of 
the scale 
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ATC Level 4 relative market 
entrance 
5 Minimum limit of 
the scale 
1 Maximum limit of 
the scale 
ATC Level 5 relative market 
entrance 
5 Minimum limit of 
the scale 
1 Maximum limit of 
the scale 
Phase 1 number of new 
indications 
0 Minimum limit of 
the scale 
10 20% higher than 
the best 
performing 
option 
Phase 2 number of new 
indications 
0 Minimum limit of 
the scale 
16 20% higher than 
the best 
performing 
option 
Phase 3 number of new 
indications 
0 Minimum limit of 
the scale 
2 20% higher than 
the best 
performing 
option 
Marketing 
authorisation 
number of new 
indications 
0 Minimum limit of 
the scale 
1 20% higher than 
the best 
performing 
option 
Delivery Posology types of delivery 
system & posology 
combinations 
Oral, every day - 
one off + IV, 
every 3 weeks - 1 
hour* 
Minimum limit of 
the scale 
Oral, every day - 
one off* 
Maximum limit of 
the scale 
Special 
instructions 
types of special 
instructions 
No food + 
concomitant 
and/or pre-
medication* 
Minimum limit of 
the scale 
None* Maximum limit of 
the scale 
SOCIO-ECONOMIC 
IMPACT 
Medical costs 
impact 
GBP (£) 10,000 20% higher than 
the worst 
performing opt. 
0 BSC 
7.2.7 MCDA Technique (Model Assessment and Appraisal) 
A value framework based on a value measurement method was adopted making use of a 
simple additive aggregation model (i.e. linear, weighted average approach) which assumes 
preference independence between the different attributes, with overall value V(.) of an option 
a defined by Equation 4 421. Overall, the additive value model is assumed as a working 
hypothesis and therefore the model construction is done to respect its underlying properties 
(see section 1.1.4), requiring positive weights summing one and the use of explicit reference 
values of 0 and 100, see Table 7.2. 
Value functions were elicited from the workshop participants using the Measuring 
Attractiveness by a Categorical Based Evaluation Technique (MACBETH), a pairwise 
qualitative comparison approach where qualitative judgements about the difference of value 
between different pairs of attribute levels are expressed in word categories (no difference, 
very weak, weak, moderate, strong, very strong, extreme, or anything in between) 406,447. By 
only requiring semantic judgements which are then converted into a cardinal scale, 
MACBETH provides a simple, interactive and constructive approach, with various real 
world applications illustrating its usefulness as a decision support tool 408-411, while being 
based on strong theoretical foundations 407. An indirect (qualitative) swing weighting 
technique was used to elicit relative criteria weights 447, given that direct questions of 
importance for a criterion that do not take into account their attribute ranges are known to 
be one of the most common mistakes in making value trade-offs 202.  
In turn, M-MACBETH was used as a decision support system in order to construct 
the value tree, elicit criteria value functions (based on which options were scored), assign 
relative criteria weights through a qualitative swing weighting protocol, combine preference 
value scores and weights together using additive aggregation (i.e. simple additive model) to 
derive overall weighted preference value (WPV) scores, and perform sensitivity analysis on 
criteria weights 448,449. The software automatically performs consistency checking between 
the qualitative judgements expressed, and in addition a second consistency check was 
manually performed by the author to validate the cardinality, i.e. interval type, of the 
emerging value scale by comparing the sizes of the intervals between the proposed scores 
and inviting participants to adjust them if necessary 450, a requirement which is essential for 
the application of simple additive value models. More information regarding the technical 
details of MACBETH is available in Appendix (7.3). 
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7.2.8 Costs Calculation (Model Assessment and Appraisal) 
Drug costs were calculated according to UK prices (excl. VAT), pack sizes and dosage 
strengths as found on the British National Formulary (BNF 68); the recommended dosages 
and treatment durations were taken from its pivotal trial for the case of cabazitaxel 461, its’ 
respective NICE technology appraisal for the case of enzalutamide 467, and its labelling and 
package leaflet (EPAR- Annex III) for the case of abiraterone 477. Vial wastage was assumed 
in all calculations. Drug administration costs for cabazitaxel were kept consistent with the 
respective NICE TA472. The UK perspective was adopted as a neutral benchmark partly 
because of the readily available data but primarily to allow the measurement of cost(s) in a 
common unit across a series of similar case studies in different European countries, so that 
overall WPV scores can then be viewed against the same cost denominator to produce 
directly comparable cost-value ratios.   
 
7.3 Results 
7.3.1 Criteria Validation and Amended Value Tree for Metastatic Prostate Cancer   
Overall, consensus (i.e. full agreement) was reached relatively easily in terms of criteria 
inclusion and exclusion. Most importantly though, no criteria were deemed to be missing. 
The final version of the value tree, as emerged following the open discussion with the 
participants of the workshop is shown in Figure 7.2. In total, 10 out of the 18 attributes were 
removed from the value tree because they were judged from the participants to be non-
fundamental for the scope of the exercise. Most of these attributes however were lying under 
the innovation level cluster, with all attributes relating to  ATC level of the drugs (five 
attributes) and spill-over effects (four attributes) being eliminated. The only additional 
attribute removed was the PSA response attribute under the therapeutic impact cluster, 
because it deemed to reflect no value of concern given the existence of the remaining 
therapeutic attributes.  
An example of a value judgements matrix and its conversion into a value function 
for the case of the Overall Survival (OS) is shown in Appendix (7.4). Effectively all attributes 
produced linear value scales, either based on quantitative or qualitative performance levels. 
The value functions for all attributes are shown in Appendix (7.4).  
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7.3.2 Performances of Options, Criteria Weights and Overall Preference Value Rankings 
The performance of the options across the different attributes together with the “lower” and 
“higher” reference levels is shown in Table 7.3.  
The overall WPV scores of the options and their break down into their partial value 
scores across the different criteria attributes with their respective weights are shown in Table 
7.4. Enzalutamide scored the highest overall WPV score of 58.7. Abiraterone and 
cabazitaxel produced overall WPV scores of 6.9 and 1.4 respectively, partially because of 
relatively high “negative” performances in the treatment discontinuation attribute, producing 
absolute preference value scores of -95.3 and -87.5 respectively, and weighted preference 
value scores of -20.2 and -18.6 respectively. This was due to the fact that their performance 
on the treatment discontinuation attribute (19% and 18% respectively), lied below the lower 
reference level of the scale (i.e. 10%). A stacked bar plot of the overall WPV scores of the 
alternative treatments across the attributes is shown in Figure 7.3.  
The relative weights assigned to the different attributes are shown in Figure 7.4. By 
taking into account the “lower”-“higher” ranges of the attributes, the greatest relative 
weights were yielded for the case of Overall Survival, Treatment Discontinuation and 
HRQoL (with relative magnitudes of 23, 21, and 15 out of 100 respectively), adding up a 
combined relative weight of 60% of the total. In regards to the total weights assigned across 
the criteria clusters, therapeutic impact cluster totaled a relative weight of 44 in total (three 
attributes), the safety profile cluster totaled a relative weight of 33 (two attributes), the 
innovation level cluster totaled a relative weight of 7 (two attributes), and the socioeconomic 
impact cluster totaled a relative weight of 15 (single attribute) out of 100. 
 
7.3.3 Value for Money Analysis 
A plot of the options’ overall WPV scores versus their costs (purchasing costs plus any 
administration costs) is shown in Figure 7.5. By using rounded up cost figures of £24,600 
for enzalutamide, £21,900 for abiraterone and £23,900 for cabazitaxel (£22,190 drug cost 
and £ 1,710 administration cost) and dividing them with overall WPV scores, the costs per 
unit of MCDA value were calculated to be £419, £3,173, and £17,509 respectively (Table 
7.4).  Therefore in terms of value-for-money, cabazitaxel is shown to being dominated by 
abiraterone, while also being very close to be dominated by enzalutamide (£500 difference). 
Enzalutamide on the other hand is associated with a higher cost (£2,500 difference) and a 
higher overall WPV score (51.8 difference) compared to abiraterone.  
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Figure 7.2: Final value tree for metastatic prostate cancer (post-workshop) 
 
 
* image produced using the M-MACBETH (beta) software version 3.0.0 
 
 
 
212 
 
7.3.4 Sensitivity and Robustness Analysis 
Parameter uncertainty relating to the estimation of weights was addressed by conducting 
deterministic sensitivity analysis. At the end of the workshop, the impact of baseline 
weights’ changes on options’ rankings was explored. In order for cabazitaxel to become 
better ranked than abiraterone, the PFS relative weight would have to change from 5.8 to 
15.6, the Treatment Discontinuation relative weight from 21.2 to 53.9, or the Special 
Instructions relative weight would have to increase from 4.1 to 12.2 (figures shown in 
Appendix, 7.5). Alternatively, for cabazitaxel to become better ranked than enzalutamide, 
the PFS relative weight would have to change from 5.8 to more than 89.5 (figure shown in 
Appendix, 7.5). No scenario would result in abiraterone being ranked above enzalutamide. 
Therefore, conclusions were robust as the ranking of the treatments was not sensitive to 
single variations of up to at least 100% along the attributes’ weight range.  The robustness 
of the results was also validated by conducting 8-way sensitivity analysis in the reference 
levels of the attributes using the respective function of the M-MACBETH software 
(“Robustness analysis”), which showed that a simultaneous change of up to 10% across all 
of the attribute reference levels would not impact the ranking of the alternative treatments 
(figure shown in Appendix, 7.5).  
Other types of uncertainty also exist, including stochastic uncertainty, structural 
uncertainty and heterogeneity that could possibly be addressed with other approaches (or 
combinations of techniques), such as probabilistic sensitivity analyses, Bayesian 
frameworks, fuzzy set theory or grey theory 208. For instance, if significant uncertainty exists 
with regards to option performance due to sampling variation from clinical trials, or in terms 
of criteria weights due to lack of agreement with them, the application of point estimates 
might be inappropriate in which case stochastic multi-criteria acceptability analysis (SMAA) 
could be used 451. 
Table 7.3: Options performance across the criteria attributes 
Attribute name 
Attribute 
metric 
Lower level Abiraterone Cabazitaxel Enzalutamide Higher level 
Overall survival months 13.6 15.8 15.1 18.4 22.1 
HRQoL utility (EQ-5D) 0.72 0.76 0.76 0.76 0.82 
Radiographic tumour 
progression 
months 2.9 5.6 8.8 8.3 10.6 
Treatment discontinuation % of patients 10 19 18 8 0 
Contra-indications 
types of 
contra- 
indications 
hyp + hep 
imp + low 
neut 
hyp + hep 
imp 
hyp + hep 
imp + low 
neut 
hyp None 
Delivery Posology 
types of delivery 
system & 
posology 
combinations 
oral, daily - 
one off + IV, 
every 3 wks 
- 1 hr 
oral,  
daily - one 
off 
oral, daily - 
one off + IV, 
every 3 wks 
- 1 hr 
oral,  
daily - one off 
oral,  
daily - one 
off 
Special instructions 
types of special 
instructions 
Concomitant 
and/or pre- 
med + no 
food 
Concomitant 
and/or pre- 
med + no 
food 
Concomitant 
and/or pre- 
med  
None None 
Medical costs impact GBP (£) 10,000 5,750 7,992 567 0 
*Used the same score of the other two options as data not available. hyp: hypersensitivity; hep imp: hepatic impairment; low neut: low neutrophil count 
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Table 7.4: Overall weighted preference value (WPV) scores, partial preference value scores, relative weights, costs and cost per unit of value 
  
Lower  
level 
Abiraterone Cabazitaxel Enzalutamide 
Higher 
level 
Relative  
Weights 
Overall WPV score 0 6.9 1.4 58.7 100 100 
Overall survival 0 26.2 17.9 56.3 100 23 
HRQoL 0 40.0 40.0 40.0 100 15 
Radiographic tumour 
progression 
0 26.5 74.0 66.8 100 6 
Treatment discontinuation 0 -95.3 -87.5 20.0 100 21 
Contra-indications 0 33.3 0.0 83.3 100 12 
Delivery Posology 0 100.0 0.0 100.0 100 3 
Special instructions 0 0.0 60.0 100.0 100 4 
Medical costs impact 0 40.5 19.1 93.7 100 15 
Cost (£)   21,900 23,900 24,600     
Cost per unit of value   3,173 17,509 419     
 
HRQoL: health related quality of life  
 
 
 
Figure 7.3: Stacked bar plot of treatments’ overall weighted preference value (WPV) 
scores across all attributes 
 
 
 
Figure 7.4: Criteria weights stacked bar 
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Figure 7.5: Cost benefit plot of overall weighted preference value (WPV) scores versus 
costs 
 
* image produced using the M-MACBETH (beta) software version 3.0.0 
 
 
7.4 Discussion 
This case study demonstrated an application of a recently developed MCDA 
methodological process and value framework in practice 332,421, for a set of alternative 
mCRPC treatments from the perspective of an HTA agency. In terms of design, 
implementation and review of the analysis, the process adopted is effectively in 
alignment with the recent ISPOR good practice guidelines on the use of MCDA for 
health care decisions 200.   
The participants of the workshop felt this was a useful simulation exercise and 
that the value framework has the prospects of acting as a valuable decision supporting 
tool, mainly because it provides the opportunity to explicitly assess the performance of 
a set of options across am encompassing number of evaluation criteria, while eliciting 
trade-offs on their relative importance, flexibly and transparently.  
In regards to the removal of the spill-over effect attributes under the innovation 
level cluster, this took place on the grounds that they “currently go beyond the agency’s 
remit” and therefore should not be considered in the first place. However, the opinion 
was evident that in reality this information could act as supplementary evidence in 
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current practice, not primarily for affecting the coverage of the respective drugs, but 
possibly for other secondary purposes like awarding reimbursement extensions or 
communicating internally possible new indications in the near future. In any case, all 
innovation spill-over attributes were excluded. 
 
7.4.1 Value for Money Considerations 
Alternative options were assessed and ranked based on their overall WPV scores 
reflecting their performance against an explicit set of evaluation criteria weighted for 
their relative importance based on the preferences of the group, therefore acting as a 
more holistic benefit component. Incorporation of drug costs (purchasing and 
administration costs) enabled the estimation of “cost per unit of value” ratios which 
showing no overall “value for money” dominance between the treatments but only 
between two of them.   
Budget impact considerations could be incorporated in the cost-value ratio estimates at 
system level by taking into account the expected number of patients receiving the 
treatments; however, given that the scale of costs is not restricted in contrast to benefits, 
costs could be overestimated compared to benefits which could produce a bias towards 
the cheapest options, and therefore costs and benefits should ideally be estimated in 
comparable terms such as a per-patient basis 200.  
Future research might need to investigate the opportunity cost associated with 
disinvestments which could feed the development of incremental cost value ratio 
(ICVR) thresholds, acting as efficiency cut-off points similarly to current incremental 
cost effectiveness ratio (ICER) thresholds used in economic evaluations. This would 
face however all the current challenges associated with the technical difficulties in 
estimating sound ICER thresholds based on opportunity cost 485,486.  
 
7.4.2 Limitations and Challenges 
Among the limitations of the case study was the use of un-synthesised evidence to 
inform the clinical attributes given the lack of relative treatment effects, therefore 
limiting the extent to which the results can inform real policy-making. An important 
challenge would relate to the technical difficulties in ensuring that all attributes possess 
the required theoretical properties, and more specifically the fact that potential 
preference-dependence was observed between the OS and HRQOL attributes which 
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was addressed by deriving OS value functions that were effectively conditional on the 
range of the HRQOL attribute. However, the use of conditional value functions might 
be incompatible with the use of an additive model and, therefore, it should be used with 
caution, as for example within descriptors of performance.   In order to be able to use 
an additive model under the existence of preference dependence, the effect between the 
two attributes would have to equal zero, or in other words the product of their value 
scores would have to be zero; for a more extensive discussion around the use of linear 
additive model together with conditional value functions due to preference dependence 
see section 8.3.2.  Another limitation would be that the HRQOL of the progressive 
disease was not assessed because none of the treatments assumed to have any effects 
on it, something which might not hold true in other conditions. Among the main 
challenges was the relative subjectivity in setting “higher” and “lower” reference levels, 
something which was addressed through expert opinion and investigated in secondary 
analysis following the workshop. These limitations and challenges are extensively 
discussed in the Limitations and Challenges section in the last chapter of the thesis 
(section 8.3.2).  
 
7.5 Conclusion  
In health care systems with significant budgetary pressures HTA challenges relating to 
the evaluation of and resource allocation for novel treatments require novel 
methodologies of assessment with a more encompassing value-based assessment 
approach. Such methodologies should be based on robust theoretical principles so the 
results can lead to credible decisions. In this case study a multi-criteria methodology 
was tested to evaluate expensive therapies for the treatment of metastatic prostate 
cancer while taking into account the preferences of assessors from TLV, producing a 
transparent ranking of their value across a number of value dimensions. Future research 
could help validate the robustness and usefulness of the current value framework by 
conducting similar case studies with other HTA bodies across different European 
countries.    
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Chapter 8 – Conclusions, Policy implications, Limitations and Future 
Research Directions 
 
8.1 Key Conclusions  
8.1.1 Identification of Limitations in Current Value Assessment Approaches of New 
Medicines 
Current evaluation approaches in HTA examine the comparative clinical benefit or 
cost-effectiveness of new medicines as part of formal and explicit processes, through 
the elicitation of ‘Scientific Value Judgements’ (ScVJ) relating to their clinical 
performance and usually in relation to their costs, therefore addressing comparative 
efficacy/effectiveness and efficiency concerns. However, important inconsistencies and 
uncertainties exist on how other value concerns are accounted for, especially those 
relating to dimensions of benefit falling under the evidence domains of burden of 
disease, innovation level and socioeconomic impact.  
Principal among the lessons learned, was the fact that although such ‘Social 
Value Judgements’ (SoVJ) might exert an influence on decisions, they rarely take place 
as part of a structured process; instead, they are often taken into account in an informal 
way or an ad hoc basis following non-transparent discussions.  The selectivity in 
measuring the performance of new medicines across these social value dimensions as 
part of a deliberative process, in addition to the lacking clarity around their relative 
importance to the overall decision and the value trade-offs decision-makers are willing 
to make, both keep the interplay between SoVJ and ScVJ unknown. This can diminish 
the reasonableness, efficiency and credibility of the decision-making process and its 
outcomes.  
Research findings pointed towards the need to develop transparent 
methodologies that allow the explicit incorporation and structured analysis of 
preferences around multiple criteria and their value trade-offs. This can lead to more 
rational evidence-based decision-making, which could improve the efficiency of 
resource allocation decisions and as a result increase societal welfare, while on the same 
time raising public confidence and the perceived fairness of decision outcomes. 
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8.1.2 Conceptual Verification of MCDA as a Viable Alternative Approach for HTA 
The thesis proposes the use of MCDA as an alternative to economic evaluation in the 
context of HTA. It is argued however that the use of MCDA needs to adhere to decision 
analysis theory for the results to be robust so that they can facilitate decision-making. 
An MCDA methodology process based on Multi Attribute Value Theory (MAVT) for 
the context of HTA is recommended which can be divided into the phases of problem 
structuring, model building, model assessment, model appraisal, and action plans. A 
“value-alternative hybrid thinking” approach can be adopted for structuring a value tree 
in model-building, according to which a generic set of criteria are created first as part 
of a top-down approach driven by the overall value concern, followed with the 
adaptation of the criteria for the particular decision-making context and the definition 
of attributes as part of a bottom-up approach driven by the decision alternatives as part 
of an “alternative-focused thinking” approach. For the analysis to be robust and for 
decision recommendations to be ultimately meaningful, criteria and attributes should 
adhere to a number of properties which could act as best practice requirements for the 
model-building phase.  
Implementation of MCDA methodologies and their linkage with policy-making 
could take place in the form a supplementary “incremental” mode to cost-effectiveness 
analysis (CEA) adjusting the incremental cost effectiveness ratio (ICER) through the 
incorporation of additional benefit dimensions, or in the form of a pure “clean-slate” 
mode where value is derived without the use of CEA.  
Among the lessons learned from the adoption of the latter approach in this thesis 
included that a pure “clean-slate” MCDA for use in HTA could be associated with 
certain benefits as it can possibly address some theoretical and methodological 
limitations associated with the incorporation of costs and quality of evidence concerns. 
However, as demonstrated through one of the case studies (and also mentioned below), 
the application of MCDA approach that shares some characteristics to the 
supplementary or “incremental” mode might enable an easier exploration and 
implementation by decision-makers in real-world. Therefore, both approaches are 
associated with different advantages and disadvantages and as a result, the choice 
between the two approaches should be made depending on the decision context of 
interest, taking into account the current evaluation guidelines in place and the flexibility 
of the decision-makers.  
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Ultimately, the aggregate metric of value that is derived from the MCDA 
process is more encompassing because multiple dimensions of benefit are incorporated, 
together with their relative importance, as reflected by the preferences of the decision-
makers. Adoption of MCDA-derived metrics as the benefit component can be used in 
combination with costs of the decision alternatives to estimate incremental cost value 
ratios (ICVRs) that could in turn inform resource allocation decisions on a similar basis 
to ICERs. 
 
8.1.3 Methodological Construction of a New MCDA Value-Based Model and 
Framework  
The development of a novel methodological framework for the evaluation of new 
medicines is described following an MCDA methodology based on MAVT, comprising 
a generic value-based model taking the form of a value tree (Advance Value Tree). A 
top-down “value-focused thinking” approach driven by the overall value concern (as 
part of an overall “value-alternative hybrid thinking” mode) was adopted for the 
construction of the value tree and in alignment with decision theory, which was 
informed from secondary and primary data collected from the literature and expert 
consultations as part of a five-stage process.   
The value tree incorporated a number of criteria in a structured hierarchy form 
which can be adapted for different decision problems pertaining to different disease 
indications and therapeutic classes, aiming to capture various value concerns of 
decision-makers in the context of HTA that have traditionally been considered either 
explicitly in a systematic manner, or implicitly on an ad hoc basis. Value concerns were 
grouped into top-level criteria clusters relating to burden of disease, therapeutic impact, 
safety profile, innovation level and socioeconomic impact characteristics, which were 
then decomposed into mid-level criteria and bottom-level sub-criteria or attributes.    
A precise combination of MCDA modelling techniques was proposed for 
operationalising the value tree through the construction of value judgements and 
elicitation of preferences as part of model assessment and model appraisal. An indirect 
elicitation technique based on pairwise qualitative comparisons and the use of value 
functions can be used for scoring the options (MACBETH), combined with an indirect 
swing weighting technique for eliciting relative criteria weights, and a simple additive 
technique for aggregating scores and weights together.  
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Altogether, the application of the selected MCDA techniques for the estimation 
of the generic value tree, while adopting a societal perspective which allows the 
incorporation of views from the wider stakeholder community, completed the 
development of the value framework (Advance Value Framework). Ultimately, it can 
enable decision-makers to understand their preferences and construct their perceptions 
for ranking and identifying the best decision alternative, therefore possibly acting as a 
decision support tool for decision-making.  
 
8.1.4 Empirical Testing of the Value Framework with Multiple Stakeholders in 
England  
The Advance Value Framework was tested in practice through a proof-of-concept case 
study adopting an integrated multi-criteria approach simulating an HTA context for the 
case of three metastatic colorectal cancer (mCRC) treatments. It engaged multiple 
stakeholders using the scope of the National Institute for Health and Care Excellence 
(NICE) in England, but in addition supplementary evidence was considered for value 
concerns not explicitly addressed by the Institute.  
A bottom-up “alternative-focused thinking” approach driven by the decision 
alternatives was followed for adapting the Advance Value Tree and constructing a 
disease-specific value tree for the mCRC treatments in alignment with decision theory 
principles as part of the model-building phase. A facilitated decision analysis modelling 
approach was adopted for validating the value tree and eliciting the value preferences 
of thirteen participants through a decision conference, as part of the model assessment 
and model appraisal phases. Alternative treatments were indirectly scored across the 
criteria through the elicitation of value functions using MACBETH, an indirect MAVT 
elicitation technique. Relative weights were assigned to criteria using an indirect 
qualitative swing technique and overall weighted preference value (WPV) scores for 
the treatments were derived using a simple additive aggregation technique based on 
weighted averages.  
This first application of the Advance Value Framework produced overall value 
rankings for three mCRC treatments across an explicit set of evaluation criteria through 
the incorporation of preferences from multiple stakeholders. Stakeholders’ experience 
suggested that the methodology adopted can aid the evaluation process by making it 
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more structured and transparent, however further research is recommended to enhance 
its use for policy-making.   
One of the lessons learned was that the facilitated model-building approach used 
through decision conferencing and as part of the framework proved to be essential for 
creating a shared understanding of what constitutes value in the particular decision 
context. Under these circumstances of a heterogeneous participants group with multiple 
stakes, the consensus approach used for preference elicitation as part of an open 
discussion where debate was actively sought proved to be challenging at times but 
overall worth the effort.  For such a consensus and shared understanding to be reached 
however appropriate facilitation turned out to be crucial, entailing the appropriate 
intervention to ensure that participants group remains on task and that weaker “voices” 
are also heard, therefore guiding the discussions but impartially without contributing to 
them. In addition, carrying out sensitivity analysis on the spot at the end of the 
workshop and exploring the impact of weight changes on overall options rankings 
proved to be helpful for resolving any remaining preference disagreements between the 
participants which might have persisted throughout the discussions, therefore helping 
to accept the final outcomes.  
Another lesson was about the potential application of the methodology for the 
evaluation of medicines in other decision contexts. The value framework could be 
potentially beneficial if adapted accordingly and applied earlier or later in the life-cycle 
of new medicines. In the former case it could be used to enable the communication of 
the new product’s value with decision-makers when it might be still possible to amend 
some of its performance characteristics, allowing for a targeted redesign in the clinical 
development process (if feasible) and the collection of additional evidence if deemed 
necessary. In the latter case it could be used between clinicians and patients to enable 
the understanding of a medicine’s benefits and risks and construction of preferences 
around them, therefore acting as a catalysing tool in the shared decision-making process 
of treatment selection.  
Overall, involvement of participants that were eager to share their views and 
challenge others’ as part of a shared commitment, turned out to be a crucial factor in 
the conduct of a successful multi-stakeholder evaluation using this value framework 
and with such a decision conference approach. 
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8.1.5 Empirical Testing of the Value Framework with Decision-Makers in Sweden 
The Advance Value Framework was tested in practice through another proof-of-
concept case study adopting a theory-based integrated multi-criteria approach for 
assessing the value of three metastatic castration resistant prostate cancer (mCRPC) 
treatments. It engaged real world decision-makers using the scope of the Swedish 
Dental and Pharmaceutical Benefits Agency (TLV) in Sweden, but in addition 
supplementary evidence was considered for value concerns not explicitly addressed by 
the Agency.  
A bottom-up “alternative-focused thinking” approach driven by the decision 
alternatives was followed for adapting the Advance Value Tree and constructing a 
disease-specific value tree for the mCRPC treatments in alignment with decision theory 
principles as part of the model-building phase, feeding from the literature and expert 
opinion. A facilitated decision analysis modelling approach was adopted for validating 
the value tree and eliciting the value preferences of four participants through a decision 
conference, as part of the model assessment and model appraisal phases. Alternative 
treatments were indirectly scored across the criteria through the elicitation of value 
functions using MACBETH, an indirect MAVT elicitation technique. Relative weights 
were assigned to criteria using an indirect qualitative swing technique, and overall 
weighted preference value (WPV) scores for the treatments were derived using a simple 
additive aggregation technique based on weighted averages.  
This second application of the Advance Value Framework produced overall 
value rankings for three mCRPC treatments across an explicit set of evaluation criteria 
through the incorporation of preferences from decision-makers. Decision-makers’ 
experience suggested that the methodology adopted has the prospects of facilitating 
their decision-making because it allows for explicitly assessing performance across a 
multiplicity of criteria, while incorporating trade-offs on their importance, in a 
structured and transparent way. However further research is recommended to address 
technical difficulties and advance its use for informing policy-making.   
Having gained clarity on the preference elicitation and the underlying 
construction process, the final results were accepted from the group as a whole due to 
the transparency and the step-wise manner characterising the methodological process. 
The systematic elicitation of preference across all attributes individually, followed by 
the visual presentation of the options’ respective performance, enabled the participants 
to develop a holistic and confident understanding around the overall strengths and 
225 
 
 
weaknesses of the options.  As a result, distinguishing between the performance of the 
options and the valuation of these performances, as operationalised through the indirect 
scoring and weighting techniques used, was critical.    
Among the lessons learned was that for the possible implementation of the 
methodology to be catalysed even at a testing phase, the development of the model, and 
the application of the value framework altogether, should be aligned with the formal 
remit of the decision-makers. Establishing clear goals for the role of the results would 
be beneficial for the initial exploration of the methodology.  In settings where strict 
guidelines and requirements exist around the application of specific HTA methods as 
in Sweden with the use of economic evaluation, the exploration of a supplementary 
“incremental” MCDA mode to CEA might be more attractive and realistic option to 
decision-makers so that the results can be more readily adaptable to their current needs 
and therefore being more easy to implement in their daily practice. In turn, adaptation 
of a pure “clean-slate” mode could still be viable but involving the assessment of more 
concise value trees that restrict the number of criteria around the formal value concerns 
currently in explicit use. This would allow capturing the primary value concerns as 
specified by the evaluation guidelines and requirements while still offering the added 
benefits of analysing value through a decomposition approach that could enable the 
facilitation of decision-making through the step-wise and transparent elicitation and 
construction of value preferences. Following such a testing phase, decision-makers 
could acquire important confidence that could enable the exploration of incorporating 
additional value concerns, therefore catalysing a shift to change any institutional remit 
in place.  
 
8.1.6 Overall Thesis Conclusion and Contributions 
Assessing and appraising the value of new and expensive medicines and health care 
interventions in general acts as a major challenge for health care systems especially in 
settings of significant budgetary pressure. Novel methodological approaches for the 
evaluation of new medicines are urgently needed that can improve the HTA decision-
making process to support better decisions, to improve efficiency in resource allocation 
and therefore drive an increase in population health.  
This thesis proposes that evaluation procedures aiming to rank alternative 
treatment options should be characterised by extensive comprehensiveness and full 
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transparency, enabling the structured elicitation and explicit incorporation of 
preferences across multiple value dimensions and from a range of stakeholders, for the 
decision-making process to be rational and their outcomes credibly accepted.  
The key research question in this thesis is whether - and how - MCDA could 
provide the basis of an alternative methodological framework for assessing the overall 
value of new medical technologies by explicitly capturing all relevant value aspects. 
The overall aim of the thesis is decomposed into a number of secondary research 
questions relating to: i) the design of a robust MCDA methodological process for HTA, 
ii) the identification of value parameters that are applied as evaluation criteria in HTA 
across different EU countries, iii) the development of a value-based model that can 
capture multiple value dimensions for the evaluation of new medicines in HTA as part 
of a broader MCDA methodological framework and in alignment with decision theory, 
and iv) the adaptive application of this value framework by means of two case studies 
to assess and rank a set of alternative treatment options allowing the elicitation of 
stakeholder and decision-makers preferences that could inform coverage decisions.  
The secondary research questions are addressed separately through the five 
empirical papers of the thesis. Initially a structured MCDA methodological process was 
constructed based on MAVT for the context of HTA. Then, a systematic literature 
review and expert consultation was conducted to study current HTA practices in 
Europe, identifying value concerns of decision-makers and evaluation criteria in HTA 
while highlighting the limitations of the methodological approaches in place. These 
results fed into the development of a MAVT methodological framework, incorporating 
a value-based model taking the form of a generic value tree that can be adapted to 
capture decision-makers’ value concerns, operationalised through a combination of 
MCDA modelling techniques. Finally, the new value framework was applied and tested 
in practice through two case studies involving the participation of stakeholders and 
decision-makers.  
As a result, the contribution of the thesis comprises conceptual, theoretical, 
methodological and empirical components. The completion of the tasks in the different 
thesis papers required me to transcend the current HTA methods I had been exposed to, 
making it essential to acquire, develop and apply important interdisciplinary skills. An 
extensive amount of work had to be completed, involving a wide range of tasks relating 
to understanding and gaining knowledge, conceptual and critical thinking, theoretical 
construction, review of the literature, conduct of semi-structured interviews, 
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consultation with experts, organisation and facilitation of decision conferences, 
analysing results, and policy recommendations.        
Ultimately, the methodological framework produced could enable HTA 
decision-makers to understand and construct their value perceptions and preferences 
for the purpose of assessing, ranking and identifying the best decision alternative, 
therefore acting as a decision support tool for facilitating their decision-making process. 
Future research could inform the validation of the value framework’s robustness while 
possibly showcasing its usefulness through other practical applications involving HTA 
bodies and decision-makers across different countries while engaging multiple 
stakeholders. Importantly, the application of the value framework and its methodology 
could be explored in other decision contexts along the life-cycle of new medicines and 
health care interventions. Application for early pre-marketing evaluation as part of 
clinical development could enable the communication of value to decision-makers and 
help streamline collection and preparation of evidence requirement, whereas use by 
clinicians and patients could assist them with understanding the benefits and risks of 
new treatments and aid their selection process. 
 
8.2 Policy Implications 
The MCDA methodological process (Chapter 3 – Paper 1) resulted in the development 
of a value framework for the assessment of new medicines in the context of HTA 
(Chapters 4 and 5 – Papers 2 and 3). The value framework was tested in practice with 
two real-world applications in the context of coverage decisions: a case study on 
metastatic colorectal cancer with multiple stakeholders while adopting the perspective 
of the English HTA agency (NICE) for assessing and ranking the overall value of 
second line biological treatments, and a case study on metastatic prostate cancer with 
the Swedish HTA agency (TLV) to assess and rank the overall value of a set of 
treatments from the viewpoint of the agency.  
The case studies proved to be successful applications of the MCDA 
methodological framework in practice for the context of HTA from the perspective of 
the stakeholders and decision-makers. Overall, the participants of the workshops felt 
these were very interesting simulation exercises with useful insights and with the actual 
process proving to be easier and less complicated than originally expected.  
Perceived benefits of the value framework included the explicit incorporation 
of multiple “non-traditional” value dimensions, especially innovation related attributes, 
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the facilitation in recognising and expressing the relevance of different value concerns 
for the particular decision context and the ability to illustrate differences in views within 
the group. In addition, the overall process enabled participants to realise that it is 
possible to consider multiple value dimensions within the HTA process (for which they 
were positive about) and that an explicit and quantitative performance measurement 
turned out to be feasible for a range of value concerns for which originally only implicit 
and qualitative assessment approaches were thought to be applicable. Furthermore, 
besides the prospects of acting as a decision-making tool it was suggested that the value 
framework could also be used as an important negotiation tool during the discussions 
with the manufacturers and as part of the early dialogue process, aiding communication 
and “signalling” their preferences down to them due to its comprehensiveness and 
transparency. 
 
8.2.1 Reflections on the Link between Value and Policy-Making 
Assuming the proposed methodological process is adhered to, the application of MCDA 
presents a number of advantages to decision-makers in the context of HTA and the 
wider context of value based assessment compared with currently used HTA 
approaches such as economic evaluation techniques. 
Firstly, it acts as an instrument of more complete value assessment leading to 
improved comprehensiveness given the explicit incorporation of multiple criteria and 
construction of value judgements on the performance of alternative options that can 
help decision-makers to construct their overall value perceptions. Secondly, assignment 
of quantitative criteria weights can reﬂect differences in the relative importance of the 
evaluation criteria, enabling decision-makers to realise the value trade-offs they are 
willing to make and therefore understand their value preferences. Thirdly, the 
methodological process can be informed through extensive expert engagement and 
direct stakeholder participation leading to an encompassing nature of value perceptions 
and value preferences. Fourthly, it provides flexibility given that the details and 
technical characteristics of the different methodological stages can be adapted to 
accommodate particular decision-makers’ needs. Finally, the entire process is fully 
transparent, allowing to illustrate the rationale behind the decision outcomes which 
could help them become credible and accepted from the wider stakeholder community 
and society.  
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Therefore an important difference between economic evaluation methods such 
as CEA and MCDA is that the latter facilitates a decision support system, as illustrated 
in Figure 8.1. As can be viewed from the top of the Figure, in CEA the analysis of costs 
and health gains is first taking place explicitly as part of the assessment process (left-
hand side), and value trade-offs are then elicited implicitly possibly involving other 
types of benefit gains and stakeholder views on an ad hoc basis as part of the appraisal 
process (right-hand side), so that a decision can ultimately be made. In contrast, as 
evident from the bottom of the Figure, in MCDA the analysis for all types of benefit 
gains and their value trade-offs as informed through stakeholder views are altogether 
explicitly incorporated in the overall process, thus better linking assessment and 
appraisal of evidence and supporting decision-making.  
The resulting overall WPV scores derived from the MCDA process can act as a 
more encompassing measure of value given that multiple benefit dimensions are 
explicitly assessed and therefore could be used to drive the coverage decision and 
pricing negotiations of new medicines and health care interventions in a more 
comprehensive manner. Consideration of purchasing costs in parallel with the overall 
value of the alternatives options can then be used to estimate incremental cost value 
ratios (ICVRs) for the different health care interventions and contribute to priority 
setting and resource allocation decisions in the context of HTA. For example, funding 
for the coverage of a set of interventions could be allocated based on their ICVRs 
rankings, from the lowest ratio to the highest ratio, until the available budget is 
exhausted. In turn, budget impact considerations could be incorporated in the cost-value 
ratio estimates at system level by taking into account the expected number of patients 
receiving the respective interventions.  
In this context, the case studies conducted aimed to assess and rank alternative 
treatment options for the same disease indication. A number of disease-specific clinical 
endpoints were incorporated as evaluation criteria as they reflected a number of 
common value concerns relating to the particular intra-indication decision context of 
interest.  Such an attempt at a broader inter-indication level, aiming to assess the value 
of alternative treatments for the purpose of different disease indications might be more 
challenging as it would have to ensure the use of a common value model (in terms of 
attributes, value functions and relative weights) that adequately addresses the value 
concerns for the alternative treatments across diseases with different characteristics.  In 
this instance, criteria and attributes might need to become more generic and less 
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disease-specific, using health benefit metrics such as the QALY, in which case trade-
offs might have to take place between the sensitivity/specificity of assessing the 
different treatments and the comprehensiveness of the analysis. 
Ultimately, because of its characteristics enabling a structured process, MCDA 
could facilitate overall decision-making acting as a decision-support system, enabling 
its use as a reasonable resource allocation tool that, among others, incorporates a more 
holistic approach to value. 
 
8.2.2 Responding to HTA Issues at Systems Level: From Methodological Robusteness 
to Practical Relevance 
So far, decision-makers and even health care evaluation researchers exploring the 
application of MCDA-like approaches might not pay adequate attention to the 
theoretical foundations and good practices of MCDA as for example the different set 
of properties that the multi criteria evaluation models need to possess for the analysis 
to be robust. Recent evidence has shown that only one healthcare MCDA study 
explained that criteria were deﬁned to meet MCDA requirements such as avoiding 
double counting 487, with others acknowledging as a concern the fact that MCDA 
responders might not understand some of the attributes being used 84, possibly because 
of difﬁculties in interpreting the meaning of the respective attribute performance 488. 
Taking into consideration that MCDA in itself posits a departure from currently 
used HTA techniques, the application of an MCDA approach and its principles in the 
context of HTA requires careful reflection on a number of fronts.  
 
 
Figure 8.1: Differences between cost effectiveness analysis (CEA) and multiple criteria 
decision analysis (MCDA) in decision-making 
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Firstly, it is important to clarify whose preferences to consider. Assuming that 
an HTA agency acts as a proxy decision-maker, then it would be appropriate to adopt 
the perspective of the respective HTA agency. For example, if the decision context is 
England, France or Sweden, it would be reasonable to adopt the perspective of the 
National Institute for Health and Care Excellence (NICE), the Haute Autorite de Sante 
(HAS) and the Dental and Pharmaceutical Benefits Board (TLV), respectively. 
Consequently, any social judgements individual HTA agencies adopt, including the 
participants and their preferences, will need to reflect the particularities of each setting. 
As different countries or settings are likely to have different priorities and objectives, 
the analysis should be tailormade to their needs. Alternatively, if the adoption of such 
an existing perspective is not possible, some formal stakeholder analysis could be used 
to identify the key players that should be involved 489.  
A second, but related issue, is how to combine the preferences of individual 
stakeholders. Ideally, a consensus approach should be aimed for, through which a single 
agreed value judgement (i.e. score, weight) would be derived. Alternatively, if 
mathematical aggregation is used, the median (or mean) of the responders’ preferences 
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could be used, especially in settings where motivational biases from some stakeholders 
exist (i.e. strongly against vs. strongly in favour). In any case, the complete range of 
value judgements should be recorded and be used for the purpose of sensitivity analysis, 
where the impact of different scores and weights on the options’ total value scores 
would be tested. 
A third practical issue relates to the evidence requirements and its availability. 
While MCDA has been criticised that it requires more evidence than standard HTA 
approaches in order to populate the criteria, in practice the same evidence that is 
required for standard HTA approaches can be used in the context  of an MCDA model.  
Even if certain items of information are not available, they should be readily collectable, 
or at least able to be proxied through expert opinion. 
The consistency of results would be a fourth important issue subject to criticism. 
Would the results be consistent within the same setting or could inconcistencies act as 
an obstacle to homogeneous decisions? If the value analysis is evidence-based, the 
results are likely not to be identical if the participants whose preferences are considered 
have different value judgements (i.e. different value functions and weights), but it 
would be expected to be similar. This highlights the importance of the context where 
MCDA methods should be applied. Indeed, they should act mainly as decision aiding 
tools to support health care resource priority setting conducted by the decision-maker.  
 
8.2.3 Roadmap to HTA Application and Implementation 
Given that MCDA is a departure from conventional HTA approaches, a roadmap would 
be needed on how MCDA could be factored in current HTA practices (Figure 8.2). To 
begin with, any efforts of MCDA implementation should start by building a research 
team with the appropriate technical expertise as part of an education phase. A multi-
disciplinary research team spanning the fields of decision analysis, medical and life 
sciences, health economics, and statistics would be recommended.  
A number of pilot studies could be carried out in a testing phase.  These pilots 
would act as testing exercises aiming to simulate the evaluation process and the 
production of hypothetical HTA decisions, in order for the Agency personnel to gain a 
first-hand experience on the technical aspects of the MCDA process. A variety of 
MCDA methods and techniques could be explored, following which a range of 
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techniques would be short-listed for future use based on their relative advantages and 
disadvantages. 
Actual case studies could then be conducted as part of a transition phase, using 
real evidence from past health technology appraisals. Value judgements and 
preferences could be elicited from actual members of the Agency’s appraisal 
committees while acting as participants in decision conferences taking the form of 
facilitated workshops. The results could be used to highlight any differences in 
recommendations with past appraisals, helping to realise the benefits and insight of the 
methodology as part of real practice. This phase could end with the establishment of 
clear role(s) for the envisaged use of the new methodology and its link with policy-
making. 
Finally, the MCDA approach could become fully operational as part of an 
execution phase, running in parallel with any existing formal appraisals taking place. 
The MCDA approach could start as a supplementary source of information, acting as a 
decision-making tool on top of standard appraisals, and then following the decision-
making needs and vision of the Agency it could eventually become the sole approach 
implemented. 
 
Figure 8.2: Proposed roadmap to MCDA application and implementation  
 
 
8.3 Limitations 
8.3.1 Conceptual and Theoretical Limitations 
Although the methodology proposed in this thesis is based on value measurement 
methods and precise multi-attribute value theory (MAVT) methods, other methods 
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from different “schools of thought” are also available such as satisficing and aspiration 
levels methods, outranking methods and fuzzy and rough sets methods. The MAVT 
methodology was chosen mainly because of its practical simplicity, compensatory 
nature, relevance to HTA, and popularity with health care applications altogether. In 
any case, the systematic and more extensive exploration of the other MCDA 
methodologies could help to more accurately identify different advantages and 
disadvantages between these methods, which could make the adoption of alternative 
methodologies preferred for the case of particular decision contexts or decision-makers’ 
needs and peculiarities.   
Consequently, indirect preference elicitation techniques were adopted for the 
purpose of scoring and weighting, mainly because of their theoretical robustness and 
unbiased nature. More precisely Measuring Attractiveness by a Categorical Based 
Evaluation Technique (MACBETH) was adopted because of its strong theoretical 
foundations and convenience for decision-makers, as part of which qualitative 
judgements about difference of value are constructed to elicit value functions and assign 
relative weights through indirect qualitative swing weighting. However other MCDA 
modelling techniques of varying complexity exist for the formation of value judgements 
and elicitation of value preferences, some of which might have been preferred by others. 
Subsequently, in terms of the generic value tree model developed and used as part of 
the value framework, I tried to identify and capture decision-makers concerns as 
comprehensively and objectively as possible, through a five-stage process involving 
literature reviews and consultations with experts. I focused on the value concerns of 
European decision-makers, and although the model was consulted with experts from 
Latin America and Eastern Europe, it could still turn out not being comprehensive 
enough at global level for some regions or contexts. However, it should be relatively 
straight-forward to tailor it to any missed decision-maker needs through some 
adaptation or restructuring. 
Last but not least, another challenge would relate to the next possible step 
required for MCDA implementation in policy making: setting up a hypothetical 
efficiency cut-off point, assuming it is needed, essentially an alternative to the current 
incremental cost effectiveness ratio (ICER) threshold, or in other words an incremental 
cost value ratio (ICVR) threshold. Such an attempt would not be limited to the 
application of MCDA and would face all the theoretical and practical hurdles associated 
with the estimation of a sound ICER threshold based on opportunity cost that have been 
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seen to date 485,486. In addition, it might also have to ensure that a common value model 
is used, inclusive of attributes and their value functions as well as criteria weights. 
Although this could be relatively easy for intra-indication (i.e. same disease) 
evaluations, an example of which would be the current case study, this would be more 
challenging for inter-indication (i.e. different disease) evaluations. In this latter case, 
the respective attributes might need to be less disease-specific and of a more generic 
nature, therefore leading to potential trade-offs between the sensitivity/specificity of 
assessing the different treatments and the comprehensiveness of the analysis.  
 
8.3.2 Empirical and Methodological Limitations Based on the Case Studies 
Results from the application of the value framework through the case studies should be 
interpreted with caution. It should be clear that these are simulation exercises aiming to 
test the new framework in practice and to illustrate its application and not to inform 
policy making in this instance in respect to the particular decision problem under 
consideration.  
Given the absence of head to head clinical trials comparing directly all 
treatments of interest and the existence of relative treatment effects across the clinical 
attributes of interest, un-synthesized evidence from the respective single pivotal trials 
of the alternative treatments were used. However, using evidence from different clinical 
trials to directly compare alternative treatments is not accurate, even if the populations 
of patients across the different trials are similar (in terms of disease severity and 
treatment history). Ideally, an indirect treatment comparison should be conducted first 
using a common comparator to estimate the relative effects of two treatments versus 
the comparator, or even a network meta-analysis that combines both direct and indirect 
evidence available through a mixed treatment comparison 490. Such a common 
comparator was absent among the pivotal trials under consideration and conducting a 
meta-analysis was outside the scope of the study.  
Therefore, an important limitation of this study is the lack of relative effects as 
part of clinical evidence and the use of their absolute effects from different clinical trials 
with the assumption that they can be directly compared. In real world evaluations 
aiming to inform policy-making decisions, evidence synthesis would be required to take 
place together with evidence collection as part of the model-building phase. An 
example of such an evidence synthesis stage would be the application of an SMAA 
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approach for assessing the comparative benefit-risk of alternative statins in primary 
prevention 340, using comparative effects from evidence of three meta-analyses 491-493, 
or the combination of SMAA with a network meta-analysis for assessing the 
comparative benefit-risk of second-generation antidepressants 494. 
An important challenge would relate to technical difficulties associated with 
ensuring that all attributes possess the needed properties for a multi-criteria evaluation, 
and particularly that they are preference-independent. Preference independence 
between the values of the attributes is a necessary property for the use of simple additive 
models like the one used. Also referred to as “difference independence” 495, this notion 
denotes that the difference in attractiveness – or added value of an improvement - 
between different attribute levels does not depend on the measurement of other 
attributes 496. Such a “difference consistency” between (the values of the) attributes was 
taken as a working hypothesis given that it is “so intuitively appealing that it could 
simply be assumed to hold in most practical applications” 497 (p. 284). 
However, in the course of the decision conferences it became evident that the 
criteria attributes of OS and HRQoL might not be preference independent. More 
precisely, during the elicitation of the OS value function but also during the swing 
weighting stage, it became apparent that in order to indicate the magnitude of value 
associated with an extension in OS one might need to consider the respective HRQoL 
accompanying it; however the reverse was not evident, when the HRQoL value function 
was elicited. This issue was encountered by revealing the “lower” (x_l) and “higher” 
(x_h) reference levels of the dependent HRQoL attribute (EQ-5D index scores), i.e. 
0.75 to 0.86, and 0.72 to 0.82 for the mCRC and mCRPC case studies respectively, and 
instructing the participants to assume an identical performance between the options on 
the dependent attribute (given that all three options had identical EQ-5D index scores), 
but without disclosing the exact figure.  In other words, during the elicitation of the OS 
value functions the “lower-higher” range of the HRQoL attribute was revealed, i.e. 
v(x_0.72) = 0 and v(x_0.82) = 100 for the case of mCRC case study, and v(x_0.72) = 0 and 
v(x_0.82) = 100 for the case of the mCRPC case study, while acknowledging that the 
performances of the options were indifferent (i.e. identical), therefore deriving an OS 
value function that was effectively conditional on the range of the HRQOL attribute.  
In order to be 100% theoretically correct, existence of such preference 
dependence would normally require the use of more complex multilinear (i.e. 
multiplicative) models, given that the synergy or antagonism between the two 
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respective attributes would have to be reflected in the model accordingly.  In order to 
avoid using such a less straightforward model and keep using a simple additive one, the 
synergy (or antagonism) effect between the two attributes would have to equal zero, 
which would hold true if the product of their value scores is zero. Therefore, in a 
secondary analysis the value scores of the options across the HRQOL attribute were 
changed to zero (given their indifference in their performance), which did not result in 
influencing their ranking. Another alternative to avoid using a more complicated model 
would be to just eliminate the HRQOL attribute from the model given the indifference 
in the options’ performance. As part of another secondary analysis, the HRQOL 
attribute was removed from the model, without impacting the ranking of the options 
either. It should be noted though that any of the above modifications would only be 
possible because of the indifference arising in HRQOL, and in the case that the HRQoL 
performances of the options were not identical then it would be required that the OS 
and HRQoL attributes get combined into a single aggregated attribute for the simple 
additive model to be used. A recommendation for future MCDA applications evaluating 
treatments for mCRC, mCRPC and oncology indications in general or even end-of life 
situations would therefore be to explore potential preference (i.e. difference) 
dependence between the measures of OS and HRQOL, validating any difference (in) 
consistency, while possibly also investigating the complete attribute ranges for which 
it holds true, therefore giving an insight on any conditions in place.  
Furthermore, in the present case studies only the HRQoL of the stable disease 
state was assessed because none of the treatments were assumed to have any effects 
during the progressive disease state 427,442,467. However in other disease indications this 
might not hold true in which case the relevant HRQoL attribute would need to capture 
both the stable and progressive disease states, possibly in the form of an OS-HRQoL 
aggregated attribute (given their possible preference dependency), therefore producing 
a similar metric to QALYs.    
Also, among the main challenges of the methodological approach adopted is the 
relatively subjective nature of setting the “higher and lower” reference levels on each 
attribute, based on which treatment scores are derived. For example, as explained 
above, in the case of the treatment discontinuation attribute of the mCRPC case study, 
this was not set equal to 20% less than the best performing option (the reverse logic to 
the case of the therapeutic impact attributes), but rather equal to the minimum natural 
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limit of the scale (i.e. 0%) which was regarded as an “ideal” level. This level could 
indeed be perceived as “too extreme”, or “too good to be true”.  
Possibly more important however in terms of the treatment discontinuation 
attribute’s impact on the scoring of the alternative treatments was the definition of the 
“lower” reference level as this could influence the negative performance scores 
observed in two of the treatments and consequently their overall WPV scores. The 
lower reference level of 10% adopted on the basis of Best Supportive Care (i.e. “doing 
nothing”) performance was sourced from the placebo comparator arm of 
enzalutamide’s pivotal clinical trial (AFFIRM). The choice of using the placebo arm of 
the AFFIRM trial to proxy BSC performance and not the comparator arm from any of 
the other two treatment’s pivotal trials that were used in the analysis was because it 
better resembled BSC; in abiraterone’s pivotal trial (COU-AA-301) all patients in the 
placebo comparator arm were also administered steroids (prednisone), whereas in 
cabazitaxel’s pivotal trial (TROPIC) all patients in the comparator arm were 
administered steroids (prednisone or prednisolone) on top of chemotherapy 
(mitoxantrone). As a result, abiraterone and cabazitaxel produced negative preference 
value scores in treatment discontinuation as their performance lied below the lower 
reference level.  
Setting reference levels that were not necessarily equal to the limits of the value 
scale, ensured that the scale had enough granularity to distinguish the treatments, which 
is not always the case if the maximum and minimum levels are employed as reference 
levels. The basis adopted for setting these levels are clearly and extensively described 
in the respective methods and results sections (Chapters 7 and 8), and although I tried 
to be as objective as possible, others would most probably have ended up with different 
points as anchors. However, such differences would most probably be minor, not 
necessarily affecting the overall valuation of the treatments. The final reference points 
adopted were decided following the feedback that was received during the workshop 
for the case of the mCRC case study and from a clinical specialist for the case of 
mCRPC case study. Liaising with a range of experts during the model building phase 
for ensuring the choice of relevant reference levels, possibly before the actual model 
assessment phase, seems to be a necessary step for ensuring good practice and robust 
results. 
Another challenge would be the evaluation of clusters where participants have 
less experience or knowledge.  For example, during the evaluation of the HRQoL 
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attribute in the mCRC case study, some of the participants had difficulties in 
comprehending the differences in value between the different QALY (i.e. EQ-5D 
index) scores. However, feedback from clinicians and patients helped the rest of the 
group to understand the relative differences across health states so that they could 
express their preferences. Although such an input proved crucial and to a large extent 
satisfactory to the information needs of the group, it would be advantageous if the 
QALY scores were accompanied with descriptions across the EQ-5D dimensions for 
the given scores. 
A couple of other issues were perceived by some of the workshop participants 
to act as potential limitations in the mCRPC case study.  One opinion was that too much 
attention was paid to details of the model that eventually exerted no major influence on 
the overall WPV scores or any actual impact on the options’ rankings therefore possibly 
being redundant, as for example with the case of Special Instructions and Delivery 
Posology attributes. However, although the relative importance of some attributes 
might ultimately turn out to be relatively small, this cannot be predicted before 
preferences elicitation and even in this case their combined weight might still add up to 
be critical; in the example of the Special Instructions and Delivery Posology attributes, 
the sum of their relative weights was 7.3% of the total which should not be regarded as 
insignificant and in other instances it could have affected the options’ rankings.      
The view was also expressed that cost per QALY is still favoured by health 
economists and therefore whether it might be preferable to use “number of QALYs 
gained” as the basis of value, on top of which other additional benefit components could 
then be added. The main logic behind decision analysis and MCDA is to decompose 
complicated decision problems into simpler problem components, so that they can be 
analysed separately and then combined to inform an action plan for the problem, 
essentially adopting a “divide and conquer” approach 53. In the HTA context, where 
decision problems relate to the coverage of new drugs, such an approach would 
therefore require the evaluation of the alternative interventions against all relevant value 
dimensions individually (if possible). As a result, considering and analysing the 
performance of the alternative interventions against OS and HRQoL distinctively 
should aim in helping decision-makers express their value judgements and understand 
their overall value preferences across the options. However as mentioned above, a 
plausible preference dependency observed between the OS and HRQoL attributes could 
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indeed require their combination into a single aggregated attribute of benefit resembling 
number of QALYs gained.     
 
8.3.3 Cognitive and Motivational Biases 
Importantly, research on behavioural decision analysis has indicated that construction 
of judgements as part of decision-making is prone to a number of biases, relating to 
faulty cognitive processes or due to motivations for preferred analysis outcomes 498. 
The presence of these biases could be present across the different phases of the 
methodological process developed and adopted, and especially in the model-building, 
model-assessment, and model-appraisal phases, that took place as part of the case 
studies involving the participation of experts and decision-makers. Such biases could 
potentially reduce the quality of the model and the results of the analysis.  
A number of de-biasing techniques have been recommended to overcome these 
limitations498 and although many of them were applied during the decision conference 
workshops as part of the specific modelling and preference elicitation tasks, important 
sources of biases could still remain. For example, in terms of cognitive biases, 
‘equalizing bias’ relating to the allocation of similar weights to all value concerns was 
addressed through the hierarchic elicitation of weights. ‘Gain-loss bias’ which occurs 
as alternative descriptions of a choice and its outcomes (which may lead to different 
answers) was addressed by conducting value judgements in relevance to (marginal 
change from a) best supportive care option which was used as a reference levels and 
which could act as a status quo. ‘Myopic problem representation bias’ which occurs 
when an oversimplified problem is adopted and based on an incomplete mental model 
for the decision problem was addressed by explicitly encouraging experts to think about 
more value concerns in the wider socioeconomic context. ‘Omission of important 
variables bias’ was addressed by using group elicitation techniques so that no important 
variable is overlooked. ‘Overconfidence bias’ relating to overestimation and 
overprecision was addressed by using fixed value instead of fixed probability 
elicitations. ‘Proxy bias’ which occurs when proxy attributes receive larger weights 
than the respective fundamental concerns was addressed by trying to avoid the use of 
proxy attributes. ‘Range insensitivity bias’ occurring when objectives are not properly 
adjusted to changes in the range of attributes was addressed by making attribute ranges 
explicit and using a swing weighting technique. ‘Splitting bias’ which occurs when the 
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structuring of the criteria affects their weights was addressed using hierarchal 
estimation of relative weights.  
Then in terms of motivational biases, a number of biases could exist because of 
peoples’ emotions, desires and motives 498: ‘affect influenced bias’ relating to the 
emotional predisposition for or against a specific outcome, ‘confirmation bias’ relating 
to the desire to confirm one’s belief leading to unconscious selectivity, ‘desirability of 
a positive event or consequence bias’ occurring when the desirability of an outcome 
leads to an increase in the extent to which it is expected to take place (i.e. ‘wishful 
thinking’ or ‘optimism bias’), ‘under-desirability of a negative event or consequence 
bias’ occurring when there is a desire to be cautious or conservative in estimates that 
may be related to harmful consequences, and ‘desirability of options or choice bias’ 
leading to over- or underestimating values or weights in a direction that favours a 
desired alternative. All of these were addressed by engaging multiple experts with 
alternative points of view, collecting views from a range of different experts as 
stakeholders or decision-makers to provide different value perspectives, and using 
indirect MAVT techniques for scoring the options and weighting the criteria. Therefore, 
the use of a precise combination of indirect MAVT methods and more precisely swing 
weighting hierarchic elicitation techniques at group level, taking place through 
participatory processes involving key stakeholders and experts which are facilitated 
appropriately such as through Decision Conferencing, could act as an important way 
for avoiding the occurrence of many detrimental cognitive and motivations biases in 
the context of HTA which could deteriorate results’ robustness.   
 
8.4 Future Research Directions  
Future research could explore three distinct, but interconnected areas. The first would 
be to conduct further empirical applications of the value framework in the context of 
HTA with the view to validating its use for the purpose of reimbursement and pricing 
decisions and as a resource allocation tool and, ultimately adapting it to the needs of 
decision-makers. Second, to expand the application of the framework in the decision 
context preceding HTA (notably for early HTA) and also for licencing approvals, but 
even as part of drug development during clinical trials. And, third, to adapt the 
framework in the context of treatment selection and prescribing between patients and 
clinicians, known as shared decision-making. 
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8.4.1 Validation in the HTA Context 
In terms of generating further empirical evidence in the context of HTA 
applications, a number of case studies could be conducted in different countries with a 
number of different public HTA agencies across Europe. Such a research initiative 
could seek to tailor the framework as a methodological tool that can capture the 
preferences of the decision-makers based on their needs in a robust and transparent 
manner. In doing so, the results from a number of identical evaluation contexts across 
countries using the same evidence could be compared in order to highlight the 
differences in the value judgements and preferences of different European 
payers/regulators, therefore giving an insight of important variations in the regulatory 
landscape in a cross-country comparison fashion.  
For example, together with my PhD supervisor Prof Panos Kanavos, I am 
currently in the process of organising similar case studies with different HTA agencies 
and payers across Europe with intention of advancing the framework as a tool for the 
needs of decision-makers. I have already conducted workshops with the Andalusian 
Health Technology Assessment Agency (AETSA), the Polish Agency for Health 
Technology Assessment and Tariff System (AOTMiT), and the Belgian National 
Institute for Health and Disability Insurance (INAMI-RIZIV) and I am looking forward 
for others to follow. 
Other countries could include England, France, Italy and Netherlands with the 
involvement of the national HTA agencies/insurance funds of each country (i.e. NICE, 
HAS, AIFA and NIZ respectively). An additional research objective would be to test 
the methodology with private health insurers based in the US. Given the high cost and 
uncertainty of cancer treatments, in tandem with the high burden of disease, a set of 
oncology indications such as prostate, lung, breast and skin cancer could be included 
for which a number of biological molecules and immunotherapies would be evaluated. 
Selected indications could also include less prevalent cancers with higher unmet 
medical needs such as rare blood cancers (e.g. chronic myeloid leukaemia, 
myelofibrosis), in order to eventually compare and contrast the evaluation process of 
orphan medicines versus non-orphan medicines. Assuming a relatively high number of 
case studies across different countries will be conducted, the methodology could be 
adapted for the preferences to be elicited in a virtual mode, requiring the development 
of a web-based application. Importantly, the existence of different types of behavioural 
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biases in these specific contexts as described in section 8.3.3 could be explored, together 
with possible techniques for addressing them. 
 
8.4.2 Application into Drug Development and Early HTA Context  
 In terms of expanding its application earlier in drug development, the 
methodological framework could be applied in the benefit-risk assessment taking place 
for the purpose of licencing approval as part of the traditional marketing authorisation 
process, but also as part of more innovative adaptive approaches to marketing 
authorisation which depend on continuous evidence development. Besides that, the 
framework could be adapted for evidence generated in phase 2 or 3 clinical trials to 
evaluate molecules earlier in the product-lifecycle in order to better communicate future 
value prospects with decision-makers - both regulators and payers - while improving 
alignment with evidence requirements499. In this context, the framework could be used 
as a tool for facilitating the expression of value concerns and the construction of value 
preferences of decision-makers, with the analysis including HTA (and licencing) 
related criteria that reflect payer (and regulator) concerns, but earlier on, when the 
evidence generation process as part of drug development is still amenable.  This could 
help address the gap between what payers and HTA bodies perceive as value and what 
the industry delivers following marketing authorisation requirements, helping to ensure 
that the envisaged clinical trial evidence generated for the purpose of licensing approval 
meets payer and HTA body requirements. Eventually this could help to optimise the 
overall drug development process and bring down expenditures by identifying 
redundant studies/outcomes that are necessary and might be currently missing. Given 
the high probability of failure and the high unmet need, possible case studies could use 
evidence from CNS products relating to neurological conditions such as Alzheimer’s, 
Multiple Sclerosis and Parkinson’s.   
Such a research would be in alignment with current initiatives from the 
European Medicines Agency (EMA), relating to pilot projects that explore the use of 
adaptive pathways and the cooperation between regulators and payers/HTA bodies.  
In terms of adaptive pathways, this is a product development concept for 
medicines targeting unmet needs which could be defined as “a planned, progressive 
approach to bringing a medicine to patients” 500. Under such a pathway, a new medicine 
would first receive an authorisation for a relatively small population of patients that is 
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likely to benefit the most and over time progressive licencing approvals could follow, 
extending the original indication through the collection of additional evidence in wider 
patient populations. The first such pilot project was just completed and a number of 
aspects were identified for further reflection, including the need for increased patient 
involvement, the potential to involve payers in order to provide input on pricing 
strategies and the definition of methodologically sound strategies of real-world 
evidence collection. All of these issues could potentially benefit from the application 
of MCDA approaches: involvement of patients and payers could inform the 
incorporation of patient and payer related concerns in the evaluation process and the 
elicitation of their value preferences, and flexible models could be constructed that are 
easily adaptable for the accommodation of future evidence collection.   
In terms of cooperation between regulators and HTA bodies, EMA together 
with EUnetHTA recently completed collaboration as part of a work plan with various 
aims and achievements. These included the establishment of early dialogue for 
medicines manufacturers to reduce duplication while streamlining and enhancing the 
whole development process, improving EMA assessment reports to address the 
requirements of HTA bodies, and the facilitation of rapid relative effectiveness 
assessment 501, which in turn could be addressed via the application of the framework 
for the elicitation and construction of value preferences aiding value communication 
and evidence alignment as mentioned above.    
 
8.4.3 Application in Shared Decision-Making   
With regards to the treatment prescribing application, the framework could be 
adapted in order to aid the selection process of the most appropriate treatment at patient 
level as part of a shared decision-making context involving patients and clinicians502. 
Patient centeredness and engagement has been emerging as a vital way for achieving 
better health outcomes and efficient allocation of resources, being especially relevant 
for settings with high availability of treatment options and with differences in their 
benefits and risks, usually requiring elicitation of benefit-risk trade-offs. This 
application could therefore explore clinical prescribing contexts in which multiple 
treatments for the same disease indication are routinely prescribed in clinical practice 
but which might produce heterogeneous outcomes in different patient applications. 
Heart disease could be selected as the disease indication for which a number of different 
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statins would be assessed against based on their comparative benefit-risk ratios across 
a range of health outcomes503. The methodology could be adapted so that preferences 
can be elicited from a greater number of responders (i.e. patients) and therefore conjoint 
analysis techniques could be used 452. 
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Appendix to Chapter 2 
 
Main types of Economic Evaluation: 
  CBA CEA CUA 
Objective allocative efficiency 
(economic welfare 
theory) 
technical efficiency technical or 
allocative efficiency 
(extra-welfarism 
theory) 
Outcomes single or multiple 
and not necessarily 
common across 
alternatives in 
monetary units 
single type of effect 
that is common 
between the 
alternatives being 
compared (e.g. ‘life 
years gained’) 
utility associated 
with the effects of 
comparators being 
assessed (e.g. 
QALY), which can 
be single or multiple 
and not necessarily 
common across the 
alternatives 
Costs monetary units monetary units monetary units 
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Perspective societal Decision-maker health care policy 
maker 
Result net benefit ratio 
(ratio of cost to 
benefits) 
cost per unit of 
outcome (e.g. cost 
per life year gained), 
or effect per unit of 
cost (e.g. life year 
gained per dollar 
spent) 
cost per utility-
adjusted health 
outcome (e.g. 
QALY) 
 
Sources: 108,118,121  
 
 
 
 
 
Appendix to Chapter 5 
 
The available clinical evidence used for the assessment of therapeutic benefit will in 
most cases be sourced from explanatory trials that reflect ideal conditions, conducted 
on a highly selected group of patients and under strictly controlled environments while 
ensuring regimen compliance. In contrast, pragmatic trials are conducted under real 
world settings and on patients representing the full population spectrum which may 
show varying compliance 504. Indeed, evidence from electronic monitoring for a range 
of diseases including hypertension, glaucoma, seizure disorders and others, indicate that 
good adherence to prescribed regimens is only observed in between 50% and 60% of 
patients, with 5% to 10% adhering poorly and 30% to 45% adhering to an intermediate 
but widely variable degree 396,505-508. Ergo, and unless the clinical evidence are coming 
from pragmatic trials resembling real world conditions, acknowledging that there is an 
impact on health outcomes from (un)ease and/or (un)convenient regimens could act as 
an adjustment or “fixture” towards the reflection of a more realistic clinical picture.  
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Appendix to Chapter 6 
 
6.1 Methodological Framework 
At first, as part of the problem structuring phase, the decision problem and the aims of 
the analysis are defined, and the relevant decision-makers and other key stakeholders 
are identified. Next, as part of the model-building phase, objectives and/or relevant 
criteria are identified in order to reflect decision-makers’ goals and areas of concern, 
and attributes are selected to operationalise the criteria. In addition, under the same 
phase, selection of the alternative options takes place and evidence on their performance 
across the selected criteria is identified. Following that, under the model assessment 
phase, the performance of options against the criteria is assessed (i.e. scoring) and 
criteria are weighted according to their relative importance (i.e. weighing). 
Subsequently, as part of the appraisal phase, scores and weights are combined in order 
to produce overall WPV scores, taking the form of a value index (i.e. aggregation). In 
combination with sensitivity analysis, the results are examined and their robustness is 
determined. Finally, as part of action planning, the outcome of the analysis can be used 
to inform resource allocation decisions, of a coverage or pricing nature.  
 
6.2 Evidence Considered and Alternative Treatments Compared 
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As part of TA242, for the case of cetuximab and panitumumab, NICE considered 
clinical evidence coming from two open label, Phase 3 RCTs respectively; the first one 
investigating the use of cetuximab plus best supportive care (BSC) compared to BSC 
alone125 (CO.17 trial) 509 and the second one investigating the use of panitumumab plus 
BSC compared to BSC alone (AMGEN trial) 445, in patients with chemotherapy-
refractory mCRC. For the case of bevacizumab, as part of TA242, only one RCT had 
been identified investigating bevacizumab as a second line treatment (E3200 trial) 510. 
However in that trial, bevacizumab was administered in combination with an 
oxaliplatin-containing chemotherapy which was outside the appraisal’s scope, and 
hence outside the scope of our analysis.  
As part of TA307, the clinical evidence for aflibercept was taken from a 
prospective multinational, randomized, double-blind, parallel-arm, phase 3 study 
investigating the addition of aflibercept to FOLFIRI in patients with mCRC previously 
treated with an oxaliplatin-based regimen (VELOUR trial) 433.  
Finally, for the case of regorafenib, no clinical evidence was considered as part 
of TA334 because no evidence submission was received from the manufacturer and the 
appraisal was terminated early.  
No indirect comparison was conducted given the lack of a common comparator 
among the three treatments of interest among the above clinical studies. A mixed-
treatment comparison lied outside the aim of the simulation exercise which was to 
operationalise the value framework in place through the elicitation of preferences across 
a range of explicit criteria from a group of stakeholders. As a result, for the case of 
cetuximab and panitumumab clinical evidence was used from a latest head to head, 
open label, randomised, multicentre Phase 3 non-inferiority study directly comparing 
both treatments (ASPECCT trial) 434, whereas for the case of aflibercept in combination 
with non-oxaliplatin based chemotherapy evidence was used from the same clinical 
study that NICE considered. However, data from the BSC comparator arms of the two 
trials that NICE considered as part of TA242 for the case of cetuximab and 
panitumumab (CO.17, AMGEN) 445,509, were used for the purpose of setting the 
reference levels on the attributes.    
  
                                                 
125 No evidence were submitted to NICE for cetuximab in combination with chemotherapy, therefore 
this combination fell outside the scope of our exercise too. 
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6.3 MCDA Technique 
MACBETH uses seven semantic categories ranging between “no difference” to 
“extreme difference”, in order to distinguish between the value of different attribute 
levels. Based on these qualitative judgements of difference and, by analysing 
judgmental inconsistencies, it facilitates the move from ordinal preference modeling, a 
cognitively less demanding elicitation of preferences, to a quantitative value function. 
An example of the type of questioning being asked would be “What do you judge is the 
difference of value between x’ and x’’?” where x’ and x’’ are two different attribute 
levels of attribute x, across the plausible range (i.e. x* ≤ x’, x’’ ≤ x*). The approach has 
evolved through the course of theoretical research and real world practical applications, 
making it an interactive decision support system that facilitates decision-makers’ 
communication.   
Following the elicitation of value functions, criteria baseline weights can be 
elicited. Questions of direct importance for a criterion such as “How important is a 
given criterion?” are known to be as one of the most common mistakes when making 
value trade-offs because they are assessing them independent of the respective attribute 
ranges 202. In contrast, indirect weighting technique that assess value trade-offs in 
tandem with the respective ranges of attributes should be employed. For example, the 
quantitative swing weighting technique asks for judgments of relative value between 
‘swings’ (i.e. changes) from standard lower level x* to higher reference level x* on each 
x-th attribute) taking the form “How would you rank the relative importance of the 
criteria, considering their attributes ranges relative to 100 for the highest-ranked 
criterion considering its range?”. Each swing, i.e. a relative change from a lower 
attribute level to a higher attribute level, is valued between 0 and 100, with the most 
valuable swing anchored as 100 54. Normalised weights are then calculated, as a 
proportion of each swing weight, so the normalised weights summed to 100%. Instead, 
relative attribute weights were calculated using an alternative qualitative swing 
weighting protocol, by using the MACBETH procedure to elicit the differences in 
attractiveness between the lower and higher reference levels of the different attributes, 
initially at individual level and then at criteria cluster level (i.e. by considering multiple 
attribute swings on the same time) 407,447.  
Finally criteria preference value scores and the respective weights can be 
combined together through an additive aggregation approach as described in Eq. X (if 
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the adequate conditions of complete and transitive preferences are met as well as multi-
attribute preferential independence conditions – see 54.  
 
6.4 Options Performance, Criteria Weights and Overall Value Rankings126 
 
 
 
 
 
 
6.4.1 Example of a value judgement matrix for the Overall Survival attribute and its 
conversion into a value function 
 
                                                 
126 images produced using the M-MACBETH (beta) software version 3.0.0 
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Caption: In this example, the question asked for the case of OS was the following: “What do 
you judge to be the difference of value between 0 months OS and 14.9 months OS? No 
difference, very weak, weak, moderate, strong, very strong, or extreme?” Once a consensus was 
reached, the next question came along: “What do you judge to be the difference of value between 
3 months OS and 14.9 months OS? No difference, very weak, weak, moderate, strong, very 
strong, or extreme?” The same process was followed until value judgments for all the different 
combinations of attribute levels were elicited, filling in the different rows from the right-hand 
side (i.e. lower range) to the left-hand side (i.e. higher range), top to bottom.  
6.4.2 Example of a value judgement matrix for the Health Related Quality of Life 
attribute and its conversion into a value function 
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Caption: In this example, the question asked for the case of HRQoL was the following: “What 
do you judge to be the difference of value between 0.6 EQ-5D index score OS and 0.86 EQ-5D 
index score? No difference, very weak, weak, moderate, strong, very strong, or extreme?” Once 
a consensus was reached, the next question came along: “What do you judge to be the difference 
of value between 0.7 EQ-5D index score OS and 0.86 EQ-5D index score? No difference, very 
weak, weak, moderate, strong, very strong, or extreme?” The same process was followed until 
value judgments for all the different combinations of attribute levels were elicited, filling in the 
different rows from the right-hand side (i.e. lower range) to the left-hand side (i.e. higher range), 
top to bottom.   
 
6.4.3 Value scale for the Progression Free Survival attribute 
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6.4.4 Value scale for Grade 4 AEs attribute 
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6.4.5 Value scale for ATC L4 attribute 
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6.4.6 Value scale for Phase 3 attribute 
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6.4.7 Value scale for Marketing Authorisation attribute 
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6.4.8 Value scale for Posology attribute 
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6.4.9 Value scale for Medical costs impact attribute 
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6.5 Sensitivity and Robustness Analysis127  
6.5.1 Sensitivity analysis on weights for Cetuximab versus Panitumumab 
 
 
 
 
                                                 
127 images produced using the M-MACBETH (beta) software version 3.0.0 
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6.5.2 Sensitivity analysis on weights for Panitumumab vs Aflibercept plus FOLFIRI 
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6.5.3 Sensitivity analysis on weights for Cetuximab vs Aflibercept plus FOLFIRI 
 
300 
 
 
 
 
 
 
 
 
301 
 
 
 
 
 
 
 
 
302 
 
 
 
 
 
 
 
 
 
303 
 
 
6.5.4 Robustness analysis on reference levels: 
 
 
Red triangles denote “dominance” (an option dominates another if it is at least as attractive as 
the other in all criteria and it is more attractive than the other in at least one criterion). Green 
crosses denote “additive dominance” (an option additively dominates another if it is always 
found to be more attractive than the other through the use of an additive model under a set of 
information constraints. 
For more information please see M-MACBETH user manual 448.  
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Appendix to Chapter 7 
 
7.1 Methodological Framework 
At first, as part of the problem structuring phase, the decision problem and the aims of 
the analysis are defined, and the relevant decision-makers and other key stakeholders 
are identified. Next, as part of the model-building phase, objectives and/or relevant 
criteria are identified in order to reflect decision-makers’ goals and areas of concern, 
and attributes are selected to operationalise the criteria. In addition, under the same 
phase, selection of the alternative options takes place and evidence on their performance 
across the selected criteria is identified. Following that, under the model assessment 
phase, the performance of options against the criteria is assessed (i.e. scoring) and 
criteria are weighted according to their relative importance (i.e. weighing). 
Subsequently, as part of the appraisal phase, scores and weights are combined in order 
to produce overall WPV scores, taking the form of a value index (i.e. aggregation). In 
combination with sensitivity analysis, the results are examined and their robustness is 
determined. Finally, as part of action planning, the outcome of the analysis can be used 
to inform resource allocation decisions, of a coverage or pricing nature. 
 
7.2 Evidence Considered and Alternative Treatments Compared 
As part of NICE TA255 472, for the case of cabazitaxel in combination with prednisone, 
NICE primarily considered clinical evidence coming from one phase III, randomised, 
open-label, multicentre trial (TROPIC) investigating the use of cabazitaxel plus 
prednisone (or prednisolone) compared to mitoxantrone plus prednisone (or 
prednisolone) in men with hormone-refractory metastatic prostate cancer. Patients had 
to be aged over 18 years with an Eastern Cooperative Oncology Group (ECOG) 
performance score of 0–2, and with evidence of disease progression during or after 
completion of docetaxel-containing treatment 461. The same clinical trial was used by 
TLV as part of a health economic exercise (no formal appraisal).  
As part of TA259 466, the decision problem considered whether treatment with 
abiraterone plus prednisolone was clinically effective compared with mitoxantrone 
(with or without prednisolone) or best supportive care for castration-resistant metastatic 
prostate cancer previously treated with a docetaxel-containing regimen. NICE primarily 
considered clinical evidence coming from a phase III, placebo-controlled, randomised, 
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double-blind, multicentre trial (COU-AA-301), investigating the use of abiraterone in 
combination with prednisone (or prednisolone) versus placebo in combination with 
prednisone (or prednisolone), in men whose disease had progressed on or after 
docetaxel therapy 462. Patients were aged over 18 years, with an Eastern Cooperative 
Oncology Group (ECOG) performance score of 0–2. A similar decision problem was 
adopted in TLV TA4774/2014 for the case of abiraterone in combination with 
prednisolone versus prednisolone on its own for patients who had received docetaxel 
or comparable chemotherapy, with clinical evidence coming from the COU-AA-301 
trial 474.  
As part of TA316 467, for the case of enzalutamide NICE primarily considered 
clinical evidence coming from a phase III randomised double-blind placebo-controlled 
study (AFFIRM) which investigated the use of enzalutamide plus best supportive 
care128 (i.e. with or without the use of prednisone or other glucocorticoids) compared 
with placebo plus best supportive care 463. Eligible patients were aged over 18 years, 
with metastatic hormone-relapsed prostate cancer who had previously received 1 or 2 
cytotoxic chemotherapy regimens, at least 1 of which contained docetaxel. Patients who 
had received abiraterone or treatment with any other investigational agents that block 
androgen synthesis were excluded. A similar decision problem was adopted in TLV 
TA2775/2013 for the case of enzalutamide versus best supportive care for patients who 
had progressed during or after docetaxel treatment, with clinical evidence base from the 
AFFIRM study 473.  
In addition, as part of NICE TA316 evidence for abiraterone plus prednisone from the 
COU-AA-301 trial was also considered in order to indirectly compare enzalutamide 
versus abiraterone (plus prednisone) using placebo as a common comparator whereas 
TLV TA4852/2014 used the same pivotal trials to compare enzalutamide versus 
abiraterone , either (1) when treatment with hormonal therapy has not worked or when 
treatment has not worked in men without symptoms or with only mild symptoms that 
do not need chemotherapy yet (i.e. pre-chemotherapy), or (2) adult men with 
progressive disease during or after docataxel-based chemotherapy (i.e. post-
chemotherapy); none of these two scopes were considered. 
 
                                                 
128 Best supportive care in AFFIRM could include radiopharmaceuticals, analgesics, bisphosphonates, 
hormonal therapies, corticosteroids, and radiotherapy 
306 
 
 
7.3 MCDA Technique 
MACBETH uses seven semantic categories ranging between “no difference” to 
“extreme difference”, in order to distinguish between the value of different attribute 
levels. Based on these qualitative judgements of difference and, by analysing 
judgmental inconsistencies, it facilitates the move from ordinal preference modeling, a 
cognitively less demanding elicitation of preferences, to a quantitative value function. 
An example of the type of questioning being asked would be “What do you judge is the 
difference of value between x’ and x’’?” where x’ and x’’ are two different attribute 
levels of attribute x, across the plausible range (i.e. x* ≤ x’, x’’ ≤ x*). The approach has 
evolved through the course of theoretical research and real world practical applications, 
making it an interactive decision support system that facilitates decision-makers’ 
communication.  
Following the elicitation of value functions, criteria baseline weights can be 
elicited. Questions of direct importance for a criterion such as “How important is a 
given criterion?” are known to be as one of the most common mistakes when making 
value trade-offs because they are assessing them independent of the respective attribute 
ranges 202. In contrast, indirect weighting technique that assess value trade-offs in 
tandem with the respective ranges of attributes should be employed. For example, the 
quantitative swing weighting technique asks for judgments of relative value between 
‘swings’ (i.e. changes) from standard lower level x* to higher reference level x* on each 
x-th attribute) taking the form “How would you rank the relative importance of the 
criteria, considering their attributes ranges relative to 100 for the highest-ranked 
criterion considering its range?”. Each swing, i.e. a relative change from a lower 
attribute level to a higher attribute level, is valued between 0 and 100, with the most 
valuable swing anchored as 100 54. Normalised weights are then calculated, as a 
proportion of each swing weight, so the normalised weights summed to 100%. Instead, 
relative attribute weights were calculated using an alternative qualitative swing 
weighting protocol, by using the MACBETH procedure to elicit the differences in 
attractiveness between the lower and higher reference levels of the different attributes, 
initially at individual level and then at criteria cluster level (i.e. by considering multiple 
attribute swings on the same time) 203,407. 
Finally criteria preference value scores and the respective weights can be 
combined together through an additive aggregation approach as described in Eq. X (if 
307 
 
 
the adequate conditions of complete and transitive preferences are met as well as multi-
attribute preferential independence conditions – see 54 and section 1.1.4).   
 
7.4 Criteria Validation and Amended Value Tree for Metastatic Prostate 
Cancer129  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
129 images produced using the M-MACBETH (beta) software version 3.0.0 
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7.4.1 Example of value judgements matrix for the Overall Survival attribute and their 
conversion into value functions 
 
 
 
Caption: In the Overall Survival example, the question asked was the following: “What do 
you judge to be the difference of value between 13.6 months OS and 22.1 months OS? No 
difference, very weak, weak, moderate, strong, very strong, or extreme?” Once a consensus 
was reached, the next question came along: “What do you judge to be the difference of value 
between 16.4 months OS and 22.1 months OS? No difference, very weak, weak, moderate, 
strong, very strong, or extreme?” The same process was followed until value judgments for 
all the different combinations of attribute levels were elicited, filling in the different rows 
from the right-hand side (i.e. lower range) to the left-hand side (i.e. higher range). 
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7.4.2 Value scale for the Health Related Quality of Life attribute 
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7.4.3 Value scale for the Tumour Progression attribute 
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7.4.4 Value scale for the Treatment discontinuation attribute 
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7.4.5 Value scale for the Contraindications attribute 
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7.4.6 Value scale for the Delivery System & Posology attribute 
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7.4.6 Value scale for the Special Instructions attribute 
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7.4.7 Value scale for the Medical Costs Impact attribute 
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7.5 Sensitivity and Robustness Analysis130 
 
7.5.1 Exploring changes in the relative weights of Progression Free Survival (PFS), 
Treatment discontinuation (TREAT DIS), Special Instructions (Special Instru) and 
their impact on treatments’ rankings 
 
 
 
 
 
                                                 
130 images produced using the M-MACBETH (beta) software version 3.0.0 
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7.5.2 Exploring changes in the ranges of the reference levels and their impact on 
treatment rankings.  
 
 
Red triangles denote “dominance” (an option dominates another if it is at least as attractive as 
the other in all criteria and it is more attractive than the other in at least one criterion). Green 
crosses denote “additive dominance” (an option additively dominates another if it is always 
found to be more attractive than the other through the use of an additive model under a set of 
information constraints. 
For more information please see M-MACBETH user manual available via: http://www.m-
macbeth.com/help/pdf/M-MACBETH%202.4.0%20Users%20Guide.pdf 
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